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Summary 
DNA methylation helps regulate transcriptional activity and is widely studied in cancer biology. 
This investigation aimed to establish the significance of Human Papillomavirus (HPV) DNA 
methylation in HPV-associated disease both in terms of basic biology and as a potential 
biomarker. 
Assays to assess DNA methylation and gene expression were developed and evaluated. 
Pyrosequencing was used to assess DNA methylation of four regions of the HPV16 genome (E2, 
L1/L2, enhancer, promoter). Gene expression was assessed using quantitative PCR with assays 
for E2, E6 and E7. HPV integration was assessed using Detection of Integrated Papillomavirus 
Sequences (DIPS).  
The relationship between HPV methylation, gene expression and integration was explored in 
vitro and in vivo using cell cultures and clinical cohorts. A variety of sample materials were 
used including short term and immortal cell lines, cervical cancer biopsies, cytology samples 
and Vulval Intraepithelial Neoplasia (VIN) biopsies. 
In general, hypermethylation of the HPV genome was associated with low HPV gene 
expression and the presence of integrated HPV genomes. 
To better understand the potential clinical utility of HPV DNA methylation, the relationship 
between HPV DNA methylation and various stages of cervical disease was determined. The 
HPV genome was progressively hypermethylated with increasing severity of cervical disease 
and certain regions of the HPV genome were more affected than others. A longitudinal study 
was also performed in order to determine a relationship between HPV methylation and clinical 
outcome. Differences in HPV methylation among patients who had persistent HPV infection 
and low grade disease, persistent infection and high grade disease and patients that cleared 
HPV infections were observed. Throughout the study the potential application of a HPV 
biomarker was considered and the correct biomarker design procedures were referred to. 
Several of the early biomarker development steps were successfully achieved. 
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Abbreviations 
Abbreviation Definition 
AIN Anal intraepithelial neoplasia 
ANOVA Analysis of variance 
APOT Amplification of papillomavirus oncogene transcripts 
BS Bisulfite (i.e. Sodium bisulfite) 
CIN Cervical intraepithelial neoplasia 
CpG Cytosine-guanine dinucleotide 
CRUK Cancer Research UK 
Ct Cycle threshold number 
DIM Diindolylmethane 
DIPS Detection of integrated papillomavirus sequences 
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E1-E8 The HPV early genes 
E2-(1-8) The 8 E2 CpGs tested 
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HDAC Histone deacetylase 
HPRT Hypoxanthine guanine phosphoribosyl transferase  
HPV Human papillomavirus 
HrHPV High risk HPV 
HSIL High grade squamous intraepithelial lesion 
L1 and L2 The HPV late genes 
L1/L2 The overlap between L1 and L2 
L1L2-(1-4) The 4 CpGs of the L1/L2 regions tested 
LBC Liquid based cytology 
LCR Long control region 
LCR1 The LCR1 assay (enhancer) 
LCR1-(1-3) The 3 LCR1 CpGs tested 
LCR2 The LCR2 assay (promoter) 
LCR2-(1-5) The 5 LCR2 CpGs tested 
LrHPV Low risk HPV 
LS Lichen sclerosus 
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meCpG Methylcytosine-quanine dinucleotide 
MS-PCR Methylation specific PCR 
ORF Open reading frame 
P97 The HPV16 early promoter 
Pap Papanicolaou (stain) 
PC08/09 Primary culture 08/09 - short term cell lines 
qMS-PCR Quantitative methylation specific PCR 
qPCR Quantitative PCR (also qRTRTPCR) 
qRTRTPCR Quantitative reverse transcriptase real time PCR 
RQ Relative quantification 
RT Reverse transcription/transcriptase 
SCC Squamous cell carcinoma 
TBP TATA-binding protein 
VAIN Vaginal intraepithelial neoplasia 
VIN Vulval intraepithelial neoplasia 
VLP Virus like particle 
W12Ser7 Series 7 of the W12 cell line 
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Opening Notes 
This project was an investigation into the biological and clinical significance of HPV DNA 
methylation. DNA methylation at several sites of the HPV genome was assessed and the 
relationship between DNA methylation, gene expression and HPV integration investigated.  
A vital component of this investigation was the development of suitable assays with which to 
assess DNA methylation and gene expression. Method development formed a large part of the 
study and is described in a separate chapter. The experiments described in the four other 
results chapters were designed to test hypotheses concerning the relationship between HPV 
DNA methylation and other characteristics. 
Several components of the various studies were common to, or had broader relevance to 
more than one study. As such, discussion of these topics was grouped together into the 
general discussion in order to avoid repetition. 
This investigation is organised in the following manner: 
 Chapter 1. Introduction: HPV and HPV-Associated Cancer 
 Chapter 2. Introduction: DNA Methylation and Epigenetics 
 Chapter 3. Methods and Materials 
 Results and Discussion Chapters 
o Chapter 4. Method Development 
o Chapter 5. DNA Methylation and Disease Grade 
o Chapter 6. DNA Methylation and Clinical Outcome 
o Chapter 7. DNA Methylation, Integration and Gene Expression in vitro 
o Chapter 8. DNA Methylation, Integration and Gene Expression in vivo 
 Chapter 9. General Discussion 
 Chapter 10. General Conclusions 
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Chapter 1. Introduction: HPV and HPV-Associated Cancer 
 
1.1. Human Papillomaviruses 
Papillomaviruses (PV) are a diverse range of viruses that infect squamous and glandular 
epithelial tissues in a range of species. At least 120 types of Human Papillomavirus (HPV) are 
capable of infecting humans (Bernard et al., 2010) with around 40 HPV types infecting the 
anogenital tract (Sanders and Taira, 2003, Stanley, 2006a). HPV infection is very common and 
most individuals contract a genital HPV at some point in their lives, however relatively few 
people experience symptoms or HPV-associated anogenital neoplasia (Woodman et al., 2001, 
Ho et al., 1998). Although the majority of infections are subclinical and transient, HPV infection 
occasionally results in benign or malignant tumours of the cutaneous and mucosal epithelia; 
most notably of the cervix where HPV is associated with >99% of cancers (Duensing and 
Münger, 2004, McIndoe et al., 1984, Stanley, 2007). 
Mucosal HPV are further classified according to their oncogenicity. Low risk HPV (LrHPV) types 
rarely or never lead to cancers; types 6 and 11 for example are implicated in the formation of 
benign genital warts and are rarely associated with cancers. Other HPV types are denoted as 
High risk HPV (HrHPV) due to their common association with the development of cancers 
(Sanders and Taira, 2003, Braaten and Laufer, 2008, Doorbar, 2006). Persistent infection with 
HrHPV is considered a risk factor for the development of anogenital neoplasia (Ho et al., 1995). 
The HrHPV types most commonly associated with anogenital cancer are HPV16 and HPV18 
which are present in around 70% of cervical cancers worldwide (Muñoz et al., 2004) and in 
varying proportions of other anogenital carcinomas. 
1.1.1. Taxonomy of Human Papillomaviruses 
There are 12 genera of Papillomaviruses (PV), defined as having at least 60% sequence identity 
of the L1 gene. Human papillomaviruses are divided into alpha, beta, gamma, mu and nu 
(Bernard et al., 2010). The two main genera of HPV are the Alpha and Beta papillomaviruses, 
approximately 90% of all characterised HPV fit into one of these two groups and have a 
general tendency to infect either cutaneous or mucosal epithelia. Beta papillomaviruses are 
typically associated with unapparent cutaneous infections, and only tend to cause clinically 
relevant disease if the patient is immunocompromised or suffering from epidermodysplasia 
verruciformis (Doorbar, 2006). Alpha papillomaviruses include the HPV types associated with 
genital/mucosal infections and several cutaneous types such as HPV2 which tend to cause 
common warts (Doorbar, 2006, de Villiers et al., 2004). PV genera are divided by species, 
2 
 
representing 60-70% L1 sequence identity to other PV of the same species; viral type (71-89% 
L1 identity); viral subtype (90-98% L1 identity) and variant (over 98% L1 identity) (Howley and 
Lowy, 2006). 
1.1.2. HPV and the HPV Lifecycle 
The structure, genetics and lifecycle of HPV will now be considered before the functions of the 
HPV gene products and the association between HPV and cancer are discussed. 
1.1.2.1. HPV 
HPV has a double stranded, circular DNA genome of approximately 8,000 bp in length (e.g. 
HPV16 is 7,904 bp) and clinically important HPV typically encode 8 Open Reading Frames 
(ORFs). The terms ORF and gene are widely used interchangeably in the literature. There are 
six early genes, E1, E2, E4, E5, E6 and E7 that encode regulatory proteins and the two late 
genes L1 and L2 that encode structural capsid proteins (Figure 1.1). The early gene products 
include those involved with regulating viral DNA replication and are primarily transcribed from 
the early promoter (e.g. P97 for HPV16) whilst the late genes are transcribed from the late 
promoter (e.g. P670 in HPV16) (Abdul et al., 2009, Zheng and Baker, 2006). Early promoter 
activity and the regulation of replication is governed by interactions with the approximately 1 
kbp non-coding Long Control Region (LCR) that contains the viral origin of replication and a 
multitude of transcription factor binding sites and DNA regulatory elements (Chiang et al., 
1992, Demeret et al., 1997, Dollard et al., 1993, Dong et al., 1994, Tan et al., 1994, Berg and 
Stenlund, 1997). 
HPV virions are comprised of a DNA genome encapsulated in an icosahedral capsid 
approximately 55 nm in diameter (Scheurer et al., 2005). Capsids are constructed from 72 
capsomers and each capsomer is a pentamer of the HPV L1 protein. The HPV L2 minor capsid 
protein occurs at a frequency of about 12 proteins per capsid (Modis et al., 2002). 
 
 
Figure 1.1: Linear representation of the HPV16 genome.  
Adapted from (NCBI, 1993), (GenBank ID NC001526.1). Orange arrow labelled ori represents the origin 
of replication, green arrows represent early ORFs and blue arrows represent late capsid ORFs, the 
direction of the arrow indicates the direction of transcription. The Long Control Region (LCR) is a non-
coding region that contains binding sites for viral and cellular regulatory proteins and includes the 
viral origin of replication. 
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1.1.2.2. The HPV Life Cycle in a Productive Infection 
1.1.2.2.1. Infection 
Recently, a new model of infection initiation has been proposed. Infection with HPV requires 
micro-abrasion of the epithelium which exposes the basement membrane to HPV virions. HPV 
L1 proteins bind structures on the epithelial basement membrane which induces 
conformational changes that expose L2. L2 is cleaved and previously concealed parts of the L1 
protein are exposed to cell surface receptors on keratinocytes that have migrated across the 
basement membrane as part of the wound healing process (Schiller et al., 2010, Kines et al., 
2009). 
Following attachment to keratinocytes, the HPV virions enter the cell via an endocytic pathway 
and are localised within an endosome where the virus eventually uncoats. An L2 dependent 
mechanism promotes escape from the endosome; L2 bound HPV DNA moves through the 
cytoplasm and enters the nucleus. In the nucleus the L2-DNA complex associates with sub-
nuclear domains and RNA transcription is initiated (Schiller et al., 2010). 
The HPV lifecycle from initial infection onwards is intrinsically associated with the 
differentiation programme of the keratinocyte that it infects. As such, the study of the HPV 
lifecycle in vitro is especially difficult and very few cell culture models exist that are not derived 
from transformed cancer lines. 
1.1.2.2.2. Genome Maintenance/Cell Proliferation 
The HPV16 early promoter (P97) governs the transcription of the early genes. Located at the 3’ 
end of the LCR, transcription from the P97 promoter is controlled by the binding of various 
cellular transcription factors and the E2 viral gene product (Kammer et al. 2000; Thain et al. 
1996). P97 activation by the binding of cellular transcription factors allows initial low level E2 
and E1 expression which direct host cell replication factors to the viral origin of replication, 
driving viral genome replication and the maintenance of infection (Kadaja et al., 2009, Steger 
and Corbach, 1997). Viral genome replication occurs and the HPV genome is maintained as low 
copy number episomes (50-100 copies per cell) using host DNA replication processes (Flores et 
al., 1999). In addition to providing an important contribution to viral replication and 
transcription, E2 plays a major role in ensuring long term episomal maintenance and 
establishment of a productive HPV infection. E2 is involved in the partitioning of episomal 
genomes during mitosis by anchoring viral genomes to mitotic spindles during cell division, 
thus ensuring efficient viral genome segregation into daughter cells (You et al., 2004, Van Tine 
et al., 2004a, Lehman and Botchan, 1998). 
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For DNA replication, HPV require the cellular polymerases and other cellular factors that are 
produced only in mitotically active cells. As infected keratinocytes begin differentiation, E6/E7 
activity is up-regulated (Middleton et al. 2003; Schwartz 1998). E7 targets pRb (retinoblastoma 
protein) family proteins for degradation, disrupting the association between pRb and the E2F 
family of transcription factors which results in the transactivation of certain cellular factors 
required for viral DNA replication (Dyson et al., 1989, Gage et al., 1990, Scheffner et al., 1991). 
E6 effectively targets p53 for proteasomal degradation, inhibiting cellular apoptosis that would 
otherwise result from E7 mediated cell cycle entry in the differentiated epithelial layers 
(Scheffner et al., 1991, Scheffner et al., 1990, Doorbar, 2006). Together, low level E6 and E7 
activity allow terminally differentiating cells to avoid differentiation and continue cycling. This 
both maintains the availability of S-phase cellular factors required for viral genome replication 
and increases the number of cells producing progeny HPV virions (Middleton et al., 2003, 
Ruesch and Laimins, 1997, Stanley et al., 2007, Münger and Howley, 2002).  
P97 is responsible for transcription of E2. Low E2 concentration positively regulates P97 
activity whilst high E2 concentration negatively regulates P97 activity, as such P97 activity is 
essentially self regulating (Steger and Corbach, 1997). Regulated P97 activity results in a 
relatively constant level of the other viral gene products. E1 and E2 contribute to the 
maintenance of a relatively stable level of genome replication during viral maintenance in 
undifferentiated cells.  
1.1.2.2.2.1. Origin Identification and Initiation of DNA Replication 
HPV E1 proteins are highly conserved and recognise AT rich sequences at the HPV origin of 
replication. E1 alone has a weak DNA affinity. E2 binding sequences are located adjacent to E1 
recognition sites and allow E2 to direct the origin specific recruitment of E1 proteins (Sedman 
and Stenlund, 1998). Once an E1-E2-DNA complex is formed, E2 can be displaced in an ATP-
dependent step and additional E1 molecules are added to form an active E1 hexamer. E2 
effectively directs the formation of a DNA specific E1 complex to the viral origin (Sanders and 
Stenlund, 1998).  
E1 proteins exhibit both ATPase and 3'-5' helicase activities, bind DNA polymerase α/primase 
and aid the recruitment of other cellular replication complexes to the viral origin of replication 
(Longworth and Laimins, 2004, Lin et al., 2002, Conger et al., 1999, Hughes and Romanos, 
1993). Helicase activity at the origin of replication allows the unwinding and separation of the 
two complementary strands of a supercoiled DNA double helix, exposing the base sequence to 
the relevant DNA replication machinery (Sedman and Stenlund, 1998). Purified E1 protein has 
been shown to elicit efficient DNA unwinding in vitro and requires topoisomerase I, single-
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stranded-DNA-binding protein, ATP and supercoiled DNA as a substrate (Lin et al., 2002, 
Conger et al., 1999). 
1.1.2.2.3. Genome Amplification 
Premature keratinocytes, including those infected with HPV, progress further into the 
suprabasal layers of the epithelial tissue. Upon detachment from the basement membrane, 
epithelial cells begin to terminally differentiate and exit the cell cycle (Madison, 2003, Stanley 
et al., 2007). In more terminally differentiated cells, activation of the E2 independent late 
promoter (P670 in HPV16) results in increased levels of the proteins involved in DNA 
replication (E1, E2, E4 and E5) (Spink and Laimins, 2005, Grassmann et al., 1996, Klumpp and 
Laimins, 1999). The HPV early and late promoters are not exclusively involved in early/late 
gene expression, each promoter can fulfil some functions of the other (Spink and Laimins, 
2005). As a result of increased early protein levels, vegetative viral DNA replication occurs and 
results in a viral copy number of at least 1,000 copies per cell (Flores and Lambert, 1997).  
1.1.2.2.4. Viral Encapsidation and Release 
Whilst L1/L2 pre-mRNA can be detected in less terminally differentiated cells, L1 and L2 
protein is only detectable in highly differentiated cells (Stoler et al., 1989). A variety of post-
transcriptional regulatory mechanisms are implicated in the apparent lack of translation of the 
late mRNAs.  
L1 and L2 proteins accumulate following genome amplification. Viral assembly is the result of 
the coordinated associations between viral DNA, L1, L2 and E2 proteins and human proteins 
(Doorbar, 2006). HPV cannot lyse infected cells. Instead, HPV utilises desquamation of 
epithelial cells to facilitate the spread of infective virions (Woodman et al., 2007, Flores et al., 
1999). HPV E4 protein may be involved in final release of HPV virions through involvement in 
processes which result in destabilisation of cellular keratin networks and disruption of the 
cornified envelope (Doorbar et al., 1991, Bryan and Brown, 2000).  
 
1.1.3. HPV Genome and Gene Products 
1.1.3.1. The Long Control Region 
The LCR of HPV varies between types, however most HPV LCRs contain binding sites for the 
same subset of factors, the most significant of which appear to be YY1, CDP, Ap1, Sp1 and TBP 
(Spink and Laimins, 2005, O'Connor et al., 2000, Ai et al., 2000). For the promoter region, YY1 
and CDP binding is associated with repression of P97. The expression of YY1 and CDP decreases 
upon differentiation alleviating these repressive effects (O'Connor et al., 1996, O'Connor et al., 
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2000). The viral enhancer contains several Ap1 binding sites. Ap1 expression and abundance 
varies with cellular differentiation and binding of the viral enhancer is altered as a result 
(Thierry et al., 1992, Sen et al., 2004). 
Specific cell factors bind the HPV LCR and are responsible for the tissue specific tropisms 
exhibited by HPV (Apt et al., 1993). Four palindromic E2BSs (E2 binding site; consensus 
sequence, 5’-ACCN6GGT-3’) upstream of the promoter are bound by E2, regulating P97 activity 
(Howley and Lowy, 2006). Three of the four HPV E2BSs; E2BS2, E2BS3 and E2BS4 are involved in 
HPV16 P97 repression (Figure 1.2). E2 functions as a transcriptional repressor of P97 by 
competing with cellular transcription factors for binding sites (Romanczuk et al., 1990). E2 
bound to E2BS4 for example prevents the binding to an adjacent TATA box by the TFIID 
complex (binding mediated by the TBP (TATA box binding protein) subunit) (Dostatni et al., 
1991) and may affect the stability of the preinitiation complex once TBP binding has occurred 
(Hou et al., 2000). P97 activation is functionally dependent on Sp1 binding. The Sp1 binding site 
is separated by only a single nucleotide from E2BS3 (Gloss and Bernard, 1990). E2 binding at 
E2BS3 can displace Sp1 and any associated TBP from the adjacent Sp1 binding site (Tan et al., 
1994, Emili et al., 1994). E2 binding at E2BS1 increases early gene expression (Steger and 
Corbach, 1997, Dong et al., 1994) by stimulating YY1 function at the adjacent YY1 binding site 
(Tan et al., 2003). 
 
 
Figure 1.2: Diagram of the HPV16 LCR including binding positions of several HPV and human cellular 
factors.  
Adapted from (Snellenberg et al., 2012). There are four E2BSs within the HPV16. Binding sites for 
Specificity factor 1 (Sp1), Ying Yang 1 (YY1), Transcription Factor I (TFI), Nuclear Factor (NFI) Activator 
Protein 1 (AP1), Transcription Factor IID (TFIID) are shown. 
 
E2BSs also function in genome replication with E2BS2 playing a major role in terms of E1 origin 
recruitment (Badal et al., 2003, Tan et al., 1994). The affinity of E2 for the repressive E2BS is 
7 
 
much lower than the affinity of E2 for the transcriptional activator E2BS1. E2 has high affinity 
for E2BS1, E2BS1 is located several hundred bp upstream of the promoter and E2 binding to 
E2BS1 increases promoter activity (Demeret et al., 1998). Thus, low concentrations of E2 will 
stimulate E6 and E7 transcription whereas high concentrations of E2 repress transcription 
(Steger and Corbach, 1997, Badal et al., 2003). 
Histone Deacetylase (HDAC) activity at the HPV genome results in histone deacetylation and 
specific positioning of two nucleosomes over the viral enhancer and promoter that can inhibit 
promoter function (O'Connor et al., 2000, Stunkel and Bernard, 1999). A series of nuclear 
matrix attachment regions are also present in the HPV16 LCR which are thought to be 
responsible for altering the topology of the DNA and HPV gene expression in association with 
HPV integration (Stunkel et al., 2000). Methylation of cytosine residues has also been shown to 
repress viral and cellular gene expression as methylated DNA can result in the displacement of 
transcription factors and the alteration of chromatin configuration via the focusing of HDAC 
activity (Kalantari et al., 2004). 
In summary, the LCR is responsible for regulating HPV early gene expression and is affected by 
a multitude of factors, both HPV and human in origin. 
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1.1.3.2. Post-Transcriptional Regulation of HPV Gene Expression 
HPV transcripts originating from P97 are polycistronic and typically contain three exons and 
two introns. Variable splicing of transcripts leads to early mRNA transcripts with a range of 
coding potential (Figure 1.3) (Zheng and Baker, 2006). Papillomaviruses further utilise 
inefficient splice signals to differentially express early viral proteins throughout the HPV 
lifecycle (Zheng and Baker, 2006). 
 
 
Figure 1.3: Early splice variants originating from the P97 promoter. 
Adapted from (Zheng and Baker, 2006). A variety of potential splice variants exist; thin lines indicate 
regions spliced out, the coding potential of each spliced transcript is indicated on the right. 
 
As well as splice variants, translational inefficiency also appears to affect HPV gene expression. 
HPV transcripts are polycistronic, translation of downstream ORFs requires ribosomes to 
bypass upstream ORFs in order to translate downstream ORFs (Zheng and Baker, 2006). 
Several potential mechanisms have been proposed including translation reinitiation, leaky 
ribosome scanning and ribosome shunting across the transcripts (Remm et al., 1999, Sen et al., 
2004, Stacey et al., 2000, Zheng et al., 2004). The two most likely mechanisms appear to be 
leaky ribosomal scanning and translation reinitiation (Zheng et al., 2004, Remm et al., 1999, 
Longworth and Laimins, 2004). Leaky ribosome scanning means start codons towards the 5’ 
end of an mRNA are skipped and initiation of translation occurs via ribosomal binding at 
downstream start codons (Longworth and Laimins 2004; Remm et al. 1999). By this complex 
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mechanism, transcriptional regulation depends upon the position of an ORF on the 
polycistronic mRNA, with 5’ cistrons being translated with greater efficiency than 3’ cistrons. 
The HPV early promoter produces a transcript in the order 5’- E6, E7, E1, E2, E4, E5 - 3’ which 
would explain the almost negligible amounts of E4 and E5 protein produced (Remm et al., 
1999). As a consequence of differentiated cell optimised codon usage, late promoter activation 
and alternative splicing of late mRNAs, transcription and translation of the late gene products 
(L1 and L2) occurs (Zhou et al., 1995, Zhou et al., 1999, McPhillips et al., 2004, Stoler et al., 
1989). Various additional post-transcriptional regulatory mechanisms have also been 
proposed. A negative regulatory element in the 3’ regions of the HPV16 late (L1 and L2 
containing) mRNA transcripts negatively influences late gene expression, reduces the stability 
of mRNA species and binds cellular proteins (Howley and Lowy, 2006, Koffa et al., 2000). As an 
infected host cell undergoes cellular differentiation, the range and distribution of cellular 
factors fluctuates which may remove post-transcriptional repression of HPV late mRNAs 
permitting their translation (Koffa et al., 2000, Howley and Lowy, 2006). 
1.1.3.3. Viral Gene Products 
Each of the HPV gene products have additional functions that were not previously discussed 
but are pertinent to the role of HPV in HPV-associated carcinogenesis and require further 
consideration. 
1.1.3.3.1.  E1 and E2 
E1 proteins are comprised of three regions: an N-terminal region, a variable length spacer 
region and a large, highly conserved C-terminal region that has homology to characterised 
ATPases and helicases (Wilson et al., 2002). E1 displaces the H1 histone protein, suggesting 
that E1 can promote the initiation of replication and elongation by altering the viral chromatin 
structure and disrupting nucleosomes at the replication fork (Sedman and Stenlund, 1998). 
E2 protein function can be isolated to specific regions within the protein; for instance the C-
terminus DNA binding domain is a dimeric ß-barrel structure that bends DNA and interacts 
with E1, whilst the N-terminus contains a transactivation domain (Hegde et al., 1992, Chen and 
Stenlund, 2000). The E2 ORF can give rise to multiple E2 gene products e.g. the E2TA full length 
protein and the truncated E2TR polypeptides, Bovine Papillomavirus (BPV) studies also find an 
additional array of E8^E2TR polypeptides (Lambert et al., 1990, Kim et al., 2003). Truncated E2 
forms appear to repress full length E2 activity via competitive exclusion at E2BS or the 
formation of inactive heterodimers (Lambert et al., 1990). E2 is occasionally described as 
having a proapoptotic effect on the infected host cell. E2 expressing cells effectively repress E6 
and E7 expression, thus p53 is stabilised, p21 is activated and the cell cycle arrests at G1 
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(Blachon and Demeret, 2003). The repression of E6 and E7 by E2 also appears to be largely 
responsible for the cellular senescence exhibited by these arrested cells (Goodwin et al., 2000). 
In addition, several HrHPV E2 proteins when expressed ectopically induce a cell death with the 
characteristic features of apoptosis, independent of E2 DNA binding and functional 
transcriptional regulation of the oncogenes (Blachon and Demeret, 2003). The introduction of 
in vitro truncated E2 proteins efficiently induced apoptosis in HeLa cells (Blachon and Demeret, 
2003). 
1.1.3.3.2. E4 and E5 
In comparison to the other HPV encoded proteins, the roles of E4 and E5 are less well defined. 
HPV E5 is a small hydrophobic transmembrane protein primarily associated with the 
endoplasmic reticulum and the Golgi apparatus (Conrad et al., 1993). E5 overexpression for 
some, but not all, HPV inhibits the degradation of and increases the phosphorylation of 
Epidermal Growth Factor (EGF) receptors (Straight et al., 1993, Fehrmann et al., 2003). E5 
forms a complex with EGF receptors (Hwang et al., 1995) and binds cellular proteins in order to 
delay endosomal acidification (Genther et al., 2003, Conrad et al., 1993, Straight et al., 1995). 
This might indirectly influence the recycling of cell surface growth factor receptors, such that 
there is an increase in EGF-mediated receptor signalling. As a consequence of increased 
sensitivity to EGF, a replication competent environment is maintained in the otherwise 
differentiated layers of the epithelia, permitting genome amplification (Doorbar, 2006). HPV E5 
appears to have a minor role in genome amplification in the productive stages of a HPV 
infection. E5 mutants show fewer supraparabasal cells undergoing DNA synthesis in 
comparison to differentiation competent cell lines with wild type E5 (Genther et al., 2003). In 
terms of carcinogenesis, several roles of E5 could be relevant to early carcinogenesis by 
modulation of integrant selection, viral persistence, evasion of the host immune system and 
insensitivity to homeostatic growth control signals from neighbouring cells (Venuti et al., 2011) 
E4 is produced from a spliced mRNA transcript as an E1^E4 fusion protein, i.e. formed from the 
N-terminus of the E1 ORF product (first 5 amino acids) and most of the E4 ORF product 
(Longworth and Laimins, 2004, Roberts et al., 2008b). Transfection of keratinocytes with 
HPV16 genomes containing mutant E4, produces transformed cells that are incapable of 
completing viral amplification (Nakahara et al., 2005). The exact role of E4 in regulation of viral 
amplification is poorly defined, however due to the organisation of the HPV late polycistronic 
mRNA; late gene expression and thus productive virus replication coincides with a large 
increase in HPV E4 protein (Longworth and Laimins, 2004, Roberts et al., 2008b). 
Overexpressed HrHPV E1^E4 in cell lines can associate with cellular keratin networks, inducing 
their collapse (Doorbar et al., 1991), may interfere with cornified envelope formation (Bryan 
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and Brown, 2000) and may incite cellular apoptosis in differentiated cells via alteration of 
mitochondrial function (Raj et al., 2004); thus suggesting a role of E4 in viral egress (i.e. escape 
from desquamated keratinocytes) (Longworth and Laimins, 2004). It has also been 
hypothesised that the inhibition of cell cycle progression and DNA synthesis by coexpressed 
truncated E4 proteins serves to inhibit competing host DNA synthesis and favour viral genome 
amplification (Roberts et al., 2008b). 
1.1.3.3.3. E6 and E7 
HrHPV E6 and E7 oncoproteins (so named due to their implication in HPV induced 
carcinogenesis) can effectively transform cells upon transfection to form a hyperproliferative, 
immortal cell line. Both E6 and E7 are required to effectively transform cells (Hawley-Nelson et 
al., 1989, Giarre et al., 2001).  
Many of the cellular factors required by HPV for DNA synthesis are transcriptionally regulated 
through an E2F-dependent mechanism. In turn, the E2F family of transcription factors are 
regulated by pocket proteins such as pRb (retinoblastoma protein) whose regulation is 
determined by cyclical phosphorylation and dephosphorylation. E2F responsive genes 
(encoding e.g. DNA polymerase alpha, dihydrofolate reductase, thymidine kinase etc) are 
important for the progression through S-phase (Münger and Howley, 2002, Howley and Lowy, 
2006). 
Some of the key components of the following events are presented in Figure 1.4. 
Hypophosphorylated pRb (as found in G1 of the cell cycle) complexes with E2F in order to 
repress its activity as a transcription factor. Conversely, hyperphosphorylated pRb does not 
interact with E2F and E2F is free to transcriptionally activate the E2F responsive genes (Howley 
and Lowy 2006; Münger and Howley 2002; Pan and Griep 1994). Late in M-phase, 
hyperphosphorylated pRb is dephosphorylated and the E2F-pRb inactive transcription factor 
complex is reformed (Münger and Howley, 2002). An interesting and important role for HrHPV 
E7 is the proteolytic degradation of the retinoblastoma proteins pRb and related pRb family 
proteins p107 and p130 (Duensing and Münger, 2004).  
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Figure 1.4: E2F regulation in normal and HPV infected epithelium.  
E2F if negatively regulated by bound pRb. Phosphorylated pRb does not bind E2F and E2F are free to 
enhance the transcription of S-phase gene products. p16 represents a negative feedback loop and one 
consequence of E2F deregulation is enhanced p53 level. In HPV infected epithelia, deregulation of E2F 
is caused by E7 binding pRb whilst enhanced p53 level is counteracted by E6 mediated degradation of 
p53 protein. 
 
The E7 proteins of HrHPV types but not LrHPV types have a high affinity for pRb and target pRb 
for proteolytic degradation (Boyer et al., 1996, Gage et al., 1990). Proteasomal degradation of 
pRb prevents downregulation of E2F dependent genes, independent of cyclin dependent 
kinase activity. This results in increased expression of cyclin E and cyclin A and aberrant Cyclin 
dependent kinase 2 (Cdk2) activity (Duensing and Münger, 2004). Aberrant Cdk2 activity 
induces cellular transformation and the transcription of the G1/S-phase enzymes required for 
DNA replication in terminally differentiated cells (Münger and Howley, 2002, Doorbar, 2006). 
E7 expression is thus responsible for expression of DNA synthesis genes required for a 
productive HPV infection (Flores et al., 2000). 
The majority of cervical carcinomas exhibit increased levels of p16INK4a mRNA and protein as a 
result of E7 expression and E2F activation (Ivanova et al., 2007). p16INK4a acts as a repressor of 
cell cycle progression by inhibiting the phosphorylation of pRb. Most cervical carcinomas 
exhibit p16INK44a overexpression, to the degree that the detection of overexpressed p16INK4a has 
been widely proposed and tested as a potential biomarker of cervical disease (Ivanova et al., 
2007, Wentzensen et al., 2005, Lesnikova et al., 2009). 
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p21 is normally induced during keratinocyte differentiation. p21 reduces the activity of 
cyclin/Cdk2 complexes, negatively regulates cell cycle progression and can also bind to 
proliferating cell nuclear antigen. p21 may thus effectively block DNA synthesis in 
differentiated keratinocytes (Gartel and Radhakrishnan, 2005). A range of factors influence 
p21 cellular protein levels, most notably the activity of p53 tumour suppressor protein which is 
a major determinant of p21 transcription level. Downregulation of p53 activity results in 
reduced p21 activity (Gartel and Radhakrishnan, 2005). The induction of E2F by E7 mediated 
pRb deregulation may inadvertently stabilise p53 by compromising the action of mdm2 
(Münger and Howley, 2002). Thus the result of E7 activity is increased p53 protein which could 
result in an apoptotic response (Ruesch and Laimins, 1997).  
HrHPV E6 complexes with the cellular HECT domain E3 ubiquitin ligase E6-AP (E6 associated 
protein) to target p53 for ubiquitinylation. Ubiquitinylation of p53 leads to proteasomal 
degradation (Huibregtse et al. 1993; Snijders et al. 2006). The proteasomal degradation of p53, 
and inhibition of p21 by HrHPV E7 results in a decreased intracellular pool of active p53 and 
p21 (Gartel and Radhakrishnan, 2005, Münger and Howley, 2002). This significantly reduces 
the integrity of the G2 cell cycle checkpoint in response to DNA damage (Bunz et al., 1998) and 
the ability of p21 to orchestrate p53 mediated cell cycle arrest at the G1/S checkpoint 
(Waldman et al., 1995). The effect of HrHPV E6 and E7 activity on cell cycle controls effectively 
maintains a replication permissive background as required for genome amplification, late gene 
expression and the avoidance of apoptosis (Münger and Howley, 2002, Ruesch and Laimins, 
1997). 
The catalytic subunit of human Telomerase Reverse Transcriptase (hTERT) is expressed in cells 
such as stem cells that do not undergo replicative senescence. hTERT is a ribonucleoprotein 
polymerase and prevents telomere shortening with multiple cell divisions by the addition of 
the telomere repeat TTAGGG (NCBI, 2009). Somatic cells typically repress hTERT expression 
but hTERT activation is a common observation in cancerous cells (Cheng et al., 2008) and is 
required for cellular immortalization by HPV (Kiyono et al., 1998). HPV E6 indirectly promotes 
the activation of hTERT expression; hTERT is transcriptionally activated by the binding of c-Myc 
and Sp1 transcription factors to the hTERT promoter (Oh et al., 2001). p53 both represses MYC 
(the c-Myc gene) transcription and binds Sp1 thus preventing its access to the hTERT promoter; 
degradation of p53 by E6 activity effectively circumvents hTERT repression (Xu et al. 2000). E6 
also directly activates hTERT expression, the hTERT promoter repressor NFX1-91 is also 
targeted by E6 for proteasomal degradation and the ability of c-Myc to activate the hTERT 
promoter is increased in the presence of E6 (Xu et al., 2008, Liu et al., 2009, Veldman et al., 
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2003). Further, E6 associates with telomeric DNA and physically interacts with hTERT protein 
enhancing telomerase activity (Liu et al., 2009). Enhanced hTERT activity enables cancer cells 
to resist cellular senescence and undergo successive rounds of replication (Yugawa and Kiyono, 
2009). 
 
1.2. HPV and Cancer 
The causal link between HPV and cervical cancer was first postulated by Harald zur Hausen in 
the 1970s (zur Hausen et al., 1974, zur Hausen, 1976, zur Hausen, 1977). Since then, HPV DNA 
has been consistently identified in over 99% of cervical cancers and up to 94% of women with 
Cervical Intraepithelial Neoplasia (CIN) and the association between HPV and cancer is now 
firmly established (Scheurer et al., 2005).  
HPV are typically found in around 10% of normal cervical cytology samples, although the 
incidence of HPV infection varies with geographical location and some studies have identified 
HPV in up to 46% of the cytologically normal women studied (de Sanjose et al., 2007). Most 
(over 80%) of infections in the cervix with high risk HPV types (HrHPV) are likely to be 
transient, without resulting in CIN (Meijer et al., 2000).  
In 2008, the global incidence of cervical cancer in women was an estimated 529,000 cases, 
leading to 274,000 deaths. More than 85% of cervical cancer deaths occurred in developing 
countries where it is frequently the commonest cancer to affect women, accounting for 13% of 
all female cancers (W.H.O., 2010). Developing countries lack the resources and infrastructure 
to facilitate effective screening and prevention strategies, as well as lacking medical facilities 
for treatment. HPV is also linked to a large percentage of carcinomas and intraepithelial 
neoplasias of the vulva, vagina, anus, penis, and head and neck (Table 1.1) (Stanley, 2007). The 
majority of these cases also occur in developing countries. 
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Developed countries Developing countries 
Site 
Attributable 
to HPV (%) 
Total 
cancers 
Attributable 
to HPV 
Total 
cancers 
Attributable 
to HPV 
Cervix 100 83,400 83,400 409,400 409,400 
Penis 40 5,200 2,100 21,100 8,400 
Vulva, vagina 40 18,300 7,300 21,700 8,700 
Anus 90 14,500 13,100 15,900 14,300 
Mouth 3 91,200 2,700 183,100 5,500 
Oropharynx 12 24,400 2,900 27,700 3,300 
Other 0 4,779,100 0 5,148,600 0 
Total at all Sites   5,016,100 111,500 5,827,500 449,600 
Table 1.1: The incidence of a range of malignancies and the number of which are attributable to an 
infection with HPV.  
Adapted from (Stanley, 2007).The data is divided between occurrence in economically developed and 
developing countries. 
 
1.2.1. Risk Factors 
Several factors such as promiscuity, unprotected sexual encounters, early age of first sexual 
contact and relationships with high risk partners are more likely to result in infection with HPV 
(Braaten and Laufer, 2008, de Sanjose et al., 2007). Most cervical cancers arise at the 
squamocolumnar junction between the columnar epithelium of the endocervix and the 
squamous epithelium of the ectocervix (also known as the transformation zone) (Doorbar, 
2006). The transformation zone is a site of continuous metaplastic change where squamous 
epithelium is replaced with glandular columnar epithelium and vice versa, the greatest risk of 
infection correlates to periods of high metaplastic activity (Burd, 2003). Metaplastic changes of 
the cervix are at their greatest level at puberty and first pregnancy and the level declines after 
menopause. Age is an important determinant of risk of HPV infection and HPV-associated 
disease. HPV infection is most common in young, sexually active women between 18 and 30 
years of age, however cervical cancer is most common in women older than 35 years of age, 
indicating that persistent infection is associated with HPV mediated cervical carcinogenesis 
(Burd, 2003, Ho et al., 1995). A multitude of other factors such as race, low socioeconomic 
status, gender, tobacco use, oral contraceptive use and even a genetic determinant increase 
the risk that a given HPV infection will develop into a neoplasia (Braaten and Laufer, 2008, 
Frazer, 2009, de Sanjose et al., 2007). 
The host immune response is vital for protection against an HPV infection. Immunodeficient 
hosts show increased persistence and neoplastic progression of HPV-induced intraepithelial 
lesions in several instances (O'Brien and Saveria Campo, 2002). HIV mediated 
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immunosuppression for instance is associated with an increased risk of developing HSIL and 
carcinoma. Prior to the HIV epidemic, the incidence of anal cancer was estimated at 36.9 per 
100,000 among high risk groups. This incidence is similar to the incidence of cervical cancer 
prior to the widespread adoption of cervical cancer screening programmes (Arain et al., 2005). 
Since the beginning of the HIV epidemic, the incidence of anal Squamous Cell Carcinoma (SCC) 
and Anal Intraepithelial Neoplasia (AIN) have dramatically increased among homosexual males 
and anal SCC incidence in HIV positive populations is typically twice that of HIV negative 
populations (Arain et al., 2005). 
 
1.2.2. Detection of Cervical Intraepithelial Neoplasia 
The Papanicolaou (Pap) stain is a staining procedure that permits cervical epithelial cells to be 
cytologically examined for dysplastic changes, an indicator of the pre-malignant condition 
intraepithelial neoplasia. CIN can then be treated, thus preventing the development of cervical 
cancer. Cervical screening is widely regarded as the most successful cancer screening program 
in the world and has been attributed to reducing cervical cancer deaths by 50-75% (Nephew, 
2009, Etzioni et al., 2003, Kurman Rj and et al., 1994). Liquid Based Cytology (LBC) reduced the 
rate of inadequate samples and replaced the traditional Pap in England from 2003 (Albrow et 
al., 2012). Cervical SCCs are the most common histological type of cervical cancer. The classical 
model of HPV induced cervical carcinogenesis is that cervical carcinoma develops from CIN of 
increasing severity over the course of many years. However, some CIN2/3 lesions are thought 
to develop rapidly after initial HPV infection i.e. within three years (Sherman and Kelly, 1992). 
CIN is classified histologically based upon the degree of atypia and abnormality of squamous 
maturation of the epithelial cells layers (Snijders et al., 2006). 
Worldwide, cervical cytology results are reported using a variety of classifications. In the UK, 
cytology results are reported according to British Society for Clinical Cytology (BSCC) guidelines 
based on the presence and severity of dysplastic cell changes, ranging from normal, to 
borderline changes, mild dyskaryosis, moderate dyskaryosis and severe dyskaryosis (Figure 
1.5). Mild, moderate and severe dyskaryosis loosely correlate with CIN1, CIN2 and CIN3 on 
histological examination respectively (Snijders et al., 2006). 
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Figure 1.5: UK cervical cytological screening results in ascending order of severity.  
Adapted from (NHS Cervical Screening Programme, 2012). 
 
Whilst cytological examination determines the morphology of individual cells, biopsy of 
epithelial tissue allows the progression of atypical cells from basal epithelial layers to 
suprabasal differentiated epithelial layers to be detected and quantified by histological 
examination. The extent of atypical cells through the epithelium forms the basis for CIN 
grading; CIN1 indicates mild dysplasia (atypia of the lower third of the epithelium), CIN2 
indicates moderate dysplasia (atypia of up to the lower two thirds of the epithelium) and CIN3 
represents severe dysplasia (atypia of over two thirds of the epithelium) which is sometimes 
called carcinoma in situ (Figure 1.6). Other nomenclature includes Low grade Squamous 
Intraepithelial Lesion (LSIL) and High grade Squamous Intraepithelial Lesion (HSIL) which 
correspond to CIN1 and CIN2/3 respectively (Snijders et al., 2006).  
 
Figure 1.6: Schematic presentation of the classification of morphological alterations seen in cervical 
lesions.  
Adapted from (Snijders et al., 2006). 
 
Whilst cytological screening has been successful, a non-subjective molecular approach that 
includes HPV typing has been shown more sensitive for CIN2+, whilst allowing the study of HPV 
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epidemiology. A molecular based approach may also facilitate risk assessment for a given HPV 
infection. HPV based cervical screening would also be useful in assessing the effect of the 
prophylactic HPV vaccination programme (Hibbitts et al., 2008). 
 
1.2.3. Other Anogenital Neoplasias 
1.2.3.1. Genital Warts 
Various LrHPV types are also the causative agent of warts, including genital warts. Genital 
warts are primarily caused by HPV6 and HPV11 and are relatively common. In 2011, there 
were 76,071 cases of genital warts in England alone (Health Protection Agency, 2012, Lacey et 
al., 2006). 
1.2.3.2. Vulval Intraepithelial Neoplasia 
Several components of this investigation relied on the use of material from Vulval 
Intraepithelial Neoplasia (VIN) lesions. In the UK, VIN is typically graded histologically using a 
scale similar to that used for CIN (Figure 1.6). An additional means of VIN classification has 
been proposed to reflect the potential difference in aetiology between two types of VIN (usual 
and differentiated) and the inconsistent definition of VIN1 as a precursor of vulval cancer 
(Sideri et al., 2005) however it is not universally used in the UK.  
HPV-associated VIN is known as usual VIN (van de Nieuwenhof et al., 2008). Many (50-80%) 
vulval SCCs are not HPV-associated (JCNI, 2010, van de Nieuwenhof et al., 2009) and arise via a 
different route and premalignant phase to HPV-associated vulval SCC (van de Nieuwenhof et 
al., 2011, van de Nieuwenhof et al., 2008). Lichen sclerosus (LS) is a chronic inflammatory skin 
condition that affects both male and female patients, it is most common in the anogenital 
region of post-menopausal women (Tasker and Wojnarowska, 2003). LS is not typically 
associated with HPV infection (van de Nieuwenhof et al., 2008) and LS patients are on average, 
older than HPV-associated VIN patients (Bonvicini et al., 2005). A multitude of factors have 
been implicated in the aetiology of LS including several infectious agents, genetic 
predisposition, oestrogen level, vulval irritation and autoimmune disorders (van de 
Nieuwenhof et al., 2008). LS is associated with progression to SCC and progression is observed 
in 2-6% of cases. For most vulval SCC patients, LS can also be found in adjacent areas (Kagie et 
al., 1997, Leibowitch et al., 1990, Carli et al., 1995).  
Differentiated VIN is a rare diagnosis and its existence is disputed (McCluggage, 2009). When 
diagnosed, differentiated VIN usually occurs in a background of LS and whilst its aetiology is 
uncertain, it is not associated with HPV (Bonvicini et al., 2005). 
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1.2.4. HPV, the Immune System and the HPV Vaccine 
Both the innate and adaptive immune effector mechanisms are influenced by triggering of the 
innate immune mechanisms; dsRNA, ssDNA and foreign antigens either free or displayed by 
host cells are capable of initiating an immune response. The life cycle and gene expression of 
HPV however occurs within differentiating epithelial cells, there is no viraemic stage, no 
cellular lysis and virions are released by the desquamation of keratinised epithelial cells 
(Stanley, 2006b, Frazer, 2009). The immune system thus has limited opportunity to detect HPV 
infection and relies on the identification of cells displaying stress signals due to E6 and E7 
mediated cell cycle deregulation (Frazer, 2009). Hence the ability of the host to detect and 
subsequently clear an HPV infection is severely limited and HPV infections can be chronic and 
difficult to clear (Stanley, 2006b). Chronic HPV infection is associated with CIN and cancer (Ho 
et al., 1995, Stanley et al., 2007). 
In August 2008 the UK initiated a nationwide prophylactic vaccination programme for 
adolescent females, utilising the bivalent vaccine “Cervarix” manufactured by GlaxoSmithKline 
UK which provides protection against HPV16 and HPV18 induced anogenital neoplasia. The 
vaccine utilises Virus Like Particles (VLPs). In vitro L1 proteins spontaneously self assemble to 
form VLPs which are structurally very similar to HPV capsids (Hagensee et al., 1994). Several 
types of VLP can be constructed; L1 and L2 chimeric VLPs, L1 external chimera VLPs and L1 
internal chimera VLPs. L1 external chimeras (as used in Cervarix) and L1 and L2 mixed chimeras 
are structurally very similar. Internal chimeras of L1 are an interesting prospect as they could 
allow the incorporation and expression of polypeptides of other viral and cellular proteins into 
the VLPs, the polypeptides could be for instance HPV early gene products or even the gene 
products of another virus (Schiller and Lowy, 2000). L1 external chimeras induce a good 
humoral immune response, produce significant quantities of serum antibody and thus 
effectively confer some degree of resistance against HPV infection (Breitburd et al., 1995, Kahn 
and Burk, 2007). Cervarix contains equal quantities of L1 protein from HPV16 and HPV18, is 
administered in three stages over the course of six months (GlaxoSmithKline, 2008) and 
functions with a high efficacy against the target HPV types. The HPV18 L1 component also 
appears to offer some protection against HPV45 (Kahn and Burk, 2007). A quadrivalent vaccine 
manufactured by Merck (“Gardasil”) contains VLPs for HPV16, 18, 6 and 11 thereby conferring 
protection against HPV16 and 18 anogenital neoplasia and in addition, protection against 
LrHPV types 6 and 11 which are responsible for over 90% of genital warts (CDC, 2011). 
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1.2.5. Carcinogenesis 
In high grade cervical lesions, viral genome amplification and E6 and E7 oncogene expression 
occur closer to the epithelial surface than in low grade cervical lesions and expression of the 
late proteins is retarded (Middleton et al., 2003). The malignant transformation of a host cell is 
an accidental event that is atypical of the normal viral lifecycle, and is associated with 
persistent HPV infection (Ho et al., 1995). Malignant cells are incapable of viral amplification 
and late gene expression such that no new virions can be produced and the productive life 
cycle terminates (Münger and Howley, 2002). Several factors may stimulate oncogene 
deregulation, including viral integration and the mutation/deletion of transcriptional 
repressors (Badal et al., 2003). Deregulated and aberrant E6 and E7 expression in high grade 
disease results in the disruption of the usual cell cycle control mechanisms via the interaction 
of HPV proteins with a range of host factors including p53 and pRb. Essentially, p53 mediated 
DNA damage cell cycle controls cannot be enforced, cells resist apoptosis and the 
accumulation of mutations may go unchecked (Doorbar, 2006).  
Genomic instability is an early event in HPV induced carcinogenesis (zur Hausen, 1991) and 
results in alterations of chromosome number and localised structural anomalies (Duensing and 
Munger 2002; Heselmeyer et al. 1996). In the context of HPV induced cancers, some viral 
lifecycle and molecular events affect genomic stability which may lead to carcinogenesis. For 
example, E6 and E7 mediated degradation of p53 and pRb results in reduced ability to arrest in 
response to DNA damage (Thorland et al., 2003). 
Activity of the HPV E1 and E2 proteins from integrated HPV is associated with deletion of host 
DNA proximal to the integration site, the presence of multiple HPV genomes in the host 
genome may also generate sources of homology for homology dependent recombination 
resulting in genomic instability (Kadaja et al., 2007). The HPV E7 mediated induction of 
centrosome duplication results in supernumerary spindle poles (Duensing et al., 2000). E6 
mediated p53 degradation effectively represses DNA damage controls and cell cycle 
checkpoint integrity, such that aneuploid cells and cells with major genomic changes are not 
detected and/or apoptosed (Duensing et al., 2000). The improper detection and response to 
DNA breakage due to the action of E6 and E7 may lead to structural aberrations of the host cell 
chromosomes such as anaphase bridges. Anaphase bridges may result in the development of 
chromosomal rearrangements; translocations, duplications and deletions (Yugawa and Kiyono, 
2009). HPV E6 both directly and indirectly activates hTERT expression, and physically interacts 
with the hTERT protein enhancing its telomerase activity expression (Veldman et al., 2003, Liu 
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et al., 2009). Enhanced hTERT activity enables cancer cells to resist cellular senescence and 
undergo successive rounds of replication (Yugawa and Kiyono, 2009).  
The accumulation of mutations, genomic rearrangements and deletions in cells with 
deregulated DNA maintenance mechanisms and a lack of cellular senescence signals promotes 
selection of cells that exhibit deregulated cell cycle controls and thus a growth advantage. HPV 
integration typically leads to the retention of the E6 and E7 genes (Thorland et al., 2003) but 
loss of E1, E2 and other downstream sequences leading to the lack of E2 trans-acting 
repression of the P97 promoter (Howley and Lowy, 2006, Cricca et al., 2009). HPV integration 
also appears to influence E6 and E7 protein levels through the stabilising effects on the 
polycistronic E6 and E7 mRNA as a result of fusion of the E6 and E7 ORFs to downstream 
cellular DNA (Howley and Lowy, 2006). Integrated HPV E6/E7 transcripts often include 3' 
cellular untranslated sequences and polyadenylation signals, increasing the stability of the 
transcript (Klaes et al., 1999). Increased E6/E7 mRNA stability results in elevated E6 and E7 
translation, and thus increased levels of E6 and E7 oncoproteins which are considered 
important factors in HPV induced carcinogenesis (Jeon and Lambert, 1995).  
 
1.2.6. Viral Integration 
1.2.6.1. Integration is Associated with Disease 
Cell cultures with integrated HPV16 demonstrate a selective growth advantage over cells 
harbouring episomal HPV16 (Jeon et al., 1995) and the majority of cervical cancers contain 
integrated forms of HPV (Choo et al., 1987). HPV integration is often considered an early event 
in HPV induced carcinogenesis and frequently results in the loss of E2 and/or E1 (Arias-Pulido 
et al., 2006). Loss of E2 trans-acting repression of the LCR may correspond to the deregulated 
expression of E6 and E7 (Jeon and Lambert, 1995, Thierry, 2009, Romanczuk and Howley, 
1992, Rosl et al., 1993). HPV integration initially occurs within a background of episomal HPV, 
and therefore functional E2 protein produced by episomal HPV. Loss of E2 expression via 
episomal clearance might therefore be necessary for integration induced transformation and is 
a feature of certain cell lines (Pett et al., 2006, Pett and Coleman, 2007). HPV integration can 
also affect human gene expression; integrants were found proximal to the MYC locus in several 
HPV containing tumour cell lines, and as a result MYC was overexpressed (Herrick et al., 2005, 
Peter et al., 2006). 
HPV16 and HPV18 are more commonly integrated in more severe cervical disease; in cervical 
cancers, rates of integration of up to 80% and 100% are observed for HPV16 and HPV18 
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respectively (Corden et al., 1999, Cullen et al., 1991, Pirami et al., 1997, Melsheimer et al., 
2004, Arias-Pulido et al., 2006). There also appears to be a correlation between integration 
status and risk of CIN progression (Arias-Pulido et al., 2006). Nonetheless, a proportion of 
HPV16 induced cervical carcinomas are purely episomal, indicating that HPV16 integration is 
only one of several factors associated with an increased risk of progression. 
1.2.6.2. Aetiology of HPV Integration 
There are two main types of HPV integrants described during integration studies; single 
insertions and concatemeric insertions. These terms represent events where HPV genomes 
have integrated as individual copies (possibly at multiple sites) and as repeated concatemers 
integrated into the host cell genome respectively (Jeon and Lambert, 1995, Jeon et al., 1995). 
HPV integration by non-homologous end joining between the viral and host genomes is 
thought to be a random event, however HPV integration occurs most frequently at or close to 
common fragile sites (CFSs) (Dall et al., 2008, Thorland et al., 2003, Matovina et al., 2009). 
Nonetheless, no consensus sequence has been observed, and integration at similar sites in 
different tumours occurs within disparate sequences (Pett and Coleman, 2007). CFSs are 
unstable, recombinogenic chromosomal loci of the genome and are preferential sites for sister 
chromatid exchange, translocations, deletions, intrachromosomal gene amplification and 
integration of plasmid and oncogenic virus DNA (Smith et al. 1998; Thorland et al. 2003).  
Linear HPV genome fragments produced by defective viral replication of episomal HPV or 
dsDNA breaks may serve as templates for HPV integration into the host genome via non-
homologous end joining (Mannik et al., 2002, Kadaja et al., 2007). Once integrated, HPV origins 
are still targeted for amplification by episomal E1 and E2 proteins and can result in replication 
of the integrated HPV sequences and human sequences adjacent to HPV to produce 
homologous linear DNA sequences (Kadaja et al., 2007). Further recombination of these linear 
fragments with the host genome could result in DNA rearrangement, deletion and/or further 
integration (Kadaja et al., 2007, Pett et al., 2004), i.e. characteristics of cancers (Klausner, 
2002, Duensing and Münger, 2004).  
Whilst integration is very common in cancers, many cervical cancers and many more 
precancerous cervical lesions do not contain integrated HPV. Integration could be a result of 
oncogene deregulation and associated genomic instability, rather than a cause of deregulation 
and transformation. As such, an alternative means of initial deregulation may exist 
(Vinokurova and von Knebel Doeberitz, 2011). Epigenetics represents a series of potential 
alternative transforming events for a HPV infection. 
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1.2.7. Integration Study Techniques 
Integration of HPV DNA into the host genome is a very common event in HPV induced 
malignancies and has been proposed as a potential molecular biomarker of an increased risk of 
progression to cancer (Pett and Coleman, 2007).  
 
1.2.7.1. APOT 
Amplification of Papillomavirus Oncogene Transcripts (APOT) is an assay that permits the 
differentiation of HPV mRNAs produced by transcriptionally active integrated and episomal 
HPV genomes (Klaes et al., 1999). The technique amplifies HPV-human fusion transcripts that 
can be sequenced to allow the identification of human sequences at the 3’ end of viral 
oncogene transcripts (Figure 1.7). 
 
Figure 1.7: The APOT procedure. 
1; mRNA transcripts are reverse transcribed with an oligo dT primer with an adapter to form cDNA. If 
the HPV is integrated then there is a chance that a HPV-human fusion transcript will be produced with 
human sequence on the 3’ end of the transcript. 2; a primary PCR is performed on the cDNA using a 
primer specific to HPV E7 and a primer specific to the adapter sequence. 3; A second round of PCR is 
required using another E7 specific HPV primer downstream of the first and a reverse primer that is 
specific to the oligo dT primer sequence. 4; the resulting PCR products are separated by 
electrophoresis, excised and sequenced. Integrated sequences will contain both papillomavirus and 
human sequences and sequencing will allow the identification of the location of the integration 
events (Klaes et al., 1999). 
 
 
24 
 
1.2.7.2. RS-PCR 
Restriction site PCR (RS-PCR) is DNA based and uses a series of HPV specific primers and 
primers specific to the recognition sequence of several restriction enzymes. The restriction 
enzymes chosen are those without, or with only one restriction site within the HPV genome. 
The basis of this technique is that restriction sites are a common occurrence in the human 
genome and have a known sequence. As such, if one of the targeted restriction sites occurs in 
a human genome within close proximity of the integrated HPV it should be amplified by one of 
the PCR reactions (using a HPV specific and restriction site specific PCR primer) (Ragin et al., 
2004). 
1.2.7.3. E2 PCRs 
HPV16 integration frequently results in the disruption of the E2 gene (Baker et al., 1987). A 
simple method of detecting E2 disruption is to use overlapping PCRs that cover the whole E2 
gene (Collins et al., 2009). If E2 is disrupted then one or more of the PCR reactions will fail. It is 
important to consider that this method does not detect integration events where the E2 gene 
remains intact or integration events that have resulted in concatemeric HPV sequences (such 
as observed in CaSki) (Collins et al., 2009). Knowledge of E2 disruption is biologically relevant 
because of the important regulatory role of E2 (Collins et al., 2009, Baker et al., 1987). 
1.2.7.4. DIPS 
Detection of integrated papillomavirus sequences (DIPS) is DNA based. DIPS relies on cutting 
human DNA located 5’ to HPV DNA using restriction endonucleases, then ligating an adapter of 
known sequence to the sticky end (Figure 1.8). For integrated HPVs, the result would be HPV 
DNA at the 3’ end of the DNA, human DNA of unknown sequence at the 5’ end, but with an 
adapter of known sequence positioned at the very end. The ligated constructs are first 
amplified in a linear manner using a HPV specific primer, and then amplified in an exponential 
manner using a HPV primer and an adapter specific primer. These products are then separated 
by electrophoresis, the bands excised, purified and sequenced in order to identify both HPV and 
human sequence in the amplimers (Luft et al., 2001). 
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Figure 1.8: Schematic representation of the DIPS method.  
Adapted from (Luft et al., 2001, Ragin et al., 2004). 1; Possible structure of an integrated HPV genome. 
Dotted lines represent endonuclease restriction sites and grey triangles represent HPV specific primer 
sites. 2; Restriction of genomic DNA yields four classes of fragments, HPV only (B), human only (D) and 
both human and HPV (A and C). Episomal HPVs produce type B only. 3; Endonuclease specific dsDNA 
adapters (green arrows) are ligated to the restriction fragments which introduces PCR primer binding 
sites. 4; Linear PCR is performed using HPV specific primers to amplify fragment types A, B and C. 
Single stranded PCR products are generated. 5; An exponential nested PCR is performed using HPV 
specific and adapter specific primers to generate double stranded PCR products for sequencing. B type 
products are identified based on size and are not sequenced (Luft et al., 2001). 
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Chapter 2. Introduction: DNA Methylation and Epigenetics 
Epigenetic inheritance is defined as cellular information other than DNA sequence that is 
heritable during cell division. This includes DNA methylation, histone modification and 
nucleosome positioning (Feinberg and Tycko, 2004, Esteller, 2002). 
2.1. DNA Methylation 
DNA methylation is the covalent addition of a methyl group to the 5’ position of cytosine 
(Figure 2.1). In mammals, this normally occurs within cytosine-guanine dinucleotides (5’-CpG-
3’, also known as CpGs) and there is an overwhelming tendency for symmetrical methylation 
(i.e. methylation on both strands of the DNA) (Law and Jacobsen, 2010, Lister et al., 2009). 
DNA methylation outside of the CpG context is considerably less common. Non-CpG 
methylation at CHH and CHG (where H is A, C or T) has been described in stem cells, primarily 
within gene bodies, and correlates with gene expression (and is less common in protein 
binding sites and enhancers) (Lister et al., 2009). The role and mechanisms of non-CpG 
methylation within human cells are poorly understood but appear to be involved in 
pluripotency (Portela and Esteller, 2010). 
 
Figure 2.1: A schematic diagram of cytosine methylation. 
 
Timely and accurate DNA methylation is essential for the development and maturation of cells 
and organisms; more specifically for normal embryonic development, X-chromosome 
inactivation, genomic imprinting and the suppression of parasitic DNA sequences (Robertson 
and Jones, 2000). Many human diseases, including cancers, neurological diseases and 
autoimmune diseases occur as the result of untimely or inaccurate DNA methylation (Chen and 
Li, 2004, Zilberman et al., 2007). In vitro studies using mice with knockout mutations in genes 
involved in DNA methylation produced a range of defects as diverse as early developmental 
arrest, embryonic lethality, death at a young age, neural tube defects, abnormal behavioural 
patterns in adulthood, sterility, complex neurological defects, tendency to be overweight and 
issues surrounding X-inactivation (Li, 2002). 
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2.2. Histone Modification 
Histone modification is another well studied example of epigenetic information that plays an 
important role in development and gene expression (Portela and Esteller, 2010). There are 4 
core histones H2A, H2B, H3 and H4 that form a complex of two H2A-H2B dimers and one H3-
H4 tetramer to form the nucleosome (Luger et al., 1997). A length of 147 bp of DNA is 
wrapped around each nucleosome and there is a short stretch of linker DNA with an average 
length of 50 bp between adjacent nucleosomes (Figure 2.2). Histone H1 binds this linker DNA 
in order to seal off the nucleosomes where the DNA is exposed (Daujat et al., 2005). All of the 
histones can be chemically modified post-transcriptionally, these modifications occur mainly in 
the N-terminal tails and include acetylation, methylation, phosphorylation, ubiquitination and 
others (Portela and Esteller, 2010). Histone modifications are mediated by a similarly diverse 
array of enzymes, for example histone acetyltransferases (HATs), deacetylases (HDACs), 
methyltransferases (HMTs) and demethylases (HDMs), kinases and phosphatases, ubiquitin 
ligases and deubiquitinases, SUMO ligases and proteases (Rodriguez-Paredes and Esteller, 
2011). 
 
Figure 2.2: Diagram of DNA wrapped around nucleosomes.  
Adapted from (Luong, 2009).  
 
The presence, absence and interactions of histone modifications modulate chromatin 
conformation to influence the transcriptional activity of a DNA region. Transcriptionally active 
euchromatin and silenced heterochromatin are each characterised by a different subset of 
histone modifications (Rodriguez-Paredes and Esteller, 2011, de Ruijter et al., 2003). Similarly, 
gene expression microarray studies observe specific promoter histone modification profiles 
(especially modifications of H3 histones) that were predictive of transcription level (Karlic et 
28 
 
al., 2010). Abnormal histone modification profiles are also a hallmark of certain cancers (e.g. 
skin, prostate, and colon cancers) (Fraga et al., 2005, Esteller, 2007a). 
Many combinations of histone modifications have been defined with a variety of potential 
biological outcomes in a wide range of processes (Ernst and Kellis, 2010). To add to the 
complexity, there is also significant interplay between different epigenetic modifications, for 
example the DNA Methyltransferase (DNMT) DNMT3L specifically interacts with H3 histones, 
recruits other DNMTs and induces DNA methylation, this interaction is inhibited by 
methylation of lysine 4 of the H3 histone (Ooi et al., 2007). There are also several histone 
methyltransferases that recruit DNMTs and direct DNA methylation to specific regions of the 
genome, and several histone methyltransferases and demethylases can modulate the stability 
of DNMT proteins, regulating DNA methylation level (Portela and Esteller, 2010). The converse 
is also true in that DNA methylation can direct histone modifying enzymes (Portela and 
Esteller, 2010). In summary, histone modifications play a role in a diverse range of biological 
processes and abnormal histone modification profiles are a hallmark of cancer (Rodriguez-
Paredes and Esteller, 2011, Arico et al., 2011). 
 
2.3. The Role of DNA Methylation 
2.3.1. DNA Methylation and Early Development 
DNA methylation plays a crucial role in early development. Post-fertilisation, the maternal and 
paternal gamete genomes are epigenetically different and functionally non-equivalent (Surani 
et al., 1984, McGrath and Solter, 1984). This phenomenon is known as genomic imprinting and 
results in maternal/paternal specific allele expression for many genes (Reik and Walter, 2001).  
Genomic imprints are erased upon the formation of germ cells and a new imprinting profile is 
established. In somatic cells, genomic imprints are maintained and later modified during 
development (Reik and Walter, 2001). Abnormal genomic imprinting is implicated in several 
syndromes that result in developmental, sexual and mental deficiencies (i.e. Beckwith-
Wiedemann Syndrome, Prader-Willi syndrome and Angelman syndrome) and also numerous 
human cancers such as neuroblastoma, Acute Myeloblastic Leukemia (AML), Wilms' tumour, 
rhabdomyosarcoma, sporadic osteosarcoma and familial glomus tumours (Falls et al., 1999). 
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2.3.2. DNA Methylation and Cellular Differentiation 
Many genes involved in differentiation following cellular specialisation appear to be affected 
by DNA methylation. For example the Oct4 and Nanog genes, which regulate pluripotency are 
silenced by promoter hypermethylation in differentiated cells but are hypomethylated and 
expressed in germline cells (Hattori et al., 2004, Berdasco and Esteller, 2010, Hattori et al., 
2007). Indeed, several hundred genes have been identified in mouse and human studies that 
are differentially methylated in undifferentiated somatic tissues compared to differentiated 
germline tissues (Mohn et al., 2008, Schilling and Rehli, 2007). Nonetheless, the role of DNA 
methylation in the establishment and maintenance of cell-type-specific expression of 
developmentally regulated genes is not completely understood. Methylation of these genes in 
many instances was not negatively correlated with gene expression as might be expected 
(Eckhardt et al., 2006, Berdasco and Esteller, 2010). 
 
2.3.3. Mechanisms of DNA Methylation 
Methylation of mammalian CpG dinucleotides is mediated by a family of DNA-[cytosine-5] 
methyltransferases that catalyse the transfer of a methyl group from S-adenosyl methionine to 
cytosine residues in DNA. There are five DNMTs currently reported in humans, these are 
DNMT1, DNMT2, DNMT3A, DNMT3B and DNMT3L however only DNMT1, DNMT3A and 
DNMT3B possess methyltransferase activity (Portela and Esteller, 2010). DNMT1 is thought to 
function as the primary maintenance methyltransferase, and has a strong preference for 
hemimethylated CpG sites produced during DNA replication (Pradhan et al., 1999). This allows 
for replication of the existing methylation pattern onto newly synthesised DNA strands 
(Portela and Esteller, 2010, Chen and Li, 2004). The two de novo methyltransferases DNMT3A 
and DNMT3B (Chen and Riggs, 2011) act to establish the methylation patterns of the genome 
during gametogenesis, embryogenesis and somatic tissue development (Rodriguez-Osorio et 
al., 2010). 
Several diseases are caused by genetic defects in the DNA methylation machinery genes. The 
extremely rare condition Immunodeficiency, Centromere instability and Facial abnormality 
(ICF) syndrome and some cases of AML for example have been found to possess DNMT3B and 
DNMT3A mutations respectively (Ley et al., 2010, Jiang et al., 2005). Methylation is also 
important for early embryonic development; mammalian embryos deficient in DNMT3A/B do 
not survive (Okano et al., 1999). DNMT3L does not possess methyltransferase activity, but acts 
as a stimulatory factor for DNMT3A and DNMT3B (Zilberman et al., 2007). DNMT2 has very 
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little DNMT activity and does not appear to methylate DNA, but does methylate tRNAAsp (Goll 
et al., 2006). 
The distinction between the roles of DNMT3A/B and DNMT1 may not be as clear as once 
thought. A new model suggests a role for DNMT3A and DNMT3B in maintenance methylation 
and a role for DNMT1 in de novo methylation (Jones and Liang, 2009). In this model, DNMT1 is 
bound to Proliferating Cell Nuclear Antigen (PCNA) during DNA synthesis and is therefore 
directed towards the replication fork. In this position DNMT1 methylates the vast majority of 
newly synthesized hemimethylated daughter DNA strands. Rather than being located at the 
replication fork, DNMT3A and DNMT3B are bound to nucleosomes in areas of DNA 
methylation, in this position DNMT3A and DNMT3B act to maintain the methylation state in 
these areas and methylate hemimethylated CpGs missed by DNMT1 (Jones and Liang, 2009). 
DNA regions rich in CpGs are susceptible to a range of negative consequences including 
silencing by methylation and increased mutation rates (Bird and Wolffe, 1999, Jones, 1996, 
Jones et al., 2001). As such, most CpGs have been lost during evolution and only occur at 20% 
of their statistically expected frequency (Schorderet and Gartler, 1992, Badal et al., 2003). The 
evolutionary loss of CpGs is not however universal throughout the genome, some regions 
retain CpGs at a higher density. These regions, mostly 0.5 to several kb in length, are termed 
CpG islands (Robertson and Jones, 2000, Bird, 1986). CpG islands are defined as regions longer 
than 200 bp with a G+C content of over 50% and a ratio of observed to statistically expected 
CpG frequencies of at least 0.6 (Portela and Esteller, 2010). 
The increased rate of mutation for methylated DNA sequences is a result of the biochemistry 
of cytosine and methylcytosine nucleotides. Cytosine nucleotides will spontaneously undergo 
hydrolytic deamination to form uracil nucleotides. Because uracil is only normally found in 
RNA, it is easily detected and removed by the highly abundant and efficient Base Excision 
Repair (BER) enzyme uracil DNA glycosylase (UDG) (Robertson and Jones, 2000, Jones, 1996). 
Methylated cytosine (5-methylcytosine) however spontaneously deaminates to form thymine, 
a naturally occurring DNA base that is considerably more difficult to detect and repair via the 
thymine DNA glycosylase pathway (TDG). TDG mismatch repair is less efficient and up to 
several hundred times slower than UDG repair (Jiricny, 1996, Jones, 1996). The elevated rate of 
cytosine to thymine transitions for methylated residues is a source of increased mutability and 
over time has resulted in a decreased frequency of CpG dinucleotides (Jiricny, 1996).  
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2.4. Methylation of the Human Genome 
Most (up to 80%) of the CpGs in the human genome are highly methylated however those 
within CpG islands are typically less methylated (Takai and Jones, 2002). The human genome 
contains up to 45,000 CpG islands, most are found within or proximal to 5’ untranslated 
promoter regions or the first exons of genes (Antequera and Bird, 1993). CpGs are distributed 
such that up to 50% of the gene promoters in the human genome contain CpG islands (Bird, 
1986) and over 70% of gene promoters have been described as having a CpG density that is 
higher than the genome average (Saxonov et al., 2006). The maintenance of CpG islands might 
be either a requirement of high sequence fidelity (a large proportion of CpG islands are 
associated with housekeeping genes (Bird, 1986)) or a requirement for the region to be 
regulated by methylation. A variety of genes are under the control of promoters located within 
CpG islands, which importantly in the context of carcinogenesis, includes numerous genes 
involved in cell cycle control (e.g. ARF, INK4a, INK4b) (Esteller, 2002). CpG islands occur 
infrequently within the coding sequence of a gene and the 3’ region of genes; these CpG 
islands are more likely to become methylated than typical CpG islands and were assumed not 
to have an effect on the progression of the relevant RNA transcript (Bird, 1986, Jones, 1999). 
However more recent studies suggest that in some instances intragenic, or gene body, 
methylation can have a demonstrable effect on gene expression/protein translation (Lorincz et 
al., 2004). 
Provided that the relevant transcription factors are available, the unmethylated state of a 
typical CpG island permits an uncondensed chromatin structure that is favourable to 
transcription (Esteller, 2007b). A notable feature of CpG islands is the presence of acetylated 
H3 and H4 histones (forming the nucleosomes) and a distinct reduction of H1 linker histone 
resulting in the relaxed chromatin state (Tazi and Bird, 1990). The majority of CpG 
dinucleotides within the genome occur within mobile genetic elements and the ancestral 
remnants of a range of parasitic DNA sequences that comprise upwards of 40% of the entire 
human genome (Robertson and Wolffe, 2000). DNA methylation has been proposed as a 
mechanism evolved to silence the expression, mobility and thus the multiplication of such 
genetic elements. Silencing of these regions of DNA would be essential to prevent 
retrotransposon activity, and to maintain genomic structural integrity by preventing 
recombination between homologous sequences (Robertson and Wolffe, 2000). 
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2.4.1. DNA Methylation and Transcriptional Regulation 
DNA methylation plays a significant role in transcriptional regulation. The promoters of 
transcriptionally active genes are often located within or proximal to unmethylated CpG 
islands which when methylated can silence the expression of these genes (Eden and Cedar, 
1994). Typical CpG islands lack methylation at any stage of development and allow the 
expression of associated genes if the appropriate transcription factors are present and the 
chromatin structure is accessible (Esteller, 2002). A range of genes containing CpG islands are 
found to be hypermethylated in tumours, these include a number of cell cycle control genes 
and tumour suppressor genes (Robertson, 2001, Badal et al., 2003). 
Transcriptional repression due to DNA methylation may occur through several mechanisms, 
these include the inability of several transcription factors to bind methylated target sites (Bird 
and Wolffe 1999; Thain et al. 1996) and the alteration of chromatin conformation around 
binding sites or even entire gene promoters (Jones et al., 2001). The most direct method by 
which DNA methylation can affect transcription is the inhibition of binding of DNA binding 
proteins to their target sites (Kuroda et al., 2009). These proteins include the transcriptional 
machinery and transcription factors that require contact with cytosine in the major groove of 
the DNA double helix. Many mammalian transcription factors contain GC-rich binding sites and 
often contain CpGs within their DNA recognition elements (Bird and Wolffe, 1999). CpG 
methylation at transcription factor binding sites may impede the ability of a transcription 
factor to bind DNA however not all transcription factors are affected by methylation (i.e. Sp1) 
and there are some instances of highly methylated genes that are still transcribed (Bird and 
Wolffe, 1999).  
It is thought that transcriptional regulation through the inhibition of binding of transcription 
factors to methylated binding sites is a relatively rare event in the human genome (Weber et 
al., 2005, Li, 2002). For example the glial fibrillary acidic protein is activated during astrocyte 
differentiation by the demethylation of a CpG in a STAT3 (signal transducer and activator of 
transcription 3) binding element in its promoter region (Takizawa et al., 2001). Conversely, 
DNA methylation of a silencer element of the Igf2 (insulin like growth factor 2) gene blocks the 
binding of repressor proteins such that transcription from the promoter increases (Murrell et 
al., 2001).  
In order to transcribe a given region of DNA, the supercoiled tertiary structure must be relaxed 
to allow the necessary cellular enzymes access to the DNA. In the supercoiled state the genes 
within the DNA region are transcriptionally silenced. This supercoiled chromatin state is 
generated by the action of HDAC proteins on the nucleosomal histones of newly synthesised 
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DNAs (Jones et al., 2001). Histone deacetylation involves the removal of acetyl groups from 
lysine residues at the N-terminus of histone proteins; acetylated histones show a markedly 
reduced affinity for DNA (de Ruijter et al., 2003) permitting a more relaxed and accessible 
structure. Histone deacetylation therefore encourages the maintenance of a supercoiled 
structure by promoting the association between histone proteins and DNA, permitting DNA 
supercoiling. Repression by DNA methylation works by effectively targeting this HDAC activity 
towards specific areas of the genome which results in histone deacetylation, supercoiling and 
silencing of methylated regions (Burgers et al., 2002). DNMT1 (the maintenance methyl 
transferase active during DNA synthesis) is found at the replication forks, and the association 
between DNMT1 and HDAC2 (HDAC2 associates with the DNMT1 non-catalytic N-terminus) 
acts to direct HDAC activity towards newly synthesised DNA (Burgers et al., 2002). DNMT3A 
and DNMT3B also recruit HDACs to silence genes independent of their methyltransferase 
activity (Burgers et al., 2002). 
In addition to the association between the methyltransferases and HDACs, the HDAC complex 
can be directed to methylated DNA via proteins such as methyl-CpG binding proteins (de 
Ruijter et al., 2003). Two methyl-CpG binding proteins (MeCP1 and MeCP2) recruit HDAC 
complexes to areas containing methylcytosine in order to mediate transcriptional repression. 
MeCP2 is comprised of a methyl-CpG-binding domain which recognises methylated CpG 
dinucleotides and a transcriptional repression domain which represses transcription through 
an interaction with the cellular transcriptional protein TFIIB (Jones et al., 2001, Robertson and 
Wolffe, 2000). MeCP2 can bind to histone bound DNA and in some instances is responsible for 
H1 displacement. MeCP2 also recruits HDAC containing transcriptional repression complexes 
via its interaction with the Sin3A corepressor (Jones et al., 2001, Robertson and Wolffe, 2000). 
In summary, the recruitment of HDACs to methylated DNA sequences through various 
mechanisms results in histone deacetylation and chromatin condensation, a state of DNA that 
is inaccessible to the cellular transcription machinery. 
2.4.1.1. Intragenic Methylation 
Intragenic or gene body methylation was traditionally assumed to not affect transcription. 
Whilst this is still a poorly understood and considerably understudied area, more recent 
studies have shown otherwise. Intragenic methylation can have a significant effect on 
transcription elongation of mammalian transgenes, possibly as a result of an association with a 
more condensed chromatin state that reduces elongation efficiency (Lorincz et al., 2004). 
Intragenic methylation of Arabidopsis thaliana genes was also shown to inhibit transcriptional 
elongation. Gene body methylation in plant protoplasts was also seen to interfere with 
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elongation, especially if the methylation was close to the 5’ end (Hohn et al., 1996); this 
inhibition might be dependent on both the length and activity of the gene (Zilberman et al., 
2007). It is hypothesised that intragenic DNA methylation might prevent spurious initiation of 
transcription by preventing binding of transcription factors to gene body binding sites which 
might actually improve the transcription rate in some instances (Maunakea et al., 2010, 
Zilberman et al., 2007).  
The role of intragenic methylation in humans is poorly understood. Human intragenic 
methylation might also be associated with repression or enhancement of transcription 
depending on the precise nature of the genes in question. Gene body methylation and 
promoter hypomethylation are positively correlated with gene expression during X-
inactivation in early development. A similar scenario was observed in human B cells where it 
was also suggested that intragenic methylation might regulate the use of alternative human 
promoters (Hellman and Chess, 2007, Rauch et al., 2009). In a range of human tissues, 
promoter hypomethylation and gene body hypermethylation are associated with a higher rate 
of cell division (Aran et al., 2011). However data are contradictory regarding whether 
intragenic methylation is a cause or a consequence of high gene transcription (Shenker and 
Flanagan, 2012). Despite this, it is well established that aberrant DNA methylation of the 
human genome is associated with cancer and various roles (e.g. transcriptional regulation, 
suppression of non-coding RNA expression, cellular defence etc) could be assigned to aberrant 
intergenic, intragenic and promoter hypermethylation (Shenker and Flanagan, 2012). 
 
2.4.2. DNA Demethylation 
Aside from cancer cells, the genomic DNA methylation pattern of mature cells is usually 
considered to be a fixed state, recently however this has been questioned. DNA demethylation 
has been observed in several contexts and appears to be achieved by both an active and 
passive means (Wu and Zhang, 2010). Passive DNA demethylation occurs when the 
maintenance DNMT, DNMT1 is inhibited or absent during DNA replication. The newly 
synthesised DNA strands are not methylated which leads to gradual demethylation with cell 
division (Wu and Zhang, 2010). Passive demethylation is also observed due to exclusion of 
maternal DNMT1 from the nucleus during blastocyte development in a cell division dependent 
manner, however imprinted genes resist demethylation (Monk et al., 1987, Rougier et al., 
1998). The alternative to passive demethylation is the active demethylation of DNA as a result 
of enzymatic activity. The significance of active demethylation has been controversial (Ooi and 
Bestor, 2008).  
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Ramchandani et al proposed that DNA methylation is a dynamic state that is the result of the 
balance between DNA methylation and enzymatic demethylation (Ramchandani et al., 1999, 
Szyf et al., 2004). Active DNA demethylation is observed as a genome wide effect at specific 
times during early development and in more specific loci in somatic cells in response to various 
stimuli (Wu and Zhang, 2010). 
During fertilisation, genome wide demethylation is seen in the paternal pronuclei shortly after 
fertilisation, prior to the first cell division and is not affected by replication inhibitors, implying 
that an active demethylation event is responsible (Wu and Zhang, 2010, Mayer et al., 2000). As 
per passive demethylation, several regions of the genome are resistant to active 
demethylation (Santos et al., 2002, Rougier et al., 1998, Olek and Walter, 1997, Lane et al., 
2003). Experiments involving injecting sperm nuclei from one species into the eggs of others 
revealed that demethylation was variably species specific, but consistently paternal genome 
specific (Beaujean et al., 2004, Rougier et al., 1998, Barton et al., 2001, Santos et al., 2002). As 
well as global active demethylation, there are reports of active demethylation of specific loci, 
each of which were triggered by various stimuli and in the absence of DNA replication, thereby 
excluding passive demethylation (Szyf et al., 1985, Metivier et al., 2008, Kim et al., 2009, 
Gjerset and Martin, 1982, Hu et al., 2000). 
There are several putative demethylases, the most significant of which appears to be Methyl-
CpG Binding Domain protein 2 (MBD2). MBD2 has a methylcytosine binding domain with a 
propensity towards CpGs, MBD2 also has DNA demethylase activity towards 5-methyl cytosine 
(Hamm et al., 2008, Bhattacharya et al., 1999), and thus demethylase activity could be directed 
towards sites of CpG methylation. Other proposed mechanisms of active demethylation 
include BER, nucleotide excision repair, oxidative demethylation and radical S-
adenosylmethionine based demethylation. 
2.4.2.1. DNA Methylation as a Result of Chromatin Structure 
An extension of the theory that DNA methylation is a dynamic state is that DNA methylation 
may not be the cause of gene repression, but rather a consequence of other changes that lead 
to repression. Several observations support this theory. It is normally assumed that areas rich 
in DNA methylation are associated with protein complexes that result in histone modifications, 
repressing the DNA region. However histone modifications and the subsequent silencing of the 
tumour suppressor p16INK4a has been observed prior to and independently of DNA 
hypermethylation; suggesting that repressive chromatin structures could promote DNA 
methylation (Bachman et al., 2003).  
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Additionally, active chromatin formations may actively demethylate DNA; treating certain 
mammalian cell lines or Neurospora with histone deacetylase inhibitors (acetylated histones 
are associated with condensed chromatin structures) results in global genomic demethylation 
(Selker, 1998, Szyf et al., 1985). In summary, a bilateral relationship between DNA methylation 
and chromatin structure might exist, i.e. the presence of DNA methylation could affect 
chromatin structure however the chromatin structure could in turn have an effect on DNA 
methylation (Szyf et al., 2004). 
 
2.5. DNA Methylation and Cancer 
It is widely recognised that aberrant patterns of methylation and histone modification are a 
characteristic of many tumours. Cancer cells typically display a massive global reduction in 
methylation and have approximately 20-60% less methylcytosine than non-cancerous cells 
(Hellman and Chess, 2007, Rodriguez-Paredes and Esteller, 2011). Typically, tumour cells 
exhibit hypomethylation for most of the genome and hypermethylation of specific regions 
such as gene promoters (Robertson, 2001, Weber et al., 2005).  
A range of gene promoters, including promoters of cell cycle control, tumour suppressor and 
DNA repair genes (e.g. INK4a, INK4b, ARF, p73, APC, BRCA1, hMLH1, GSTP1, MGMT, CDH1, 
TIMP3 and DAPK) are found to be frequently hypermethylated in cancers, often in a conserved 
and characteristic manner for that cancer type (Esteller et al., 2001). Approx 100-400 
hypermethylated promoter CpG islands are found in any given tumour (Esteller, 2007a). The 
epigenetic repression of cell cycle control and DNA repair genes by DNA methylation may also 
predispose a cell to the accumulation of genetic mutations. For example, DNA 
hypermethylation associated inactivation of the DNA repair gene O6-MGMT (O6-
methylguanine-DNA methyltransferase) is a hallmark of some cancers (e.g. lymphomas, colon, 
head and neck and non-small-cell lung cancer) that results in the enhanced accumulation of G-
A point mutations (Esteller et al., 1999, Esteller and Herman, 2004).  
As well as promoter hypermethylation, abnormal hypomethylation has been linked to the 
activation of certain protooncogenes (Watt et al., 2000) and is also associated with various 
tumours (Wilson et al., 2007). Additionally, whilst tandemly repetitive DNA sequences in 
normal cells are silenced by hypermethylation (Robertson, 2001, Badal et al., 2003), in 
tumours these regions tend to be hypomethylated which may be associated with genomic 
instability (Deng et al., 2006, Rodriguez-Paredes and Esteller, 2011).  
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Epigenetic features typical of cancers are commonly seen in benign neoplasias and early stage 
tumours. Epigenetic deregulation therefore may precede the typical transforming events 
(tumour suppressor and/or protooncogene mutation and genomic instability) (Rodriguez-
Paredes and Esteller, 2011). Following mutation of one allele of a tumour suppressor gene, 
methylation might then be responsible for silencing the remaining functional allele and 
providing the second hit for cancer initiation (Rodriguez-Paredes and Esteller, 2011). BRCA1 
(Breast Cancer 1) for instance is frequently hypermethylated in ovarian and breast cancer 
(Esteller, 2002). 
2.5.1.1. Therapeutic Demethylation 
The DNA methylation profile of several cancers includes hypermethylation of specific CpG 
islands, many of which are known to be associated with tumour suppressor genes and other 
cell cycle control genes (Esteller, 2007a). The idea behind therapeutic demethylation is to 
relieve the repression of these regions by reducing the amount of DNA methylation, thereby 
elevating the levels of tumour suppressor gene products. Most demethylating agents are 
nucleotide analogues. A benefit of nucleotide analogues is that they are specifically targeted to 
cells undergoing DNA replication, i.e. cycling cells such as cancer cells. The most highly studied 
demethylating agents are analogues of cytidine and deoxycytidine, five of which are especially 
well characterised (Figure 2.3); 5-aza-2′-deoxycytidine, 5-azacytidine, 5′-fluoro-2′-
deoxycytidine and 2-Pyrimidone-1-β-D-riboside (Zebularine), all of which appear to have 
varying potential as anticancer agents (Cai et al., 2011). 5-azacytidine for instance is approved 
in several countries for the treatment of myelodysplastic syndrome (Cai et al., 2011), but has 
also been trialled against various solid tumours (Chik and Szyf, 2011). 
 
Figure 2.3: The chemical structure of deoxycytidine and several methylation inhibiting nucleoside 
analogues. 
 
Most nucleoside analogues appear to demethylate DNA via a similar mechanism (Cai et al., 
2011). 5-aza-2'-deoxycytidine is an analogue of 2′-deoxycytidine in which the 5-carbon of the 
pyrimidine ring has been replaced by nitrogen (Momparler, 2005). 5-aza-2'-deoxycytidine is 
rapidly taken into cultured cells and incorporated into the DNA, at sub-toxic doses this leads to 
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incorporation into newly synthesised DNAs (Momparler, 2005). When these new DNAs are 
bound by DNMT1 the 5-azacytosine ring in the 5-aza-2'-deoxycytidine residues become 
covalently and irreversibly bound to the DNMT1 enzyme, leading to a depleted cellular level of 
DNMT1 and passive DNA demethylation (Jüttermann et al., 1994). This demethylating effect is 
widely utilised to study the relationship between DNA methylation and gene suppression 
(Christman, 2002). 5-aza-2′-deoxycytidine also inhibits DNMT3B and leads to enhanced 
acetylation of histones H3 and H4 at promoter regions (Cai et al., 2011), treatment with 5-aza-
2'-deoxycytidine leads to demethylation and subsequent reactivation of silenced tumour 
suppressor genes and prometastatic genes (Chik and Szyf, 2011). In breast cancer cells, 
tumourigenicity is suppressed by the addition of 5-aza-2'-deoxycytidine and the alleviation of 
methylation of certain tumour suppressor genes (e.g. PDLIM2) (Qu et al., 2010). Breast cancer 
cell line work also suggests that 5-aza-2′-deoxycytidine could have a role in enhancing 
chemosensitivity of breast cancers to other anticancer agents (Mirza et al., 2010) 
In addition, a growing list of non-nucleoside based DNA methylation inhibitors are becoming 
available that inhibit DNA methylation by binding directly to the catalytic region of the DNMT, 
without first incorporating into DNA (Schuebel and Baylin, 2005, Chuang et al., 2005). 
However, very few non-nucleoside inhibitors have yet made it into clinical trials (Cai et al., 
2011). 
 
2.6. HPV and DNA Methylation 
HPV16 E7 has been shown to bind directly to DNMT1 (Burgers et al., 2007). This is significant 
as in addition to the transcriptional modulation associated with DNA methylation, DNMT1 
activity may also be intrinsically associated with carcinogenesis. Elevated DNMT1 activity 
effectively induces the transformation of mouse fibroblasts (Wu et al., 1993). Elevated DNMT1 
activity and mRNA levels have also been reported in various cancers (e.g. intestinal, colon and 
lung cancer) and inhibition of elevated DNMT1 is associated with suppression of 
tumourigenesis (Robertson, 2001, el-Deiry et al., 1991, Laird et al., 1995, Belinsky et al., 1996). 
Given the role of DNMT1 in the methylation of newly replicated DNA, its association with the 
maintenance of chromatin structure and its implication in carcinogenesis, it is interesting to 
note the observed interactions between cellular DNMT1 and HPV E7. HPV16 E7 binds directly 
to DNMT1 which is associated with an increased methyltransferase activity in vitro (Burgers et 
al., 2007). The action of E7 on DNMT1 is a potential mechanism of cellular transformation in 
addition to E7’s role in pRb degradation and may be implicated in the aberrant cellular CpG 
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methylation patterns observed for HPV induced cancers (Burgers et al., 2007, Robertson, 
2001). 
As per the human genome, the HPV genome also presents a low CpG frequency; the HPV18 
genome for instance is 7,857 bp in length and the expected CpG frequency is about 400 per 
genome, however the actual occurrence is only 172 (Badal et al., 2004). Similarly, the HPV16 
genome at 7,904 bp contains only 111 CpG dinucleotides (GenBank ID NC001526.1) suggesting 
that the evolutionary consequences of a genome susceptible to methylation are similar for 
both human and HPV genomes.  
Transcriptional regulation by methylation is an interesting concept for HPV biology as it 
provides another potential mechanism of HPV gene regulation. Both integrated and episomal 
HPV16 genomes are known to be methylated by the cellular methylation machinery and 
genomes that have been methylated in vitro are transcriptionally silenced, suggesting a 
potential role of methylation in viral gene regulation and/or a host defence mechanism acting 
to silence foreign DNAs (Badal et al., 2003, Rosl et al., 1993). In keeping with de novo 
methylation as a defence against foreign DNAs, recombination of HPV DNA into cellular 
chromosomes appears to incite DNA methylation whilst episomal forms of HPV and repetitive 
DNA sequences are also regarded as sites for DNA methylation (Yoder et al., 1997, Badal et al., 
2003). 
The methylation status of the HPV16 genome has been assessed in several studies and is seen 
to vary with several characteristics of the host cell/sample, including cellular differentiation, 
HPV integration and disease grade. The relationship between HPV methylation and a variety of 
disease characteristics has also been briefly considered from the perspective of biomarkers. 
Various techniques have been used to assess DNA methylation, including methylation specific 
PCR, bisulfite sequencing, methylation sensitive restriction enzymes, pyrosequencing and 
several others. 
2.6.1. HPV Methylation and Cellular Differentiation 
Investigations utilising laser capture microdissection showed that the methylation status of 
HPV16 correlated with the differentiation status of the host cell. HPV16 genomes (including 
the LCR) were typically hypomethylated in well differentiated cells and hypermethylated in less 
differentiated cells. The LCR in undifferentiated cells also commonly contained methylated 
E2BSs (Kalantari et al., 2008a, Vinokurova and von Knebel Doeberitz, 2011, Kim et al., 2003). 
40 
 
2.6.2. HPV Methylation and Disease Grade 
Several studies have investigated the relationship between HPV methylation and cervical 
disease, and have established that patterns and levels of HPV16 DNA methylation vary with 
disease grade. HPV16 in cervical cancer and precancerous CIN lesions have a different 
methylation state than HPV16 in lower grade disease, this is especially apparent in the L1 ORF 
and the LCR (Sun et al., 2011, Fernandez and Esteller, 2010). The HPV16 genome is typically 
observed to become more methylated with progression from low grade disease, to 
precancerous cervical lesions through to cervical carcinomas (Kalantari et al., 2004, Fernandez 
et al., 2009, Sun et al., 2011, Kalantari et al., 2009) although one study observed progressive 
hypomethylation (Badal et al., 2003). 
The changes in methylation observed are specific to regions of the HPV genome. The HPV LCR 
may remain hypomethylated with disease progression, however this is contentious. Several 
studies have reported that the HPV16 LCR remained, or became hypomethylated during 
progression to high grade disease (Badal et al., 2003, Hublarova et al., 2009, Patel et al., 2012, 
Piyathilake et al., 2011) whilst others reported LCR hypermethylation with high grade disease 
(Kalantari et al., 2004, Bhattacharjee and Sengupta, 2006a, Ding et al., 2009, Brandsma et al., 
2009, Hong et al., 2008). Similarly varied is the reported methylation status of the HPV16 LCR 
in HPV16 positive, but very low grade disease (i.e. LSIL/normal cytology/no CIN samples) 
where both LCR hypermethylation and hypomethylation have been reported (Hong et al., 
2008, Ding et al., 2009, Fernandez et al., 2009, Bhattacharjee and Sengupta, 2006a, Badal et 
al., 2003, Patel et al., 2012, Kalantari et al., 2004). Despite the variety of results, studies agree 
that HPV methylation is associated with disease grade and thus may be clinically useful. 
Each of the studies considers DNA methylation and disease grade from a different perspective, 
targeting different CpGs and using a variety of methylation assessment methods. Bisulfite 
sequencing can be performed non-quantitatively or semi-quantitatively by the cloning of PCR 
products prior to sequencing. The presence/absence of a cloning step might have a profound 
effect on the results (Badal et al., 2003, Fernandez et al., 2009, Kalantari et al., 2004). Recently, 
fewer bisulfite sequencing studies have been published without the cloning steps and the use 
of quantitative methods such as pyrosequencing has become more common. 
2.6.3. Integration and Methylation 
Whilst the methylation and integration status of several HPV-associated cell lines are quite 
widely reported, there have been relatively few studies that have assessed both DNA 
methylation and HPV integration in vivo. Methylation of the HPV genome was typically higher 
for clinical samples containing integrated HPV than for non-integrated samples (Fernandez et 
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al., 2009, Kalantari et al., 2008a, Kalantari et al., 2010). Fernandez et al considered integration 
and methylation in vitro and observed hypermethylation of most of the HPV genome (LCR, E6, 
E7, E5 and L1 excluded) to be associated with HPV integrating into the host genome of primary 
foreskin keratinocytes (Fernandez et al., 2009).  
Newly integrated HPV DNAs could be targeted by host methylation mechanisms, in order to 
maintain a transformed phenotype the continued expression of E6 and E7 is required. As such 
many regions (including the LCR) of single insertion integrants such as those observed in the 
SiHa cell line often lack methylated CpGs (Kalantari et al., 2008a, Kalantari et al., 2004, Badal et 
al., 2003, Fernandez et al., 2009). HPV genomes inserted as concatemers however are 
frequently heavily methylated. The cell line CaSki for example contains several hundred HPV16 
genomes inserted as concatemers at various host genome loci, and yet all but one is repressed 
by hypermethylation of the LCR which may reflect properties of the flanking human DNA 
(Kalantari et al., 2008a, Van Tine et al., 2004b, Kalantari et al., 2004, Fernandez et al., 2009).  
In an early in vitro study using the precancerous cervical disease cell line W12, Kalantari et al 
observed a relationship between HPV methylation and integration. High copy number 
integrants were typically hypermethylated in the regions tested whilst single copy integrants 
were hypomethylated (Kalantari et al., 2008a). This data formed the basis of a later study to 
identify a relationship between L1 methylation, integration and disease grade in a clinical 
cohort. A relationship was observed however there was considerable variation among the 
samples (Kalantari et al., 2010).  
There are not many studies that have considered both HPV integration and methylation, 
however de novo methylation of integrated DNAs other than HPV are well known. Upon 
integration, foreign DNAs including adenoviral, plasmid and bacteriophage DNAs are 
hypermethylated which may be a cellular defence mechanism to repress foreign DNA 
elements (Sutter et al., 1978, Orend et al., 1995, Heller et al., 1995, Doerfler, 2008). If a more 
robust relationship between HPV methylation and integration is established, human cells 
actively targeting foreign DNA elements for silencing by DNA methylation might be a suitable 
explanation (Doerfler et al., 2001, Doerfler, 2011). The cell differentiation status also appears 
to have minimal affect on the methylation status of the L1 and LCR of integrated HPV16, 
indicating a different methylation strategy for integrated HPV genomes (Kalantari et al., 
2008a). 
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2.6.4. Methylation of Other HPV Types and Disease Sites 
As well as HPV16 methylation in cervical samples, a small number of studies have considered 
methylation of other HPVs and HPVs in other anogenital sites. There was good agreement 
between the methylation studies in cervical disease, and those concerning penile carcinoma 
(Kalantari et al., 2008b), AIN and oral SCC (Balderas-Loaeza et al., 2007, Kalantari et al., 2008b, 
Wiley et al., 2005). There was also similarity between the results of HPV16 methylation in 
cervical lesions, and those for HPV18 in cervical lesions (Badal et al., 2004, Kalantari et al., 
2008b, Turan et al., 2007, Turan et al., 2006, Fernandez et al., 2009). 
The relationship between disease severity and hypermethylation is not specific to HPV. The 
dsDNA tumour causing viruses HBV (Hepatitis B Virus) and EBV (Epstein Barr Virus) also 
undergo progressive hypermethylation with increasing disease severity (Fernandez et al., 
2009). Both EBV and HBV have a latency period, and whilst HPV has no known latency stage, 
long term persistence is a feature of HPV that is associated with cervical disease. Progressive 
methylation of dsDNA tumour virus genomes indicates that foreign DNA is efficiently targeted 
for de novo methylation, or that methylation is involved in the latency mechanisms (Tao and 
Robertson, 2003, Fernandez et al., 2009, Vinokurova and von Knebel Doeberitz, 2011).  
2.6.5. Consequences of HPV Methylation 
The methylation state of the long control region is of particular interest due to its role in 
regulation of HPV gene expression and the known effects of DNA methylation on gene 
expression. Methylation of the LCR has been determined in multiple studies and it is usually 
found to be generally hypomethylated but with hypermethylation of the E2 binding sites in 
high grade disease/cancer (Fernandez et al., 2009, Brandsma et al., 2009, Sun et al., 2011, 
Kalantari et al., 2004, Kalantari et al., 2009).  
The LCR contains four E2BS and each E2BS contains two CpGs (Figure 1.2). Methylation of 
these E2BS CpGs prevents E2 binding, inhibition of E2 mediated P97 repression could 
potentially result in E6 and E7 deregulation, as required for cellular transformation and 
carcinogenesis (Fernandez et al., 2009, Thain et al., 1996). Whilst E2BS hypermethylation is 
likely associated with increased P97 activity, general LCR hypermethylation is likely associated 
with decreased P97 activity. The topological structure of the DNA may become altered through 
HDAC recruitment to methylated sequences, resulting in enhanced chromatin condensation 
(Burgers et al., 2002). A compact and inaccessible chromatin structure at the LCR could deny 
access to the multitude of cellular transcription factors that have binding sites in the LCR, 
negatively affecting HPV gene expression (Spink and Laimins, 2005, Stunkel et al., 2000, Ai et 
al., 2000). 
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The methylation status of a series of HPV16 positive primary cervical cancers was analysed. Of 
the samples without E2 deletion, the majority (6 of 8) were shown to contain hypermethylated 
E2BSs (Fernandez et al., 2009). Nonetheless, the data set was small and was determined using 
the imprecise Methylation Specific PCR (MS-PCR) method. Further study may confirm a role for 
E2BS methylation as an alternative route of E6 and E7 deregulation in episomal infections, or 
in integrated HPV infections where disruption of the E2 ORF has not resulted in the loss of E2 
mediated P97 repression (Fernandez et al., 2009). Sp1 binding to the LCR is essential for the 
activation of P97 (Tan et al., 1994), whilst E2 cannot bind to a methylated E2BS, Sp1 binding to 
the P97 enhancer region is not affected by methylation (Thain et al., 1996, Fernandez et al., 
2009, Harrington et al., 1988). As such, selective methylation of specific CpGs of the LCR might 
result in a variety of potential outcomes, i.e. P97 activity by specific CpG methylation or P97 
repression due to conformational changes of the chromatin structure. 
Even within the LCR, CpGs appear to be differentially methylated. For instance, the various 
E2BSs are differentially methylated, as are CpGs within the LCR but outside of the E2BSs 
(Vinokurova and von Knebel Doeberitz, 2011). The various CpGs of the early enhancer and 
promoter are frequently methylated to varying degrees (Vinokurova and von Knebel 
Doeberitz, 2011, Fernandez et al., 2009, Kalantari et al., 2004). The establishment and 
maintenance of the variable methylation patterns observed could plausibly be directed by the 
host cell or could be manipulated by HPV (Burgers et al., 2007, Vinokurova and von Knebel 
Doeberitz, 2011). 
Little research has been conducted to relate HPV gene expression with methylation status of 
the LCR. That which has been performed involved in vitro chemical demethylation of the CaSki 
cell line using nucleoside analogue methylation inhibitors, but the results have been varied. 
One study reported an increase in gene expression for some, but not all cells as a result of 
demethylation (Van Tine et al., 2004b) another a decrease in E6/E7 gene expression as a result 
of demethylation, thought to be the result of E2BS hypomethylation and subsequent E2 trans-
acting repression (Fernandez et al., 2009) whilst others reported no effect (Kalantari et al., 
2008a). In summary, the results of such experiments were inconclusive. 
HPV methylation could speculatively be either a cause of HPV gene silencing through 
interaction with the LCR, or a consequence of HPV oncoprotein activity. HPV oncogenes are 
known to influence the DNMTs and there are also suggestions that HPV methylation might be 
associated with persistent HPV infection in the absence of clinically relevant disease (Burgers 
et al., 2007, Wiley et al., 2005, Vinokurova and von Knebel Doeberitz, 2011). In both clinical 
and cell line material, where multiple integration events were present, transcription was 
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observed primarily from a single integrated HPV genome whilst the rest were repressed via 
DNA methylation (Fernandez et al., 2009, Rajeevan et al., 2006, Van Tine et al., 2004b). 
In summary, HPV methylation is varied across the genome and within the LCR and the 
potential effects of HPV methylation could be similarly varied. A range of sites are identified as 
differentially methylated in association with disease grade and integration state and whilst our 
understanding of HPV methylation is improving, it is far from complete. 
 
2.7. DNA Methylation Study Techniques 
There are a range of methods by which to study the quantity and location of methylated 
cytosines within a region of DNA. These methods include techniques based on bisulfite 
conversion, methylation sensitive restriction enzyme digestion and affinity purification of 
methylated DNA (Zilberman and Henikoff, 2007). Methylation sensitive restriction mapping of 
various sized DNAs has provided a means by which to assess methylation status, however the 
utilisation of sodium bisulfite as a cytosine deaminating agent has allowed the application of 
existing and novel technologies to the study of DNA methylation. 
2.7.1.1. Sodium Bisulfite Conversion 
The most commonly used methods for assessing DNA methylation depend on treatment of the 
DNA with sodium bisulfite (BS) (Figure 2.4). Cytosine nucleotides but not methylcytosine 
nucleotides will deaminate upon treatment with sodium bisulfite to form uracil. During PCR 
amplification uracil is recognised by DNA polymerases as thymine and as such, adenine 
residues will be incorporated onto any newly synthesised antisense DNA strand where uracil is 
found in the template strand. Upon successive rounds of PCR, cytosine nucleotides will be 
replaced by thymine nucleotides (Herman et al., 1996) and the result is that conserved 
cytosine residues indicate methylcytosines whilst those amplified as thymines indicate 
unmethylated cytosines (Frommer et al., 1992). Methylation status can then be assessed by a 
variety of analyses. 
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Figure 2.4: Bisulfite conversion of an unmethylated cytosine to uracil.  
Methylated cytosines are resistant to this conversion. 
 
2.7.1.2. Methylation Specific PCR 
MS-PCR utilises the annealing specificity of two different primer sets to selectively amplify a 
small region of either methylated or unmethylated bisulfite converted DNA (Herman et al., 
1996). If the primer set specific to the methylated sequence can anneal and a PCR product is 
produced, the area is considered methylated. Conversely, if no product is produced by the 
methylated primers but a product is produced by a PCR with the unmethylated primers the 
area is unmethylated. One of the limitations of this technique is that DNAs with a 
heterogeneous methylation pattern will provide positive results for both the methylated and 
unmethylated primer sets. The limitations of MS-PCR on heterogeneous DNA samples can be 
overcome by the use of a cloning step after bisulfite treatment and prior to MS-PCR on 
numerous cloned DNAs. This labour intensive step allows MS-PCR to produce semi-
quantitative methylation data and is known as quantitative MS-PCR or qMS-PCR. 
qMS-PCR is also used to describe the use of methylation specific TaqMan probes on non-
methylation-specific PCR products. TaqMan probes utilise the 5’-3’ exonuclease activity of the 
Taq DNA polymerase to degrade bound probes and release a detectable marker (Holland et al., 
1991). Methylated and unmethylated TaqMan probes labelled with different fluorophores are 
used to probe PCRs of BS treated DNAs, if binding is achieved, the fluorophore is released. 
Comparing the relative intensities of the methylated and unmethylated specific fluorophore 
allows quantitative assessment of the methylation state (Eads et al., 2000). 
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2.7.1.3. Bisulfite Sequencing 
Bisulfite sequencing is a commonly used technique that utilises conventional Sanger 
sequencing to determine the sequence, and therefore the methylation state of BS converted 
DNA. When bisulfite sequencing is used on a heterogeneous DNA mix (i.e. DNAs with a mix of 
methylation states), the sequencing results will contain both T and C peaks for a single position 
and only the highest chromatogram peak is reported. To combat this issue, cloning of the PCR 
products into a bacterial vector can be performed, individual clones grown and the vectors 
containing the cloned PCR products sequenced separately. This allows for semi-quantitative 
data to be produced and removes the weak banding peaks produced by partially methylated 
CpGs that are found in heterogeneous DNAs. The advantages of bisulfite sequencing are that 
the techniques are firmly established, widely used, the equipment required is widely available 
and the sequencing reads can also be several hundred bases long. The disadvantages are that 
the cloning steps are time consuming and laborious, the data is semi-quantitative at best (e.g. 
Six out of ten clones were methylated equals 60% methylation) and in order to get an accurate 
estimate of methylation a large number of clones are required, thus increasing the cost of 
reagents and labour. 
2.7.1.4. Pyrosequencing 
Pyrosequencing is a real-time sequencing technique whereby short sequences can be 
sequenced rapidly and quantitatively (Ronaghi et al., 1998). Figure 2.5 is a schematic 
representation of the pyrosequencing reaction. It is a sequencing by synthesis method that 
requires the iterative addition of each dNTP, if the dNTPs added are incorporated then light is 
produced by an enzymic reaction utilising luciferase (Ronaghi et al., 1998). The amount of light 
produced is proportional to the amount of dNTP incorporated. Automated devices are now 
used to control the addition of the dNTPs, the detection of light signals and the analysis of the 
pyrograms. Whilst pyrosequencing can be used to sequence completely unknown sequences, 
it is more suited for detecting and quantifying small changes in an otherwise known sequence 
as is required during SNP and DNA methylation analysis. Pyrosequencing is also functionally 
limited to smaller sequencing reads and is of limited use in whole genome studies where the 
lower throughput and short read length are undesirable (Ronaghi, 2001). 
Pyrosequencing is well suited for use in methylation studies as it provides quantitative 
methylation data on heterogeneous DNAs without the need for a cloning step. Recently, the 
cost of equipment and reagents has decreased considerably, and smaller sections of DNA can 
be sequenced very efficiently and with greater sensitivity than conventional Sanger 
sequencing. Compared to bisulfite sequencing with cloning, the cost of pyrosequencing is now 
very competitive. 
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Figure 2.5: Schematic diagram of the biochemistry of pyrosequencing.  
If the added dNTP does not correspond to the next base in the extending sequencing polymer then it 
is hydrolysed by apyrase to form a nucleoside monophosphate plus inorganic phosphate (Smith et al., 
2002, Ronaghi et al., 1998). If the dNTP is incorporated by DNA polymerase then the diphosphate (PPi) 
released during incorporation is used by sulfurylase to generate ATP, this ATP is subsequently used by 
luciferase to generate light. The amount of light produced is proportional to the number of dNTPs 
incorporated (Ronaghi et al., 1998). 
 
2.7.1.5. Miscellaneous Methylation Assays 
Less frequently used assays include some based on mass spectrometry (Ehrich et al., 2005) and 
methylation sensitive high resolution melting (Wojdacz and Dobrovic, 2007). Mass 
spectrometry is a novel approach that involves first producing an RNA transcript of the 
bisulfite treated/non-treated DNAs to be examined, followed by base specific RNase A 
cleavage at cytosine and uracil ribonucleotides (Ehrich et al., 2005). Varying cleavage patterns 
translate into a differing mass spectrum that are representative of the CpG methylation 
pattern of the source DNA (Ehrich et al., 2005).  
Methylation Sensitive High Resolution Melting (MS-HRM) utilises bisulfite induced sequence 
variation in order to determine the degree of DNA methylation (Wojdacz and Dobrovic, 2007). 
The temperature at which dsDNA melts to ssDNA is largely dependent on the length and GC 
content of the DNA sequence. The GC content of BS treated DNA is altered by the level of DNA 
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methylation such that methylated and unmethylated sequences can be differentiated by 
comparing melting temperatures (Wojdacz and Dobrovic, 2007).  
2.8. Biomarkers 
A biological marker (biomarker) is DNA, RNA, protein, protein modification or a metabolite 
that reflects a biological state. It is a characteristic that is objectively measured and evaluated 
as an indicator of normal biologic processes, pathogenic processes or pharmacologic responses 
to a therapeutic intervention (Nature Biotechology, 2010). 
Several types of biomarker have been defined (Cancer Research UK, 2012b). Diagnostic 
biomarkers indicate the type or stage of cancer. Predictive biomarkers are used to identify 
subpopulations of patients who are most likely to respond to a given therapy. Prognostic 
biomarkers indicate the likely course of disease and are used to estimate patient outcome. 
Screening/early detection biomarkers aid in identifying disease at an early stage in a screening 
environment. In the context of cervical disease, cytological screening for cervical cancer can be 
considered a screening biomarker. While a prognostic biomarker might for example, be used 
to identify which patients with low grade disease are likely to progress to high grade disease, 
regress to a disease free state or persist as low grade disease (Cancer Research UK, 2012b). 
2.8.1.1. How Biomarkers are Developed 
Guidelines in the form of a “roadmap” pertaining to the development of screening, diagnostic 
and predictive/prognostic biomarkers have been published (Cancer Research UK, 2012d, 
Cancer Research UK, 2012e, Cancer Research UK, 2012c). These roadmaps were produced in 
order to improve the quality of biomarker studies and are presented in Appendix I. The early 
stages of development for each type of biomarker are very similar and several criteria in the 
“rationale” section should be met before proceeding. Next, another series of criteria should be 
met prior to proceeding further with marker development. A prospective biomarker study 
should be mindful of good development practice when designing the study. For this study, two 
classes of biomarker have relevance; these are prognostic biomarkers and screening 
biomarkers (Appendix I).
49 
 
2.8.2. DNA Methylation as a Biomarker 
The 2008 UK introduction of an effective prophylactic HPV vaccine is likely to reduce the 
number of cytologically positive cervical samples and reduce the positive predictive value of 
cytological screening. HPV testing is more sensitive for detecting CIN than cytology and will be 
used in the UK, initially for triage of women with low grade cytological abnormalities and for 
test of cure following treatment for CIN (Cuzick et al., 2006). HPV testing has a greater 
negative predictive value, might allow use of self sampling (Katki et al., 2011, Brink et al., 2006) 
and eventually, HPV testing is likely to replace primary cytological screening in the UK. 
Nonetheless, HPV testing is considerably less specific than cytology and HPV testing alone 
would identify many transient infections and HPV infections with a low risk of progression 
(Wentzensen et al., 2009). As such, molecular markers of CIN and cervical cancer for use in 
conjunction with HPV testing would greatly improve the positive predictive value of HPV 
screening, may allow the identification of lesions likely to progress, and thus may improve the 
specificity of HPV testing (Nephew, 2009, Wentzensen et al., 2009). The ideal potential 
screening biomarkers are cellular and molecular characteristics associated with high grade 
cellular dysplasia and carcinoma that are not associated with low grade lesions and non-
infected tissues.  
Aberrant genomic DNA methylation has recently been the focus of much research as a 
potential molecular biomarker; it is a heritable marker that is present in 1-5% of all CpG islands 
in human tumours, is detectable and quantifiable and may be directly implicated in the onset 
of carcinogenesis (Nephew, 2009). DNA methylation shows considerable potential as a 
biomarker for several cancers. Lung cancer has been particularly well studied. A range of gene 
promoters are specifically hypermethylated in lung cancer, several of which have been further 
studied as early detection, predictive and prognostic biomarkers (e.g. RASSF1, CDKN2A, CYGB, 
EDNRB, RARbeta, MGMT, APC, DAPK, FHIT etc) (Liloglou et al., 2012). Many of these genes 
have also been identified for other tumour sites, for example melanoma (RASSF1, RARbeta) 
oesophageal (APC) and breast cancer (RASSF1, APC) biomarker studies (Muller et al., 2003, 
Mori et al., 2005, Kawakami et al., 2000). 
Numerous studies have focussed on both human and HPV DNA methylation as a marker for 
cervical cancer. The most promising human methylation markers appear to be CADM1 (cell 
adhesion molecule 1) and Mal (T-lymphocyte maturation associated protein). CADM1 and Mal 
are associated with later and earlier events in HPV-associated carcinogenesis respectively and 
both show promoter hypermethylation in cervical cancer (Steenbergen et al., 2004, Overmeer 
et al., 2009).  
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2.8.2.1. HPV Methylation as a Biomarker 
Whilst many studies have aimed to identify methylation differences between different grades 
of cervical disease (occasionally with conflicting results), fewer studies have attempted to 
evaluate the potential of HPV methylation as a biomarker of cervical disease. Brandsma et al 
identified patterns of DNA methylation that were associated with various disease grades. HPV 
genomic hypomethylation was associated with lower grade cervical disease (normal cytology 
and negative histology in most instances) and hypermethylation at several regions (E5, L1 and 
L2) was associated with higher grade disease in most instances however the sample size was 
very small (n=13) and there was considerable variation (Brandsma et al., 2009).  
Mirabello et al used a HPV genome wide approach on a large sample set (n=154) and identified 
numerous CpGs where methylation was significantly different between the disease grades 
studied. These CpGs were located primarily in the L1, L2 and E2/E4 regions although CpGs 
throughout other areas of the genome were also significantly associated with disease grade. L1 
and L2 methylation was deemed especially predictive of disease grade (Mirabello et al., 2012).  
Kalantari et al considered the potential of L1 methylation as a biomarker of cervical disease. 
There was an association between L1 methylation and integration, and the authors considered 
that integration could be a marker of disease progression (Kalantari et al., 2010). Nonetheless, 
the study had a small sample size (n=21) and there was a degree of variation. 
As previously discussed, DNA methylation of other HPV and HPV in other anogenital sites was 
largely concordant with HPV16 methylation in cervical specimens. This increases the likelihood 
of a cervical disease biomarker developed for HPV16 and CIN having wider clinical utility. 
 
2.8.2.2. Biomarker Investigation 
The earliest stages of biomarker development (Cancer Research UK, 2012d, Cancer Research 
UK, 2012e) concern assay design and the evaluation of variation within the prospective sample 
cohort (Appendix I). This investigation was mindful of these requirements during study design 
and method development. Several DNA methylation assays were trialled, methylation at 
various regions of the HPV genome was assessed and both the basic biology of HPV and the 
potential clinical utility of knowledge of HPV methylation were considered throughout. 
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2.9. Chapter Introductions  
In order to study the biology and potential clinical utility of HPV DNA methylation, four 
interrelated studies were devised, presented here as separate chapters. Method development 
is also presented as a short chapter. Aspects of each chapter are relevant to other chapters 
and the results of earlier studies influenced both the hypotheses and design of later studies. 
2.9.1.1. Method Development 
The first steps in this investigation were the development of assays to determine HPV 
methylation status and gene expression status of HPV. The major steps involved in method 
development of qPCR and pyrosequencing are detailed and discussed in this chapter. 
2.9.1.2. HPV Methylation and Disease Grade (the NSC Study) 
The relationship between HPV methylation and disease grade was determined. Three sample 
series were used, these were: Liquid Based Cytology (LBC) material displaying normal cytology, 
LBC material showing severe dyskaryosis, and formalin fixed cervical cancers. This study was 
primarily devised to determine the differences in DNA methylation between various stages of 
cervical disease and consider the potential clinical utility that a knowledge of HPV DNA 
methylation status may provide. In addition, this study constituted a means by which to 
facilitate further method development and compare data produced by pyrosequencing to 
published methylation data. 
2.9.1.3. HPV Methylation and Clinical Outcome (the CRISP Study) 
There is a distinct lack of longitudinal HPV methylation data in the literature. The CRISP study 
was proposed in order to relate HPV methylation of low grade cytological abnormalities with a 
variety of clinical outcomes 6 months later. Three groups of samples were extracted from a 
large cohort. The first group represented those patients that had cleared a HPV16 infection 
during the course of 6 months. The other two groups represented patients that had low grade 
histology at 6 months, or high grade histology at 6 months. This study allowed further 
elaboration of the potential clinical utility of HPV DNA methylation, and also allowed changes 
in HPV methylation over time to be considered. 
2.9.1.4. DNA Methylation, Integration and Gene Expression in vitro (the Cell 
Lines Study) 
The cell lines study included methylation assessment of a variety of HPV-associated human cell 
lines and was primarily designed to make use of a well characterised series of VIN/VAIN short 
term culture cell lines. The use of cell lines allowed the assessment of changes in methylation 
over time (i.e. with passages) and an in vitro assessment of the relationship between DNA 
methylation, integration and HPV gene expression. In addition to the short term culture cell 
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lines, a W12 cell line which underwent integration whilst in passage allowed the relationship 
between methylation and integration to be further investigated. This study examined the 
relationship between methylation, integration and gene expression in vivo. 
2.9.1.5. DNA Methylation, Integration and Gene Expression in vivo (the VR 
Study) 
The VR study utilised a series of predominantly VIN2/3 biopsies for which both DNA and RNA 
were available. HPV methylation, integration and gene expression assessment were performed 
and the relationship between these three characteristics was explored. Hypotheses generated 
in previous studies were tested here and differences/similarities between the studies were 
explored further. The VR study also permitted characterisation of the methylation status of the 
VIN2/3 series from the perspective of biomarker development and HPV type distribution. 
2.9.1.6. General Discussion 
Several aspects of the previous 5 chapters had broader relevance or commonalities among the 
studies. In order to avoid repetition, topics common to several chapters are discussed in the 
general discussion. 
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Chapter 3. Methods and Materials 
 
3.1. Methods 
3.1.1. Nucleic Acid Extraction 
Several methods of nucleic acid extraction from VIN biopsy material were used during this 
investigation.  
3.1.1.1. TRIzol DNA and RNA Extraction 
TRIzol Reagent (Invitrogen, Paisley, UK) extraction of DNA and RNA was performed for several 
VIN biopsy samples before an alternative VIN biopsy protocol was used. Biopsies were cut into 
pieces of 1 mm3 or smaller using a disposable sterile scalpel and placed into 1 ml of TRIzol. 
Biopsy material was then disrupted using a TissueRuptor (Qiagen, Hilden, Germany) at full 
speed for 20 s using disposable probe tips. Samples were incubated at room temperature for 
10 mins then 200 µl of chloroform was then added, mixed and the samples incubated for a 
further 5 mins at room temperature. 
Sample mixes were centrifuged for 15 mins (10,000 rpm, 4 °C). The aqueous phase was used 
for RNA extraction whilst the organic phase and interphase were used for DNA extraction. 
3.1.1.1.1. RNA Extraction 
To the aqueous phase, 500 µl of isopropanol (100%) and 1 µl of glycogen (20 mg/ml) were 
added the tube was then vortexed and incubated at -20 °C overnight before being centrifuged 
for 10 mins (8,000 rpm, 4 °C). The supernatant was discarded and 1 ml of 70% ethanol was 
added, vortexed and centrifuged for 10 mins (8,000 rpm, 4 °C). The supernatant was removed 
again before the pellet was air dried and resuspended in 28 µl of water. RNAs were later 
purified further using a NucleoSpin RNA Cleanup XS Kit (Machery-Nagel, Duren, Germany) 
performed according to manufacturer’s instructions and eluted into 30 µl of RNase free water. 
3.1.1.1.2. DNA Extraction 
After all of the aqueous phase was removed, 0.3 ml of 100% ethanol was added to the organic 
phase and interphase; this was mixed by inversion and incubated at room temperature for 5 
mins. Samples were then centrifuged for 10 mins (4,000 rpm, 4 °C). The supernatant was 
discarded and 1 ml of 0.1 M Sodium citrate in a 10% ethanol solution was added and incubated 
at room temperature for 30 mins with periodic mixing. The samples were centrifuged and the 
Sodium citrate wash and centrifugation steps were repeated. The supernatant was removed 
and the DNA pellet was allowed to air dry for 15 mins before being resuspended in 250 µl of 
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NaOH (8 mM) and 21.5 µl of HEPES (0.1 M). The mix was centrifuged at for 10 mins (10,000 
rpm) to collect cellular debris and the supernatant was removed for further purification. 
DNAs were further purified using the DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany) 
protocol. To the 271.5 µl sample, 180 µl of ATL buffer was added and the DNA purification 
from animal tissues, spin column protocol followed precisely from step 2 onwards (Handbook 
July/2006, p.29). The protocol involved binding of DNA to a spin column membrane, several 
washing steps and final elution into 2 x 100 µl of AE buffer. 
3.1.1.2. VIN RNA/DNA Extraction Protocol 
This protocol was adopted part way through the investigation as it was shown to produce 
higher quantity/quality DNA than TRIzol extraction during a small scale nucleic acid yield test. 
Two stages of nucleic acid extraction were performed, one stage using the RNeasy Fibrous 
Tissue Kit (Qiagen, Hilden, Germany) for RNA extraction and the other using the QIAamp DNA 
extraction kit (Qiagen, Hilden, Germany) for DNA extraction. Initial processing was performed 
using the RLT buffer from the RNeasy Kit. 
The biopsies were placed into locking microcentrifuge tubes and rinsed with 1 ml of sterile 
water. Tissue pieces larger than 3 mm in diameter were cut into pieces using a sterile scalpel 
to ensure efficient disruption. The water was aspirated and 360 μl buffer RLT (with 10 μl/ml β-
mercaptoethanol) was added to each tube. Biopsy samples were then disrupted using a 
TissueRuptor (Qiagen, Hilden, Germany) at full speed for 20 s using disposable probe tips. 
708 μl of RNase free water and 20 μl of proteinase K were added to the tissue suspension. This 
was followed by incubation at 55 °C for 10 mins before centrifugation for 3 mins (13,000 rpm) 
to form a pellet. A volume of 650 μl of the supernatant was transferred to a labelled tube and 
the remaining supernatant/cell pellet were resuspended and returned for further incubation at 
55 °C. The protocol then split into two stages, one each for the elution of RNA and DNA. 
3.1.1.2.1. RNA Extraction 
The RNA extraction stage used the 650 μl of supernatant processed previously. To the cleared 
lysate, 325 μl of ethanol (100%) was added and the solution was repeat pipetted to mix. The 
remainder of the extraction protocol was performed as per the instructions of the RNeasy 
Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany), from step 10 onwards (Handbook Oct/2010, 
p.17). This consisted of washing the bound RNA with a series of buffer solutions and eluting in 
2 x 50 µl of water. 
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3.1.1.2.2. DNA Extraction 
Using the remaining cell pellet and lysate, DNA was extracted using the QIAamp DNA kit 
(Qiagen, Hilden, Germany). To each sample, 350 μl Buffer AL was added, mixed and incubated 
at 70 °C for 10 mins; 350 μl ethanol (100%) was then added to each sample. Up to 600 μl of 
supernatant was added to each spin column, which as then centrifuged at 13,000 rpm for one 
minute. The flow through was discarded and the remaining sample was added to the spin 
column and centrifuged. A new collection tube was used and the instructions of the QIAamp 
DNA kit, tissue extraction spin protocol were followed from step 8 onwards (Handbook 
April/2010, p.36). This consisted of washing the bound DNA with a series of buffer solutions 
and eluting in 2 x 100 μl of AE buffer. 
3.1.1.3. Qiagen AllPrep DNA/RNA Extraction Kit 
DNA and RNA were extracted from cell line material using the AllPrep DNA/RNA Mini kit 
(Qiagen, Hilden, German) according the manufacturer's instructions (animal cells protocol). 
Briefly, the protocol consisted of lysing the cells within the culture vessel. The lysate was then 
homogenised using a 20 gauge needle and a disposable syringe. DNA was then bound to a spin 
column, washed and eluted into 2 x 50 µl of Buffer EB. RNA was bound to a second column, 
washed and eluted into 2 x 50 µl of RNase free water. 
3.1.1.4. QIAamp MinElute Media Kit 
DNA was extracted from LBC material using the QIAamp MinElute Media kit (Qiagen, Hilden, 
Germany). LBC cell pellets were resuspended in 500 µl of TRIS (10 mM, pH 7.4) and a 100 µl 
aliquot was taken for DNA extraction. The remaining material was stored at -80 °C. To the 
sample, 150 µl of TRIS (10 mM, pH 7.4), 80 µl of ATL buffer and 20 µl of proteinase K were 
added and the mix was then incubated at 56 °C for 30 mins and periodically vortexed. Carrier 
RNA was prepared in AVE/AL buffer according to the instructions, 250 µl of AL (with carrier 
RNA) was added to the sample and after vortexing, incubated at 70 °C for 15 mins. 
To each sample, 300 µl of ethanol (100%) was added. The samples were then vortexed and 
incubated at room temperature for 5 mins. To each QIAamp MinElute column, 500 µl of lysate 
was added and centrifuged (8,000 rpm, 3 mins). The eluate was discarded and the remaining 
lysate was added and centrifuged. Bound DNAs were washed with 650 µl of AW2 and 
centrifuged (8,000 rpm, 3 mins) and then washed with 650 µl of ethanol and centrifuged 
(8,000 rpm, 3 mins). The collection tubes were emptied and the membranes were dried by 
centrifugation (13,000 rpm, 3 mins) followed by placing the column in a clean tube DNA/RNA 
and heating at 56 °C for 3 mins to evaporate residual ethanol. DNA was then eluted into 100 µl 
of AVE elution buffer (13,000 rpm, 3 mins). 
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3.1.2. General Techniques 
3.1.2.1. Nucleic Acid Concentration 
DNA and RNA concentration were quantified using a ND-1000 spectrophotometer (NanoDrop 
products, Wilmington, DE, USA). DNA/RNA (1.5 µl) was tested against a blank of DNA/RNA free 
elution buffer/water. 
3.1.2.2. RNA Handling 
RNA is highly susceptible to enzymatic degradation. Several aspects of this study included RNA 
work (qPCR, nucleic acid extraction, APOT). All RNA work was performed within a HEPA filtered 
PCR cabinet treated with 30 mins UV light and all surfaces and equipment were thoroughly 
treated with RNaseZAP (Sigma-Aldrich Company Ltd, Dorset, UK). Separate sets of 
reagents/consumables were used for RNA work and where applicable, equipment/materials 
were also treated with UV light. RNase/DNase free microcentrifuge tubes and pipette tips and 
DEPC treated or RNase free water were used throughout. 
3.1.2.3. DNA Handling 
DNA is susceptible to enzymatic degradation. PCR and DNA work were conducted in a HEPA 
filtered PCR cabinet sterilised between uses with 15 mins UV light. All water used for DNA/PCR 
was DNA grade water that had been further sterilised with UV light. DNase free tubes and 
pipette tips were used throughout. 
3.1.2.4. PCR 
PCR and gradient PCR were performed using Techne TC-412 and Techne TC-512 thermal 
cyclers (Bibby Scientific Ltd, Staffs, UK). 
 
3.1.3. HPV Typing: Greiner Bio-One PapilloCheck 
The PapilloCheck assay (Greiner Bio-One GmbH, Frickenhausen, Germany) allows the 
simultaneous identification of 24 HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 
59, 66, 68, 70, 73, 82, 6, 11, 40, 42, 43, and 44). The assay uses multiplex PCR with fluorescent 
primers to amplify a 350 bp fragment of the HPV E1 gene. HPV type specific sequences are 
then detected using a microarray consisting of 5 replicate spots of 28 probes. Hybridisation of 
PCR products to probes was then assessed using the CheckScanner array reader. Valid results 
were those which passed each of the numerous PapilloCheck internal controls (including DNA 
adequacy, sample inhibition, and hybridization). The assay includes amplification of the human 
ADAT1 gene in order to identify false negatives. The manufacturer’s instructions were followed 
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throughout. For each multiplex PCR reaction, 20 µl of PCR master mix (Table 3.1) was added to 
a 5 µl of sample DNA and run according to the PCR timing/temperatures in Table 3.2. 
 
 
1 reaction 13 reactions (1 chip) 
Volume (µl) Volume (µl) 
PapilloCheck Master Mix 19.8 257.4 
HotStarTaq Polymerase (5 U/µl) 0.2 2.6 
Uracil-N-Glycosylase* 1 13 
Total volume  21 273 
Table 3.1: Greiner PapilloCheck PCR master mix recipe. 
Included are the volumes required for one reaction, or a chip of (n=13) reactions. * Uracil-N-
Glycosylase was first diluted 1/200 with sterile water. 
 
Temperature (°C) Time (s) Cycles 
95 900 1 
95 30   
55 25 40 
72 45   
95 30 15 
72 45   
Table 3.2: Greiner PapilloCheck PCR timing and temperature settings. 
 
Following PCR, PCR products were hybridised to DNA arrays and washed. Wash solution was 
prepared using 140 ml of distilled water, 14 ml of PapilloCheck buffer A and 1.75 ml of buffer 
B, mixed and then divided equally among three 50 ml falcon tubes labelled 1-3. Wash buffer 
tube 2 was heated to 50 °C before use. Five µl of PCR product was added to 30 µl of 
PapilloCheck hybridisation buffer. After mixing, 25 µl of the hybridisation mix was transferred 
to a compartment of the chip. The chip was incubated at room temperature in the 
PapilloCheck humidifier box for 15 mins. Three wash steps were then performed which 
involved vigorous agitation for 10 s in wash buffer tube 1, 60 s in tube 2, 10 s in tube 3 before 
drying by centrifugation. 
Chips were then scanned and data analysed using the GBP CheckScanner and the CheckReport 
Software as per the manufacturer’s instructions. 
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3.1.4. Quantitative Real Time Reverse Transcriptase PCR 
3.1.4.1. Reverse Transcription 
Prior to Reverse Transcription (RT), RNAs were DNase treated to remove residual DNA.  
3.1.4.1.1. DNase Treatment 
DNase treatment was performed using amplification grade DNase I (1 U/µl) and reaction 
buffer (Invitrogen, Paisley, UK). One µg RNA was treated using 1 µl of DNase I, 1 µl of 10x 
Reaction Buffer and DEPC treated water in a final volume of 10 µl. The reagents were mixed 
gently (DNase I is susceptible to physical denaturation) and then incubated at room 
temperature for 15 mins. Inactivation of DNase I was then performed by adding 1 µl of EDTA 
(25 mM) and incubating at 65 °C for 10 mins. 
3.1.4.1.2. Reverse Transcription (cDNA synthesis) 
RT was performed using random primers (hexamers) and the SuperScript III Reverse 
Transcriptase (RT) kit (Invitrogen, Paisley, UK). RT was performed using 1 µl of random primers 
(200 ng/µl), 0.5 µg of RNA (DNase treated), 1 µl of dNTP mix (10 mM) and RNase free water to 
13 µl. This mix was incubated at 65 °C for 5 mins, and then kept on ice for 1 min.  
The following components of the SuperScript III RT kit (Invitrogen, Paisley, UK) were then 
added: 4 µl of 5x First Strand Buffer, 1 µl of 0.1 M DTT (Dithiothreitol), 1 µl of RNaseOUT and 1 
µl of SuperScript III RT. This was mixed gently, incubated at 25 °C for 5 mins, 50 °C for 60 mins 
and then inactivated at 70 °C for 15 mins. To correct for undigested genomic DNA in later qPCR 
steps, all reactions were performed in duplicate using H20 instead of RT. 
3.1.4.2. qPCR Reaction Protocol 
Quantitative Real Time Reverse Transcriptase PCR (qRTRTPCR or qPCR) was performed using 
the LightCycler carousel-based qPCR system (Roche Applied Science, Mannheim, Germany). 
LightCycler DNA Master SYBR Green I reagent kits and LightCycler reaction capillary tubes 
(Roche Applied Science, Mannheim, Germany) were used. FS mix was produced by adding 10 
µl of LightCycler reagent 1a to a full vial of defrosted reagent 1b. After mixing, this reagent was 
kept at 4 °C and not refrozen. The qPCR master mix (Table 3.3) was prepared in a cooling block. 
  
59 
 
 
Primer pair 
 
E2/E6/HPRT E7 TBP2 
Reagent µl per reaction 
Forward primer (5 µM) 2 2 2 
Reverse primer (5 µM) 2 2 2 
FS Mix 2 2 2 
MgCl2 (25 mM) 1.6 2 2.4 
Water 10.4 10 9.6 
Template cDNA 2 2 2 
Table 3.3: qPCR master mix preparation protocol.  
The table represents the required reagents per reaction for each of the 5 primer pairs. 
 
18 µl of the qPCR master mix was dispensed into the top of each glass capillary tube, and then 
2 µl of the appropriate cDNA was added to each tube before a short centrifugation step (3,000 
rpm, 5 s) was performed. cDNAs from the RT reaction were typically diluted 1/10 for clinical 
samples and 1/100 for cell lines. Water was used as a negative control and all runs included 
1/100 CaSki cDNA in triplicate. To correct for undigested genomic DNA, RT negative controls 
were also run. 
The carousel was loaded with reaction capillaries, placed into the LightCycler and the PCR 
reaction performed according to the timing/temperature in Table 3.4. 
 
Temperature (°C) Time (s) Cycles 
Initial denaturation 95 600 1 
Denaturation 95 10 
 Primer annealing 58/60/62* 5 60 
Extension 72 5 
 
 
Temperature (°C) Rate of change (°C/s) Cycles 
Meting Curve 65-95 0.1 1 
Table 3.4: qPCR temperature and timing protocol.  
Details are listed for both the qPCR reaction and the subsequent melting curve. *Annealing 
temperatures were specific to each primer pair. E2 (58 °C), E6/HPRT/TBP (60 °C) and E7 (62 °C). 
 
3.1.4.2.1. Data Analysis 
The LightCycler software’s capacity for data analysis was limited. It does not allow for the 
analysis of data using calibration curves from more than one standard curve or from sample 
data run in duplicate. There were also RT negative controls which could not be accounted for 
in the analysis. Instead, calibration curves were produced (Chapter 4) and imported into the 
LightCycler software. The LightCycler software was then used to generate Ct values and 
express those values as CaSki cDNA concentrations (e.g. if a sample generated the same Ct as 
CaSki 1/10 cDNA, the calculated concentration would be 0.1).  
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The difference in calculated concentration between the RT positive and the RT negative 
samples was equal to the amount of signal attributable to cDNA, corrected for undigested 
genomic DNA. These values were converted back into Ct values and used for relative 
quantification. Relative quantification was performed with two reference genes using the PCR 
efficiency corrected equation described by Vandesompele et al (Vandesompele et al., 2002). 
This is discussed in greater detail in the methods development chapter (Chapter 4) 
3.1.4.3. Primer Sequences 
The qPCR primer sequences are detailed in Table 3.5. 
 HPRT 
Name Hypoxanthine guanine phosphoribosyl transferase (HPRT) 
Sense primer TGACACTGGCAAAACAATGCA 
Antisense primer GGTCCTTTTCACCAGCAAGCT 
Amplified DNA 4982 bp (nt 133627546-133632438 of Chr X) 
Amplified RNA 94 bp (nt 496-589 of M31642.1) 
Reference (Allen, Winters et al., 2008) 
TBP2 
Name TATA binding protein, 2nd pair of primers (TBP2) 
Sense primer TCAAACCCAGAATTGTTCTCCTTAT 
Antisense primer CCTGAATCCCTTTAGAATAGGGTAGA 
Amplified DNA 803 bp (nt 170880539-170881341 of Chr 6) 
Amplified RNA 122 bp (nt 1128-1224 of M55654.1) 
Reference (Minner and Poumay 2008) 
E6 
Sense primer CTGCAATGTTTCAGGACCCA 
Antisense primer TCATGTATAGTTGTTTGCAGCTCTGT 
Amplified DNA/RNA 80 bp (nt 99-178 of NC001526.1) 
Reference (Wang-Johanning, Lu et al., 2002) 
E7 
Sense primer AAGTGTGACTCTACGCTTCGGTT 
Antisense primer GCCCATTAACAGGTCTTCCAAA 
Amplified DNA/RNA 78 bp (nt 739-816 of NC001526.1) 
Reference (Wang-Johanning, Lu et al., 2002) 
E2 
Sense primer AACGAAGTATCCTCTCCTGAAATTATTAG 
Antisense primer CCAAGGCGACGGCTTTG 
Amplified DNA/RNA 82 bp (nt 3362-3426 of NC001526.1) 
Reference (Roberts, Ng et al., 2008) 
Table 3.5: qPCR primer sequences and original source for each primer pair.  
The primer sequences and source of the sequences are listed for each primer pair. For the human 
reference genes two amplicon lengths are given because the primer pairs are junction spanning, the 
mRNA amplicons are shorter than the DNA amplicons. Regions amplified are accompanied by 
GenBank ID. 
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3.1.5. Pyrosequencing 
3.1.5.1. Bisulfite Treatment 
Treatment of DNA with Sodium bisulfite (BS) was conducted using the EZ DNA Methylation Kit 
D5001 (Zymo Research Corporation, CA, USA). The protocol included modifications 
recommended by the manufacturer to improve conversion efficiency. Kit reagents were 
prepared by adding 24 ml of ethanol (100%) to the 6 ml of M-Wash Buffer concentrate, and by 
adding 750 µl of water and 210 µl of M-Dilution Buffer to a tube of CT Conversion Reagent. CT 
Conversion Reagent was then vortex mixed until required. 
Each reaction required 500 ng of DNA made up with H20 to 32.5 µl. For several low 
concentration DNA samples less than 500 ng was used. To each sample 7.5 µl of M-Dilution 
Buffer was added and incubated at 42 °C. After 30 mins of incubation, 97.5 µl of prepared CT 
Conversion Reagent was added to each reaction and the samples were incubated at 50 °C 
overnight (12-16 hrs). For negative controls, water was used in place of CT Conversion 
Reagent. 
After incubation, the samples were cooled on ice for 10 mins, loaded into Zymo-Spin columns 
containing 400 µl of M-Binding Buffer, mixed by inversion and centrifuged. All centrifugation 
steps were performed at 13,000 rpm for 30 s and collection tubes were emptied when 
necessary. Samples were washed by adding 100 µl of M-Wash Buffer and centrifuging the 
tubes. Desulphonation buffer (200 µl) was added and samples were incubated at room 
temperature for 15-20 mins before centrifugation. Final wash steps were performed by adding 
200 µl of M-Wash Buffer to each column and centrifuging this was performed twice. 
Finally, DNAs were eluted into 10 µl of M-Elution Buffer by centrifugation. 
3.1.5.2. Pyrosequencing PCR 
Pyrosequencing PCRs were performed in 50 μl reactions. Two μl of 1/10 diluted BS converted 
sample DNA was used for each PCR reaction using clinical DNAs. CaSki BS treated DNA was 
typically used at 1/100 dilution. ZymoTaq hot start DNA polymerase premix was used (Zymo 
Research Corporation, CA, USA). 
For each primer pair, the PCR reaction mixes are listed in Table 3.6. 
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 Primer pair 
 
E2 LCR1 LCR2 L1/L2 
Reagent Volume per 50 μl reaction (μl) 
ZymoTaq premix 25 25 25 25 
F primer (5 μM) 2 2 2 2 
R primer (5 μM) 2 2 2 2 
Water 17 16 16 16 
MgCl2 (25 mM) 2 3 3 3 
Template DNA 2 2 2 2 
    
 
    
Reaction [Mg2+] (mM) 2.75 3.25 3.25 3.25 
Table 3.6: Pyrosequencing PCR master mix recipes.  
Values in the table represent the volume required per reaction. Template DNA refers to appropriately 
diluted BS treated DNA. Final [Mg
2+
] refers to the final reaction concentration of Mg
2+
 ions in mM for 
each master mix. 
 
Into each well of a PCR plate, 48 μl of master mix and 2 μl of diluted BS treated DNA were 
pipetted. A negative control (water or BS negative controls) and a CaSki positive control were 
included for each primer pair. PCR was performed according to the timing and temperatures 
listed in Table 3.7. 
 
Temperature (°C) Time (s) Cycles 
Initial denaturation 95 600 1 
Denaturation 95 30 
 Primer annealing 48/51/54* 45 40 
Extension 72 30 
 Final extension 72 600 1 
Table 3.7: Pyrosequencing PCR temperature and timing protocol.  
*Annealing temperatures were specific to each primer pair. E2/LCR1 (48 °C), LCR2 (51 °C) and L1/L2 
(54 °C). 
 
3.1.5.3. Pyrosequencing Reaction 
Most equipment and reagents used for the pyrosequencing reaction were supplied by Qiagen 
(Qiagen, Hilden, Germany). This included the PyroMark Q96 ID Instrument, PyroMark CpG 
Software v1.0.11, PSQ96 Reagent Cartridges, PSQ Plate Low (PSQ reaction plates), PyroMark 
Q96 Vacuum Prep Workstation, PyroMark Gold Q96 Reagents, PyroMark buffer solutions. In 
addition, Streptavidin Sepharose beads (30% w/v) (GE Healthcare Life Sciences, 
Buckinghamshire, UK) were also required. 
3.1.5.3.1. Process 
PCR products were diluted by adding 27 μl of PCR product to 13 μl DNA grade water. The 
vacuum workstation was assembled and the trays were filled with the appropriate solutions 
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(Figure 3.1) (1/10 diluted wash buffer, 70% ethanol, water (deionised and autoclaved), 
denaturation buffer). 
 
 
Figure 3.1: The correct tray and plate positions on the PyroMark Q96 Vacuum Prep Workstation. 
 
The vacuum prep tool head was rinsed through with clean water for 20 s. Details of the 
reaction and samples were inputted into the PyroMark CpG Software.  
Pyrosequencing PCR was performed using a biotin labelled primer. PCR products were 
immobilised by adding 1.75 µl of streptavidin sepharose bead suspension and 38.25 µl of 
PyroMark Binding Buffer per reaction. The mixes were then shaken on a shaking hot plate for 
at least 5 mins (1,400 rpm, 22 °C). Sequencing primers were made up by diluting (per reaction) 
1.5 μl of 10 μM sequencing primer with 43.5 μl of PyroMark Annealing Buffer. Into each well of 
a PSQ reaction plate, 45 μl of sequencing primer mix was dispensed and the plate was placed 
into the correct compartment of the vacuum workstation (Figure 3.1). 
The PCR product/sepharose bead mix was removed from the hotplate and placed into the 
correct position on the vacuum workstation. Within 30 s of cessation of shaking, vacuum was 
applied to the workstation and the sepharose beads with immobilised PCR products were 
captured by slowly lowering the vacuum prep tool into the PCR plate. The vacuum prep tool 
was then placed into each the following solution trays (in order) for 5 s each; 70% v/v ethanol 
solution, PyroMark Denaturation Solution, 10% v/v PyroMark Washing Buffer. The prep tool 
was held vertically and any residual fluid was aspirated. The vacuum switch was closed and the 
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prep tool was lowered into the PSQ reaction plate containing sequencing primer and agitated 
to release the captured PCR products. By this point, PCR products had been denatured into 
single stranded products and the complementary strand had been removed. 
The PSQ plate containing beads and sequencing primer was heated at 80 °C for 2 mins then 
cooled to room temperature. The PyroMark Gold Q96 Reagent kit contained lyophilised 
enzyme and substrate pellets as well as dNTP mixes. Enzyme and substrate were reconstituted 
with the volume of water specified on the container 10 mins prior to use. The PSQ96 Reagent 
Cartridge was filled using the volumes specified by the pyrosequencing software and the wells 
specified in Figure 3.2. 
 
Figure 3.2: A diagram of the PSQ96 Reagent Cartridge detailing compartments of the cartridge where 
each reagent was loaded. The cartridge label was positioned at the front, facing the operator. 
Nomenclature: S = substrate mix; E = enzyme mix; G = dGTP solution; T = dTTP solution; A = dATP 
solution; C = dCTP solution. 
 
The cartridge and reaction plate were secured within the PyroMark Q96 ID Instrument and the 
run was started. At the end of the run, the data was analysed automatically and a pyrogram 
was produced for each pyrosequencing reaction (e.g. Figure 3.3).  
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Figure 3.3: The LCR2 pyrogram for CaSki.  
The string of sequence across the top is the sequence to analyse. The string of sequence across the X-
axis is the dNTP dispensation order (E=enzyme, S=substrate). The Y-axis scale is Relative Light Units 
(RLU). The height of peaks represents the strength of the signal, here 25, 50 and 75 RLU are equal to 
approximately 1, 2 and 3 incorporated nucleotides respectively. Areas shaded grey represent sites of 
CpGs; both C and T are dispensed and the height of the peaks compared to determine DNA 
methylation % of that CpG. Methylation % is indicated in the coloured box above each CpG and the 
colour indicates the data quality (blue = good, yellow = check for acceptability and red = significant 
inadequacies). 
 
Values considered by the pyrosequencing software to have failed the internal controls 
(indicated by a red box (Figure 3.3)) were not included in the data analysis. Due to the nature 
of the pyrosequencing reaction, it was more difficult to accurately determine the amount of 
methylation at some CpGs than it was at others. As such, for some sample cohorts there were 
missing values for some CpGs, some assays or even entire samples. All samples were repeated 
in duplicate in order to improve the likelihood of producing a complete data set and to 
improve the reliability of the data analysis. Failed reactions were repeated (in duplicate) at 
least once, data of the highest quality was selected and where two runs of equal quality (as 
determined by passing/failing the internal controls) existed, to avoid selection bias runs were 
chosen for inclusion in chronological order.  
3.1.5.3.2. Clean Up 
Careful clean up was especially important as blockage of the reagent cartridge and/or vacuum 
prep tool would result in failed reactions. Immediately after the sequencing reaction had 
finished, the PSQ96 Reagent Cartridge was thoroughly cleaned with sterile water. 
Clean up of the vacuum workstation required all solution trays to be emptied and rinsed. The 
vacuum prep tool was rinsed with water, then ethanol before the head was fully aspirated of 
fluid and allowed to dry. All equipment was protected from the ingress of particulates by being 
stored in clean plastic containers in a lint free environment. 
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3.1.5.4. Assay Design 
Pyrosequencing assays were designed within PyroMark Assay Design Software 2.0 (Qiagen, 
Hilden, Germany). The manufacturer’s instructions were followed and primer sets were chosen 
based on primer length, melting temperature, GC content, GC clamp, presence of secondary 
structure (primer and template), and the presence of single and dinucleotide repeats. For 
L1/L2, a very limited range of alternative primers were available due to the amplimer size 
limits and the presence of secondary structures either side of the region of interest. 
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3.1.5.5. Primer Sequences 
For each pyrosequencing assay, the primer sequences, regions amplified and dispensation 
order for sequencing are listed in Table 3.8. 
E2 
Sense primer GTGAAATTATTAGGTAGTATTTGG 
Antisense primer BTN-CAACAACTTAATAATATAACAAAAA 
Sequencing primer GTGAAATTATTAGGTAGTA 
Dispensation order ATTGCTATGATTCTGTCAGTCGATTATATAATGTCAGTCGTTTGGTGATCGAGAA 
  TATAGTATCGATATTATGTCGA 
Amplified DNA 148 bp (nt 3378-3525 of NC001526.1) 
Sequenced CpGs nt 3411, 3414, 3416, 3432, 3435, 3447, 3461, 3472 
Reference Dr T Liloglou, University of Liverpool, personal communication (Dec 7th 2010) 
LCR1 
Sense primer BTN-ATTGTATTATGTGTAATTATTGAA 
Antisense primer CCAAAAATATATACCTAACAAC 
Sequencing primer CCAAAAATATATACCTAACAAC 
Dispensation order CAGATAGTATAAATCGATATCGACAT 
Amplified DNA 104 bp (nt 7611-7714 of NC001526.1) 
Sequenced CpGs nt 7691, 7679, 7673 
Reference Dr T Liloglou, University of Liverpool, personal communication (Dec 7th 2010) 
LCR2 
Sense primer GTAAAATTGTATATGGGTGT 
Antisense primer BTN-TAAAATATCTACTTTTATACTAACC 
Sequencing primer TAATTTATGTATAAAATTAAGG 
Dispensation order AGTCGTCGATCGTAATCGTGTATCGTAATCGTA 
Amplified DNA 156 bp (nt 7832-83 of NC001526.1) 
Sequenced CpGs nt 31, 37, 43, 52, 58 
Reference Dr T Liloglou, University of Liverpool, personal communication (Dec 7th 2010) 
L1/L2 
Sense primer BTN-TTATTGTTGATGTAGGTGATTT 
Antisense primer CCCAATAACCTCACTAAACAACC 
Sequencing primer TAACCTCACTAAACAACCAA 
Dispensation order GCAAAAACAATCTAAAAAAATGATAATAAATCGATTATCGATACGATTTACGATAC 
Amplified DNA 118 bp (nt 5551-5668 of NC001526.1) 
Sequenced CpGs nt 5615, 5609, 5606, 5600 
Table 3.8: The primer sequences, regions amplified and CpGs sequenced for the pyrosequencing 
assays.  
BTN refers to the position of a biotin label. NC001526.1 is the HPV16 reference sequence. 
Dispensation order is the order used by the pyrosequencing instrument to sequence, by synthesis, the 
pyrosequencing PCR products. 
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3.1.6. DIPS 
Detection of Integrated Papillomavirus Sequences (DIPS) (Luft et al., 2001) was used to 
determine the integration status of HPV in the VR series clinical cohort (Figure 1.8). 
3.1.6.1. DNA Digestion and Ligation of Adapter Sequence 
Two aliquots of 1.2 µg DNA were digested using 10 U of Sau3AI or Taq1 (New England Biolabs, 
Beverly, MA.) in a 20 µl reaction according to Table 3.9. Reactions were prepared in PCR plates, 
sealed, incubated at 37 °C for 15 hrs and then incubated at 80 °C for 20 mins on a thermocycler 
to inactivate the restriction enzymes. HPV negative (Mono Mac 6) and HPV positive (CaSki) cell 
line DNAs were included in each run as controls. 
Sau3AI digest Taq1 digest 
Reagent Volume (µl) Reagent Volume (µl) 
DNA (1.2 µg) - DNA (1.2 µg) - 
Sau3AI (10 U) 2.5 Taq1 (10 U) 0.5 
Buffer 1 (10x) 2 Buffer 4 (10x) 2 
BSA (100x) 0.2 BSA (100x) 0.2 
H20 to 20 µl H20 to 20 µl 
Table 3.9: Sau3AI and Taq1 DNA digestion reaction volumes.  
Units listed are the volumes required per reaction. 
 
Ligation was performed using double stranded DNA adapters specific to either the Sau3AI or 
Taq1 digested DNAs. Taq1 and Sau3AI adapters were produced using the 25 µM adapter recipe 
in Table 3.10. The volumes listed produced enough adapter for 200 reactions. Reaction mixes 
were heated to 90 °C for 2 mins then allowed to cool in an overnight protocol to 4 °C in a 
thermocycler. Adapter mixes were then stored at -20 °C. 
 Reagent Volume (µl) 
AL1 primer (100 µM) 25 
TaqI or Sau3AI AS primer (100 µM) 25 
Sterile TrisHCl (66 mM) 50 
Table 3.10: The reagent volumes required to produce a 25 µM adapter stock solution. 
 
The Sau3AI and Taq1 adapters were ligated to the DNA digests using T4 Ligase (New England 
Biolabs, Beverly, MA). The volumes and reagents used for each reaction are listed in Table 
3.11. This mix was incubated at 22 °C for 2 hrs, then inactivated by heating to 65 °C for 10 mins 
before 6 µl of sterile water was added to bring the final volume to 40 µl. 
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Reagent Volume (µl) 
TaqI or Sau3AI digested DNA 20 
Ligase Buffer (10x) 2.4 
T4 Ligase (400 U/µl) 1 
TaqI or Sau3AI Adapter (25 µM) 0.48 
Water 0.12 
Total volume 24 
Table 3.11: The reagent volumes required per DIPS reaction to ligate adapters to digested genomic 
DNA.  
The 20 µl of digested DNA refers to the complete mix listed in Table 3.9. 
 
3.1.6.2. Linear PCR 
Linear PCR was performed using 9 separate reactions; 8 pairs of HPV specific primers and one 
pair of control primers. Separate master mixes were prepared for each primer (n=9) for both 
DNA digests/ligations (Sau3AI and Taq1) according to Table 3.12. For each reaction 23 µl was 
aliquoted into PCR plates and 2 µl of digested/ligated DNA was pipetted into each reaction. 
Each sample had 18 PCR reactions, i.e. 9 for each DNA digest/ligation. Plates were sealed and 
the PCR reaction performed according to the time/temperatures listed in Table 3.13. 
Reagent Volume (µl) 
10x buffer with 15 mM MgCl2 2.5 
dNTP (10 mM) 0.5 
HPV PCR 1 primer (1-9) (10 µM) 0.5 
Hot star Taq (1 U) 0.125 
H20 19.375 
Total volume 23 
Table 3.12: Linear PCR master mix recipe.  
Volumes are given for each reaction. 
 
 
Temperature (°C) Time (s) Cycles 
Initial denaturation 95 900 1 
Denaturation 94 30   
Primer annealing 66 30 40 
Extension 72 180   
Final extension 72 420 1 
Table 3.13: PCR timing and temperature for the DIPS linear PCRs. 
 
3.1.6.3. Nested PCR 
For the Nested PCRs, the linear PCR products were amplified exponentially using an adapter 
specific primer and a HPV specific primer. As such, 18 reactions are required for each sample; 
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one reaction mix for each HPV primer for both DNA digests. For each sample, the reaction mix 
in Table 3.14 was prepared and 20 µl aliquoted into a PCR plate. The plates were loosely sealed 
and taken to the post-PCR laboratory where 5 µl of linear PCR product was dispensed into the 
appropriate well of the second PCR plate. The plates were sealed and PCR reactions run 
according to the temperature/timing in Table 3.15. Remaining linear PCR products and 
completed nested PCR products were stored at -20 °C until required. 
Reagent Volume (µl) 
10x buffer with 15 mM MgCl2 2.5 
dNTP (10 mM) 0.5 
Hot Star Taq (1 U) 0.125 
HPV PCR 2 Primer (1-9) (10 µM) 1 
AP1 Primer (10 µM) 1 
H20 14.875 
Total volume 20 
Table 3.14: Nested PCR master mix recipe.  
Volumes are given for each reaction. 
 
 
Temperature (°C) Time (s) Cycles 
Initial denaturation 95 900 1 
Denaturation 94 30   
Primer annealing 66 30 30 
Extension 72 180   
Final extension 72 420 1 
Table 3.15: PCR timing and temperature for the DIPS nested PCRs. 
 
3.1.6.4. Gel Electrophoresis 
25 µl of nested PCR products were run on a 1% w/v agarose TBE gel with 2 µl/100 ml of 
ethidium bromide (10 mg/ml) and alongside 100 bp DNA ladder in order to estimate product 
size. Gels were run at 120 V for 1-2 hrs or until adequate separation of the PCR products was 
achieved. 
Once run, the gels were photographed and bands of interest were cut out using a clean 
disposable scalpel and a UV transilluminator. Suitable PPE was worn to protect the operator 
from UV light. As much excess gel was removed as possible and excised band gel fragments 
were placed in clean microcentrifuge tubes. This was performed for all bands of interest for all 
samples, for all primer sets. 
Following excision, gel fragments containing PCR products were purified using the Illustra GFX 
PCR DNA and Gel Band Purification Kit (GE Healthcare Life Sciences, Buckinghamshire, UK). 
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Extraction was performed according to the manufacturer’s instructions. Briefly, this involved 
dissolving the agarose gel pieces using heated buffers, binding the PCR product to a 
membrane, washing the PCR product with a series of wash buffers and final elution into 15 µl 
of sterile nuclease free water.  
Upon purification, 5 µl of eluate was run on a 2% w/v agarose gel containing 20 mg/100 ml 
ethidium bromide. This was performed to check for successful PCR product purification, check 
for the presence of a single band and to roughly estimate DNA concentration by comparing 
against known concentration/intensity 100 bp ladder. 
3.1.6.5. Sequencing 
Sanger sequencing of PCR products was performed by Source BioScience UK Ltd (Nottingham, 
UK). HPV primer 2 (i.e. the HPV specific nested primer) was used as the sequencing primer. The 
requirements for sequencing are presented in Table 3.16. 
 
Sequencing requirements 
 
Volume (µl) Concentration 
PCR products 5 1 ng/µl/100 bp* 
Primers 5 3.2 µM 
Table 3.16: The sequencing requirements for purified PCR products.  
Values listed are per reaction. * For PCR products, for every 100 bp in length 1 ng/µl of DNA was 
required. 
 
3.1.6.5.1. Data Analysis 
Sequence data was returned as a chromatogram with base calling. Sequences were checked 
manually to improve the base calling and to check for the parallel sequencing of multiple 
fragments (indicated by overlapping sequence). Sequence of poor quality or with background 
noise was removed from the sequence reads and not considered for data analysis. 
Several stages of sequence analysis were performed. First, alignment of sequences against 
human genomic DNA sequences, and against the HPV16 reference sequence (GenBank ID 
NC001526.1) was performed using the NCBI BLAST (Basic Local Alignment Search Tool). Two 
BLAST algorithms were used, first megablast, then blastn. Megablast worked well for larger 
closely related sequences, blastn worked better for shorter and/or less closely related 
sequences. For the VR series, megablast identified the majority of potential integration events 
and blastn identified two events where a shorter section of human DNA was present.  
To identify the region of the human genome where integration events were detected, 
identified human sequences were aligned using the UCSC BLAT (Blast Like Alignment Tool). 
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3.1.6.6. Primer Sequences 
Table 3.17 contains the primer sequences used for DIPS. Essentially, the DIPS protocol 
described by Luft et al was used in conjunction with the restriction site PCR HPV specific 
primers described by Thorland et al as these were found to produce better results. Other 
primer/adapter sequences are as described by Luft et al (Thorland et al., 2000, Luft et al., 
2001) 
Adapter and adapter specific primers 
AL1 primer GGGCCATCAGTCAGCAGTCGTAGCCCGGATCCAGACTTACACGTTG 
AP1 primer GGCCATCAGTCAGCAGTCGTAG 
TaqI AS primer PO4-CGCAACGTGTAAGTCTG-NH2 
Sau3AI AS primer PO4-GATCCAACGTGTAAGTCTG-NH2 
 Primary PCR primers 
HPV PCR 1 primer 1 ACAAAGCACACACGTAGACATTCG 
HPV PCR 1 primer 2 AGTAATAAATCAACGTGTTGCGATTG 
HPV PCR 1 primer 3 TTTGGTTACAACCATTAGCAGATGC 
HPV PCR 1 primer 4 GTGCCAACACTGGCTGTATCAAAG 
HPV PCR 1 primer 5 TACCAATTCTACTGTACCTAATGCCAG 
HPV PCR 1 primer 6 ACTTATTGGGGTCAGGTAAATGTATTC 
HPV PCR 1 primer 7 AGTAGATATGGCAGCACATAATGAC 
HPV PCR 1 primer 8 GTTGGCAAGCAGTGCAGGTCAG 
Control PCR 1 primer 9 TTCTCTATGTGCGTTCTCTCCCTG 
Nested PCR primers (PCR2) 
HPV PCR 2 primer 1 CGTACTTTGGAAGACCTGTTAATGG 
HPV PCR 2 primer 2 GGACTTACACCCAGTATAGCTGACAG 
HPV PCR 2 primer 3 AATAGGTATGTTAGATGATGCTACAG 
HPV PCR 2 primer 4 ACAAGCAATTGAACTGCAACTAACG 
HPV PCR 2 primer 5 GAGGTTAATGCTGGCCTATGTAAAG 
HPV PCR 2 primer 6 CCCTGTATTGTAATCCTGATACTTTAGG 
HPV PCR 2 primer 7 TGCGTGTAGTATCAACAACAGTAAC 
HPV PCR 2 primer 8 TTAAACCATAGTTGCTGACATAGAAC 
Control PCR 2 primer 9 CAAACTCCAGGTCTCCAACCAG 
Table 3.17: Primer and adapter sequences used for DIPS. 
 
3.1.7. APOT 
Amplification of Papillomavirus Oncogene Transcripts (APOT) was used briefly during this 
project and was trialled on cell line material and some VR series samples (Figure 1.7). APOT 
was performed as detailed by Vinokurova et al (Vinokurova et al., 2008). The VR samples failed 
the APOT assay repeatedly. VR RNAs were tested for quality/integrity using a 2100 Bioanalyser 
(Agilent Technologies Inc, Santa Clara, CA) and the mean fragment size appeared inadequate 
for APOT. APOT was abandoned for DIPS. 
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3.2. Materials 
3.2.1. Cell Lines 
3.2.1.1. CaSki 
The Ca Ski (CaSki) cell line was sourced from the European Collection of Cell Cultures (ECACC) 
(catalogue number 87020501). The CaSki cell line was originally derived from an epidermoid 
carcinoma of the cervix, metastatic to the small bowel mesentery of a 40 year old Caucasian. 
CaSki DNA and RNA were extracted using the Qiagen AllPrep (Qiagen, Hilden, Germany) 
protocol. The identity of the CaSki cell line was confirmed using STR typing. CaSki contains 
multiple HPV16 genomes inserted as a concatemer. There are 30 reported point mutations 
and a single 1 nt deletion in the vast majority of HPV16 genomes (Meissner, 1999). 
3.2.1.2. SiHa 
The SiHa cell line was sourced from the American Type Culture Collection (ATCC) (ATCC 
number HTB-35). The SiHa cell line was originally derived from a cervical squamous cell 
carcinoma of a 55 year old Asian. SiHa is reported to contain integrated HPV16, with between 
1 and 2 copies per cell. Integration is associated with disruption of the HPV16 genome and a 
deletion at nt 3133-3385, there are also deletions at nt 3460-3512 and nt 7757-7794 
(Meissner, 1999). 
3.2.1.3. W12 
The W12 cervical keratinocyte model is a nonclonal cell culture derived from a cervical lesion 
with CIN1/LSIL histology (Stanley et al., 1989). Early passage W12 in organotypic raft culture 
exhibits an LSIL like phenotype and contains approximately 100 HPV16 genomes/cell in 
episomal form (Pett et al., 2004), however E2 silenced integrated forms can also be detected 
(Pett et al., 2006). Long term cultures of W12 undergo clearance of episomal HPVs and cells 
containing integrated HPV16 genomes dominate (Gray et al., 2010). Genomic instability occurs 
as a result and the organotypic raft cultures adopt a HSIL/SCC phenotype. In long term culture 
of discrete clones of W12, different integration events are selected for, resulting in a series of 
diverse cell lines (Pett et al., 2004). The DNAs used in this study were from W12 Series 7 
(W12Ser7), sourced from Professor Nicholas Coleman (University of Cambridge, personal 
communication) (Gray et al., 2010). 
3.2.1.4. PC08 and PC09 
Primary Culture 08 and 09 (PC08 and PC09) were established as primary culture of anogenital 
biopsies. The primary culture lines were grown for several passages, after the first passage the 
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lines are no longer considered primary culture and the term “short term culture” is more 
accurate. PC08 was derived from a vulval biopsy of a 46 yr old woman with histologically 
confirmed VIN3. PC09 was derived from a vaginal biopsy of a 31 year old woman with 
histologically confirmed VAIN3.  
The PC08 and PC09 cell lines were initially established as heterogeneous lines, single cell 
cloning was then performed to establish homogeneous lines. Six clones were provided for this 
study, the PC08 clones M, P and Y and the PC09 clones A, D and H. Each homogeneous clone 
was cultured further and at each passage, DNA and RNA were extracted. For the PC08 clones, 
single cell cloning was performed at two different passages. Cloning of early passage 
heterogeneous lines produced the M and P clones whilst cloning of later passage 
heterogeneous lines produced the Y clone. For this reason, clone Y8 starts at passage 9 whilst 
the others start at passage 5. All characterisation and cell culture was performed by Tiffany 
Onions, (School of medicine, Cardiff University). For this project, Tiffany Onions supplied DNAs 
for DNA methylation analysis and provided APOT results and Ct values from qPCR. DNAs were 
extracted using the Qiagen AllPrep protocol. 
 
3.2.2. Clinical Material 
3.2.2.1. The CRISP Study 
The Cervical Randomised Intervention Study Protocol (CRISP) clinical trial was conducted to 
determine the effect of diindolylmethane (DIM) on low grade cervical abnormalities (Castanon 
et al., 2012). It was a double blind, randomised controlled trial to study the effect of 6 months 
of DIM supplementation women with newly diagnosed, low grade cervical abnormalities. Of 
the 600 women eligible for inclusion in the study, 439 women had paired LBC samples at 0 and 
6 months for HPV typing. DIM supplementation was found to have no effect as a treatment for 
cervical abnormalities and was not considered for this study of DNA methylation. HPV typing 
was performed for the CRISP clinical trial using the PCR ELISA HPV typing system described by 
Jacobs et al (Jacobs et al., 1997, Castanon et al., 2012). 
For this investigation, DNAs were extracted using the QIAamp MinElute Media kit protocol on 
frozen cell pellets. All samples used were HPV16 positive at 0 months, samples were divided 
into three groups. First, those infections that were HPV16 positive at 0 months, but HPV16 
negative at 6 months were classified as the Cleared (C) group. Twenty-four samples met this 
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criteria, one of these was excluded on the basis that the histology at 6 months revealed a CIN2 
lesion. 
The second group of samples were HPV16 positive and were associated with high grade 
histology (CIN2 and CIN3) at 6 months. This group comprised of 11 patients with both 0 and 6 
month DNA samples and were termed the Persistent High grade (PH) group.  
Finally, those samples that were HPV16 positive and were associated with low grade histology 
(i.e. CIN1) at 6 months were selected. A total of 48 patients met this criteria however only 12 
patients’ DNAs were required for the study. The first 9 patients were selected because they 
had histologically confirmed CIN1 at 6 months, the final 3 were chosen at random. This group 
was termed the Persistent Low grade (PL) group and represents samples that had maintained a 
HPV16 infection for more than 6 months in the absence of significant disease. 
3.2.2.2. The Prevalence Study 
The prevalence study described the prevalence of HPV in South Wales in relation to age, 
cytology and social depravation. A total of 1,911 patients were included in the study. DNA was 
extracted by Hibbitts et al and involved disruption of LBC material using proteinase K and 
purification by centrifugation as described (Hibbitts et al., 2006). These DNAs were then HPV 
typed using the PCR ELISA HPV typing system described by Jacobs et al (Jacobs et al., 1997, 
Hibbitts et al., 2006). For this study, 20 samples were identified with normal cytology and 20 
with severe dyskaryosis and DNAs were provided for the purpose of performing DNA 
methylation analysis (Chapter 5). 
3.2.2.3. Archival Cancers 
A series of DNAs previously extracted from Formalin Fixed Paraffin Embedded (FFPE) cervical 
cancers were used in this study (Chapter 5). The samples were initially collected for prevalence 
studies of HPV in cervical cancers (Powell et al., 2011, Powell et al., 2009). The FFPE cervical 
cancers were collected from various hospitals before sectioning and DNA extraction using the 
Qiagen DNeasy Blood and Tissue kit without xylene washes (Powell et al., 2011). 
The samples for inclusion in the study were selected using the following criteria: HPV16 
positivity was required, samples collected from University Hospital of Wales (n=57) were 
excluded as they were fixed using low pH unbuffered (rather than neutral buffered) formalin 
which typically provides DNAs of poor quality. DNA concentrations of the remaining samples 
were determined and arranged in descending order (n=79), the top 20 sample DNAs were 
selected. Seven additional samples were later sought for inclusion to account for samples that 
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had failed to amplify by PCR, or had persistently failed to produce a usable result in the 
pyrosequencing assay. Failure was likely the result of DNA degradation of DNA in storage 
and/or prior to extraction. A total of 24 samples provided DNA methylation data of sufficient 
quality to be included in the analysis. Of these there were SCC (n=19), adenocarcinoma (n=3), 
adenosquamous carcinoma (n=1) and carcinosarcoma (n=1) DNAs. 
 
3.2.2.4. VIN Biopsy Series 
A large series of anogenital biopsies (n=171) was available for this project and were used for an 
investigation into HPV distribution. Of these, 118 were DNAs and 53 were biopsies fixed in 
ThinPrep LBC media. The 53 biopsies were coined the VR series as they were of vulval origin 
and both DNA and RNA was extracted. The VR series is a series of VIN and VAIN biopsies 
(primarily VIN3). Various nucleic acid extraction methods were used for the series in order to 
try and improve the quality and quantity of DNA and RNA produced. The first 37 samples (VR1-
37) were extracted using the TRIzol extraction protocol, the remaining 16 samples (VR38-53) 
were extracted using the VIN RNA/DNA extraction protocol. 
VIN DNAs were HPV typed using the PapilloCheck assay described previously. The HPV typing 
data was used as the basis of a HPV type distribution in VIN study. The sample selection 
criteria involved exclusion of non-VIN biopsies, cancers and samples with incomplete clinical 
data. Finally, where duplicates existed (i.e. more than one sample from the same patient) the 
earliest samples were excluded. Sixty-two samples remained for analysis. 
 
3.3. Statistical Analysis 
Statistical analysis was performed in Minitab 16.1.0 using procedures described by Bowker 
(Bowker, 2007). This section contains a brief explanation of the tests used whilst Table 3.18 
contains a glossary of terms. 
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Term Meaning 
H0 – Null 
hypothesis 
The default position i.e. No relationship/difference between 
factors/means 
H1 – Alternative 
hypothesis 
The alternative position i.e. A significant relationship/difference between 
factors/means 
P-value Probability value, typically reject the H0 and accept H1 at P<0.05 
DF Degrees of freedom 
Type 1 error When H0 is true but rejected, i.e. a false positive 
Type 2 error When H0 is false but accepted, i.e. a false negative 
Table 3.18: A glossary of statistical terms used and their meanings. 
 
3.3.1.1. Correlation 
Correlation analysis objectively tests for a linear relationship between two variables derived 
from independent, random samples. The H0 is that there is no significant correlation between 
the two variables (Bowker, 2007). 
Spearman’s rank non-parametric correlation coefficient tests for an association between two 
quantitative or categorical variables that can be ranked from low to high. Normal distribution 
of the variables is not required (Bowker, 2007). Correlation coefficients range from -1 to +1. 
The further from zero, the stronger the correlation. A positive or negative number represents 
an upwards or downwards sloping scatter plot respectively (Bowker, 2007). 
3.3.1.2. Linear Regression 
Linear regression analysis is used to predict and draw a straight line of best fit between two 
quantitative variables according to the equation:  
           
Here: X=the cause/independent variable, Y=the effect/dependent variable, m=gradient of the 
slope, c=intercept of the line through Y and ε = error in Y around the line of best fit. The 
residuals should be normally distributed (Bowker, 2007). 
3.3.1.3. Anderson Darling 
The Anderson Darling normality test tests the H0 that the data is not normally distributed. 
Many statistical analyses rely on normal distribution of either the data or the residuals. Where 
normal distribution is not achieved (P>0.05), data transformation may improve the distribution 
(Bowker, 2007). 
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3.3.1.4. Homogeneity of Variances 
Many statistical analyses require that groups of data have equal variances. There are several 
tests depending on the application and the number of groups being compared, each test tests 
the H0 that the groups have equal variances. Bartlett’s test for equal variances was used prior 
to ANOVA and the F-test variance ratio statistic was used prior to T-tests (Bowker, 2007). 
3.3.1.5. Data Transformation 
Where data has not met the assumptions of a statistical test, the data is transformed and 
tested for suitability again. Data transformation for this study included the following: 
untransformed (X) data, Log10(X), Log10(X+1), X
2, (X-mean)/standard deviation). Unless 
otherwise noted in the text, Log10(X+1) transformation provided the best DNA methylation 
data and Log10(X) provided the best qPCR data and were used prior to data analysis.
 
3.3.1.6. T-test and Associated Tests 
The Student’s T-tests are parametric tests to compare two groups of independent data, paired 
data before and after a known treatment/event and one group of data to a standard value. T-
tests assume that the data is normally distributed, and the two groups have equal variances. 
For this study, the two-sample T-test was used and tests the H0 that no difference between the 
means of the groups exist (Bowker, 2007).  
Where the assumptions of the two-sample T-test were not met, the non-parametric equivalent 
Mann-Whitney U-test was used to test the H0 that the two groups had the same median. 
Where comparison of multiple groups of data is required alternative tests should be used (i.e. 
ANOVA) instead of multiple two-sample tests as multiple tests increase the chance of a Type 1 
error. 
3.3.1.7. Bonferroni Correction 
The Bonferroni correction is used to reduce the likelihood of a Type 1 error occurring when 
multiple statistical analyses are used (i.e. P-value of 0.05 = likely to have one type 1 error every 
20 analyses). The Bonferroni correction reduces the P-value to compensate for multiple 
analyses by dividing the original P-value by the total number of comparisons. The Bonferroni 
correction is often criticised for being too conservative, in this study interpretation of results 
significant at both P=0.05 and a Bonferroni corrected P-value was considered. 
3.3.1.8. One-way ANOVA and Kruskall-Wallis 
One-way Analysis Of Variance (ANOVA) is applied to quantitative variables separated into two 
or more groups. ANOVA is a parametric test that requires normally distributed residuals and 
homogenous variances and assumes independent random samples. ANOVA tests the H0 that 
there is no difference between the means of the groups (Bowker, 2007). 
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The ANOVA does not perform a comparison of means between pairs of groups. Pairwise 
comparison is performed using Tukey-Kramer a posteriori tests for unplanned differences or 
Fisher’s a priori tests for planned differences (Bowker, 2007). 
The Kruskall-Wallis test is a non-parametric equivalent of the ANOVA and tests the H0 that 
there is no difference between the medians of the groups. Kruskall-Wallis is far less powerful 
than the ANOVA and has no function to perform pairwise comparison of means (Bowker, 
2007).  
It is common practice in exploratory, hypothesis generating studies to lower the requirements 
of the ANOVA and proceed even with violations of the assumptions on the basis that the 
results are interpreted with caution (Bowker, 2007). For this study, several tests violated one 
or more assumptions of the ANOVA. Because these statistics were exploratory and hypothesis 
generating in nature, it was felt that the advantages of the one-way ANOVA and Tukey-Kramer 
over the Kruskall-Wallis test (and multiple Mann-Whitney U tests for pair wise comparisons) 
far outweighed the risks involved with using the one-way ANOVA with violations. Where the 
analysis was continued, the results were interpreted with caution, frequently reported 
alongside an additional Kruskall-Wallis test for additional confirmation and the violations were 
listed in the text. 
3.3.1.9. Multifactor ANOVA 
Multifactor ANOVA allows the analysis of data grouped with respect to multiple factors. A two-
way ANOVA tests the H0 that neither factor has a significant effect and that the means of each 
group are the same. Several models of two-way ANOVA were used in this study. The two-way 
ANOVA General Linear Model (GLM) allows for the analysis of data with an unbalanced design 
(the majority of analyses). Several instances occurred where a balanced design without 
replication existed, for these analyses a standard two-way ANOVA was used. 
Two-way ANOVA assumes equal variances in each factor combination and normally distributed 
standardised residuals. No suitable non-parametric equivalent of the GLM exists; where the 
assumptions were violated, a decision was made in each instance whether to continue with 
the analysis or use multiple one-way ANOVA/Kruskall-Wallis tests with a Bonferroni correction. 
Multiple one-way ANOVA are not advised both because of the increased rate of type 1 error, 
and because they remove a level of detail from the analysis. Where multifactor ANOVA was 
continued, the results were interpreted with caution, often presented alongside additional 
analyses and the violations were listed in the text. 
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When analysing DNA methylation data both on a per-assay and a per-CpG basis using 
multifactor ANOVA, the individual CpGs (i.e. E2-1...E2-8) were nested within the assay (i.e. E2, 
LCR1, etc) to allow for a more thorough analysis acceptable to the GLM. 
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Chapter 4. Method Development 
4.1. HPV Gene Expression 
This investigation required assessment of the expression of three HPV genes, the E6 and E7 
oncogenes and the E2 repressor. A literature search identified a study in which E6 and E7 
mRNA level were quantified in cell line and clinical material (Wang-Johanning et al., 2002). E6 
and E7 primers were complementary to regions included in various splice variants for each 
gene (Zheng and Baker, 2006). E2 primers were identified from a separate study in the same 
literature search (Roberts et al., 2008a). The primers were trialled briefly and satisfactory 
results were produced which warranted further optimisation. 
Selection of suitable reference genes required more thorough consideration. Quantifying the 
stability of a panel of reference genes in diseased and disease free epithelial tissues was 
outside of the scope of this project. In order to improve the reliability of the results two 
reference gene assays that covered a range of expression levels were sought (i.e. one highly 
expressed and one lowly expressed). Potential reference genes were identified from published 
studies that had quantified the stability and ranked the suitability of prospective reference 
genes. Two genes (and primer pairs) were chosen on the basis of high stability in a range of 
keratinocyte lines, these were TBP (TATA box binding protein) and HPRT (Hypoxanthine 
guanine phosphoribosyl transferase) (Allen et al., 2008). Further literature searches confirmed 
the apparent suitability of these reference genes for epithelial RNA studies. The TBP assay was 
repeatedly problematic and inconsistent during optimisation and was eventually replaced with 
a second primer pair amplifying a different region of TBP (Minner and Poumay 2008). HPRT 
and both TBP assays were intron spanning such that the DNA amplimer was considerably 
larger and more difficult to amplify than the RNA. This was not possible for HPV genes where a 
complex array of potential splice variants exist. 
4.1.1. qPCR Optimisation and Method Development 
Several significant issues were encountered during the course of qPCR optimisation. The main 
issues and solutions are summarised below. 
4.1.1.1. Initial Failure 
During initial trial of the qPCR assays, failure of the PCR reaction was very common. Failure 
could have been caused by several factors. First, the RT reaction was tested to determine 
whether the RT was functioning properly and in each instance, a demonstrable difference 
between positive and negative RT controls was noted. Similarly, cDNAs that were amplified in 
some reactions were not amplified in subsequent reactions, i.e. there was considerable 
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inconsistency. A large variety of conditions were trialled using gradient PCR and a series of 
qPCRs in order to optimise the PCR conditions. However, the success or failure of reactions 
appeared random and further optimisation could not continue until the issues had been 
solved. 
To rule out operator error, a senior member of staff demonstrated, then supervised and finally 
performed the same experiments independently. Subtle differences in technique were initially 
associated with a considerable difference in success rate, however this was later deemed 
coincidental after the inconsistent pass/fail rate resumed. The ambient temperature might 
have affected the heating and cooling rate of the LightCycler instrument so a thermometer 
was placed into the qPCR laboratory and the ambient temperature was recorded. No 
relationship between ambient temperature and success rate was observed. All reagents 
required for qPCR (cDNAs, primers, MgCl2, water, SYBR green master mix, plastics) were 
replaced but inconsistent qPCR reactions continued to be observed. The LightCycler 
instrument was beginning to be suspected so was replaced as a precaution. The results 
improved considerably, but were still inconsistent. Several small checks and measures 
suggested by Roche technical support were implemented with little effect. 
Eventually, it transpired that the LightCycler capillary tubes were out of date. The capillary 
tubes contain a coating to prevent interaction of the glass with the reagent mix, this coating 
was found to degrade with time and the tubes in use were out of date by several years. 
Replacement tubes were trialled and the inconsistent failure/success rate was solved. 
Throughout the qPCR method development, DNase treatment of sample RNAs was only 
partially successful. Several RNA purification kits were tested, DNases from several 
manufacturers were tested and a variety of treatment protocols were trialled with varying 
degrees of success. In order to correct for an incomplete DNA digestion during DNase 
treatment (residual genomic DNA was shown to contribute as much as 10% to the signal 
strength), RT negative (RT-ve) controls were included in duplicate for each sample alongside 
the RT positive (RT+ve) reactions. The linear regression equations produced from calibration 
curves were used to calculate the relative DNA concentration of the RT+ve and the RT-ve 
samples (concentration expressed relative to 1x CaSki cDNA). The mean calculated cDNA 
concentration of the RT-ve repeats was subtracted from that of the RT+ve repeats to leave the 
amount of PCR product in the RT+ve samples that was attributable to just the cDNA. This DNA 
concentration was then used in the linear regression equation to produce a new Ct value that 
reflected the amount of cDNA in the RT+ve reaction, corrected to remove the amplified 
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genomic DNA in the sample. Reactions where a non-specific PCR product had been amplified 
were excluded from the analysis. 
4.1.1.2. Optimisation 
Once the cause of inconsistency in the qPCR reaction had been removed, optimisation of the 
qPCR reactions was resumed. The cycle number, input cDNA amount, annealing temperature 
and Mg2+ ion concentration were optimised and for most assays, reliable results were 
produced. For TBP, the results were still inconsistent. Eventually, a number of suitable 
reference gene primer sets were trialled and a second TBP set were adopted. 
4.1.1.3. Data Collection 
The 6 VIN biopsy samples with the largest RNA yield were trialled, further optimisation was 
performed and the trial was extended to the remaining VR samples. RNAs from the VR series 
were analysed by E2, E6, E7, HPRT and TBP qPCR assays. Several methods of relative 
quantification exist, two common methods being the comparative Ct method and the 
efficiency corrected comparative Ct method proposed by Pfaffl (Pfaffl, 2001). The choice of 
relative quantification method can have a huge effect on the outcome and reliability of the 
qPCR data. 
 
4.1.2. Relative Quantification 
4.1.2.1. Comparative Ct Method 
The comparative Cycle threshold (Ct) method of relative quantification (commonly called the 
delta delta Ct or ddCt method) is widely used, and is the method of analysis used by the 
Applied Biosystems DataAssist v3.0 software; a software package designed to analyse the 
output data from multiple Applied Biosystems quantitative PCR systems. Livak and Schmittgen 
discussed the derivation of the (RQ) = 2-ΔΔCt formula in detail (Livak and Schmittgen, 2001). The 
main disadvantage of the comparative Ct method is that the PCR efficiencies are assumed to 
be close to 2 (i.e. a perfectly exponential PCR reaction) and that target and reference gene PCR 
efficiencies are equal to within 0.05 (Schmittgen and Livak, 2008, Livak and Schmittgen, 2001). 
Inevitably, different PCR primer pairs tend to amplify at different efficiencies. The effect of 
varying PCR efficiency is illustrated in Table 4.1 where five theoretical PCRs reactions of varying 
efficiency amplify a single template cDNA. These reactions would all reach the qPCR threshold 
point at very different cycle numbers, leading to diverse estimates of the number of template 
copies in the input cDNA. 
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The comparative Ct equation does not allow for the inclusion of delta Ct values of multiple 
reference genes. Despite using the comparative Ct equation for analysis, the Applied 
Biosystems DataAssist v3.0 software allows for the selection of multiple reference genes using 
the arithmetic mean of the reference gene Ct values as the basis of the ΔCt calculation. 
 
 PCR efficiency 
Cycle 
number 100% 95% 90% 80% 70% 
0 1 1 1 1 1 
1 2 1.95 1.9 1.8 1.7 
2 4 3.8025 3.61 3.24 2.89 
3 8 7.414875 6.859 5.832 4.913 
25 33554432 17818260 9307650 2408866 577062.7 
30 1.07E+09 5.02E+08 2.3E+08 45517160 8193466 
35 3.44E+10 1.42E+10 5.71E+09 8.6E+08 1.16E+08 
40 1.1E+12 3.99E+11 1.41E+11 1.63E+10 1.65E+09 
Table 4.1: The number of template copies at each cycle in 5 theoretical PCR reactions with a starting 
amount of 1 PCR template copy.  
Each PCR reaction has a different PCR efficiency, this table illustrates the potential for error caused by 
differences in PCR efficiency. Each number is the number of template cDNA copies. 
 
4.1.2.2. The Pfaffl Equation – PCR Efficiency Correction 
In order to overcome the previously discussed limitations, Pfaffl (Pfaffl, 2001) proposed a 
modification to the comparative Ct method that accounted for the PCR efficiency of the target 
and reference gene PCRs. The so called “Pfaffl equation” is detailed below (Equation 4.1). 
   
          
                          
             
                             
 
Equation 4.1: The Pfaffl equation.  
E refers to the PCR efficiency, target refers to target genes (i.e. E2, E6 and E7), control refers to CaSki, 
sample refers to the sample of interest and Ct refers to the crossing point. ΔCt refers to change in the 
Ct. 
 
The Pfaffl equation allows the different PCR efficiencies of target and reference genes to be 
considered in the generation of relative quantification ratios (Pfaffl, 2001), if both target and 
reference genes had a PCR efficiency of 100% (i.e. 2) the results of using the Pfaffl equation 
and the comparative Ct/Livak equation would be identical. The Pfaffl equation is very 
commonly used for relative quantification studies and forms the basis of the Qiagen, REST 
2009 relative quantification software and its predecessors (Pfaffl et al., 2002, Qiagen, 2009). A 
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limitation of the Pfaffl equation, is that it allows for only one reference gene (addressed in 
some situations in the REST 2009 software), a slightly modified alternative equation is in use 
that allows for the quantification of target genes against multiple reference genes. The Pfaffl 
equation is only slightly updated for the Vandesompele equation, except that in the Pfaffl 
equation, the denominator is calculated for a single gene (Vandesompele et al., 2002). In the 
updated Vandesompele equation, the Pfaffl equation denominator is calculated for each 
reference gene, and the geometric mean of these results is used in place of the denominator 
used in the Pfaffl equation (Vandesompele et al., 2002). This approach has been used for 
multiple published studies (Hoebeeck et al., 2005, Hellemans et al., 2004, Vandesompele et al., 
2002, Loeys et al., 2005, Poppe et al., 2004) and is the basis of the qBasePlus qPCR analysis 
software algorithm (Hellemans et al., 2007, qBasePlus, 2007). Equation 4.2 is the updated 
Pfaffl equation (Vandesompele equation) for multiple reference genes (Hellemans et al., 
2007). 
   
          
                          
                
                               
 
 
 
Equation 4.2: The Vandesompele equation.  
E refers to the PCR efficiency, target refers to target genes (i.e. E2, E6 and E7), control refers to CaSki, 
sample refers to the sample of interest and Ct refers to the crossing point, n is the number of 
reference genes. 
 
Errors in the calculation of PCR efficiency could have a profound effect on the calculated 
expression ratios; hence it is important that efficiency is determined in an appropriate manner. 
4.1.2.3. PCR Efficiency 
There are several ways of calculating the PCR efficiency. These broadly fall into two categories, 
those based on the Ct values of a calibration curve and those based on the actual PCR 
dynamics of single or multiple PCR reactions.  
4.1.2.3.1. Estimating PCR Efficiency Using the Calibration Curve Method 
This common method is the method best supported by the Roche LightCycler used in this 
study. It is widely used in the literature, including the earlier work of Pfaffl (Pfaffl, 2001). This 
simple method relies on observing the relationship between input cDNA concentration and Ct 
value across a dilution series and using linear regression to produce an equation for the 
relationship. Figure 4.1 is an example of a calibration curve produced for a CaSki DNA dilution 
series using the HPV16 E6 qPCR primer pair. Here, a total of three calibration curves were run 
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and plotted alongside each other. Linear regression was performed and an equation 
representative of the three calibration curves produced according to Equation 4.3. 
                                
Equation 4.3: The Linear regression equation.  
For a linear relationship, m represents the gradient and c represents the intercept. 
 
Which for the E6 primer pair, linear regression analysis produces the formula: 
                                          
The calibration curve enables both the estimation of DNA concentration (in relation to the 
cDNA used in the calibration curve (i.e. CaSki cDNA)) and the estimation of PCR efficiency. 
Using the slope (m) from the linear regression line, the efficiency (E) of the PCR can be 
calculated according to Equation 4.4 (Pfaffl, 2001, Rassmussen, 2001). 
           
Equation 4.4: The PCR efficiency calculation formula.  
Here, E represents efficiency, and m represents the gradient calculated in Equation 4.3. 
 
For the E6 primer pair, this becomes: 
                
         
Or 
                
A perfect doubling (i.e. every template is amplified into two more templates) is achieved at a 
PCR efficiency of E = 2 or 100%. 
A limitation of the calibration curve method of PCR efficiency calculation is that it is presumed 
that PCR efficiency is the same for all dilutions of template cDNA. However, when a template is 
diluted, any inhibitors to PCR in the template will also be diluted; this can lead to more 
efficient amplification in more dilute samples (Ramakers et al., 2003). As such, other methods 
that rely on the PCR dynamics of single/multiple PCR runs can be used to negate this effect. 
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Figure 4.1: An example of a threefold dilution series of CaSki cDNA.  
The dilution series was repeated in triplicate experimental repeats (represented by the three different 
colours/point shapes) and is used to calculate PCR efficiency and to calculate the Log10 CaSki cDNA 
DNA concentration equivalent to a sample Ct. 
 
4.1.2.3.2. Estimating PCR Efficiency from PCR Dynamics 
These approaches use the fluorescence measurement recorded at each cycle of the PCR to 
analyse PCR kinetics and determine the reaction efficiency of single PCR reactions. Single PCR 
reaction PCR efficiencies can be calculated using several different mathematical models (Liu 
and Saint, 2002, Ruijter et al., 2009) and the choice of model has a large influence on the PCR 
efficiency calculated (Regier and Frey, 2010). Others suggest that the PCR efficiency of serial 
dilutions of samples must be used, as single sample reaction efficiency calculations are 
responsible for increasing the random error of qRTRTPCR quantifications and must be avoided 
(Nordgard et al., 2006). The most reliable approach has since been shown to be to calculate 
the amplification efficiency from individual amplification plots and then use the mean 
efficiency for all samples as the amplification efficiency for that primer pair (Regier and Frey, 
2010). These typically automated methods for correcting for PCR efficiency offer the best 
chance of accurately correcting for PCR efficiency for each primer pair.  
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4.1.2.3.3. PCR Efficiency Calculation for This Study 
For this study, the calibration curve method was used. Calibration curves were produced with 
7 points of a 3 fold dilution of CaSki cDNA, from 1/3 diluted down to 1/2187. The calibration 
curves were produced in triplicate and linear regression was performed on the calibration 
curve Ct values to produce an equation for the curves in the format of Equation 4.3. 
Linear regression was performed on the results of the three calibration curves separately, and 
the mean of the resulting m and c values was used in calculations of PCR efficiency and the Ct 
value correction applied to account for reverse transcriptase negative samples. Performing 
one linear regression analysis for the triplicate repeats produces an identical line equation. 
Scatter plots with linear regression lines are included for each gene in Appendix II.  
Using the slope (m) from the linear regression line, the efficiency (E) is calculated using 
Equation 4.4. A summary of the linear regression line equations data and the PCR efficiencies 
calculated from the slope value of the line equations are shown in Table 4.2. 
  
Primer pair Slope (m) Intercept (c) PCR efficiency PCR efficiency % 
E2 -3.297 15.960 2.0105 101.05 
E6 -3.629 15.914 1.8861 88.61 
E7 -3.533 15.843 1.9189 91.89 
HPRT -3.538 18.110 1.9171 91.71 
TBP2 -3.742 23.568 1.8503 85.03 
Table 4.2: The mean slope and intercept values produced by linear regression of the dilution series 
calibration curves for each qPCR primer pair.  
Also included are the PCR efficiencies calculated according to the formula E = 10
-1/slope
, expressed both 
as a decimal and as a percentage. 
 
4.1.3. Issues with qPCR: the Biopsy Dosage Effect 
One of the potential issues with using qPCR on VIN biopsies is that several characteristics of 
the biopsy, both biological and experimental can affect the outcome. A large determinant of 
RNA yield is the size of the biopsy, i.e. larger biopsies tend to produce more RNA. A problem 
when looking at HPV16 gene expression is that not every cell in the biopsy will contain HPV16, 
the total number of cells containing HPV will be determined by the biology of the infection and 
the biopsy sampling surgery. In human gene expression studies, every cell contains the 
potential to express both the target gene and the reference gene. In HPV containing biopsy 
qPCR studies, some of the cells in each biopsy will not contain HPV16. This can lead to several 
scenarios that can affect the RQ ratio of HPV genes.  
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In Figure 4.2, scenario A, two biopsies with an equal number of HPV infected cells, each cell 
expressing the same amount of HPV gene are sampled, but the two biopsies vary in size. This 
would mean that for the larger biopsy, more human mRNA is produced than the smaller 
biopsy. Despite expressing the same expression of HPV genes in the HPV infected cells, the RQ 
ratio of HPV-human gene expression will be lower for the larger biopsy because of larger 
number of human mRNAs in the sample. 
In Figure 4.2, scenario B, two identically sized biopsies have a different number of HPV infected 
cells; each cell in both biopsies is expressing the same amount of HPV gene. The biopsy with 
more HPV infected cells will have a higher RQ, purely as a result of a larger number of HPV 
infected cells, not because of higher HPV gene expression. 
In Figure 4.2, scenario C, two biopsies of equal size are sampled. One has a small number of 
HPV infected cells with a high level of HPV gene expression per cell, the other sample contains 
a large number of HPV gene expressing cells that are expressing low amounts of HPV genes per 
cell. The RQ results of both biopsies could be very similar, the larger number of cells in the 
second biopsy making up similar numbers of mRNA as the fewer higher HPV gene expressing 
cells. The number of HPV containing cells masks the true differences in HPV gene expression 
between the two biopsies. 
 In Figure 4.2, scenario D, both samples are identical in size, gene expression and the number 
of HPV infected cells. One sample has a large amount of adipose tissue, yielding less mRNA 
than epithelial tissue. This alters the amount of human gene mRNA in comparison to the HPV 
gene mRNA, potentially affecting the RQ ratios. 
Several other factors are also masked by biopsy sampling. It is widely accepted that within a 
HPV lesion, different regions exhibit different HPV biology. Laser Capture Microdissection 
(LCM) studies for instance have revealed that within one lesion, there can be distinct areas 
containing different HPV types (Quint et al., 2012), and variation in HPV DNA methylation and 
viral copy number in different parts of the same tumour (Kalantari et al., 2009, Vinokurova and 
von Knebel Doeberitz, 2011). It is also well established that there is variation in gene 
expression in different epithelial layers (Doorbar, 2006). How much of the biopsy contained 
different cell types, or even identical types of cells with distinct patterns of HPV mRNA 
expression is difficult to establish. qPCR on mRNA from biopsies does not show differences in 
gene expression between different parts of the biopsy, rather, an average expression for the 
whole biopsy is returned.  
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LCM would have solved several of these issues however the technique is expensive, time 
consuming and is highly unlikely to be applicable to routine cytology/histology. It was also 
outside of the scope of this project both financially and in terms of time commitments. 
Figure 4.2: The biopsy dosage effect illustrated by punch biopsies for 8 hypothetical patients. 
The shape of the biopsy images represents a typical punch biopsy sample, the elastic epidermal top 
layer of tissue retains its shape, whilst the softer and less elastic underlying tissue tends to constrict 
into a cone shape. Pink is human biopsy tissue without HPV infected cells, blue is HPV infected tissue 
expressing HPV genes and red is HPV infected tissue highly expressing HPV genes. In scenario A, two 
biopsies with an equal number of HPV infected cells are sampled, but the two biopsies vary in size. In 
scenario B, two identically sized biopsies have different numbers of HPV expressing cells. In scenario 
C, two biopsies of equal size are sampled, one has a small number of high HPV gene expressing cells, 
the other sample contains a large number of low HPV gene expressing cells. In scenario D, two 
identically sized biopsies have an identical number of HPV gene expressing cells but one sample has a 
large amount of adipose tissue (yellow). 
 
4.1.4. Method Validation 
4.1.4.1. Comparing RQ with Deep Sequencing  
One of the VR series samples (VR49) was used for deep sequencing of the human and HPV 
transcriptome. The data and the analysis did not constitute part of this investigation and the 
data/results are not reported here. However, for the vulval sample, the RQ ratio and RPKM 
(Reads Per Kilobase of exon model per Million mapped reads) of E2, E6 and E7 can be 
compared. RPKM is the current de facto standard for quantifying expression levels for RNA 
deep sequencing data sets (Mortazavi et al., 2008). A simple visual comparison of the 
difference in RQ between E2, E6 and E7 against the difference in RPKM suggests that RQ ratio 
difference between E6 and E7 are fairly accurate whilst E2 RQ was slightly overestimated. RQ 
ratios are expressed relative to CaSki. That E2 expression is slightly overestimated suggests 
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that CaSki E2 mRNA transcription is slightly lower level than E6 and E7. Nonetheless, the 
overestimation is not huge and the relative ratios of E6 and E7 appear to be very similar 
considering the methodological differences. 
 
Deep sequencing qPCR 
HPV gene Exon (nt) RPKM Region (nt) RQ 
E6 83-559 1397 99-178 1.08 
E7 562-858 2347 739-816 2.61 
E2 2755-3852 5124 3362-3426 10.30 
Table 4.3: RPKM and RQ for E6, E7 and E2 of VR49. 
 
4.1.4.2. Reproducibility and Sensitivity 
The reproducibility of the qPCR assays is demonstrated by the CaSki calibration curves 
produced to determine PCR efficiency (Appendix II). There was little variation between runs. 
To further support this observation, the Ct values of 0.01x diluted CaSki cDNA from several 
independent RT treatments and independent qPCR runs are displayed in Figure 4.3. This figure 
shows that little variation was present between independent runs. The sensitivity of the assays 
was also determined, the lowest dilution of CaSki cDNA at which consistently repeatable 
results were produced for all assays was 1/78125 diluted (i.e. 0.000128x). 
TBP2HPRTE2E7E6
29
28
27
26
25
24
23
22
21
20
Assay
C
t 
V
a
lu
e
CaSki Ct value stability across several independent repeats
 
Figure 4.3: The stability of Ct value for multiple 0.01x CaSki repeats. 
Included are 3 full independent repeats, repeated in triplicate (i.e. n=9). 95% confidence interval bars 
(blue bars) and individual values (red circles) are also included. 
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4.2. DNA Methylation 
4.2.1. Method Development 
Initial attempts at determining HPV methylation status utilised Methylation Specific PCR (MS-
PCR). The EZ DNA methylation kit (Zymo Research Corporation, CA, USA) was the most 
commonly used BS conversion kit identified during a literature search. The conversion 
efficiency of the EZ DNA methylation kit was doubted at various stages during the study and 
the manufacturer’s suggestions to improve conversion efficiency were adopted. BS conversion 
was tested using a fully methylated human control DNA (Zymo Research Corporation, CA, USA) 
and BS positive and negative controls and in each instance was found to be efficiently 
converted. 
4.2.1.1. Methylation Specific-PCR 
MS-PCR primers specific to part of the L1, L2 and LCR regions of HPV as described by 
Fernandez et al (Fernandez et al., 2009) were tested. PCRs specific to methylated or 
unmethylated DNA regions were performed (M and U primer pairs respectively). CaSki and 
SiHa had various methylated and unmethylated primer sets amplify, in some instances both 
primer sets would amplify whilst in others, neither would amplify. Rather than a range of 
methylation statuses, the results were more likely down to incomplete BS conversion, 
heterogeneous DNA methylation, a lack of primer specificity and/or incorrect PCR 
optimisation. Further optimisation was performed with little improvement. A fully methylated 
and a fully unmethylated HPV16 positive control DNA were required. 
To produce the unmethylated control DNAs, two approaches were taken. First, CaSki and SiHa 
were treated with the demethylating agent 5-aza-2′-deoxycytidine using two treatment 
protocols (Fernandez et al., 2009, Kalantari et al., 2008a) with limited degrees of success. In 
addition, an Escherichia coli pSP64 plasmid vector containing a cloned HPV16 genome was 
acquired. To produce the methylated control, treatment of pSP64 with M.SssI 
methyltransferase was performed according to the protocol detailed by Brandsma et al 
(Brandsma et al., 2009). Whilst this appeared to offer a suitable series of control DNAs, the 
limitations of MS-PCR had become apparent. MS-PCR was insensitive, required cloning to offer 
data of a quantitative nature and analysed only a few CpGs per assay. 
4.2.1.2. Bisulfite Sequencing 
Bisulfite sequencing was adopted and performed as described by Brandsma et al (Brandsma et 
al., 2009). A series of bisulfite sequencing primers were trialled. CaSki and SiHa DNAs were 
bisulfite sequenced without cloning and aligned against published data. PCRs were optimised 
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successfully and included various annealing temperatures, MgCl2 concentrations, PCR cycles 
and various attempts at nested PCR. It was apparent that quantitative methylation data was 
essential for the successful assessment of methylation status. Cloning of BS treated DNAs prior 
to bisulfite sequencing would provide semi-quantitative methylation data (Fernandez et al., 
2009) however access to a pyrosequencer was secured and the bisulfite sequencing assays 
were eventually abandoned. 
4.2.1.3. Pyrosequencing 
Pyrosequencing had the advantage of producing quantitative data, being rapid and high 
throughput, accurate, assessed multiple CpGs within a short region of DNA and did not require 
a cloning step. E2, LCR1 and LCR2 assay details and primer sequences were provided by Dr T 
Liloglou (University of Liverpool, personal communication, Dec 2010) and a basic PCR protocol 
was adapted from the ZymoTaq (Zymo Research Corporation, CA, USA) instruction booklet 
with some modifications. 
The E2, LCR1 and LCR2 assays were chosen for several reasons. LCR2 represented the HPV 
promoter including E2BS3 and E2BS4 which have a suspected role in P97 regulation and were 
observed to be hypermethylated in most cervical cancers (Fernandez et al., 2009). LCR1 
represented the viral enhancer, another interesting region of the LCR, but importantly a region 
without E2BSs such that LCR methylation could be assessed independent of the potentially 
strong influence of E2BS methylation. E2 was chosen as there was reason to suspect E2 
intragenic methylation might affect E2 transcription/translation and it was a region outside of 
the LCR with which to assess HPV genomic methylation. 
Initial attempts at pyrosequencing PCRs produced multiple secondary products. Further 
optimisation using gradient PCR and the addition of Qiagen HotStarTaq Q-mix (Qiagen, Hilden, 
Germany) appeared to minimise secondary product formation in some instances. 
Pyrosequencing was successfully applied to a range of DNAs. We had attempted to test the 
quantitative nature of the pyrosequencing reaction by mixing increasing amounts of 
hypomethylated control DNAs with hypermethylated control DNAs but the attempts were 
unsuccessful. Pyrosequencing had revealed that the 5-aza-2′-deoxycytidine treatment regime 
was not particularly effective at demethylating CaSki DNAs and whilst in vitro 
methyltransferase treatment worked well, pyrosequencing of the cloned pSP64 HPV16 
genome consistently failed. Sequencing of the pSP64 HPV16 E2 region revealed considerable 
sequence diversity that was likely responsible for this failure. Several DNA extracts and clones 
were trialled until this avenue of investigation was abandoned. Pyrosequencing works in a 
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“sequencing by synthesis” manner, each dNTP is added sequentially, incorporated and a light 
signal is produced. If inefficient extension of the sequencing product occurs (e.g. as a result of 
sequence diversity), part of the sequencing product will remain unextended until the next 
addition of the relevant dNTP. This causes amplification of sequencing products in several 
phases/frames, creating background noise and causing the runs to fail. 
Subtle modifications to the dispensation protocol were performed in order to improve 
sequencing efficiency and diluting the PCR product 2/3 with water prior to sequencing 
improved data quality considerably. DNA input amount was optimised alongside PCR 
conditions and the volume of sepharose beads required for PCR product immobilisation. 
Two additional assays were developed to target the L1/L2 overlap and E2BS1. The L1/L2 
overlap was chosen for several reasons. Whilst most studies considered methylation of only a 
few CpGs of the HPV genome, genome wide studies have assessed the entire methylome of 
HPV16 in a range of cervical disease states. Several regions of the HPV genome (especially L1 
and L2) were progressively methylated with increasing disease severity whilst the LCR 
remained largely unmethylated in all samples (Fernandez et al., 2009). L1/L2 was away from 
areas of transcriptional regulation (i.e. LCR) and potential transcriptional regulation (i.e. E2 
intragenic methylation). L1 and L2 were also regularly cited as areas with potential clinical 
utility in terms of a methylation biomarker. E2BS1 was sought because it was the activator 
E2BS, we hypothesised that this E2BS might be differentially methylated from the repressor 
E2BSs in a manner which might be associated with high transcriptional activity. The E2BS1 and 
L1/L2 assays were difficult to design as both regions were flanked by long TA repeats and had 
considerable secondary structure. Whilst L1/L2 was eventually optimised and applied to 
various cohorts, the E2BS1 assay was deemed unsuitable due to repeated failure of the 
pyrosequencing internal controls. 
 
4.2.2. Method Validation 
The early stages of biomarker design require the development of an accurate and reproducible 
assay that is suitable for the range of material that it will be applied to. As such, the sensitivity 
and reproducibility of pyrosequencing were tested. 
First, the limits of sensitivity were tested. Two independent dilution series of CaSki BS treated 
DNA were performed in duplicate. CaSki was diluted from 1x (BS treated DNA) down to 
0.0001x. The success of these PCRs is depicted in Figure 4.4. CaSki 0.001x was the lowest 
concentration that produced a band that might be expected to be successfully pyrosequenced; 
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this represented an input of BS treated DNA of approximately 0.01 ng/PCR. For data collection, 
CaSki DNA was typically used at 0.01x concentration in PCR, whilst clinical samples were 
typically used at 0.1x concentration. 
 
Figure 4.4: PCR success for a 1/10 dilution series of CaSki BS treated DNAs.  
Five levels of a CaSki BS DNA 1/10 dilution were tested in the pyrosequencing PCRs. A and B represent 
two fully independent repeats (i.e. independent BS treatment and PCR). Negatives were full process 
negatives, i.e. water instead of DNA for BS treatment. The bands produced for negative reactions 
were small and most likely represented primer dimers. 
 
These PCR products were then pyrosequenced. No difference in methylation level was 
observed between the diluted DNAs. The lowest concentration to produce a successful 
pyrosequencing result was 0.001x for all assays, and 0.0001x for L1/L2 and LCR1. In summary, 
pyrosequencing can function with a very small amount of input DNA. 
To test variability between pyrosequencing reactions, 6x CaSki repeats were performed. The 
results are summarised in Appendix III. There was little variation between runs. 
 
4.3. Conclusions 
qPCR and various assays for measuring DNA methylation were evaluated. Protocols were 
produced and optimised. Relative quantification was performed using a modified variant of the 
Pfaffl equation. For methylation analysis, pyrosequencing was chosen because it measures 
multiple CpGs and is quantitative, high throughput, sensitive and reproducible. 
Studies in the various cohorts demonstrate that pyrosequencing can be applied to DNA 
extracted from several types of material including LBC samples. 
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Chapter 5. The NSC Study - DNA Methylation and Disease Grade 
 
5.1. Results 
This study was performed in order to investigate the relationship between DNA methylation 
and cervical disease. A series of HPV16 positive LBC samples with normal cytology (normal 
group, n=20) and severe dyskaryosis (severe group, n=20) and a series of FFPE cervical cancer 
DNAs (cancer group, n=27) were analysed using the pyrosequencing assays targeting the E2, 
LCR1, LCR2 and L1/L2 regions. Several of these samples failed various pyrosequencing assays 
(most likely as a result of DNA quality). Poor quality data was excluded from the analysis which 
meant that the results of 17 normal samples, 20 severe samples and 24 cancer samples were 
used in the final statistical analysis. 
The DNA methylation data was analysed by addressing a hierarchical series of hypotheses 
about HPV16 DNA methylation and the relationship between methylation and cervical disease 
grade. A description of the statistical analyses used, including a description of the 
requirements is presented in the materials and methods section. 
 
5.1.1. Hypothesis 1: DNA Methylation Varied among Regions of the Genome 
There appeared to be considerable variation in the level of DNA methylation among the four 
HPV16 regions (Figure 5.1). To test for a significant difference among the regions, a two-way 
ANOVA GLM was ideal as it considered DNA methylation for all three regions simultaneously. 
The two-way ANOVA found significant differences among the mean DNA methylation of each 
region (P=0.000). In addition, the two-way ANOVA GLM partly tested the next hypothesis and 
found significant differences among the three disease groups (P=0.000). One violation of the 
two-way ANOVA existed, the data did not have equal variances (P=0.000) however no suitable 
non-parametric alternative exists. 
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Figure 5.1: The relationship between disease grade and DNA methylation for four regions of the 
HPV16 genome. 
Coloured bars represent mean methylation and individual values are plotted as red circles. 95% +/- 
confidence intervals for mean are included. 
 
5.1.2. Hypothesis 2: There is a Difference in DNA Methylation among the 
Different Disease Grades 
In general, there appeared to be a pronounced increase in DNA methylation within each region 
with increasing grades of cervical disease, with the highest seen in the cancers and the lowest 
in normal cytology samples (Figure 5.1). There was also considerable variation in the amount 
of DNA methylation at each HPV16 region within the disease groups. For example, the HPV16 
E2 region of individual cancer samples ranged from 8.5-85% methylated. This massive variation 
suggests that the cause or consequences of HPV DNA methylation were not common to each 
of the cancers or that a higher level of complexity existed. 
The simplest way of comparing DNA methylation was to compare the means of the three 
disease groups statistically. The previously performed two-way ANOVA GLM test revealed a 
significant difference among the disease groups (P=0.000) but the GLM does not permit 
pairwise comparisons. As such, DNA methylation at each region for each of the three disease 
groups was compared using one-way ANOVA tests (one test for each region) and then Tukey-
Kramer tests were used to identify pairwise differences between the disease groups. The 
methylation data for several regions violated one or more of the assumptions of the one-way 
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ANOVA test; however because these statistics were exploratory and hypothesis generating in 
nature, the advantages of the one-way ANOVA and Tukey-Kramer over the non-parametric 
Kruskall-Wallis test and multiple Mann-Whitney U tests outweighed the consequences of the 
violations. Significant results must be interpreted with caution and the one-way ANOVAs 
performed ideally require a Bonferroni correction of P=0.013 to be considered. To increase the 
reliability of the interpretation of the results, Kruskall-Wallis tests were also performed. The 
results of the one-way ANOVA, Tukey-Kramer and Kruskall-Wallis tests are presented in Table 
5.1. The details of any violations of the assumptions of the ANOVA are included in the table 
legend. 
There were highly significant differences among the means of the three disease groups for all 
tested regions. There were also significant differences between the cancer group and the 
normal/severe groups for every region and a significant difference between the severe and 
normal groups for the L1/L2 region.  
 
 
HPV16 Region 
 
E2 LCR1 LCR2 L1/L2 
One-way ANOVA (P-value) 0.000 0.000
*1
 0.000
*2
 0.000
*3
 
Significant Tukey-Kramer C vs. S, C vs. N C vs. S, C vs. N C vs. S, C vs. N C vs. S, C vs. N, 
results 
   
S vs. N 
Kruskall-Wallis (P-value) 0.000 0.000 0.000 0.000 
Table 5.1: The results of one-way ANOVA tests, Tukey-Kramer pairwise comparison tests and Kruskall-
Wallis tests to compare the differences among the three disease groups. 
One-way ANOVA tests were performed to compare the means of the three disease groups in each 
HPV region. P is significant at P<0.05 or P<0.013 (Bonferroni corrected). The Tukey-Kramer pairwise 
comparisons significant at P=0.05 are presented, here N is the normal cytology group, S is the severe 
dyskaryosis group and C is the cancer group, e.g. “C vs. S” represents a significant difference between 
the mean methylation of C and S for that region. Kruskall-Wallis P-values are included and represent a 
difference among the medians of the three groups. Violations of the one-way ANOVA assumptions *1; 
unequal variances (P=0.042) and non-normally distributed residuals (P=<0.005), *2; unequal variances 
(P=0.004), *3; unequal variances (P=0.026). 
 
5.1.3. Hypothesis 3: DNA Methylation Varies within Regions 
The pyrosequencing assays each cover several CpGs so as well as differences among regions, 
differences among individual CpGs within each region can be determined. There appeared to 
be variation in the amount of methylation of different CpGs within each site, and a rather well 
conserved pattern of methylation at each CpG, i.e. the same CpGs seem to be the most 
methylated in each disease group despite large differences between the disease groups 
overall. The E2-4 (the 4th CpG of the E2 region) for instance was highly methylated in all 
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disease groups relative to the other CpGs, conversely, E2-3 was low in each instance despite 
the CpGs being separated by only 14 bp. CpGs E2-1, E2-2 and E2-3 are very close together (E2-
2/E2-3 are directly adjacent and E2-1/E2-2 are separated by 1 bp) and yet DNA methylation 
among these CpGs varied considerably, possibly suggesting that a very specific mechanism 
regulates HPV DNA methylation. The CpG specific methylation patterns also appeared to be 
well conserved for most of the regions, the “N” shaped pattern (i.e. CpGs L1L2-1 and L1L2-3 
lowly methylated and L1L2-2 and L1L2-4 more methylated) seen in the L1/L2 region was 
particularly evident in each disease group (Figure 5.5). 
5.1.3.1. E2 
Kruskall-Wallis one-way analysis of variance was used to determine whether a significant 
difference existed among the median methylation values at each CpG of the E2 region (Figure 
5.2). Bonferroni correction for multiple analyses means that a P=0.006 should be considered. 
There was a significant difference among the median values of methylation of the 8 CpGs of 
the E2 region in the normal cytology sample group (P=0.000) and the severe dyskaryosis group 
(P=0.001) but not the cervical cancer group (P=0.101). 
5.1.3.2. LCR1 
Kruskall-Wallis one-way analysis of variance was used to determine whether a significant 
difference existed among the median methylation values at each CpG of the LCR1 region 
(Figure 5.3). Bonferroni correction for multiple analyses means that P=0.017 should be 
considered. There was no significant difference in the median methylation at each CpG for the 
normal group (P=0.517), however there was a significant difference among the median 
methylation values of each CpG for the severe (P=0.000) and cancer (P=0.005) groups. 
5.1.3.3. LCR2  
Kruskall-Wallis one-way analysis of variance was used to determine whether a significant 
difference existed among the median methylation values at the CpGs of the LCR2 region 
(Figure 5.4). Bonferroni correction for multiple analyses means that a P=0.010 should be 
considered. There was a significant difference among the median methylation for the normal 
(P=0.000) and an almost significant difference for the severe group (P=0.028), but not for the 
cancer group (P=0.821).  
5.1.3.4. L1/L2 
Kruskall-Wallis one-way analysis of variance was used to determine whether a significant 
difference existed among the median methylation values at the CpGs of the L1/L2 region 
(Figure 5.5). Bonferroni correction for multiple analyses means that a P=0.013 should be 
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considered. There was a significant difference among the median methylation for the normal 
(P=0.011), severe group (P=0.000) and cancer group (P=0.001).  
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Figure 5.2: Variation in CPG methylation with disease grade for the E2 region of HPV16.  
The mean amount of methylation at each of the 8 CpGs of the E2 region are compared for each of the 
three sample groups (normal=N, severe=S and cancer=C). Error bars indicate 95% confidence intervals 
for mean. Red crosses indicate individual sample values. 
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Figure 5.3: Variation in CPG methylation with disease grade for the LCR1 region of HPV16.  
The mean amount of methylation at each of the 3 CpGs of the E2 region are compared for each of the 
three sample groups (normal=N, severe=S and cancer=C). Error bars indicate 95% confidence intervals 
for mean. Red crosses indicate individual sample values. 
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Figure 5.4: Variation in CPG methylation with disease grade for the LCR2 region of HPV16.  
The mean amount of methylation at each of the 5 CpGs of the E2 region are compared for each of the 
three sample groups (normal=N, severe=S and cancer=C). Error bars indicate 95% confidence intervals 
for mean. Red crosses indicate individual sample values. 
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Figure 5.5: Variation in CPG methylation with disease grade for the L1/L2 region of HPV16.  
The mean amount of methylation at each of the 4 CpGs of the E2 region are compared for each of the 
three sample groups (normal=N, severe=S and cancer=C). Error bars indicate 95% confidence intervals 
for mean. Red crosses indicate individual sample values. 
 
5.1.4. Hypothesis 4: E2BS Methylation is Associated with Disease 
Previous studies have observed a relationship between E2BS methylation and disease severity. 
LCR2 covers two E2BSs (E2BS3 and E2BS4) however LCR2 methylation was low in almost all 
precancerous neoplasias. Of the cervical cancers, only 5 samples had LCR2 methylation above 
40% whilst the rest were considerably less methylated, there was not a strong association 
between LCR2 methylation and cancer. 
5.1.5. Hypothesis 5: HPV DNA Methylation is Clinically Relevant 
One of the primary reasons for performing pyrosequencing on the three disease groups was to 
determine whether HPV methylation represents a suitable biomarker of cervical disease. An 
aspect of this was to determine what features of the methylation data were the most 
informative clinically. In order to assess which of the four regions and which of the twenty 
CpGs analysed were the most different among the three disease grades, multiple statistical 
analyses were applied.  
The regions or single CpGs with the greatest significant differences in methylation among the 
three disease grades are more likely to be of use in future biomarker studies. One-way ANOVA 
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and Tukey-Kramer pairwise comparison tests were applied to the methylation data for each of 
the regions and CpGs, and the significance of the results compared. The statistics performed in 
other parts of this investigation were exploratory and hypothesis generating in nature and so a 
degree of deviation from the assumptions of ANOVA, or P-values below the Bonferroni 
corrected P-value were acceptable providing that the results were interpreted with caution. 
Here, a direct comparison of the P-values of the tests was being performed in order to 
determine which comparisons were the most significant; as such the violation of assumptions 
may have had a considerable effect on the conclusions drawn. In order to aid interpretation of 
the results, Kruskall-Wallis non-parametric ANOVAs were also applied to compare differences 
among the median of each group. In addition to these analyses, the overall spread of the 
methylation data for each CpG and the size of the confidence intervals for the graphically 
plotted methylation data were considered when deciding which region or CpG appears to be 
the most different among the three disease groups. 
 
5.1.5.1. Which of the Four HPV Regions is the Most Informative? 
One-way ANOVA, Tukey-Kramer and Kruskall-Wallis tests were performed on the mean 
methylation data for each pyrosequencing assay, the results are summarised in Table 5.2. A 
Bonferroni corrected P-value of 0.013 was used. In order to determine which of the four 
regions was the most informative; the H-value, F-value and Tukey-Kramer results were 
considered. E2, LCR1 and L1/L2 had the highest F values however LCR1 violated the 
assumptions of the ANOVA so the results must be interpreted with caution. Only L1/L2 was 
differently methylated between the normal and severe groups and the E2 region had the 
lowest H-value. Of all the regions, mean L1/L2 methylation appeared to be the most 
informative. 
Next, similar statistics were applied to the individual CpG methylation data of each region in 
order to identify the most informative CpGs. 
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 HPV16 Region 
 E2 LCR1 LCR2 L1/L2 
Kruskall-Wallis P-value 0.000 0.000 0.000 0.000 
H value (DF) 25.26 (2) 37.40 (2) 26.41 (2) 36.75 (2) 
       
ANOVA P-value 0.000 0.000 0.000 0.000 
F value (DF) 48.04 (2) 41.32 (2) 26.70 (2) 54.45 (2) 
Equal variances Yes Close No Close 
Normal residuals Yes No Yes Yes 
       
 Significant Tukey-Kramer Pairwise Comparison? 
 E2 LCR1 LCR2 L1/L2 
Cancer vs. Normal Yes Yes Yes Yes 
Cancer vs. Severe Yes Yes Yes Yes 
Severe vs. Normal No No No Yes 
Table 5.2: The results of multiple statistical analyses on methylation data all regions.  
The non-parametric Kruskall-Wallis P-values and H-values represent the significant differences among 
the medians of each disease group, higher significance is represented by a lower P-value and a larger 
H-value. ANOVA P-values and F-values are accompanied by degrees of freedom (DF) and two 
statements for violations of the ANOVA assumptions (equal variances and normally distributed 
residuals), here three degrees of success are present, No; a violation (P=<0.01), Close; P=0.01-0.05 and 
Yes; P>0.05. Finally, the significance of Tukey-Kramer tests are listed for each comparison of disease 
group, where Yes = significance at P=0.05 and No = no significance. 
 
 
5.1.5.2. E2 CpG Methylation: Which E2 CpG is the Most Informative? 
One-way ANOVA, Tukey-Kramer and Kruskall-Wallis tests were performed for each E2 CpG, the 
results are summarised in Table 5.3. Each CpG was significantly differently methylated among 
the disease groups and met the Bonferroni corrected P-value of 0.006 in every instance. In 
order to decide which of the 8 E2 CpGs was the most differently methylated among disease 
grades, the H-value, F-value and Tukey-Kramer results were considered. E2-1, E2-2 and E2-4 
had the highest (i.e. most significant) Kruskall-Wallis H-values and ANOVA F-values. E2-2 data 
violated the assumptions of the ANOVA and so pairwise comparison was less reliable, there 
was also no difference in mean E2-2 methylation between the severe and the normal groups.  
There were however significant differences in E2-1 and E2-4 methylation among each of the 
three disease groups. When considering the individual value plot for E2 (Figure 5.2), it was 
difficult to decide which of E2-1 and E2-4 was more informative as both had overlaps among 
the three groups, and for the cancer group especially there was a wide range of individual 
methylation values. Values overlap for the severe and normal groups, but in both instances 
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narrower confidence intervals exist than for the E2 region as a whole suggesting that individual 
CpG methylation might prove more useful. 
 E2-1 E2-2 E2-3 E2-4 E2-5 E2-6 E2-7 E2-8 
Kruskall-Wallis P-
value 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
H-value  
(DF) 
30.94 
(2) 
26.91 
(2) 
25.97 
(2) 
30.22 
(2) 
17.47 
(2) 
26.19 
(2) 
21.93 
(2) 
22.87 
(2) 
           
ANOVA P-value 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
F-value  
(DF) 
42.49 
(2) 
36.61 
(2) 
33.48 
(2) 
49.61 
(2) 
18.41 
(2) 
37.30 
(2) 
27.05 
(2) 
26.20 
(2) 
Equal variances Yes Yes No Yes Yes Close Yes Close 
Normal residuals Close No No Yes Close No No No 
           
  Significant Tukey-Kramer Pairwise Comparison? 
  E2-1 E2-2 E2-3 E2-4 E2-5 E2-6 E2-7 E2-8 
Cancer vs. Normal Yes Yes Yes Yes Yes Yes Yes Yes 
Cancer vs. Severe Yes Yes Yes Yes Yes Yes Yes Yes 
Severe vs. Normal Yes No No Yes No No No No 
Table 5.3: The results of multiple statistical analyses on methylation data for the E2 CpGs.  
The non-parametric Kruskall-Wallis P-values and H-values represent the significant differences among 
the medians of each disease group, higher significance is represented by a lower P-value and a larger 
H-value. ANOVA P-values and F-values are accompanied by degrees of freedom (DF) and two 
statements for violations of the ANOVA assumptions (equal variances and normally distributed 
residuals), here three degrees of success are present, No; a violation (P=<0.01), Close; P=0.01-0.05 and 
Yes; P>0.05. Finally, the significance of Tukey-Kramer tests are listed for each comparison of disease 
group, where Yes = significance at P=0.05 and No = no significance. 
 
5.1.5.3. LCR1 CpG Methylation: Which LCR1 CpG is the Most Informative? 
One-way ANOVA, Tukey-Kramer and Kruskall-Wallis tests were performed for each LCR1 CpG 
and the results are summarised in Table 5.4. Each CpG was significantly differently methylated 
among the disease groups and met the Bonferroni corrected P-value 0.017 in every instance. 
LCR1-2 and LCR1-3 had the most significant (i.e. highest) H-values and F-values however there 
was no significant difference in LCR1-2 methylation between the severe and normal groups, 
and LCR1-3 data failed one of the ANOVA assumptions making interpretation unreliable. In 
addition, there was considerable variation among individual data points in each disease group 
and there was substantial overlap between the severe and normal groups (Figure 5.3). For 
differentiating between cancer and normal or severe samples, methylation level of the LCR1-2 
and LCR1-3 CpGs may prove clinically useful. 
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 LCR1-1 LCR1-2 LCR1-3 
Kruskall-Wallis P-value 0.000 0.000 0.000 
H value (DF) 26.26 (2) 36.49 (2) 37.71 (2) 
      
ANOVA P-value 0.000 0.000 0.000 
F value (DF) 18.79 (2) 35.20 (2) 48.29 (2) 
Equal variances Yes Yes Yes 
Normal residuals No Yes No 
      
 Significant Tukey-Kramer Pairwise Comparison? 
 LCR1-1 LCR1-2 LCR1-3 
Cancer vs. Normal Yes Yes Yes 
Cancer vs. Severe Yes Yes Yes 
Severe vs. Normal No No Yes 
Table 5.4: The results of multiple statistical analyses on methylation data for the LCR1 CpGs.  
The non-parametric Kruskall-Wallis P-values and H-values represent the significant differences among 
the medians of each disease group, higher significance is represented by a lower P-value and a larger 
H-value. ANOVA P-values and F-values are accompanied by degrees of freedom (DF) and two 
statements for violations of the ANOVA assumptions (equal variances and normally distributed 
residuals), here three degrees of success are present, No; a violation (P=<0.01), Close; P=0.01-0.05 and 
Yes; P>0.05. Finally, the significance of Tukey-Kramer tests are listed for each comparison of disease 
group, where Yes = significance at P=0.05 and No = no significance. 
 
5.1.5.4. LCR2 CpG Methylation: Which LCR2 CpG is the Most Informative? 
One-way ANOVA, Tukey-Kramer and Kruskall-Wallis tests were performed on the methylation 
data for each LCR2 CpG and the results are summarised in Table 5.5. All comparisons were 
significant even when the Bonferroni corrected P-value 0.010 was considered. None of the H-
values or F-values were exceptionally high but CpGs LCR2-3 and LCR2-4 were the most 
significantly different among the groups. However the data for all of the comparisons did not 
satisfy the assumptions of the ANOVA and none of the subsequently unreliable Tukey-Kramer 
comparisons were able to differentiate between methylation of the severe and normal 
samples. Methylation data for the LCR2 region may be useful for differentiating cancer 
samples from normal or severe disease however the data analyses had violations and were not 
particularly suitable for the analyses performed. Also, the range of DNA methylation in each 
disease group overlapped for every CpG (Figure 5.4). 
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 LCR2-1 LCR2-2 LCR2-3 LCR2-4 LCR2-5 
Kruskall-Wallis P-value 0.000 0.000 0.000 0.000 0.000 
H value (DF) 26.97 (2) 20.27 (2) 29.63 (2) 30.72 (2) 20.86 (2) 
        
ANOVA P-value 0.000 0.000 0.000 0.000 0.000 
F value (DF) 27.08 (2) 18.00 (2) 28.88 (2) 33.71 (2) 17.26 (2) 
Equal variances No Yes Close No Close 
Normal residuals No Close No No No 
        
 Significant Tukey-Kramer Pairwise Comparison? 
 LCR2-1 LCR2-2 LCR2-3 LCR2-4 LCR2-5 
Cancer vs. Normal Yes Yes Yes Yes Yes 
Cancer vs. Severe Yes Yes Yes Yes Yes 
Severe vs. Normal No No No No No 
Table 5.5: The results of multiple statistical analyses on methylation data for the LCR2 CpGs.  
The non-parametric Kruskall-Wallis P-values and H-values represent the significant differences among 
the medians of each disease group, higher significance is represented by a lower P-value and a larger 
H-value. ANOVA P-values and F-values are accompanied by degrees of freedom (DF) and two 
statements for violations of the ANOVA assumptions (equal variances and normally distributed 
residuals), here three degrees of success are present, No; a violation (P=<0.01), Close; P=0.01-0.05 and 
Yes; P>0.05. Finally, the significance of Tukey-Kramer tests are listed for each comparison of disease 
group, where Yes = significance at P=0.05 and No = no significance. 
 
5.1.5.5. L1/L2 CpG Methylation: Which L1/L2 CpG is the Most Informative? 
One-way ANOVA, Tukey-Kramer and Kruskall-Wallis tests were performed on the methylation 
data for each L1/L2 CpG and the results are summarised in Table 5.6. P-values were below the 
Bonferroni corrected threshold of 0.013 in every instance. Both L1L2-2 and L1L2-3 had high 
(i.e. highly significant) F-values and H-values. L1L2-3 data was very close to satisfying the 
assumptions of the ANOVA and showed a significant difference among all three groups. L1L2-2 
data did not satisfy the assumptions of the ANOVA so the interpretation was less reliable, but 
there was still a significant difference in methylation among the three disease groups.  
L1L2-1 methylation was different between normal or severe and cancer, but not between 
normal and severe. In terms of clinical utility, the most significant differences among the three 
disease groups were observed for L1L2-2 methylation. Whilst methylation of L1L2-2, L1L2-3 
and L1L2-4 was significantly different among the three disease groups, the smallest confidence 
intervals and the smallest degrees of overlap among the groups were observed for L1L2-2 and 
L1L2-4 (Figure 5.5). In summary, the biggest differences were observed for L1L2-2 methylation 
however methylation of all L1/L2 CpGs seemed likely to be useful, and could potentially be 
more useful than mean L1/L2 methylation alone.  
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 L1L2-1 L1L2-2 L1L2-3 L1L2-4 
Kruskall-Wallis P-value 0.000 0.000 0.000 0.000 
H value (DF) 30.56 (2) 37.38 (2) 34.7 (2) 33.39 (2) 
       
ANOVA P-value 0.000 0.000 0.000 0.000 
F value (DF) 32.14 (2) 48.10 (2) 43.58 (2) 33.66 (2) 
Equal variances Yes No Yes No 
Normal residuals No Close Close No 
      
 Significant Tukey-Kramer Pairwise Comparison? 
 L1L2-1 L1L2-2 L1L2-3 L1L2-4 
Cancer vs. Normal Yes Yes Yes Yes 
Cancer vs. Severe Yes Yes Yes Yes 
Severe vs. Normal No Yes Yes Yes 
Table 5.6: The results of multiple statistical analyses on methylation data for the L1/L2 CpGs.  
The non-parametric Kruskall-Wallis P-values and H-values represent the significant differences among 
the medians of each disease group, higher significance is represented by a lower P-value and a larger 
H-value. ANOVA P-values and F-values are accompanied by degrees of freedom (DF) and two 
statements for violations of the ANOVA assumptions (equal variances and normally distributed 
residuals), here three degrees of success are present, No; a violation (P=<0.01), Close; P=0.01-0.05 and 
Yes; P>0.05. Finally, the significance of Tukey-Kramer tests are listed for each comparison of disease 
group, where Yes = significance at P=0.05 and No = no significance. 
 
5.1.5.5.1. Summary 
Comparison of individual CpGs determined that a number of CpGs were differentially 
methylated with respect to disease grade. Methylation of these CpGs might represent a 
potential biomarker to differentiate between either cancer and severe or normal samples, or 
even differentiate all three groups. A larger data set would improve the power of the analyses 
and increase the chances of identifying suitable CpGs. It would also permit the application of 
statistics more typically associated with biomarker studies. Currently, the CpGs E2-1, E2-4, 
LCR1-2 and LCR1-3 show potential to differentiate between cancer samples and those with a 
normal cytology or severe dyskaryosis whilst the L1L2-2 and L1L2-4 CpGs shows good potential 
as a way of differentiating among all three groups; normal cytology, severe dyskaryosis and 
cancers. 
Differences among the disease grades were more significant when the E2 region was 
considered as a whole rather than for individual CpGs. However, significant differences 
specifically between the normal cytology and severe dyskaryosis groups were present for 
individual CpGs, but not for mean E2 regional methylation. Methylation differences among all 
three groups were observed for individual CpGs within the LCR and were different between 
the normal and severe disease groups whilst mean LCR1 methylation was not. Mean LCR2 
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methylation was also not different between the normal and severe groups regardless of 
whether single CpGs or the whole regions were considered and no LCR2 comparisons had 
exceptionally high F/H values.  
Finally, mean L1/L2 methylation had differences of greater significance among the three 
disease groups than individual CpGs did. The overall spread and degree of overlap for the 
mean L1/L2 methylation data was also greater than was seen for individual CpGs of the L1/L2 
region. The L1/L2 region appeared to have potential as a biomarker for cervical disease. 
Further work on a larger data set is required to better determine whether methylation at 
individual CpGs or the mean of all four CpGs is more informative. Ideally, HPV integration data 
would also be available as the high and variable methylation seen in the cancer set could be a 
result of HPV DNA integration. 
 
 
5.2. Discussion 
5.2.1.1. Aims 
This study was performed as a preliminary study prior to testing for DNA methylation in other 
clinical cohorts. It addressed the need to determine the relationship between disease grade 
and DNA methylation such that data collected for other clinical cohorts could be considered in 
context. We were also mindful of the process of biomarker development recommended by 
Cancer Research UK (CRUK) (Appendix I) and this study had the capability of fulfilling several 
aspects of the early development requirements, i.e. that there was variation within our target 
population and that there was a difference among subjects with low grade disease, high grade 
disease and cancer. It was also used to determine whether the data from this study correlated 
with published studies performed using a variety of methods and targeting a variety of HPV 
regions. There was considerable variation in the results of previous studies especially when 
concerning the methylation status of the LCR, this was an issue that we had aimed to clarify. 
5.2.1.2. Strengths 
This study had aimed to identify potential biomarkers to discriminate between HPV positive 
women with and without signs of cervical neoplasia. The potential application would be on 
HPV positive LBC material, this was reflected by the study which was primarily conducted on 
LBC samples. A series of DNAs from histologically confirmed cervical cancers were also 
included in this analysis to determine whether the trends observed in the cytology samples 
were also present in cancers and to extend the severity of disease grades studied. The sample 
110 
 
size (n=67) was above average when compared to similar studies and various significant results 
were achieved when the data were tested statistically.  
Until recently, pyrosequencing had not been widely applied for HPV methylation studies, likely 
due to the expense and limited availability of equipment. However, pyrosequencing has the 
advantage of producing fully quantitative results from a heterogeneous mix of DNAs. 
Consistent with other studies, we found bisulfite sequencing without cloning to be a poor 
method for determining DNA methylation (Kalantari et al., 2004). Bisulfite sequencing with 
cloning is semi-quantitative and the results are highly affected by low clone number 
(commonly observed in published studies) such that methylation frequencies are not 
representative. Pyrosequencing does not have these issues. In summary, the study design and 
the assay used were a good way of testing the hypotheses. 
5.2.1.3. Weaknesses 
One of the weaknesses of the study was that while the normal cytology and severe dyskaryosis 
DNAs were extracted from LBC material collected during routine screening, the cancer group 
DNAs were extracted from FFPE cancer biopsies. As the LBC samples were collected as part of 
an anonymous prevalence study, we did not have corresponding histology for the severe 
dyskaryosis samples and therefore did not know the proportion that actually had CIN. 
However, of 3,019 women referred for moderate dyskaryosis or worse, 2,556 (84%) showed 
CIN2 or worse (Cervical Screening Wales, 2011). It is therefore highly likely that the majority of 
samples with severe dyskaryosis would be associated with clinically significant disease (i.e. 
CIN2+). 
The degraded state of DNA from the FFPE cancer samples also affected the success of the 
pyrosequencing assays. Multiple repeats of the PCRs and sequencing reactions were required 
to achieve an acceptable quality of data for some of the cancer samples, which was still 
typically of a lower quality than data collected from LBC material. Samples with particularly 
poor quality data (as determined objectively by the pyrosequencing analysis software) were 
excluded from the analysis. 
To fully assess the potential of DNA methylation as a biomarker would require a much larger 
study designed specifically to test and identify disease biomarkers in a suitable population of 
LBC samples, with associated histology data. This was not achieved by this study.  
Finally, there were several violations of the assumptions of the ANOVA. The tests were used in 
spite of these violations on the basis that the multifactorial ANOVA produced data confirmed 
by other tests. It is common practice to use the tests with violations in an exploratory nature 
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to generate hypotheses under the premise that the results are interpreted with an appropriate 
degree of caution. The sample set size would ideally be larger as this would both improve the 
reliability of the data and increase the likelihood of the data being suitable for testing without 
violations being incurred. 
 
5.2.1.4. Comparison to Other Studies 
HPV methylation has quite recently become a popular avenue of investigation, several 
published studies have related HPV methylation and HPV-associated disease grade and in 
several instances, there was considerable variation in the results. 
The association between LCR methylation and cervical disease varies among studies. Most 
studies reported increased LCR methylation to be associated with higher grade disease 
(Kalantari et al., 2004, Bhattacharjee and Sengupta, 2006a, Ding et al., 2009, Brandsma et al., 
2009, Hong et al., 2008) whilst some report the opposite (Badal et al., 2003, Hublarova et al., 
2009, Patel et al., 2012, Piyathilake et al., 2011). One of the major points of contention 
appears to be LCR methylation of very low grade disease samples; several studies, including 
ours did not see LCR methylation in LSIL/normal cytology/no CIN samples (Ding et al., 2009, 
Fernandez et al., 2009, Bhattacharjee and Sengupta, 2006a) whilst others saw higher 
methylation in these samples than in higher grade precancerous disease (Hong et al., 2008, 
Patel et al., 2012, Kalantari et al., 2004, Badal et al., 2003). Nonetheless, whilst there was 
variation in the published methylation data, there was no valid reason to doubt the data 
produced by this study as the results were consistent across a diverse range of material. For 
the cell lines study for instance (Chapter 7: 7.1.2 & 7.1.3.3), cell lines derived from 
precancerous lesions (i.e. W12Ser7, PC08 and PC09) were rarely methylated in the LCR at early 
passage and LCR methylation was not commonly observed in VIN2/3 (Chapter 8: 8.2.3). 
The published studies encompass a range of material, a range of methodologies and 
determine the significance of DNA methylation from a variety of perspectives (study 
methodologies summarised in Appendix VI). Differences between LBC and biopsy material is 
liable to contribute to some of the differences as LCR methylation is known to be both 
intrinsically associated with cellular differentiation and to be heterogeneous between different 
parts of the same lesion (Vinokurova and von Knebel Doeberitz, 2011). LBC samples contain 
only desquamated cervical cells whilst biopsy material contains cells from various layers of the 
epithelium. Methodological differences, especially where DNA methylation was determined 
using non-quantitative assays (i.e. direct bisulfite sequencing/MS-PCR, or methylation sensitive 
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restriction enzymes) are also likely to have a large influence on the results and is observed in 
the literature (Badal et al., 2003, Fernandez et al., 2009). Further, the method of reporting 
results, even where the same assays have been used varied considerably; e.g. Hong et al used 
pyrosequencing to evaluate LCR methylation, including 5 CpGs covered by our LCR2 assay 
(Hong et al., 2008). Methylated samples were those with “some degree of methylation”, if 
some means >0% then every sample in all disease groups for our study had “some degree of 
methylation” at LCR1 and/or LCR2.  
Other studies have observed an association between increased L1 and/or L2 methylation and 
higher disease grades (Fernandez et al., 2009, Kalantari et al., 2009, Sun et al., 2011, Mirabello 
et al., 2012). Genome wide studies have also revealed that E2/E4 methylation appears to be 
related to disease grade (Fernandez et al., 2009, Mirabello et al., 2012). Fernandez et al used 
bisulfite sequencing, with cloning to assess the entire methylome of HPV16 in cytologically 
normal, CIN and SCC samples. Several regions of the HPV genome (especially L1 and L2) were 
progressively methylated with increasing disease severity whilst the LCR remained largely 
unmethylated in all samples (Fernandez et al., 2009). Sections of missing data were observed 
between the E2 and L2 regions (i.e. parts of E2, E4, E5, L1 and L2) for most of the SCC and CIN 
samples, these were explained as deletions (Fernandez et al., 2009) which seems somewhat 
unlikely. Nonetheless, there was a good agreement between the results of this study and our 
study. E2BS methylation has been observed for cancer samples in several studies; whilst 5 
cancer samples had what might be described as LCR2 hypermethylation, the rates of 
hypermethylation of the LCR2 E2BSs were lower than expected and lower than reported 
elsewhere (up to 90% E2BS methylation in an SCC cohort) (Fernandez et al., 2009, Snellenberg 
et al., 2012). 
Several published studies have approached DNA methylation from a biomarker perspective 
considering multiple CpGs. Brandsma et al identified patterns of DNA methylation that were 
associated with disease grades. HPV genomic hypomethylation was associated with lower 
grade cervical disease (normal cytology and negative histology in most instances) and 
hypermethylation at several regions (E5, L1 and L2) was associated with higher grade disease 
(Brandsma et al., 2009). There was however considerable variation among the samples (likely a 
result of small sample number) and no E2 hypermethylation was observed for any of the cases; 
one LSIL sample had methylation in the LCR1 and LCR2 regions however the rest were 
hypomethylated throughout the LCR (Brandsma et al., 2009). Mirabello et al used a HPV 
genome wide approach and identified numerous CpGs where methylation was significantly 
different among the disease grades studied. These CpGs were located primarily in the L1, L2 
113 
 
and E2/E4 regions although CpGs throughout other areas of the genome were also significantly 
associated with disease grade. L1 and L2 methylation could predict disease grade (Mirabello et 
al., 2012).  
 
5.2.2. Meaning 
5.2.2.1. Variation in Methylation 
The variation in methylation level among different HPV regions and among CpGs within 
regions was also seen for cell lines and other clinical cohorts. In most instances there was E2 
and L1/L2 methylation and LCR hypomethylation, this is consistent with several of the studies 
described above. Similarly, the pattern of CpG methylation in each region (i.e. when 
methylation at each CpG is plotted graphically) was also common to the other clinical/cell line 
cohorts. The pattern of L1/L2 CpG methylation for instance was common for all three disease 
groups but was also seen elsewhere in our study. The CpG specific and region specific 
methylation pattern, and possible causes/consequences are discussed in further detail in the 
general discussion (Chapter 9: 9.1.4 & 9.1.5).  
Because there was considerable variation among individual CpGs and because it would be 
much simpler to assess large numbers of samples using single CpG assessing methods like MS-
PCR, any methylation biomarker study would be well advised to consider individual CpG 
methylation as well as regional methylation. 
5.2.2.2. There was a Progressive Increase in DNA Methylation with Increasing 
Severity of Disease 
There was a progressive increase in methylation of the E2 and L1/L2 regions with increasing 
disease severity, the LCR was hypomethylated in most samples except for the cancer group 
where mean LCR methylation was higher and several samples had very high levels of LCR 
methylation. Other studies have identified a more prominent association between E2BS 
hypermethylation (4/5 CpGs of the LCR2 region are in E2BSs) and cancer which may be down 
to methodological differences (Fernandez et al., 2009, Snellenberg et al., 2012). Whether HPV 
DNA methylation changes are a cause of or a consequence of disease progression is yet to be 
established, but the variation within groups does suggest that any relationship is likely to be 
complex.  
Integration of HPV is common in higher grade disease and there is an association between 
DNA hypermethylation and integration (Fernandez et al., 2009, Kalantari et al., 2008b, 
Doerfler, 2006, Van Tine et al., 2004b, Melsheimer et al., 2004). The higher frequency of 
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integration events typically observed in the more severe disease groups might account for 
some of the DNA methylation increase observed. In our other studies (Chapter 7: 7.1.3.5 & 
Chapter 8: 8.2.3.3), most integrated HPV were very heavily methylated in the E2 and/or L1/L2 
regions. The differences between normal cytology and severe dyskaryosis could therefore be 
due to the increased integration frequency. However, whilst there were a few examples of E2 
or L1/L2 hypermethylation of the severe dyskaryosis group, most were not heavily methylated. 
Instead, small increases in methylation of the severe dyskaryosis group compared to the 
normal group were seen for most samples. These small increases in methylation are not 
consistent with an increased integration rate in the higher disease grades being the only 
explanation. As such, integration is not the only factor involved in increased methylation in 
higher disease grades.  
There is an association between HPV DNA methylation and other aspects of HPV molecular 
biology related to cervical disease; i.e. gene expression (Chapter 8: 8.2.3.4) and cellular 
differentiation (Vinokurova and von Knebel Doeberitz, 2011, Ding et al., 2009). LCM studies 
have determined that cellular differentiation in a productive infection is associated with 
changes in LCR methylation. In undifferentiated basal cells, the 5’ LCR and the P97 promoter 
(i.e. LCR2) region were hypomethylated whilst the enhancer region (i.e. LCR1) was 
hypermethylated (Vinokurova and von Knebel Doeberitz, 2011). In more differentiated cell 
layers, the 5’ LCR remained hypomethylated but there was a switch to a hypomethylated 
enhancer and a hypermethylated promoter (Vinokurova and von Knebel Doeberitz, 2011). 
Vinokurova et al also suggested that a “latent” form of infection might be associated with a 
completely hypermethylated LCR whilst cells with high grade disease appeared to be 
associated with a hypermethylated 5’LCR and enhancer, but a hypomethylated promoter 
(Vinokurova and von Knebel Doeberitz, 2011). 
The DNMTs are responsible for methylating DNA. Several oncogenic DNA viruses influence 
DNA methylation and HPV are also known to affect DNMTs both directly and indirectly (Au 
Yeung et al., 2010, Leonard et al., 2012, Burgers et al., 2007, McCabe et al., 2005, Hsu et al., 
2012). It has also been proposed that HPV can actively promote self methylation in order to 
regulate gene expression (De-Castro Arce et al., 2011) so it is not unreasonable to suspect that 
HPV DNA methylation may be at least partly self determined.  
Human cells actively target foreign DNA elements for silencing by DNA methylation and the 
association between cancer and aberrant human DNA methylation has been known for many 
years (Doerfler, 2006, Doerfler, 2008, Doerfler et al., 2001). It is difficult to determine whether 
the profile of HPV DNA methylation observed with increasing disease severity is a consequence 
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of the action of HPV, or the result of general DNA methylation changes as there are numerous 
reports of changes in human DNA methylation also being associated with HPV related cervical 
disease (Henken et al., 2007, Sun et al., 2012, Eijsink et al., 2012, Wentzensen et al., 2009, 
Leonard et al., 2012, Apostolidou et al., 2009). In summary, the observed methylation pattern 
represents a heterogeneous mix of DNAs, likely under the influence of a variety of factors of 
both viral and human origin. 
 
5.2.2.3. HPV Methylation as a Biomarker of Disease 
Several chapters of this investigation considered the potential clinical utility of HPV DNA 
methylation, in order to avoid repetition and provide a concise discussion; a more thorough 
consideration is presented in the general discussion (Chapter 9: 9.3). 
There is a pressing need for suitable biomarkers to be used in conjunction with HPV testing 
(Wentzensen and von Knebel Doeberitz, 2007). For this study, there were significant 
differences in DNA methylation among the three disease groups. The most significant 
differences were observed for the L1/L2 region, for which pairwise differences in methylation 
existed between all three groups. There were however significant overlaps in the ranges of 
each group. Several cancer samples for instance had methylation levels more commonly 
observed in the normal cytology group which is consistent with the variation observed in 
similar studies (Brandsma et al., 2009, Fernandez et al., 2009, Mirabello et al., 2012).  
Nonetheless, our results are consistent with the results of several studies, in that the E2/E4, L1 
and L2 regions were associated with disease grade (Fernandez et al., 2009, Kalantari et al., 
2009, Sun et al., 2011, Mirabello et al., 2012, Kalantari et al., 2010, Brandsma et al., 2009). 
Similarly, our observation of differences in LCR methylation among the disease grades was 
consistent with most studies (Kalantari et al., 2004, Bhattacharjee and Sengupta, 2006a, Ding 
et al., 2009, Brandsma et al., 2009) but not with others (Badal et al., 2003, Hublarova et al., 
2009). The inconsistent association between LCR methylation and disease grade is considered 
the result of methodological differences, heterogeneous and small sample sizes, and/or 
disease misclassification (Mirabello et al., 2012).  
L1 and LCR methylation have been previously tested as a diagnostic biomarker of disease 
grade (Turan et al., 2007, Kalantari et al., 2010). The results appeared to indicate that L1 
methylation was a surrogate marker of integration, and that integration was associated with 
disease grade. We however observed incremental increases in DNA methylation with disease 
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grade which was not consistent with L1/L2 methylation only being a surrogate marker of 
integration. 
A screening biomarker could have relevance as a triage test within HPV based cervical 
screening. Pyrosequencing is not currently a very high throughput means of evaluating 
methylation status and is also somewhat expensive. Therefore, the magnitude of differences 
between the disease grades for individual CpGs was determined. Of all of the CpGs tested, the 
L1L2-2 CpG appeared to be the most informative. Using just one CpG or a small number of 
CpGs as a biomarker would allow less expensive, simpler and higher throughput assays such as 
qMS-PCR to be used to quantity DNA methylation. 
 
5.3. Conclusions 
The aims of this study were to determine the methylation profile of HPV in a range of disease 
states, compare data produced using our assays to published data and apply the 
pyrosequencing assays to the early development sections of the CRUK biomarker development 
roadmaps (Cancer Research UK, 2012e, Cancer Research UK, 2012d). In these respects it 
achieved what was planned and clearly demonstrated that distinct methylation differences 
between disease of different cytological grades and between precancerous and cancerous 
disease exist. There was also an attempt to take the data analysis a stage further and 
determine which regions/CpGs are likely to represent the most informative biomarkers of 
disease. 
There were some promising results produced by this study, DNA methylation did vary among 
disease grades for several regions/CpGs however the differences were not simple and there 
was wide variation within each group which represented an undesirable characteristic for a 
biomarker. If HPV methylation is used as a biomarker, it will likely be in the form of an 
algorithm considering methylation at various HPV regions and CpGs (Brandsma et al., 2009, 
Mirabello et al., 2012). 
5.3.1. Further Work 
The results of this study suggest several avenues for future work. First, it is unknown whether 
transformation and disease progression are a result of or cause of DNA methylation changes. 
Similarly, it is unknown whether integration is the cause of initial aberrant gene expression or 
a consequence of genomic instability (Vinokurova and von Knebel Doeberitz, 2011). A 
longitudinal study, following HPV positive patients over several years might better put the 
relevance of integration and methylation changes to disease progression into context. 
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LCM studies have revealed considerable methylation differences among different parts of a 
lesion, and changes with cellular differentiation (Vinokurova and von Knebel Doeberitz, 2011). 
With this in mind, a more uniform set of samples (i.e. a set consisting entirely of LBC or biopsy 
material in conjunction with microdissection techniques) would allow better elucidation of the 
association between DNA methylation and HPV-associated disease. Whilst microdissection 
allows investigation of the relationship between DNA methylation and different aspects of 
disease and cellular biology, further investigation using LBC material is the most clinically 
relevant with respect to primary screening triage tests. 
HPV DNA methylation has great potential as a diagnostic and prognostic biomarker. There 
have been some promising studies but there are also several contradictions in the literature. 
Further investigation of HPV DNA methylation, possibly used in conjunction with another 
biomarker (i.e. p16, integration, human methylation) might prove useful and would present 
HPV methylation in context with other biological characteristics. 
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Chapter 6. The CRISP Study – DNA Methylation and Clinical 
Outcome 
6.1. Results 
Material for this study was acquired from the CRISP clinical trial (Castanon et al., 2012). Two 
LBC samples taken 6 months apart existed for each patient (the 0 and 6 month samples 
respectively). Every 0 month LBC sample had low grade cervical abnormalities as it was a 
requirement for inclusion into the clinical trial. At 6 months, cytology was repeated and the 
majority of patients then underwent colposcopy, with histology performed on any biopsied 
material. All cytology and histology results were available for this study. DNA was extracted 
from LBC cell pellets, BS treated and pyrosequencing was performed on the treated DNAs. 
 Samples were identified from the CRISP sample set that corresponded to each of three 
different outcome groups. The first group comprised of samples that were HPV16 positive at 0 
months only and represent those samples that had lost the HPV16 infection, these were the 
Cleared group (C group). The second group was the Persistent Low grade group (PL group), 
these were samples that had a persistent HPV16 infection (i.e. HPV16 positive at 0 and 6 
months) and low grade histology (CIN1 or lower) at 6 months. Finally, samples that were 
HPV16 positive at both 0 and 6 months and had high grade histology (CIN2/3) at 6 months 
were termed the Persistent High grade group (PH group). The PH group represented samples 
with high grade disease, potentially as a result of persistent HPV16 infection. In total, 23 C, 
11x2 PL (i.e. 0 and 6 months) and 12x2 PH samples were assessed by pyrosequencing. Several 
samples in each instance failed the pyrosequencing assays and the data from 14 cleared, 9 PL 
and 10 PH patients were used in final analysis. 
This chapter aimed to generate hypotheses and answer hypothesis driven questions relevant 
to the sample cohort. The study was designed to determine differences in DNA methylation 
over time, determine differences in DNA methylation between samples with different clinical 
outcomes and to assess the potential of HPV DNA methylation as a biomarker. 
 
6.1.1. Hypothesis 1: DNA Methylation Varies among Regions of the HPV 
Genome and among the CpGs within Each Region 
There was considerable variation in the amount of DNA methylation among regions, and 
among CpGs within each region (Figure 6.1). A two-way ANOVA GLM was used to determine 
whether the regions and the CpGs within the regions had a significant effect on DNA 
methylation for the C, PL and PH groups, the results are presented in Table 6.1. Any violations 
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of the assumptions of the ANOVA are detailed in the figure legend. Highly significant 
differences in mean DNA methylation were observed both among the HPV16 regions and the 
CpGs. Further statistics performed later in this chapter support these results. The Bonferroni 
corrected P-value for significance is P=0.017.  
 
Outcome group 
 
C PL PH 
CpG (P-value) 0.000*
1
 0.003*
2
 0.000*
3
 
Assay (P-value) 0.000*
1
 0.000*
2
 0.000*
3
 
Table 6.1: The results of three two-way ANOVA GLM tests with CpG and pyrosequencing assay as 
factors.  
Each value in the table is a P-value, in the CpG row this represents the difference in DNA methylation 
among different CpGs within each assay; in the Assay row this represents the difference in DNA 
methylation among the four HPV regions. Violations of the assumptions of the ANOVA: *1, unequal 
variances (P=0.003), non-normally distributed residuals (P=0.022); *2, non-normally distributed 
residuals (P=<0.005); *3, unequal variances (P=0.000). 
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Figure 6.1: Mean DNA methylation of each HPV region, for each outcome group for both the 0 and 6 
months time points.  
Coloured bars represent mean DNA methylation for each region. Error bars represent +/- 95% 
confidence intervals for mean. 
 
6.1.2. Hypothesis 2: DNA Methylation of the HPV16 Genome Varied over 
Time 
For the PL and PH groups, DNA methylation data was produced for the 0 and 6 month samples. 
It was of interest to determine whether changes in DNA methylation occurred over the 6 
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month time period and whether or not any changes observed were different for the PL and PH 
groups. The 0 and 6 month data of the PL group (Figure 6.2) and the PH (Figure 6.3) are 
presented below. There appeared to be changes between the 0 and 6 month samples in 
several instances, especially for the E2 and L1/L2 regions (Figure 6.1). The PL group had an 
increase in methylation between the 0 and 6 month samples for the E2 and L1/L2 regions 
whilst the PH group had a slight decrease in the L1/L2 region. 
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Figure 6.2: The mean amount of methylation at each assay for the persistent low grade group.  
The bars represent the overall mean methylation at each assay for each sample time. The error bars 
represent 95% confidence intervals for mean and the red circles represent mean methylation at each 
assay for each of the individual samples. 
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Figure 6.3: The mean amount of methylation at each assay for the persistent high grade group.  
The bars represent the overall mean methylation at each assay for each sample time. The error bars 
represent 95% confidence intervals for mean and the red circles represent mean methylation at each 
assay for each of the individual samples. 
 
A two-way ANOVA GLM was applied to the DNA methylation data of the PL and PH groups to 
determine whether a significant difference in DNA methylation existed between the 0 and 6 
month samples. The two-way ANOVA was ideal as additional analytical power was afforded by 
the consideration of individual CpGs, and the differences in DNA methylation among the 
individual CpGs of each assay can also be determined. Because no suitable non-parametric 
alternative exists and as the investigation was exploratory and hypothesis generating in 
nature, where the data had not satisfied the assumptions of the two-way ANOVA GLM, the 
analysis was continued and the contraventions are listed in the table legend. The results of 
these analyses are in Table 6.2 and graphical representation of the data used for the 
interpretations are presented below for the PH group (Figure 6.4, Figure 6.5, Figure 6.6 and 
Figure 6.7) and the PL group (Figure 6.8, Figure 6.9, Figure 6.10 and Figure 6.11). As a total of 8 
analyses were performed, a Bonferroni corrected P-value (P=0.006) was used however 
comparisons significant at P=0.05 were still considered. For every HPV region of the PH group, 
there were no significant differences between the amount of methylation at 0 months and 6 
months. There was however a significant difference among the methylation level of individual 
CpGs within each region. For the PL group, there was a significant difference between the 0 
and 6 month samples within the E2 region only. There was also a significant difference in DNA 
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methylation between the CpGs of the E2, LCR2 and L1/L2 region. The observed differences 
among CpGs within each HPV region support the results of hypothesis 1.  
 
  
HPV16 region 
  
E2 LCR1 LCR2 L1/L2 
PL group (P-value) CpG 0.000*1 0.873 0.006*2 0.003*3 
  Month 0.000*1 0.288 0.771*2 0.824*3 
PH group (P-value) CpG 0.000*4 0.002*5 0.000*6 0.001*7 
  Month 0.490*4 0.603*5 0.505*6 0.266*7 
Table 6.2: The results of two-way multifactorial ANOVA GLM analyses.  
The persistent low grade (PL group) and persistent high grade (PH group) group methylation data was 
tested to determine the effect of month (0 vs. 6) and each CpG of each assay on mean DNA 
methylation. Significance is assumed at P<0.05 or P<0.006 (Bonferroni corrected). A significant P-value 
for CpG indicates a significant difference in mean methylation among CpGs within a region. A 
significant P-value for month indicates that a significant difference existed between the 0 and 6 
month samples. Violations of the ANOVA assumptions: *1, non-normally distributed residuals 
(P=0.037); *2, non-normally distributed residuals (P=<0.005), unequal variances (P=0.029); *3, non-
normally distributed residuals (P=<0.005); *4, non-normally distributed residuals (P=0.006); *5, 
unequal variances (P=0.04); *6, non-normally distributed residuals (P=0.036); *7, non-normally 
distributed residuals (P<0.005). 
 
The results of these analyses must be interpreted with caution because of the contraventions 
of the assumptions of the analyses. In order to improve the strength of any conclusions drawn, 
multiple two-sample T-tests were used to compare the differences between mean DNA 
methylation of each assay for the 0 and 6 month samples. The Bonferroni corrected P-value is 
P=0.006 however comparisons significant at P=0.05 would also be considered. None of these 
comparisons were significant, the P values for the 0 vs. Six month comparisons are 
summarised in Table 6.3. There appear to be no differences between the 0 month and 6 
month samples however it is important to consider that multiple T-tests exclude a level of 
detail (i.e. the methylation data for each CpG). 
 
 0 vs. 6 months E2 mean LCR1 mean LCR2 mean L1/L2 mean 
Persistent low grade (P-value) 0.058 0.986 0.903*1 0.354 
Persistent high grade (P-value) 0.800 0.612 0.664 0.617 
Table 6.3: The P-values of multiple two-sample T-tests comparing the mean methylation values of 
each assay for the 0 and 6 month samples.  
The values given are P-values. Violation of the assumptions of a T-test: *1, this comparison included a 
data set that was not quite normally distributed (P=0.020). 
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Overall, there was no difference between the 0 and 6 month samples in every instance except 
for the persistent low grade samples, where a difference was observed in the DNA methylation 
of the E2 region. For this comparison, the two-way ANOVA GLM had only a minor violation of 
the assumptions and a highly significant P-value (Table 6.2) and the T-test had a low P-value 
that was close to significant (without a Bonferroni corrected P-value) (Table 6.3). This 
discrepancy in significance between the two types of tests (one considering every CpG, the 
other type considering only mean methylation for that region) suggest that CpG specific 
changes occurred between the 0 and 6 month samples for the PL group. Indeed, for the PL 
group, every E2 CpG was more methylated in the 6 month samples than the 0 month samples 
however the difference varied among CpGs (Figure 6.8). 
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Figure 6.4: E2 CpG DNA methylation for the PH group.  
The DNA methylation data of both the 0 and the 6 month samples are presented. Each bar represents 
the mean DNA methylation of the month/CpG of interest, blue error bars represent 95% confidence 
intervals for mean and the red circles represent individual sample data. 
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Figure 6.5: LCR1 CpG DNA methylation for the PH group.  
The DNA methylation data of both the 0 and the 6 month samples are presented. Each bar represents 
the mean DNA methylation of the month/CpG of interest, blue error bars represent 95% confidence 
intervals for mean and the red circles represent individual sample data. 
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Figure 6.6: LCR2 CpG DNA methylation for the PH group.  
The DNA methylation data of both the 0 and the 6 month samples are presented. Each bar represents 
the mean DNA methylation of the month/CpG of interest, blue error bars represent 95% confidence 
intervals for mean and the red circles represent individual sample data. 
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Figure 6.7: L1/L2 CpG DNA methylation for the PH group.  
The DNA methylation data of both the 0 and the 6 month samples are presented. Each bar represents 
the mean DNA methylation of the month/CpG of interest, blue error bars represent 95% confidence 
intervals for mean and the red circles represent individual sample data. 
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Figure 6.8: E2 CpG DNA methylation for the PL group.  
The DNA methylation data of both the 0 and the 6 month samples are presented. Each bar represents 
the mean DNA methylation of the month/CpG of interest, blue error bars represent 95% confidence 
intervals for mean and the red circles represent individual sample data. 
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Figure 6.9: LCR1 CpG DNA methylation for the PL group.  
The DNA methylation data of both the 0 and the 6 month samples are presented. Each bar represents 
the mean DNA methylation of the month/CpG of interest, blue error bars represent 95% confidence 
intervals for mean and the red circles represent individual sample data. 
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Figure 6.10: LCR2 CpG DNA methylation for the PL group.  
The DNA methylation data of both the 0 and the 6 month samples are presented. Each bar represents 
the mean DNA methylation of the month/CpG of interest, blue error bars represent 95% confidence 
intervals for mean and the red circles represent individual sample data. 
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Figure 6.11: L1/L2 CpG DNA methylation for the PL group.  
The DNA methylation data of both the 0 and the 6 month samples are presented. Each bar represents 
the mean DNA methylation of the month/CpG of interest, blue error bars represent 95% confidence 
intervals for mean and the red circles represent individual sample data. 
 
6.1.3. Hypothesis 3: There are DNA Methylation Differences among the 
Outcome Groups 
Another subject of interest was to determine whether DNA methylation differences existed 
between HPV infections that were cleared, and those that were maintained and had low grade 
or high grade disease. In order to address this question, methylation of the 0 month samples 
for each outcome group was compared (Figure 6.12). The effect of disease grade on DNA 
methylation has already been established (Chapter 5: 5.1.2). As such, PH group DNA 
methylation may already be expected to be higher than that of the C or PL group because of 
the confirmed high grade (CIN2/3) disease at 6 months that may have also been present in the 
0 month samples. The comparison of the PL and C groups was of particular interest as it could 
have provided insight into differences between maintained and cleared infections without the 
influence of high grade disease on DNA methylation. 
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Figure 6.12: The mean amount of methylation at 0 months for each assay for each of the three 
outcome groups. 
C=cleared, PL=persistent low grade, PH=persistent high grade disease. The bars represent the mean 
for the factor combination presented whilst the error bars represent 95% confidence intervals for 
mean. 
 
The 0 month samples were not highly methylated regardless of final outcome. As may be 
expected, there did appear to be methylation differences between the PL and PH groups at the 
E2, LCR2 and L1/L2 regions. Methylation was typically higher for the PH group. What was 
particularly intriguing was that the C group seemed to have more DNA methylation for the E2 
and L1/L2 assays than the PL group. One of the aims of this study was to determine if a 
knowledge of HPV DNA methylation could be used predict the outcome of an infection, i.e. 
were there DNA methylation differences between individuals that would go on to lose the 
infection or develop disease. From this perspective, the most informative region might be the 
L1/L2 region for which stark changes between the C, PL and PH groups existed. The best 
indicator of high grade histology at 6 months appeared to be methylation of the LCR2 region. 
Both the C and PL groups were methylated at a very low level and the PH group had slightly 
more methylation, albeit with a considerable variation among individual samples. These 
observations were tested statistically using a two-way ANOVA GLM and associated pairwise 
tests.  
Two-way ANOVA GLM tests were used to compare the mean amount of methylation in each 
group with respect to both the final outcome (C, PL and PH) and individual CpG methylation 
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values. In total, four comparisons were performed (one test for each region), so a Bonferroni 
corrected P-value of P=0.0125 should be considered. A summary of the results are presented 
in Table 6.4, where the comparisons violated one or more of the ANOVA assumptions, the 
details are listed in the table legend. 
 
E2 LCR1 LCR2 L1/L2 
CpG 0.000*1 0.000*2 0.000*3 0.000*4 
Outcome 0.001*1 0.951*2 0.000*3 0.008*4 
Table 6.4: The results of two multifactorial ANOVA GLM tests.  
The 0 month sample data was compared with respect to individual CpGs in each assay (CpG) and final 
outcome (Outcome). A P-value of P<0.05 for CpG indicates a significant difference among the mean 
methylation at each CpG within the assay exists, similarly, a P-value of P<0.05 for Outcome indicates 
that a significant difference exists among the mean methylation for each outcome group (C, PL and 
PH). Violations of the assumptions of the ANOVA: *1, non-normally distributed residuals (P<0.005); 
*2, non-normally distributed residuals (P=0.023), unequal variances (P=0.002); *3, non-normally 
distributed residuals (P<0.005); *4, non-normally distributed residuals (P=0.449). 
 
Each comparison violated one or more assumptions of the ANOVA. As such the results of 
comparisons should be observed with caution. Nonetheless, a significant difference was 
observed among the CpGs in each assay in every comparison and among the outcomes for all 
but the LCR1 assay. Both as a confirmation of the previously observed results and as a way of 
performing pairwise comparisons (i.e. C vs. PL); multiple one-way ANOVAs and Kruskall-Wallis 
tests were performed on mean regional DNA methylation (rather than individual CpG 
methylation). The results of these tests are presented in Table 6.5. A Bonferroni corrected P-
value of P=0.013 was used however comparisons significant at P=0.05 would still be 
considered; one violation of the ANOVA assumptions was encountered and is detailed in the 
table legend. 
 
HPV16 Region 
 
E2 LCR1 LCR2 L1/L2 
One-way ANOVA  
(P-value, F-value, DF) 0.025, 4.30, 2 0.972
*1
, 0.03, 2 0.007, 5.98, 2 0.022, 4.35, 2 
Significant Tukey-Kramer 
results (at P=0.05) PL vs. PH None 
C vs. PH, PL vs. 
PH PL vs. PH 
Kruskall-Wallis  
(P-value, H-value, DF) 0.116, 4.31, 2 0.997, 0.01, 2 0.018, 8.07, 2 0.060, 5.64, 2 
Table 6.5: The results of tests to determine whether a difference in mean/median DNA methylation 
existed among 0 month samples of the three outcome groups. 
The tests used were one-way ANOVA with Tukey-Kramer tests and multiple Kruskall-Wallis tests. 
Significant Tukey-Kramer results indicate which pairwise comparisons were significant at P=0.05 
where C=cleared group, PL=persistent low grade group and PH=persistent high grade group. 
Violations of the assumptions of the ANOVA: *1, non-normally distributed residuals (P=0.007). 
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The one-way ANOVAs confirmed the observations seen for the two-way ANOVAs, however 
without the assumption violations and at a lower significance (significant at P=0.05, but in 
some instances not at Bonferroni corrected P=0.013). The lower significance suggests that CpG 
specific methylation differences were more pronounced than mean methylation differences. 
For the E2 and L1/L2 region, differences were observed between the PL and PH groups only. 
The observation that the C group was more methylated in L1/L2 than the PL group was not 
significant, possibly as a result of relatively small sample size and therefore large confidence 
intervals. In terms of differentiating between the patients that cleared the infection (C) and 
those that maintained the infection (PL and PH), none of the HPV regions were particularly 
informative and no significant differences were observed between either C vs. PL or C vs. PH. 
That said the LCR2 region produced the most significant difference between the C and PL 
groups (low grade disease) vs. the PH group (high grade disease). 
 
6.1.3.1. For Which CpG Were the Most Significant Differences among the Three 
Outcome Groups Observed? 
The previous one-way ANOVA tests revealed that greater significance may be produced when 
the DNA methylation of the three outcome groups is compared on a per CpG basis. Multiple 
one-way ANOVA tests with associated Tukey-Kramer pairwise comparison tests, and multiple 
Kruskall-Wallis tests may be able to further expand upon this observation and determine 
which of the CpGs might become the most useful for differentiating eventual outcome group 
of 0 month samples. In order to provide a concise summary of the results, the results tables 
are presented in Appendix VI. For the E2 region, there did not appear to be a discernible 
pattern of CpG methylation for the three outcome groups and there was a wide variation in 
DNA methylation among individual samples (Figure 6.13). The only CpGs where a significant 
difference in mean DNA methylation of the three outcome groups were observed were E2-4 
(one-way ANOVA P=0.034; Kruskall-Wallis P=0.012) and E2-7 (one-way ANOVA P=0.049; 
Kruskall-Wallis P=0.123 (not significant)). None of the P-values exceeded the Bonferroni 
corrected P-value. For E2-4 there was a significant difference for C vs. PH and for E2-7 there 
was a significant difference for PL vs. PH (Tukey-Kramer, P=0.05). There were several violations 
of the ANOVA assumptions. The E2 region does not appear to be a good region for predicting 
outcome group at 6 months in this sample series. 
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Figure 6.13: The mean amount of DNA methylation at each E2 CpG for the 0 month samples of each of 
the three outcome groups. 
C=cleared group, PL=persistent low grade and PH=persistent high grade. Each bar represents mean 
DNA methylation for the indicated CpG/outcome group combination, blue error bars represent 95% 
confidence intervals for mean and red circles represent individual sample data. 
 
For the LCR1 region (Figure 6.14), there did not appear to be any discernible pattern of CpG 
methylation. The mean values were low, there was considerable variation among individual 
samples and there were large confidence intervals, especially for the PL group. The only CpG 
where significant differences were observed among the groups was LCR1-1 (one-way ANOVA, 
P=0.014; Kruskall-Wallis, P=0.017), a significant pairwise difference was observed between C 
vs. PL, and PL vs. PH (Tukey-Kramer P=0.05) and both P-values exceeded the Bonferroni 
corrected P-value. There were several violations of the ANOVA assumptions. The LCR1-1 CpG 
methylation data may have potential for predicting outcome at 6 months in this sample series. 
In this instance however there were no significant differences between the C and PH groups. 
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Figure 6.14: The mean amount of DNA methylation at each LCR1 CpG for the 0 month samples of each 
of the three outcome groups. 
C=cleared group, PL=persistent low grade and PH=persistent high grade. Each bar represents mean 
DNA methylation for the indicated CpG/outcome group combination, blue error bars represent 95% 
confidence intervals for mean and red circles represent individual sample data. 
 
For the LCR2 region (Figure 6.15), LCR2-5 was the lowest methylated in every sample group. 
LCR2-3 was methylated at a very low level in groups C and PL, but higher in group PH. The 
mean values were rather small and there was considerable variation among individual 
samples. Highly significant differences among the outcome groups were observed for LCR2-3 
only (one-way ANOVA, P=0.000; Kruskall-Wallis, P=0.000). Significant pairwise differences 
were also observed between C vs. PH, and PL vs. PH (Tukey-Kramer P=0.05) and both P-values 
exceeded the Bonferroni corrected P-value. There was one violation of the ANOVA 
assumptions. Methylation of LCR2-3 was different between the C/PL and PH outcomes and 
may be a marker of high grade histology at 6 months in low grade cytology samples. 
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Figure 6.15: The mean amount of DNA methylation at each LCR2 CpG for the 0 month samples of each 
of the three outcome groups. 
C=cleared group, PL=persistent low grade and PH=persistent high grade. Each bar represents mean 
DNA methylation for the indicated CpG/outcome group combination, blue error bars represent 95% 
confidence intervals for mean and red circles represent individual sample data. 
 
For the L1/L2 region (Figure 6.16) the characteristic “N” shaped pattern (L1L2-1 low, L1L2-2 
high, L1L2-3 low and L1L2-4 high) of CpG methylation was present that was also seen 
elsewhere in this study. No significant differences were observed among the three outcome 
groups for any of the L1/L2 CpGs. The L1/L2 region did not appear to be very informative in 
this instance. 
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Figure 6.16: The mean amount of DNA methylation at each L1/L2 CpG for the 0 month samples of 
each of the three outcome groups. 
C=cleared group, PL=persistent low grade and PH=persistent high grade. Each bar represents mean 
DNA methylation for the indicated CpG/outcome group combination, blue error bars represent 95% 
confidence intervals for mean and red circles represent individual sample data. 
 
6.1.4. Hypothesis 4: The Level of DNA Methylation of the CRISP Samples 
Should be Comparable to the Disease Grade Study  
This question was posed because despite all three outcome groups originally being 
cytologically classified as low grade cervical abnormalities, the histology of the infections at 6 
months differed considerably. Some patients lost the infection completely whilst others 
maintained the infection and had either low or high grade histology. The normal cytology vs. 
severe dyskaryosis DNA methylation comparison found significant differences in DNA 
methylation among the cytology grades (Chapter 5: 5.1.2). It was of interest to consider 
whether or not the 0 month samples of the three CRISP outcome groups were more similar to 
the normal cytology group or the severe dyskaryosis group both in terms of mean DNA 
methylation level and of CpG specific methylation profile. If the DNA methylation level/profile 
of one outcome group was more similar to the DNA methylation level/profile of a more severe 
cytology result then DNA methylation data might indicate higher grade disease at 0 months 
than the 0 month cytology had suggested. 
For the E2 region, the CpG DNA methylation profile of the three CRISP outcome groups did not 
appear to relate to the methylation profile of either the normal cytology or severe dysplasia 
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groups. Similarly, there did not appear to be a discernible similarity for the LCR1 or LCR2 
regions either. For the L1/L2 region however, the distinctive “N” shaped profile was observed 
in all outcome groups. 
Overall DNA methylation of the C and PL groups was most similar to the normal cytology 
group. This was to be expected because at 0 months, all of these samples had low grade 
cytological abnormalities and indeed for the PL group, 6 months later had low grade histology 
(Table 6.6). The PH group however were methylated at a level between the normal cytology 
and the severe dyskaryosis samples. Six months later, these samples were found to have high 
grade (CIN2/3) histology.  
 
Mean DNA methylation (%) 
 
E2 LCR1 LCR2 L1/L2 
C group (0 month) 3.7 3.1 0.7 5.2 
PL group (0 month) 2.2 3.5 0.6 2.3 
PH group (0 month) 4.1 2.6 1.9 10.9 
    
  
  
Normal cytology 2.5 3.1 1.5 5.7 
Severe dyskaryosis 6.6 2.3 2.6 16.3 
Cancer 42.7 12.8 23.7 50.1 
Table 6.6: Mean DNA methylation of each HPV region for the CRISP groups and the previously tested 
disease groups. 
Each number represents a percentage methylation which is calculated as an average of all CpGs in 
each region. 
 
6.1.5. Hypothesis 5a: There is an Association between DNA Methylation and 
Outcome Cytology 
For the CRISP samples, cytology was performed at both 0 and 6 months. All of the cytology 
results at 0 months were either second borderline or mild abnormalities. At 6 months, various 
cytology results were produced which included negative, borderline, mild, moderate and 
severe dyskaryosis. It was of interest to determine if DNA methylation data for the 0 month 
samples was different among the various grades of 6 month outcome cytology. For this 
comparison, the CRISP samples were not separated by outcome group but were instead 
grouped together (Figure 6.17). Outcome cytology results were grouped into negative 
cytology, borderline/mild abnormalities (i.e. no change from 0 months), moderate dyskaryosis 
and severe dyskaryosis. Very few patients had moderate dyskaryosis or severe dyskaryosis at 6 
months, which resulted in large confidence intervals. Nonetheless, multiple one-way ANOVAs 
were performed and determined that a significant difference in mean DNA methylation existed 
among the various 6 month cytology types for the LCR2 region (P=0.010) and almost for the 
L1/L2 region (P=0.030) (Table 6.7). ANOVA assumption violations are detailed in the table 
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legend, a Bonferroni corrected P-value of P=0.017 should be considered. The only significant 
Tukey-Kramer pairwise comparisons were for the LCR2 region, where DNA methylation of the 
moderate cytology samples was significantly lower than the samples where no change was 
observed, or those where a negative cytology result occurred (Table 6.7). 
The samples where a moderate or severe cytology result was detected at 6 months could be 
more methylated in the L1/L2 region however it is impossible to determine from this data set 
because of the small sample number, large confidence intervals and for the moderate cytology 
samples, a large range of DNA methylation values. A larger sample series would be required in 
order to further investigate this possibility. 
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Figure 6.17: The relationship between mean assay 0 month DNA methylation and 6 month cytology 
result.  
Four abbreviations are used to represent the cytology at 6 months; Neg = negative cytology, B/M = 
borderline/mild abnormalities (i.e. no change from 0 months), Mod = moderate dyskaryosis and Sev = 
severe dyskaryosis. Coloured bars represent mean DNA methylation and blue error bars represent 
95% confidence intervals for mean. Individual values are plotted as three symbols, representing the 
samples of the cleared (C) group (white triangles), the persistent low grade (PL) group (black circles) 
and the persistent high grade (PH) group (red circles). Because only two samples had severe cytology 
at 6 months the error bars were very large and if plotted, would disrupt the scale of the graph 
hindering interpretation. The upper 95% confidence interval of the L1/L2 severe dyskaryosis group 
was 67.1% methylation. 
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HPV16 region 
 
E2 LCR1 LCR2 L1/L2 
One-way ANOVA (P-value) 0.373*
1
 0.513*
2
 0.010 0.030 
Significant Tukey-Kramer results 
  
B/M vs. Mod 
 
   
Mod vs. Neg 
 Table 6.7: The results of four one-way ANOVAs to test for a difference in mean 0 month DNA 
methylation among the four different 6 month cytology results. 
B/M = borderline/moderate, i.e. no change between 0 and 6 month cytology, Mod = moderate 
dyskaryosis, Neg = negative cytology. Violations of the assumptions of the ANOVA: *1, non-normally 
distributed residuals (P<0.005), unequal variances (P=0.025); *2, non-normally distributed residuals 
(P<0.005). 
 
6.1.6. Hypothesis 5b: There is a Relationship between Outcome Cytology and 
Outcome Histology 
At 6 months, both cytology and histology were performed. Samples were assigned to the three 
groups (C, PL and PH) based on the histology and/or HPV16 positivity result. The individual 
value points in Figure 6.17 show the relationship between histology, HPV16 positivity and 
cytology in the 6 month samples. It is quite telling that all of the samples with moderate or 
severe dyskaryosis at 6 months also had high grade histology. Similarly, all of the samples with 
a negative cytology at 6 months also belonged to the cleared group, representing the loss of 
HPV16 positivity. The samples with 6 month borderline/mild abnormalities were quite variable 
and some samples belonged to each outcome group (i.e. C, PL and PH). All PL group samples 
had no change in cytology at 6 months. 
 
6.2. Discussion 
6.2.1.1. Aims 
This study was planned in order to determine whether there were characteristic differences in 
DNA methylation associated with different outcomes in a series of patients with low grade 
cytological abnormalities. It was a longitudinal investigation that aimed to correlate 
methylation patterns with disease in LBC material from women with histologically confirmed 
disease, and allow initial assessment of the prognostic potential of a knowledge of HPV DNA 
methylation. We were mindful of the biomarker development road maps published by CRUK, 
and this study partly fulfilled a component of the early prognostic biomarker development 
protocol (Appendix I) (Cancer Research UK, 2012d). 
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6.2.1.2. Strengths 
Longitudinal studies looking at HPV DNA methylation are uncommon. The only other 
longitudinal study is very recent and the design and results were remarkably similar to this 
study, albeit with small differences (Mirabello et al., 2012). The CRISP study results are where 
relevant, consistent with the NSC study (Chapter 5).  
The implications of this study are that HPV methylation assessment has potential as a method 
for differentiating low grade cytology samples which are at higher risk (i.e. those that will have 
high grade cytology/histology in 6 months time) and there are several aspects of the data that 
might suggest an association between HPV DNA methylation and episomal clearance and/or 
HPV persistence.  
Pyrosequencing is a fully quantitative method for assessing DNA methylation and we have 
targeted four regions of the genome, each identified by previous studies as regions where DNA 
methylation is potentially associated with cervical disease. 
6.2.1.3. Weaknesses 
The biggest weaknesses of the study are the relatively short duration of follow up and the lack 
of histology at 0 months. These limitations are present because the initial samples were 
collected during routine screening and as part of a clinical trial, not as a longitudinal biomarker 
study for DNA methylation. Histology is not routinely performed for the first low grade/second 
borderline result and as such was not available. 
The CRISP samples were from patients entered into a clinical trial to study the effects of 
diindolylmethane (DIM), a dimer of Indole-3-carbinol. Both compounds occur in cruciferous 
vegetables and are commonly marketed as dietary supplements. It was hypothesised that DIM 
might inhibit cervical dysplasia (Castanon et al., 2012). It could be questioned whether samples 
from a treatment trial can reliably provide information on prognosis, however the trial results 
were negative; DIM supplementation did not significantly affect disease 
progression/regression, or cause clearance of HPV infection (Castanon et al., 2012). 
Nonetheless, there was a possibility that DIM might affect HPV DNA methylation however it 
was not possible to control for this, as the methylation study was performed blind to the DIM 
treatment regime. 
Several samples failed to produce high quality pyrosequencing data. This was especially 
common for the cleared group where 9 samples failed all assays. The primary reasons for high 
failure rate of the cleared samples were likely to be a false HPV16 positivity result during the 
initial HPV typing (by PCR ELISA) and/or sensitivity limitations of the pyrosequencing assays. 
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6.2.1.4. Comparison to Other Studies 
Longitudinal studies of HPV DNA methylation are uncommon. Only one such study was 
identified by a literature search. Mirabello et al used a sample cohort grouped into three 
outcomes, similar to the outcome groups used by this study. These outcomes were; a control 
group where HPV16 clearance over the course of 2 years was observed (i.e. similar to the 
cleared group), a persistence group where persistent HPV16 infection was associated with low 
grade disease (i.e. similar to PL group) and a CIN3 group, where persistence was associated 
with CIN3 (i.e. similar to PH group) (Mirabello et al., 2012).  
The study also used pyrosequencing to assess multiple sites of the HPV genome however 
differed considerably in the statistical analysis and aims/approach of the study. The main 
findings were that methylation of several CpGs of the L1, L2 and E2/E4 regions corresponded 
with an increased risk of persistence and CIN3. This is largely consistent with the results of our 
study, albeit our C group was more (but not significantly) methylated in the E2 and L1/L2 
regions than our PL group, which was not observed by Mirabello et al. It is difficult to explain 
the differences between the studies; both used pyrosequencing, both used desquamated 
cervical cells (i.e. LBC) and for both studies only HPV16 positives were considered. However 
they differ in the observed methylation status of infections destined to be cleared of HPV16. It 
is worth noting that the analysis was conducted differently and the duration of follow up was 
also different (6 months vs. 2 years). A longitudinal study of viral clearance of HPV16 positive 
women observed a 32% clearance rate after 6 months, and 50% clearance after 12 months 
(Hildesheim et al., 2007). This suggests that most HPV16 infections take longer than 6 months 
to resolve and that our shorter duration of follow up may have for instance, identified DNA 
methylation profiles associated with an imminent loss of infection. 
The three groups derived from the CRISP study were based on outcome histology at 6 months. 
The PL (low grade histology) group was less methylated at 0 and 6 months than the PH group 
(high grade histology) for the LCR2 and L1/L2 regions, and at 0 months for the E2 region. This is 
consistent with our NSC study (where E2 and L1/L2 methylation were higher in more severe 
disease) and also with many published studies (Mirabello et al., 2012, Kalantari et al., 2004, 
Bhattacharjee and Sengupta, 2006a, Ding et al., 2009, Brandsma et al., 2009, Hong et al., 2008, 
Fernandez et al., 2009, Sun et al., 2011). It is not consistent with several studies, which have 
reported LCR hypermethylation in low grade disease (Badal et al., 2003, Hublarova et al., 2009, 
Patel et al., 2012, Piyathilake et al., 2011). It is notable that there are a range of 
methodologies, sample materials, target regions, sample numbers, as well as a range of study 
aims in these conflicting reports (Appendix VI). 
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One of the points of conflict for our NSC study was the presence/absence of LCR methylation 
in HPV positive cytologically normal samples. Substantial LCR methylation was not observed in 
either our CRISP or NSC samples which is consistent with several studies (Ding et al., 2009, 
Fernandez et al., 2009, Bhattacharjee and Sengupta, 2006a) but inconsistent with others (Hong 
et al., 2008, Patel et al., 2012, Kalantari et al., 2004, Badal et al., 2003). Again, a range of 
analytical methods and sample materials were used in these studies. Our in vitro studies 
(Chapter 7: 7.1.2 & 7.1.3.3) observed changes in HPV methylation with increasing passage 
number (i.e. number of cell culture cycles/time). This study observed rather stable DNA 
methylation over the course of 6 months in vivo suggesting that in some instances at least, the 
cell lines may not be representative of in vivo methylation processes or dynamics. 
 
6.2.2. Meaning 
6.2.2.1. DNA Methylation was Stable over 6 Months However Persistence may 
be Associated with Increased E2 DNA Methylation. 
DNA methylation did not change for the PH group and methylation did not change for the PL 
group at any region other than E2. PL group E2 methylation was seen to differ significantly 
when analysed using a multifactorial ANOVA; there was only a very minor violation of the 
analysis assumptions and the analysis appeared robust. When multiple single factor analyses 
were performed, the difference in PL group E2 methylation was not significant. The variation 
between analyses was likely the result of variable methylation differences among individual 
CpGs and the additional analytical power afforded by the multifactorial analysis. For the PL 
group, methylation at every E2 CpG increased over the course of 6 months. This was not 
observed for any other region where DNA methylation at both time points was very similar. 
The PL group had low grade histology and cytology at 6 months, suggesting that disease for 
most samples was low grade and had not progressed over the course of the study. That these 
persistent infections exhibited an increase in E2 DNA methylation in later samples might hint 
at a mechanism of persistence in the absence of disease progression, i.e. that increasing E2 
DNA methylation is associated with or even involved with persistence. Other studies have 
suggested a mechanism of HPV latency by DNA hypermethylation, albeit of the LCR and in the 
absence of visible disease (Vinokurova and von Knebel Doeberitz, 2011). We however 
observed low and consistent LCR methylation in the PL group. The differences between the 
studies might be related to differences between a persistent infection with and without signs 
of disease. DNA methylation is also implicated in the latency lifecycle of EBV (Paulson and 
Speck, 1999), although such a well defined latency period is not present for HPV. Alternatively, 
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as the 6 month study period is relatively short (i.e. the development of cervical cancer is often 
said to take 10-20 years (Cancer Research UK, 2012a, McIndoe et al., 1984), E2 methylation 
might represent an early event in the progression to a higher disease state. 
 
6.2.2.2. DNA Methylation was Associated with Clinical Outcome 
6.2.2.2.1. There is a Need for Biomarkers 
Low grade cytology (borderline/mild) is a common result (6% of the UK primary screening 
results) and has a complex management strategy (Castanon et al., 2012). These lesions cause 
considerable distress to women in whom they occur, and in several thousand low grade 
cytology cases referred to colposcopy there was a mix of HPV positivity and histology (albeit 
predominantly low grade histology) (Table 6.8). In England, HPV testing is being adopted as a 
triage test for these patients. HPV testing is likely to replace cytology as a primary screening 
method, potentially with cytology being used to triage the high number of HPV positive 
patients (Naucler et al., 2009, Rijkaart et al., 2012). In these instances, further triage with a 
prognostic biomarker with which to determine a suitable management strategy will be of 
substantial value. DNA methylation of the 0 month samples varied significantly among the 
outcome groups and may represent a means by which to risk stratify mild/second borderline 
cytology cases.  
 
Referral Cytology 
 
Inadequate/ borderline/ mild Moderate or worse 
Histology Number % Number % 
Total 4535 100 3271 100 
Cancer 3 0.1 80 2.5 
CGIN 2 0.1 31 1 
CIN3 227 5.9 1256 40 
CIN2 377 9.8 681 21.7 
CIN1 905 23.5 366 11.6 
HPV only 413 10.7 118 3.8 
No HPV/CIN 1065 27.6 323 10.3 
Normal colposcopy, no biopsy 820 21.3 266 8.5 
Inadequate biopsy 46 1.2 22 0.7 
Unknown 677 14.9 128 3.9 
Table 6.8: The relationship between cytology and histology for women referred to colposcopy.  
Figures represent data provided by (Cervical Screening Wales, 2004). 
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6.2.2.2.2. Differences Were Observed among the Outcome Groups 
Significant differences in methylation among outcome groups were observed for the L1/L2 
region. Methylation of the L1 and L2 regions is frequently associated with more severe disease 
(Fernandez et al., 2009, Kalantari et al., 2009, Sun et al., 2011, Mirabello et al., 2012), and 
CpGs of the L1, L2 and E2/E4 region were also identified as informative by a similar 
longitudinal study (Mirabello et al., 2012). Because cleared infections represent low level 
disease, we had expected to see low level methylation in the C group. However, C group mean 
L1/L2 methylation was at a level between the PL and PH groups, this is considered in further 
detail later in this discussion chapter. When individual L1/L2 CpGs were assessed, none were 
significantly differently methylated in the three outcome groups; the difference between mean 
methylation and individual CpGs is likely the result of considerable and significant CpG specific 
methylation differences in the L1/L2 region. 
Differences in 0 month LCR2 methylation were also observed; mean LCR2 methylation was 
higher in samples that had high grade histology at 6 months (PH) than those that had low 
grade histology (PL) or cleared the infection (C). When individual CpGs were considered rather 
than mean regional methylation, only two CpGs of the 20 studied were differentially 
methylated in the three outcome groups (LCR1-1 and LCR2-3). Methylation of LCR1-1 was 
different among the groups, but surprisingly not between C and PH. Highly significant 
differences between the PH group and the C/PL groups were observed for methylation of the 
LCR2-3 CpG, which might have clinical significance. 
In a similar study, differences among cleared and persistent infections and CIN3 were 
identified in CpGs of L1 and L2, and E2/E4 (Mirabello et al., 2012). That they did not identify 
LCR methylation, and we did not identify E2 methylation or L1/L2 CpG specific methylation as 
informative may stem from differences in samples size, disease misclassification, group 
classification, method of statistical analysis and duration of follow up. Nonetheless, 
consideration of methylation at multiple CpGs would likely represent an effective means by 
which to differentiate the samples in the three outcome groups. Further analysis and 
generation of a suitable algorithm is a prospect for future work. 
6.2.2.2.3. Cause/Consequence of the Differences 
There are several possible explanations for the associations between DNA methylation in the 0 
month samples and outcome at 6 months. All CRISP samples had low grade cytology at 0 
months, however cytology is occasionally a poor indicator of histology (Cervical Screening 
Wales, 2004). If the PH group underwent progression from low grade disease to high grade 
disease, we might expect DNA methylation changes over the course of the 6 months, which 
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were not observed. Rather than the differences in DNA methylation between the PL and PH 
groups representing a progression of the PH group from an initially low grade disease to an 
eventual high grade disease, it seems more plausible that there were existing differences in 
disease severity (i.e. histology) that were not represented by the first cytology result, but were 
associated with differences in DNA methylation. That is to say, the low/high grade histology 
seen at 6 months were likely also present in the 0 month samples but were not accurately 
represented by the 0 month cytology. This explanation is supported by the known differences 
in DNA methylation for different disease grades (NSC study) (Fernandez et al., 2009, Mirabello 
et al., 2012) and by the diagnosis of CIN2+ disease in women referred for low grade cytological 
abnormalities (15.9% of Inadequate/ borderline/ mild cytology cases) (Table 6.8). If this is correct, 
then assessment of DNA methylation in conjunction with cytology might be capable of 
identifying low grade cytology cases where further investigation is warranted. 
 
6.2.2.3. Outcome Cytology was Associated with Initial DNA Methylation 
Whilst at 0 months, all CRISP samples had either mild cytological abnormalities or were a 
second borderline result, the 6 months cytology reports were more diverse. We compared 0 
month methylation and 6 month cytology, to determine whether DNA methylation was 
associated with 6 month follow up cytology. The most significant differences were observed 
for the LCR2 region. Differences in L1/L2 methylation were not quite significant when the 
Bonferroni correction was applied and the two-way analyses (considering individual CpG data) 
suffered several violations of the assumptions so should be considered with caution. Whilst 
not quite significant, L1/L2 methylation did have the largest absolute differences among the 
groups, albeit with large confidence intervals and the data was difficult to analyse as a result of 
the relatively small sample size. A combination of LCR2 and L1/L2 methylation data might 
prove useful as a means of differentiating low grade cytology cases that will be low 
grade/negative cytology or moderate/severe dyskaryosis in 6 months time. 
6.2.2.4. Differences between 6 Month Cytology and Histology Were Observed 
At 6 months, all of the negative cytology cases were HPV16 negative, there was a mix of 
histology/HPV positivity for the mild/borderline cytology cases and all of the moderate/severe 
dyskaryosis samples had high grade histology. Moderate/severe dyskaryosis is typically 
associated with high grade CIN in most (62-78%), but not all instances (Cervical Screening 
Wales, 2004, Cervical Screening Wales, 2011); our 100% association is likely the consequence 
of assessing a small number of cases with moderate/severe cytology. 
144 
 
6.2.2.5.  The Cleared Group had More L1/L2 and E2 Methylation than the PL 
Group 
More severe cervical disease was associated with higher methylation of the E2 and L1/L2 
regions (Chapter 5: 5.1.2) (Fernandez et al., 2009, Kalantari et al., 2009, Sun et al., 2011, 
Mirabello et al., 2012). Nonetheless at 0 months, the cleared group had a higher degree of E2 
and L1/L2 methylation than the PL group. Whilst these differences were not significant, the 
differences were quite large and were contrary to the expected trend. They also differed from 
recently published data, where E2/E4, L1 and L2 methylation were greater in persistent (low 
grade) HPV16 infections than in infections that would be cleared and greater again in CIN3 
lesions (although these differences were small and frequently non-significant) (Mirabello et al., 
2012).  
Most of the C group samples had negative cytology at 6 months so the loss of HPV16 positivity 
seems genuine. A pertinent consideration however is that DNA methylation of the C and PH 
groups could be the result of host cell attempts to target DNA methylation to viral episomes in 
order to silence viral gene expression and/or promote HPV clearance. In different backgrounds 
of disease, episomal clearance could have diverse outcomes; for the C group, HPV16 clearance 
was achieved and the patients had predominantly negative cytology. For the PH group, 
representing patients with CIN2/3, a stage of disease where HPV DNA integration is quite 
common, clearance of the episomal forms could represent a growth advantage to the host cell 
or even result in disease progression. Several prospective treatments for HPV infection rely on 
the ability to induce an antiviral response that results in the clearing of episomal HPV 
genomes, for example, exogenous type I interferon and imidazoquinolone compounds (Cirelli 
and Tyring, 1994, Stanley, 2002). Viral clearance could result in the loss of inhibitory episomal 
HPV genomes, in vitro this can result in the emergence of cells containing integrated HPV 
genomes (Pett et al., 2006, Herdman et al., 2006). There are also accounts of elevated disease 
progression in small scale clinical trials and increased HPV oncogene expression in cells lines as 
a result of antiviral response inducing compounds (Kim et al., 2000, Koromilas et al., 2001). A 
relationship between episomal methylation and clearance has not been proven, however is 
worthy of further consideration.  
The differences between DNA methylation of the cleared group for our study and for Mirabello 
et al might lie in the duration of follow up. The shorter 6 month follow up may have identified 
samples that were soon to be cleared of HPV16 infection. The higher methylation level 
observed in our study might represent changes in HPV methylation that immediately precede 
rapid episomal clearance. There is currently no data concerning HPV methylation and episomal 
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clearance in the absence of integration. When integration is present, clearance of episomes is 
often rapid and associated with changes in DNA methylation (Chapter 7: 7.1.2) (Gray et al., 
2010). 
 
6.3. Conclusions 
This study attempted to assess the prognostic potential of methylation in a longitudinal study. 
The methylation profile of the three outcome groups was compared and differences were 
observed, particularly at the L1/L2 region and parts of the LCR. However, these differences 
could be caused by several mechanisms so the results must be interpreted with caution. The 
observation of higher methylation of the cleared group than the more severe disease PL group 
was unexpected, however could represent a mechanism of episomal clearance so is worth 
further investigation. We have at least partly fulfilled a component of the prognostic 
biomarker development protocol. The potential of HPV methylation as a biomarker is 
discussed in further detail in the general discussion (Chapter 9: 9.3).  
6.3.1. Future Work 
An interesting avenue for further work would be to establish whether a relationship between 
HPV methylation and episomal clearance exists. This could potentially be investigated in vitro 
using models like the W12 cell line or PC08/09 short term cell lines. A larger clinical study 
might involve short follow up in a series of HPV positive normal cytology samples in order to 
correlate methylation with spontaneous regression in the absence of visible disease. 
This study was performed blind to DIM treatment. Although the putative mechanism of action 
of DIM (modulation of oestrogen metabolism) does not suggest an obvious link with DNA 
methylation, it would be pertinent to determine whether an association existed between DIM 
treatment and 6 month DNA methylation. The relevant data was not available for this study 
however if access could be granted it would be an interesting avenue to explore. 
Finally, this study used a relatively small sample number and a single follow up point with a 
short time span. Expanding the number of samples, the time between points or the number of 
consecutive time points would likely improve the results as changes in disease grade might be 
observed and correlated with changes in DNA methylation. 
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Chapter 7. The Cell Lines Study - DNA Methylation, Integration 
and Gene Expression in vitro 
 
7.1. Results 
To supplement the studies conducted using clinical material, a small series of additional in vitro 
studies were performed using cell lines. These studies facilitated assay design and protocol 
development and allowed parallels to be drawn between in vivo and in vitro studies. Three sets 
of cell line material were used; the immortal cell line CaSki, the short term cell lines PC08/PC09 
and the CIN progression model W12. 
7.1.1. CaSki 
CaSki has been used in several HPV DNA methylation studies, it was important to consider how 
the DNA methylation data produced by pyrosequencing in this study corresponded to 
published DNA methylation data. Table 7.1 contains the DNA methylation data for CaSki 
produced during this study. This data is presented graphically in Figure 7.1. In summary, CaSki 
HPV16 genomes are hypermethylated in all regions, especially the E2 and LCR2 regions. 
 
E2 CpG E2-1 E2-2 E2-3 E2-4 E2-5 E2-6 E2-7 E2-8 
Nucleotide 3411 3414 3416 3432 3435 3447 3461 3472 
Methylation % 95.5 98.5 80 100 96.5 93 81.5 77 
Table 7.1.a 
        LCR1 CpG LCR1-1 LCR1-2 LCR1-3 
     Nucleotide 7691 7679 7673 
     Methylation % 63 67.5 76 
     Table 7.1.b 
        LCR2 CpG LCR2-1 LCR2-2 LCR2-3 LCR2-4 LCR2-5 
   Nucleotide 31 37 43 52 58 
   Methylation % 89.5 91.5 96.5 95.5 97 
   Table 7.1.c 
        L1/L2 CpG L1L2-1 L1L2-2 L1L2-3 L1L2-4 
    Nucleotide 5615 5609 5606 5600 
    Methylation % 74.5 87.5 76 87.5 
    Table 7.1.d 
Table 7.1.a-d: DNA methylation of CaSki HPV16.  
Four tables are present, one for each tested region of the HPV genome. Included are the 
corresponding nucleotide positions (GenBank ID NC001526.1). 
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Figure 7.1: CpG methylation of HPV16 in CaSki.  
Each of the 20 CpGs tested are listed, bars are colour coded to aid interpretation. 
 
7.1.2. The W12 Series 7 Cell Line 
Pyrosequencing was applied to DNAs from several passages of the W12 series 7 cell line 
(W12Ser7). The term passage refers to the successive subculturing of cells into new flasks, i.e. 
a flask is inoculated with cells, the cells are grown to near confluence and then a small number 
are re-inoculated into a new flask. One round of subculture represents one passage. DNAs 
from passage 11 (p11) to p50 were available. In series 7, integrated HPV16 was first detected 
at p13. Between p13-17 episomal HPV16 constituted 10-90% of viral load however after p17, 
episomal HPV16 constituted less than 10% of the viral load (Gray et al., 2010). No further 
detail about the site(s) of HPV integration was available for W12Ser7. Nonetheless, there 
appeared to be changes in DNA methylation starting during this period (p13-17). E2 
methylation was quite closely matched to LCR1 and LCR2 DNA methylation and was much 
lower than seen in the L1/L2 region (Figure 7.2).  
In addition to the low overall E2 methylation, there was a wide variation in methylation within 
the E2 region (Figure 7.3). DNA methylation at p50 for instance varied from 72.5% for CpG E2-5 
down to 8% for E2-2. Particularly intriguing was that E2-4 is separated from E2-5 by only 3 bp, 
yet DNA methylation differed by over 50%.This suggests that a very specific mechanism could 
be responsible for methylating the region. For E2-5 and E2-6, DNA methylation increased 
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substantially between p15-17 which corresponded to the integration events between p13-17. 
DNA methylation of other E2 CpGs remained constant and low.  
Similar to the E2 region, CpGs LCR1-2 and LCR1-3 appeared to become increasingly methylated 
after the integration event at p13-17 (Figure 7.4). LCR1 CpGs are present in the viral enhancer 
and are not within E2BSs. DNA methylation of the LCR2 CpGs increased following the 
integration event at passage 13 but in later passages (p42+) appeared to decline (Figure 7.5). 
Four of the LCR2 CpGs (LCR2-2... LCR2-5) are within two of the inhibitory E2BSs of the LCR. 
For the L1/L2 region, p11 data was missing so it was difficult to see when the increase in DNA 
methylation at each CpG began; the increase in methylation between p15-17 was greater than 
between p13-15, suggesting that the majority of the changes occurred somewhere between 
p15-17 (Figure 7.6). For L1/L2, there was at times more than a two-fold difference between 
the levels of DNA methylation at different L1/L2 CpGs (i.e. L1L2-4 vs. L1L2-1 for p17-31). 
Nonetheless, there was considerably less disparity among the level of DNA methylation at each 
of the L1/L2 CpGs than there was for the E2 CpGs.  
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Figure 7.2: Mean DNA methylation at each site of the HPV16 genome for the W12Ser7 cell line with 
passage number. 
Each coloured point represents a different HPV region, connecting lines are present to aid the 
interpretation of the data. 
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Figure 7.3: The mean amount of DNA methylation at each E2 CpG for the W12Ser7 cell line with 
passage number.  
Each coloured point represents a different CpG, connecting lines are present to aid the interpretation 
of the data. 
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Figure 7.4: The mean amount of DNA methylation at each LCR1 CpG for the W12Ser7 cell line with 
passage number.  
Each coloured point represents a different CpG, connecting lines are present to aid the interpretation 
of the data. 
150 
 
5040302010
25
20
15
10
5
0
Passage
D
N
A
 m
e
th
y
la
ti
o
n
 %
LCR2-1
LCR2-2
LCR2-3
LCR2-4
LCR2-5
W12Ser7 LCR2 CpG methylation with increasing passage number
 
Figure 7.5: The mean amount of DNA methylation at each LCR2 CpG for the W12Ser7 cell line with 
passage number.  
Each coloured point represents a different CpG, connecting lines are present to aid the interpretation 
of the data. 
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Figure 7.6: The mean amount of DNA methylation at each L1/L2 CpG for the W12Ser7 cell line with 
passage number.  
Each coloured point represents a different CpG, connecting lines are present to aid the interpretation 
of the data. 
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7.1.3. The PC08 and PC09 Short Term Cell Lines 
DNAs for this study were provided by another student (Tiffany Onions (TO)) from a series of 
short term culture cell lines. The PC08 and PC09 cell lines were established as primary cultures 
of biopsies from two different patients. PC08 was derived from a VIN3 biopsy whilst PC09 was 
derived from a VAIN3 biopsy. Initially, these two cultures were established as heterogeneous 
lines, then single cell cloning was performed to establish homogenous lines. In total, 3 clones 
for each biopsy were provided for use in this study, these are the PC08 clones M, P and Y and 
the PC09 clones A, D and H. These clones were then cultured and at each passage, DNA and 
RNA was extracted and gene expression, growth rate, integration status, telomere length were 
assessed (by TO). DNAs for DNA methylation analysis using the pyrosequencing assays were 
provided by TO. 
For the rest of this study, the sample names will be generated according to passage number, 
clone name and biopsy of origin, i.e. 13Y9 is the PC09 clone Y, at passage 13. This data set was 
of particular interest because it represented a unique in vitro model that allowed comparisons 
to be made between several major components of HPV biology. The PC08 and PC09 data was 
analysed by testing a series of hypotheses. 
 
7.1.3.1. HPV DNA Integration 
Integration analysis by APOT was conducted by TO (Vinokurova et al., 2008). A limitation of 
APOT is that only actively transcribed HPV sequences are detected and APOT is unable to 
confirm the absence of integration, i.e. not detecting an integration event would not 
necessarily mean that an integration event was not present. Similarly, detected episomally 
derived transcripts could in theory be derived from transcriptionally active genomes integrated 
as concatemers. Another limitation of the APOT assay stems from the use of transcript 
sequences, HPV16 mRNAs are frequently spliced at the E7/E1 880 bp site (Figure 1.3) (Zheng 
and Baker, 2006) which would essentially mask the site of HPV genome disruption due to 
splicing. 
Two passages (early and late) were chosen for each clone and assessed using the APOT assay. 
The samples included in these runs and a summary of the results are shown in Table 7.2. The 
sites of integration both of the HPV and human genome varied among clones whilst other 
clones had no detectable integration events; this suggests that the integration events were 
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acquired after initial primary culture or that a variety of integration events existed in various 
cells of the original biopsies. 
  
Details of detected fusion transcripts 
Clone Passage Junction region HPV16 site (nt) Human region 
A9 5 - - - 
A9 11 - - - 
D9 5 E2 3716 Chr.18 (p11.31) 
D9 9 E2 3716 Chr.18 (p11.31) 
D9 11 E2 3716 Chr.18 (p11.31) 
H9 5 E7/E1 882 Chr.5 (p11.2) 
H9 11 E7/E1, E2/E4 882, 3494 Chr.5 (p11.2), Chr.1 (p36.13) 
M8 5 E7/E1 880 Chr.3 (q28) 
M8 9 - - - 
P8 5 - - - 
P8 9 - - - 
Y8 9 E7/E1 882 Chr.3 (q21.31) 
Y8 13 E7/E1 x 2 882 x 2 Chr.3 (q21.31) x 2 
Table 7.2: A summary of the detected HPV-human fusion transcripts detected using the APOT assay.  
The results are listed as the junction region and HPV16 site, i.e. the HPV gene and the HPV16 nt 
(GenBank ID NC001526.1) position respectively at which the junction between HPV and human 
sequence was detected. Other transcripts were detected that did not include human transcripts, these 
are not listed. 13Y8 had two detected fusion transcripts comprising of two proximal sites of the 
human genome. 
 
7.1.3.2. PC08/PC09 Gene Expression 
For this series of short term culture DNAs, both the methylation data collected in this study 
and the gene expression data collected by TO were available. The DNA used for DNA 
methylation analysis and the RNA used for qPCR analysis were extracted from the same 
sample of cells. Expression data was provided by TO as Ct values. Ct values for E2, E6 and E7 
and the two reference genes HPRT and TBP were provided.  
Gene expression is presented as Relative Quantification ratios (RQ) and represents a fold 
difference in gene expression compared to the calibrator sample (CaSki), normalised against 
the reference genes HPRT and TBP. RQ ratios were calculated using the Pfaffl/Vandesompele 
equation (Vandesompele et al., 2002). The fold difference (i.e. RQ) of E2, E6 and E7 expression 
for the PC08 and PC09 clones are presented in Figure 7.7. RQ is interpreted such that an RQ of 
10, represents a 10 fold higher level of gene expression than CaSki and an RQ of 0.1 represents 
a 10 fold lower level of gene expression between the sample in question and CaSki.  
The data is simpler to interpret when presented on a Log10 scale (Figure 7.8) as RQ ratios lower 
than CaSki (RQ of 1; i.e. 1 x CaSki gene expression) appear as negative. Log10 RQ ratio is 
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interpreted such that a Log10RQ of +1, represents a 10 fold higher level of gene expression and 
an RQ of -1 represents a 10 fold lower level of gene expression between the sample in 
question and CaSki. When interpreting the data it is important to consider what the results 
actually represent. Considering sample 7D9 for example, all three bars are approximately the 
same height. This does not necessarily mean that each transcript is being expressed at the 
same level, only that they are being expressed more than in CaSki (and other samples) and 
that the ratio of expression between the genes is roughly equal to that of CaSki. The data is 
interpreted by comparing changes and differences between samples and clones i.e. clone D9 
expresses more of every gene than clone P8. 
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Figure 7.7: The fold difference (RQ ratio) in E2, E6 and E7 gene expression for the PC08 and PC09 
series.  
Each bar represents an RQ ratio for the PC08/PC09 sample listed on the X-axis. Each gene expression 
assay is colour coded according to the figure legend. 
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Figure 7.8: The Log10 fold difference (Log10 RQ ratio) in E2, E6 and E7 gene expression for the PC08 and 
PC09 series.  
Each bar represents a Log10 RQ ratio for the PC08/PC09 sample listed on the X-axis. Each gene 
expression assay is colour coded according to the figure legend. 
 
7.1.3.2.1. Hypothesis 1: RQ Ratios Varied among Clones and among HPV Genes 
Clone D9 appeared to transcribe E2/E6/E7 mRNA at a higher level than any other clone. 
Among the clones there was substantial variation both in overall level compared to other 
clones, and in the relative level of expression of E2, E6 and E7. A two-way ANOVA was applied 
to the passage 9 RQ values; clone M8 data was excluded from the analysis on the basis of 
missing data and as sample 9A9 had incomplete RQ data, it was substituted by sample 8A9. 
The data satisfied the assumptions of the two-way ANOVA. A significant difference was 
observed among the mean Log10 RQ values for each clone (P=0.003). The other factor tested 
was gene expression assay (i.e. E2, E6 and E7), somewhat surprisingly, no significant difference 
in mean Log10 RQ as a result of the assay was observed (P=0.475). 
7.1.3.2.2. Hypothesis 2: HPV Gene Expression is Associated with HPV DNA 
Integration 
A two-way ANOVA GLM was applied to the same passage 8/9 RQ data for the five clones used 
previously. No significant difference in mean RQ was found with respect to either integration 
status (P=0.857) or gene expression assay (P=0.832), one violation of the ANOVA assumptions 
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occurred (unequal variances, P=0.003) however multiple two-sample T-tests confirmed the 
lack of significant effect of DNA integration on mean RQ. If there was a relationship between 
DNA integration and gene expression, it was more complex than could be determined by a 
simple comparison of RQ means. 
7.1.3.2.3. Hypothesis 3: There is a Linear Relationship between E2, E6 and E7 RQ 
The classical model of P97 regulation is that E2 is a repressor of P97 activity and that the loss 
of E2 function is responsible for E6 and E7 up-regulation. A simple way of testing for this 
scenario in this data set was to correlate E2, E6 and E7 RQ. Spearman’s rank correlation 
analysis was applied to the RQ data of every passage of each clone. There was a significant 
positive correlation between all three pairs of RQ values such that overall, E2, E6 and E7 
expression were correlated with each other (Table 7.3). 
 
 
E2 RQ vs. E6 RQ E2 RQ vs. E7 RQ E6 RQ vs. E7 RQ 
Spearman's rank correlation coefficient 0.568 0.706 0.736 
P-value 0.001 0.000 0.000 
Table 7.3: The P-values and correlation coefficients of Spearman’s rank correlation coefficient tests 
between the RQ values of E2, E6 and E7 for the PC08 and PC09 clones. 
 
7.1.3.3. PC08 and PC09 DNA Methylation 
Pyrosequencing was used to determine the DNA methylation status of the PC08 and PC09 
clone DNAs. Mean DNA methylation (i.e. mean of the multiple CpGs) of each region of the HPV 
genome for the PC08 and PC09 clones are presented in Figure 7.9 and Figure 7.10. 
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Figure 7.9: Mean DNA methylation of the PC08 clones. 
Here each bar represents the mean DNA methylation for the region of the HPV genome indicated by 
the bar colour.  
 
 
Figure 7.10: Mean DNA methylation of the PC09 clones.  
Here each bar represents the mean DNA methylation for the region of the HPV genome indicated by 
the bar colour. 
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7.1.3.3.1. Hypothesis 4a: DNA Methylation Differs among HPV Regions 
For other sample cohorts, large differences in DNA methylation level were observed among 
the different regions of the HPV genome, and also among the different CpGs within regions.  
The one passage number common to every clone was p9, the DNA methylation data of these 
samples are presented graphically in Figure 7.11. A two-way ANOVA GLM was applied to the 
p9 DNA methylation data. This confirmed that statistically significant differences in DNA 
methylation existed among each HPV region (P=0.000) and within each clone. It also confirmed 
significant differences in mean DNA methylation of each clone (P=0.037). The significant 
differences among the clones are discussed later. 
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Figure 7.11: DNA methylation of the passage 9 PC08 and PC09 clones.  
Bars represent the mean DNA methylation for the clone/assay combination depicted, error bars 
indicate 95% confidence intervals for mean methylation and red circles represent the individual DNA 
methylation values for each CpG of each region.  
 
7.1.3.3.2. Hypothesis 4b: DNA Methylation Differs among CpGs within Each HPV 
Region 
For the passage 9 samples, there were noticeable differences in DNA methylation among the 
CpGs within each region (Figure 7.11). To test whether statistically significant differences 
existed, two-way ANOVA GLMs were applied to the p9 data, one test for each of the four 
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regions. The tests were used to determine whether mean methylation differed among CpGs 
and among clones, the results are presented in Table 7.4. The statistical differences among the 
various clones are discussed later. A Bonferroni corrected P-value of P=0.013 was applied. 
There was a significant difference among the amount of DNA methylation of each CpG of the 
E2, LCR2 and L1/L2 regions. 
 
Factor E2 LCR1 LCR2 L1/L2 
Clone (P-value) 0.000 0.031*
1
 0.000 0.000 
CpG (P-value) 0.000 0.157*
1
 0.156 0.000 
Table 7.4: The results of two-way ANOVA GLM tests on the PC08/PC09 passage 9 methylation data.  
The two-way ANOVA tested for differences in the mean values with respect to both clone and CpG. 
Violations of the assumptions of the ANOVA: *1, unequal variances (P=0.005).  
 
It was also worth considering whether or not differences among CpGs were consistent for all 
of the clones. CpG DNA methylation data for the p9 samples is displayed in Figure 7.12, Figure 
7.13, Figure 7.14 and Figure 7.15. Large differences in E2 methylation existed among each CpG 
and there was a remarkable conservation of the overall methylation profile as shown by the 
shape of the line for the interconnected individual values. CpG E2-1 was typically highly 
methylated, E2-2 and E2-3 considerably less so, E2-4 again highly methylated and there was a 
general decrease in the amount of methylation from there onwards (Figure 7.12). For LCR1, 
LCR1-1 was the most methylated and LCR1-3 the least for all but the highly methylated Y8 
clone for which the converse was true (Figure 7.13). The LCR2 data was similar, showing a 
consistent pattern for the five hypomethylated clones, while the profile of the Y8 clone was 
almost the exact opposite (Figure 7.14). The DNA methylation profile of the L1/L2 region had a 
similar shape for every clone. Methylation of L1L2-1 and L1L2-3 were the lowest, and L1L2-2 
and L1L2-4 were the highest, this gave rise to a distinctive “N” shaped profile (Figure 7.15). 
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Figure 7.12: DNA methylation of the E2 CpGs for the PC08 and PC09 clones at passage 9.  
The connecting lines between CpG DNA methylation values are included to aid interpretation only, no 
relationship between the points is inferred. 
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Figure 7.13: DNA methylation of the LCR1 CpGs for the PC08 and PC09 clones at passage 9.  
The connecting lines between CpG DNA methylation values are included to aid interpretation only, no 
relationship between the points is inferred. 
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Figure 7.14: DNA methylation of the LCR2 CpGs for the PC08 and PC09 clones at passage 9.  
The connecting lines between CpG DNA methylation values are included to aid interpretation only, no 
relationship between the points is inferred. 
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Figure 7.15: DNA methylation of the L1/L2 CpGs for the PC08 and PC09 clones at passage 9.  
The connecting lines between CpG DNA methylation values are included to aid interpretation only, no 
relationship between the points is inferred. 
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7.1.3.3.3. Hypothesis 5a: Differences in DNA Methylation are Detectable when 
Comparing Clones from PC08 with Those from PC09 
The PC08 and PC09 cell lines were derived from two patients with disease at different 
anogenital sites. It is reasonable to suspect that DNA methylation might be different between 
the two original biopsies, and therefore between the two sets of short term culture lines. The 
passage 9 cell line data for the 6 clones was tested using a two-way ANOVA GLM to determine 
if a statistically significant difference in mean DNA methylation between the two original 
biopsies existed. The other factor included in the analysis was HPV region, such that all four 
HPV regions were tested simultaneously. There was a statistically significant difference in 
mean DNA methylation both as a result of HPV region (P=0.000) but also as a result of original 
biopsy (P=0.029). There was a difference between cell lines from the two biopsies. 
 
7.1.3.3.4. Hypothesis 5b: There are DNA Methylation Differences among the Six 
Clones 
LCM studies have demonstrated that HPV DNA methylation level varies throughout a biopsy 
depending on the characteristics of the HPV infection in different areas (Vinokurova and von 
Knebel Doeberitz, 2011). Given that these clones originated from two heterogeneous mixes of 
cells, each potentially representing a diverse part of the same biopsy, it was interesting to 
consider if the methylation profile was different among the different clones. Previously 
performed two-way ANOVA GLM tests (passage 9 data only, one test per region, clone and 
CpG as factors) found that a significant difference among the clones was observed for the E2, 
LCR and L1/L2 regions (Table 7.4). The Bonferroni corrected P-value was P=0.013, if the 
Bonferroni correction was not applied then differences among the clones are also seen for the 
LCR1 region. 
As well as differences in mean DNA methylation among the clones, further differences were 
observed when every passage number was considered. The changes in DNA methylation with 
passage number are discussed in further detail later in this chapter, however it was of 
particular interest to note that the relationship between DNA methylation and passage 
number varied considerably for different clones. 
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7.1.3.3.5. Hypothesis 6: HPV DNA Methylation Changes with Passage 
For the E2 region (Figure 7.16), clones M8 and Y8 were the most highly methylated, the other 
PC08 clone (P8) however was hypomethylated in every passage. All three PC09 clones were 
lowly methylated in early passages. The D9 and A9 clones remained hypomethylated however 
for the H9 clone, after p8 there was a gradual increase in E2 DNA methylation. 
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Figure 7.16: Mean E2 DNA methylation of the PC08 and PC09 clones with increasing passage number.  
Each clone is represented by a different colour. Different passages of the same clone are connected 
with a coloured line in order to aid interpretation. 
 
For the LCR1 region (Figure 7.17), every clone was methylated at a low level, changes between 
passages were difficult to determine accurately because the differences were so small that 
they could be due to random variation between pyrosequencing runs and experimental noise. 
The Y8 clone, as per some other regions was more methylated than the other clones. LCR1 
methylation did not change drastically with passage number in any discernible manner for any 
of the clones. 
For the LCR2 region (Figure 7.18), all clones except for the Y8 and H9 clones were less than 5% 
methylated throughout. LCR2 methylation for the Y8 clone began to decrease at p11. The H9 
clone had a gradual decrease in DNA methylation from p5 until approximately p10. 
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Figure 7.17: Mean LCR1 DNA methylation of the PC08 and PC09 clones with increasing passage 
number.  
Each clone is represented by a different colour. Different passages of the same clone are connected 
with a coloured line in order to aid interpretation. 
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Figure 7.18: Mean LCR2 DNA methylation of the PC08 and PC09 clones with increasing passage 
number.  
Each clone is represented by a different colour. Different passages of the same clone are connected 
with a coloured line in order to aid interpretation. 
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For the L1/L2 region (Figure 7.19), DNA methylation was much more variable than for other 
HPV regions, every clone appeared to experience changes in DNA methylation with increasing 
passage number. As for other regions, the Y8 clone was the most methylated and as per the 
LCR2 region, there was a decrease in DNA methylation for the later passage. The M8 clone was 
also heavily methylated and became more methylated with increasing passage number (E2 
methylation also increased with passage number). The P8 clone became in general, more 
methylated with passage number however there was some variation at passage 8, where DNA 
methylation was lower than might be expected giving rise to an odd shaped curve. The A9 
clone was the least methylated of the clones and after an initial decrease, DNA methylation 
remained low. The D9 clone was particularly intriguing in that a positive, linear relationship 
between DNA methylation and passage number was observed; it is worth considering that 
whilst L1/L2 methylation level was high, the E2 region of D9 was hypomethylated throughout. 
The H9 clone showed a similar overall increase in DNA methylation as D9, however the 
changes were non-linear, initially experiencing a decrease before a more rapid increase. The 
increased L1/L2 DNA methylation for the H9 clone, coincided with the increase in E2 DNA 
methylation discussed previously. 
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Figure 7.19; MeanL1/L2 DNA methylation of the PC08 and PC09 clones with increasing passage 
number.  
Each clone is represented by a different colour. Different passages of the same clone are connected 
with a coloured line in order to aid interpretation. 
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7.1.3.4. The Interaction of DNA Methylation, Gene Expression and HPV 
Integration 
Comparison of DNA methylation, gene expression and HPV integration for the PC08 and PC09 
cell lines was conducted in two main stages, the first stage considered all six clones 
simultaneously and the second stage considered each clone individually. 
  
7.1.3.4.1. Hypothesis 7: There is a Relationship between DNA Methylation and Gene 
Expression 
The simplest way of determining whether a direct relationship existed between DNA 
methylation and gene expression was to perform correlation analysis. Spearman’s rank 
correlation analysis was performed on the mean DNA methylation and RQ results for every 
passage of every clone to determine whether a general relationship existed (Table 7.5). A 
significant relationship existed between E2 DNA methylation and E2, E6 and E7 RQ, LCR1 
methylation and E6 RQ, LCR2 methylation and E2 RQ and a very close to significant correlation 
existed between L1/L2 methylation and E6 RQ. The data was highly unsuitable for 
multifactorial ANOVA analysis. Further investigation into the relationship between DNA 
methylation and gene expression was performed on an individual clone basis. 
 
  
E2 RQ vs. E6 RQ vs. E7 RQ vs. 
E2 methylation Spearman's rank -0.593 -0.679 -0.702 
  P-value 0.001 0.000 0.000 
LCR1 methylation Spearman's rank -0.234 -0.357 0.028 
  P-value 0.212 0.035 0.873 
LCR2 methylation Spearman's rank -0.036 -0.421 -0.150 
  P-value 0.851 0.012 0.388 
L1/L2 methylation Spearman's rank -0.216 -0.332 -0.238 
  P-value 0.251 0.051 0.169 
Table 7.5: The results of Spearman’s rank correlation analysis to investigate the relationship between 
DNA methylation and gene expression.  
Each column represents a gene expression assay whilst each row represents a DNA methylation assay. 
Data from every clone at every passage was included. Mean DNA methylation of the multiple CpGs in 
each region was used in the analysis. Spearman’s rank refers to the Spearman’s rank correlation 
coefficient. P-values are significant where P<0.05. Significant correlations are highlighted yellow and 
correlations close to significant are coloured blue. 
 
166 
 
7.1.3.4.2. Hypothesis 8: There is a Relationship between DNA Methylation and HPV 
Integration 
Passage 9 DNA methylation data was tested to determine whether a significant difference in 
mean DNA methylation existed among HPV regions (previously confirmed), and HPV 
integration status using a two-way ANOVA GLM. For integration, two classes were defined; 
integration detected and integration not detected. No significant relationship between mean 
DNA methylation and integration status was identified (P=0.168), suggesting that if DNA 
integration had an effect on DNA methylation, it was more complex than a simple 
increase/decrease in mean DNA methylation. 
 
7.1.3.5. Individual Clone Comparisons 
The relationship between DNA methylation, gene expression and integration appeared to be 
more complex than a simple comparison of means or correlation could determine. Visual 
comparisons of the DNA methylation mean data (Figure 7.16, Figure 7.17, Figure 7.18 and 
Figure 7.19), the Log10 RQ plot (Figure 7.8) and DNA integration results (Table 7.2) were 
performed and used to generate hypotheses that could be tested statistically. 
 
7.1.3.5.1. Clone A9 
Clone A9 E2/E6/E7 transcription was fairly consistent across all passages (p9 data missing). 
There were only small changes observed with increasing passage number, however there were 
slightly greater differences between p10-11 than there were for the other passages. DNA 
methylation level of clone A9 was low and consistent with increasing passage, it had the 
lowest overall methylation of L1/L2 and one of the lowest levels of methylation for the other 
regions. No integration events were detected for clone A9 in either p5 or p11. 
7.1.3.5.2. Clone D9 
Of the six clones tested, clone D9 displayed the highest mRNA levels for each gene; there was 
also a progressive increase in the amount of E2 and E6 mRNA right up until the final sample at 
p11 where there was a sharp and pronounced decrease in the expression of all genes. This was 
a little surprising because we typically consider that increased E2 expression should have a 
negative impact on the expression of the E6 and E7 genes, as such we may expect increases in 
E2 to be followed by decreases in E6 and E7 and vice versa. 
The DNA methylation of clone D9 was also interesting in that for E2, LCR1 and LCR2 there was 
very little DNA methylation whereas for L1/L2 there was a steady and linear increase with 
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increasing passage number. E2 hypomethylation coinciding with E2 integration was of 
particular interest because a potential association between site of integration and methylation 
was identified in vitro (Chapter 8: 8.2.3.3). 
Passage 11 excluded, the increase in E2/6/7 mRNA in D9 with passage appeared to coincide 
with an increase in L1/L2 DNA methylation (Figure 7.20). Spearman’s rank correlation analysis 
was applied to determine whether gene expression and L1/L2 methylation correlate 
significantly, the results are summarised in Table 7.6. Significant correlation was observed for 
E2 RQ vs. L1/L2 mean methylation and E6 RQ vs. L1/L2 mean methylation. None of the 
correlations were significant when 11D9 (p11) was included; the p11 data may have been 
erroneous. Several explanations for the increase in DNA methylation with passage number 
could exist. It could be that the HPV16 DNA is becoming gradually more methylated in each 
cell, or alternatively, that the integrated genomes are heavily methylated and are becoming 
more common as they are selected for due to E2 disruption, E6/E7 overexpression and an 
enhanced growth rate. 
 
E2 RQ vs. L1/L2 
Methylation 
E6 RQ vs. L1/L2 
Methylation 
E7 RQ vs. L1/L2 
Methylation 
Spearman's rank correlation coefficient +0.943 +1.000 +0.543 
P-value P = 0.005 P < 0.000 P = 0.266 
Table 7.6: The P-values and correlation coefficients of Spearman’s rank correlation coefficient tests 
between the RQ values of E2, E6 and E7 and the mean methylation values at the L1/L2 region for the 
D9 clone. 
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Figure 7.20: The log10 RQ ratios for E2, E6 and E7 expression plotted against L1/L2 mean DNA 
methylation.  
Passage 11 data was excluded from the diagram and from subsequent correlation analysis. Included 
are regression lines of best fit for each of the three gene expression assays. 
 
7.1.3.5.3. Clone H9 
For clone H9 there was a slight increase in expression of E6 and E7 and a considerable 
decrease in E2 expression with increasing passage. This was more in line with what might be 
expected, i.e. a decrease in E2 expression alleviates some of the repression on the P97 
promoter allowing E6 and E7 expression to rise. Nonetheless, despite an apparent negative 
correlation between E2 RQ and E6/E7 RQ for the H9 clone, the correlation was not significant 
(Table 7.7).  
 E2 RQ vs. E6 RQ E2 RQ vs. E7 RQ E6 RQ vs. E7 RQ 
Spearman's rank correlation coefficient -0.429 -0.357 +0.857 
P-value P = 0.337 P = 0.432 P = 0.014 
Table 7.7: The P-values and correlation coefficients of Spearman’s rank correlation analysis to 
determine a relationship between the RQ values of E2, E6 and E7 for the H9 clone. 
 
The methylation profile of clone H9 was of particular interest because of the pronounced 
changes at and around p8-9 (large increases in E2 and especially L1/L2 methylation). Between 
p5-8 the expression of E2 was considerably higher than between p9-11, this coincided with 
changes in methylation in the E2 and L1/L2 regions. In addition, LCR2 methylation decreased 
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relatively rapidly between p5-7 and decreased continually for the rest of the passages 
available. Between the early and late passages there appeared to be a large difference in gene 
expression and DNA methylation that may be a consequence of the integration event detected 
in p11, but not in p5. The integration event was detected in the E2/E4 region. 
Two-sample T-tests were used to determine whether gene expression and DNA methylation 
were significantly different between the early passage (p5-8) and the late passage (p9-11), the 
results are summarised in Table 7.8. There was a significant difference between the early and 
late passage for E2 RQ and for mean L1/L2 DNA methylation, however the difference for L1/L2 
methylation was not significant if the Bonferroni correction (P=0.007) was applied. 
 
 
Difference between passages 5-8 and 9-11 with respect to: 
 
Gene expression (RQ) Mean DNA methylation 
Two-sample T-test E2 E6 E7 E2 LCR1 LCR2 L1/L2 
P-value 0.007 0.593 0.365 0.112 0.290 0.097 0.039 
Table 7.8: The results of two-sample T-tests to assess differences in mean gene expression and mean 
DNA methylation between the early and late passages of H9.  
The table is separated into DNA methylation and gene expression assays, the P-value represents the 
significance of the difference between the early passage (passage 5-8) and the late passage (passage 
9-11) samples for the assay of interest. No violations of the assumptions of the T-test were 
encountered. 
 
7.1.3.5.4. Clone M8 
Clone M8 was lacking E2 expression data so parallels between E2 and E6/E7 expression could 
not be drawn (Figure 7.8). Nonetheless there did appear to be a slight increase in E7 
expression with somewhat more variable E6 expression. As previously discussed, clone M8 had 
high E2 and L1/L2 methylation that increased slightly with passage number; it was difficult to 
draw further conclusions without the E2 RQ data. Integration was detected in the E7/E1 region 
at p5 but not at p9. This could be a selective loss of cells containing the integration event, 
silencing of the HPV sequence expressing the integration event or a failing of the APOT assay. 
7.1.3.5.5. Clone P8 
Clone P8 had a low level of DNA methylation in all regions, fairly constant E6 and E7 RQ and a 
slight increase in E2 RQ with increasing passage number. Interestingly, p9 had the highest E2 
RQ and the highest L1/L2 methylation. No integration was detected. 
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7.1.3.5.6. Clone Y8 
Finally, clone Y8 showed increasing mRNA levels for all genes of interest up until p12 where 
there was a 1 Log10 decrease in expression. By p13, mRNA levels had returned to previous 
levels except for a considerable increase in E6 RQ. Clone Y8 had the highest level of DNA 
methylation for most of the assays out of any of the clones analysed and also the lowest E6 RQ 
out of all of the clones analysed. HPV integration was detected at E7/E1 and an additional 
E7/E1 integration event was detected in p13. The increase in gene expression for p13 
(especially for E7) may be related to a decrease in DNA methylation at p13 that was observed 
at every site (E2, LCR1, LCR2 and L1/L2). 
 
 
7.2. Discussion 
 
7.2.1. CaSki 
7.2.1.1. Aims 
CaSki DNA was used as a HPV16 positive control DNA for method development and to 
compare the results produced by pyrosequencing to published data. 
7.2.1.2. Comparison to Other Studies 
Fernandez et al used bisulfite sequencing with cloning in order to assess methylation in a semi-
quantitative manner (Fernandez et al., 2009) and produced results similar to those produced 
by this study (Table 7.9, Table 7.10). Where differences are present, Fernandez et al typically 
had a low number of clones sequenced (e.g. LCR1). Even with a larger number of bisulfite 
sequenced clones there are wide confidence intervals. E2-5 for example had 8/12 clones 
sequenced, indicating methylation of 67% however the 95% confidence intervals range from 
40.4-93.6% making direct comparison with a quantitative method unreliable. 
  
171 
 
 E2 LCR1 
 1 2 3 4 5 6 7 8 1 2 3 
Nucleotide 3411 3414 3416 3432 3435 3447 3461 3472 7691 7679 7673 
CaSki repeat 1 96 97 80 100 98 92 82 76 63 68 75 
CaSki repeat 2 95 100 80 100 95 94 81 78 63 67 77 
Mean 95.5 98.5 80 100 96.5 93 81.5 77 63 67.5 76 
Fernandez et al                       
Methylated 
clones 11/12 12/12 11/12 11/12 8/12 12/12 10/12 9/12 2/2 0/2 2/2 
Methylation % 92 100 92 92 67 100 83 75 100 0 100 
Difference % 3.5 -1.5 -12 8 29.5 -7 -1.5 2 -37 67.5 -24 
Table 7.9: A comparison of CaSki methylation data collected in this study with published CaSki 
methylation data for the E2 and LCR1 region (Fernandez et al., 2009). 
The published methylation data was bisulfite sequencing data and was calculated by sequencing 
multiple bisulfite converted cloned DNAs. 
 
 LCR2 L1/L2 
 1 2 3 4 5 1 2 3 4 
Nucleotide 31 37 43 52 58 5615 5609 5606 5600 
CaSki repeat 1 90 94 98 95 95 73 86 75 85 
CaSki repeat 2 89 89 95 96 99 76 89 77 90 
Mean 89.5 91.5 96.5 95.5 97 74.5 87.5 76 87.5 
Fernandez et al                   
Methylated clones 8/8 8/8 8/8 6/8 7/8 7/10 10/10 7/10 10/10 
Methylation % 100 100 100 75 88 70 100 70 100 
Difference % -10.5 -8.5 -3.5 20.5 9 4.5 -12.5 6 -12.5 
Table 7.10: A comparison of CaSki methylation data collected in this study with published CaSki 
methylation data for the LCR2 and L1/L2 (Fernandez et al., 2009).  
The published methylation data was bisulfite sequencing data and was calculated by sequencing 
multiple bisulfite converted cloned DNAs. 
 
Another study considered DNA methylation of the CaSki HPV16 LCR and L1 region using 
bisulfite sequencing with cloning and found almost complete hypermethylation of LCR2 region 
(93% methylation of LCR2-1 and LCR2-5, 100% methylation of the other LCR2 CpGs) and LCR1 
region (87% methylation of LCR1-1, 100% methylation of the other LCR1 CpGs) (Kalantari et al., 
2004). They also observed heavy methylation of the L1 region, albeit in an area not covered by 
our assays (Kalantari et al., 2004). Direct bisulfite sequencing without a cloning step suggested 
there was methylation of all LCR1 and LCR2 CpGs in CaSki (i.e. the result is methylated or 
unmethylated) (Badal et al., 2003). Both of these studies are consistent with our results.  
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7.2.1.3.  Meaning 
CaSki HPV16 was heavily methylated in all CpGs but the level of methylation varied both 
among region of the genome and among CpGs within each region. The E2 and LCR2 (promoter) 
region were the most densely methylated, whilst the LCR1 (enhancer) and L1/L2 regions were 
hypermethylated to a lesser degree. CpG specific patterns of DNA methylation were observed 
in L1/L2 and E2 which appeared to match those observed in other sample cohorts. The “N” 
shaped L1/L2 CpG methylation pattern observed in CaSki was also present in published CaSki 
work (Fernandez et al., 2009), as was the LCR1 pattern (Ding et al., 2009). 
For our study, CaSki was a crucial part of the method development, as a source of methylated 
control DNA, a means by which to compare independent experimental repeats, and a means 
by which to compare data produced using our assays to published data. One of the first 
observations was that two experimental repeats (i.e. DNAs were separately BS treated, 
amplified by PCR and then pyrosequenced) exhibited levels of methylation that were very 
closely matched, the greatest individual difference of any CpG being 5% (Table 7.9, Table 7.10). 
The close similarities between this data and data produced by the widely used bisulfite 
sequencing technique were also reassuring. 
HPV16 genomes are integrated into the CaSki human genome at around 500 copies per cell as 
head-to-tail hypermethylated concatemers and located in several sites of the human genome 
with only a small number of transcriptionally active copies (Fernandez et al., 2009, Van Tine et 
al., 2004b, Van Tine et al., 2001, Mincheva et al., 1987). This is consistent with our observation 
of heavily methylated LCR, E2 and L1/L2 regions.  
 
7.2.2. W12 series 7 
7.2.2.1. Aims 
W12 series 7 (W12Ser7) DNA was used as a means to consider DNA methylation over a large 
number of cell passages and to consider the effect of HPV integration on DNA methylation.  
7.2.2.2. Comparison to Other Studies 
Kalantari et al studied DNA methylation of W12 cells in both episomal and integrated forms, 
and after induction of cellular differentiation (Kalantari et al., 2008a). They observed a low 
level of enhancer and promoter methylation and some methylation of the 5’LCR and L1 region 
in episomal HPV16. Upon differentiation, DNA methylation was reduced considerably in all 
regions for episomal, but not for integrated HPV16 genomes (Kalantari et al., 2008a). The 
reduction in W12 LCR methylation upon differentiation was also observed in another study 
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(Kim et al., 2003). Low level methylation of the enhancer, promoter and L1 region in these 
studies is consistent with our observation of low level LCR1, LCR2 and L1/L2 methylation in 
early passage W12, and prior to the integration events. 
Two types of integration event were detected (single insertions and concatemeric repeats) 
that corresponded to the methylation profiles of SiHa (single insertion) and CaSki (concatemer) 
respectively (Kalantari et al., 2008a, Fernandez et al., 2009). Our W12 methylation profile 
corresponds best to that of the concatemeric insertion (Kalantari et al., 2008a). Further 
comparison revealed that where we saw LCR1-1 to be less methylated than LCR1-2/3 at every 
passage, this was also reflected in published data where LCR1-1 was typically unmethylated in 
most instances (Kalantari et al., 2008a). LCR1-1 hypomethylation and LCR1-2/LCR1-3 
methylation was not frequently observed in our other sample cohorts/cell lines. In summary, 
where parallels can be drawn, our data align well to previously published W12 data from other 
W12 series. 
 
7.2.2.3. Meaning 
The information and material available for the W12Ser7 line was limited. We had no access to 
RNA with which to perform gene expression analysis, only very basic integration data has been 
published (Gray et al., 2010) and detail pertaining to the site of integration within the human 
and HPV genome was not available. There was also insufficient DNA with which to perform 
DIPS. 
W12Ser7 integration was detected from passage 13 onwards and by p17 the vast majority of 
genomes were integrated (Gray et al., 2010); this corresponded to large and distinct changes 
in DNA methylation beginning around p13. The changes observed were both region specific 
(i.e. assay) and CpG specific (i.e. within assays). All regions of the HPV genome were 
hypomethylated (i.e. approx 10%) in the first passage available (p11/p13). Changes were most 
pronounced for the L1/L2 region. LCR and E2 methylation did change with passage but not to 
the same extent. 
For the E2 region there was a large increase in DNA methylation from p13 onwards almost 
exclusively for the E2-5 and E2-6 CpGs. Adjacent CpGs, separated by only a few bp were seen 
to differ considerably, hinting at a CpG specific mechanism of DNA methylation. This was also 
observed at LCR1 and to a degree for LCR2. An interesting difference between W12Ser7 and 
other cohorts was that W12Ser7 LCR1-1 CpG was hypomethylated whilst methylation of LCR1-
2 and LCR1-3 varied with passage number. This was reflected in studies using W12 of an 
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unknown series (Kalantari et al., 2008a). LCR1-1 does not correspond to an E2BS, so it was 
unusual that it was persistently hypomethylated in W12Ser7. LCR1-1 hypomethylation possibly 
corresponded to a growth advantage to the cell hence its continued hypomethylation (as 
observed in a range of W12 lines). LCR1-1 is close to the binding sites of many cis-acting 
elements, the binding of which could be influenced by DNA methylation. Previous studies have 
noticed an association between nucleosome linker position and sites of continual 
hypomethylation (i.e. CpG 7862) (Kalantari et al., 2004) however LCR1-1 corresponds to a site 
positioned within a nucleosome (Stunkel and Bernard, 1999) and was not routinely 
hypomethylated (compared to other LCR1 CpGs) in our other work. In summary, the conserved 
methylation differences between proximal CpGs suggest that specific mechanisms of 
methylation and/or strong selection pressure could be responsible. Some of the more 
pronounced CpG specific differences for W12 were not however routinely observed in other 
cohorts, which could be due to several reasons including integration state, integration site and 
characteristics of the W12 cell lines that are not shared with any of our other cohorts. 
 
7.2.2.3.1. Integration and Methylation 
W12Ser7 HPV methylation was seen to undergo pronounced increases at the onset of 
integration which continued for over 35 passages. Methylation increased in both a region 
specific and CpG specific manner. Methylation of the L1/L2 region increased the most after the 
integration event, methylation of the other three regions occurred but not as substantially.  
Published W12, SiHa and CaSki HPV16 integration, copy number and methylation data may 
give a degree of insight into the association between methylation and integration for 
W12Ser7. HPV16 is present in SiHa at around 1-2 copies per genome and in CaSki at 
approximately 500 copies per genome (Van Tine et al., 2001, Fernandez et al., 2009). SiHa and 
CaSki HPV16 differ significantly; whilst both cell lines contain HPV16 which is heavily 
methylated in the E2-L1 regions, the LCR of SiHa HPV16 is hypomethylated (Kalantari et al., 
2004, Fernandez et al., 2009). In CaSki, HPV16 genomes exist as integrated concatemers, the 
majority of which are repressed by heavy DNA methylation. The few HPV16 integrants in SiHa 
are transcriptionally active with an unmethylated LCR (Kalantari et al., 2008a, Van Tine et al., 
2001). Similarly, W12 single HPV16 insertions were methylated in L1, but hypomethylated in 
the LCR whilst concatemeric insertions were typically hypermethylated in the enhancer, 
promoter and L1 region as per SiHa (single insertion) and CaSki (concatemer) respectively 
(Kalantari et al., 2008a, Fernandez et al., 2009). Our observation of methylation at all regions 
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(with hypermethylation of L1/L2) better corresponds to that seen for the concatemeric 
insertion type integration event (Kalantari et al., 2008a).  
Pyrosequencing is unable to differentiate between a mix of heterogeneously methylated 
genomes, and a mix of hypomethylated and hypermethylated genomes. An intriguing 
explanation for the W12Ser7 methylation profile was that the progressive increase in DNA 
methylation was due to a selection for, and eventual predominance of cells containing 
methylated, integrated HPV, with the apparent gradual increase in methylation being 
attributable to the gradual loss of hypomethylated episomes. The highest rate of change in 
DNA methylation was observed between p13 and p17 however methylation continued to 
increase in much later passages too. W12 contained almost entirely integrated forms from p17 
onwards (Gray et al., 2010) which suggests that episomal loss did contribute to the change in 
DNA methylation, but also that integrants are methylated in a gradual manner, rather than 
immediately hypermethylated upon integration. 
The selection for, and eventual dominance of W12Ser7 cells containing integrated genomes 
(Gray et al., 2010) implies that integration confers a growth advantage for the host cell (Jeon et 
al., 1995). Integration of HPV must occur in a background of episomal HPV which would 
initially be repressed by episomal E2. In this instance, loss of the episomes would confer a 
strong selective benefit which might explain why episomes were quickly lost in vitro once the 
integration event had occurred (Pett and Coleman, 2007, Pett et al., 2006). 
7.2.2.3.2. Unusual Observations 
Prior to integrant selection, there was an initial decrease in DNA methylation from p11-p15 at 
all regions. This is difficult to explain; DNA methylation is seen to be reduced during 
differentiation (Kalantari et al., 2008a) but this is not occurring, there is reason to suspect that 
HPV oncogene expression can alter DNA methylation through their action on DNMTs (Burgers 
et al., 2007, Leonard et al., 2012) so this initial change in DNA methylation might reflect known 
changes in oncogene expression prior to integration and selection for integrants (Gray et al., 
2010).  
CpG methylation of the E2 region was also different than seen elsewhere; only two E2 CpGs 
were hypermethylated in association with integration and passage number whilst CpGs 
adjacent to these two remained hypomethylated throughout. This was observed in multiple 
passages, so there is no reason to suspect it is erroneous however it is difficult to explain. DNA 
methylation of integrated genomes may operate in a manner that requires an initial seeding of 
specific sequences (Doerfler, 2008, Turker, 2002), however this seems unlikely in this instance 
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as other E2 CpGs might be expected to be methylated in passages after this initial seeding and 
this unusual pattern was not observed elsewhere. A more plausible suggestion might be that 
HPV16 integration resulted in topological changes of the E2 DNA structure and affected its 
ability to be methylated and might possibly because of the chromatin structure of adjacent 
human DNA (Doerfler, 2011). 
 
7.2.3. PC08 and PC09 
7.2.3.1. Aims 
The PC08 and PC09 cell lines are short term culture lines derived from VIN3 and VAIN3 lesions 
respectively. The aim of the study was to determine the relationship between DNA 
methylation, integration and gene expression in a tractable and well characterised in vitro 
model. 
7.2.3.2. Strengths 
The biopsy dosage effect described in the qPCR method development section (Chapter 4: 
4.1.3) would not apply to cell line material. The biopsy dosage effect is where variation in the 
size of the biopsy, the number of HPV containing cells and tissue type alters the RQ ratios 
produced. This is not a concern for a homogeneous cell line as every cell is of the same tissue 
type and every cell contains HPV16. 
CaSki, SiHa and HeLa are often used to study HPV biology. These lines were derived from 
malignant tumours, in some instances from metastases and contain an array of chromosomal 
rearrangements, deletions and duplications following decades of cell culture. Other studies 
have utilised transformation of keratinocytes with HPV genomes or plasmid constructs 
containing certain HPV ORFs. Whilst useful, these cell lines represent HPV in a manner that 
might have little relevance to a real infection or precancerous disease. W12, and now PC08 
and PC09 were derived from primary cultures of precancerous disease, such that we might 
observe events vital to carcinogenesis in vitro. 
Many assays (especially the integration assays) require a large amount of high quality 
DNA/RNA that is not readily available for clinical material, but is not an issue for cell line 
studies. Most clinical material studies are simply cross sectional. Longitudinal sample sets are 
less common and are very rarely used for HPV methylation studies. The PC08/09 cell lines 
allow for changes with time to be studied. 
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7.2.3.3. Weaknesses 
APOT only detects transcribed integrants, not those transcriptionally silenced. DNA 
methylation is a mechanism of transcriptional regulation and heavily methylated 
transcriptionally silent integrants might not be detected. This might hinder the investigation of 
an association between integration and methylation in instances where multiple integrants 
exist. Also, as APOT also utilises spliced mRNA HPV-human fusion transcripts, in many 
instances the true site of integration is spliced out from the transcript and the region of 
disruption of the HPV16 genome cannot be determined.  
 
7.2.3.4. Meaning 
7.2.3.4.1. There was Variation 
The three PC08 and three PC09 cell lines are homogenous clones derived from VIN3 and VAIN3 
biopsies respectively. Whilst differences between the two biopsies were expected (and 
observed), an intriguing feature of the PC08/PC09 series was the massive variation among 
clones derived from the same biopsy. Within the 6 clones, there was wide variation in gene 
expression, DNA methylation, and presence/absence/site of integration. That integration 
occurs in different sites for each clone, and that integration is not present in all clones suggests 
that many of the integration events occurred during cell culture. LCM studies have found large 
gene expression and DNA methylation differences between various tissue types within a 
biopsy, depending on the characteristics of the HPV infection in each area (Kalantari et al., 
2009, Vinokurova and von Knebel Doeberitz, 2011), which may explain why such a diverse 
range of clones were produced. In addition, the integration data suggests that changes have 
occurred both in heterogeneous cell culture and after cloning. Coupled with a different 
environment (i.e. cell culture) the clones are likely very different than the ancestor cells from 
the original biopsies. 
DNA methylation, integration and gene expression were seen to vary with passage number, 
i.e. there were changes with time and number of cell divisions. As per the W12Ser7 data, this 
suggests that the relationship between these three factors was dynamic and varied over time. 
For the CRISP study (Chapter 6: 6.1.2) however, minimal variation in DNA methylation was 
observed over 6 months suggesting that in vivo HPV infections are more stable. This view is 
supported by the long duration of persistent infections and the time taken for disease 
progression (Cancer Research UK, 2012a). The differences likely stem from positive selection 
for fast growing deregulated cells in culture in an environment very different from that of low 
grade disease. 
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7.2.3.4.2. General Gene Expression 
We initially compared gene expression for all clones combined; a significant, positive 
correlation was observed between E2, E6 and E7 RQ which was unexpected. It is possible that 
the classic model of P97 regulation, (i.e. E2 downregulation results in E6/E7 upregulation) 
could be an early, transient event in carcinogenesis. Initial oncogene deregulation might be 
transient in both integrated and non-integrated HPV containing cells, and might actually cause 
integration as a result of chromosomal instability (Vinokurova and von Knebel Doeberitz, 
2011). CaSki, SiHa and HeLa cell lines require continued oncogene expression in order to avoid 
senescence and maintain a transformed phenotype (DeFilippis et al., 2003, Schwarz et al., 
1985, Wells et al., 2000, Yee et al., 1985). Conversely, excessive expression of oncogenes might 
adversely affect growth and cell viability rate (i.e. through continued chromosomal instability) 
such that oncogene downregulation confers a growth advantage after initial deregulation (De-
Castro Arce et al., 2011, Gray et al., 2010, Van Tine et al., 2004b).  
A similar mechanism appears to be present in episomal infections. Early, transient oncogene 
deregulation occurred for episomal W12Ser4 where early passage W12E had low E2 
expression and translation whilst E6/E7 were highly expressed and translated (Gray et al., 
2010). At later passage, E2 expression increased to a level similar to E6 and E7, and expression 
of all three genes decreased considerably with increasing passage number (Gray et al., 2010). 
This pattern was suggested to be the result of a balance between deleterious effects of 
overexpression and expressing sufficient level of oncoprotein to maintain the infection. In 
W12, this compromise appeared to be post-transcriptionally regulated in later passages, 
where considerable divergence between mRNA and protein level was observed (Gray et al., 
2010) which could partly explain why there was a positive correlation between E2, E6 and E7 
mRNA in many of the PC08/09 lines. Most clones had low (relative to CaSki) and closely 
matched E2/E6/E7 RQ levels which could represent a state after the initial deregulation event, 
or a state in which post-transcriptional regulation is important. Other clones had considerably 
less E2 mRNA than E6/E7 mRNA, possibly representing earlier deregulatory events. 
Clone D9 had an E2 disrupted integrant, the highest transcription levels and transcription of 
E2/E6/E7 increased gradually until passage 11. There are several reasons why E2, E6 and E7 
expression could be positively correlated. First, the E2 qPCR assay amplified a region upstream 
of the E2 integration event and would not have been affected by the integration event. Whilst 
E2 mRNA levels appeared to increase dramatically with passage and were positively correlated 
to E6/E7, disruption of the E2 ORF might result in a non-functional E2 protein or perhaps even 
competitively exclude functional E2 if the E2BS binding motifs were present (Kim et al., 2003). 
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The progressive increase in gene transcription could also be explained by a gradual positive 
selection for cells producing non-functional E2 repressor protein due to an enhanced growth 
rate, and the loss of cells containing functional E2 repressor protein. In this instance, E2, E6 
and E7 transcripts could all increase in abundance without the repressor effects becoming 
apparent. 
Further evidence also suggests that E2 mRNA level does not necessarily correlate to the 
amount of full length, functional E2 protein. The E2 transcripts of many papillomaviruses 
encode additional translational products; products arising from translation at internal ATGs 
and/or fusion products with other upstream ORFs (Lambert et al., 1990), which may 
competitively exclude E2 at the E2BSs (Stubenrauch et al., 2001). HPV transcripts are 
frequently polycistronic so detection of E2 mRNA might not correlate to E2 translation (Zheng 
and Baker, 2006). 
7.2.3.4.3. DNA Methylation and Gene Expression Comparisons 
There was a significant, negative correlation between E2 methylation and E2/E6/E7 mRNA 
level, i.e. high E2 methylation was associated with low gene expression. Similarly, E6 
transcription was significantly, negatively correlated to E2, LCR1 and LCR2, and almost L1/L2 
methylation. These results are somewhat unusual; integration has previously been associated 
with deregulated oncogene expression, E2 hypermethylation with integration (Fernandez et 
al., 2009) and higher grade disease with HPV methylation (Chapter 5: 5.1.2). Here however we 
did not observe a relationship between E2 methylation and integration, and we observed a 
negative correlation between methylation and gene expression in these cell lines. These 
discrepancies might be the result of the small number of clones, that oncogene deregulation is 
an early event, or that the relationship between gene expression and DNA methylation is more 
complex than can be determined by simple correlation analysis. Intragenic methylation and 
gene expression is considered further in the general discussion (Chapter 9: 9.1.3 & 9.1.4). 
7.2.3.4.4. DNA Methylation and Integration 
The relationship between DNA methylation and integration of the PC08/09 clones appears 
complex. Whilst methylation of the E2 and L1/L2 regions varied considerably, all clones other 
than Y8 were hypomethylated in the LCR. Nonetheless, methylation of E2 and L1/L2 varied 
considerably among clones with integrated HPV16. The site of integration within the human 
genome could have an effect on the DNA methylation of the integrated HPV sequences as 
methylation may spread from areas of dense to sparse methylation (Turker, 2002, Doerfler, 
2008). Furthermore newly integrated foreign DNAs are considered a target for de novo 
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methylation (Doerfler, 2008) in a manner that might reflect the number and position of 
integrants. 
7.2.3.4.5. DNA Methylation, Gene Expression and Integration 
The 6 clones used in this study represent those single cells that exhibited a considerable 
growth advantage over most cells in the heterogeneous mix, likely as a result of oncogene 
expression. No differences in oncogene expression were observed between integrated and 
episomal HPV in various grades of cervical disease (Hafner et al., 2008). Whilst for several 
clones oncogene deregulation might be aided by the presence of integration events, P8 and A9 
had no detectable integration so another mechanism of growth deregulation must have 
existed for these clones.  
7.2.3.4.5.1. Methylation as a Mechanism of Oncogene Deregulation? 
We hypothesised that hypermethylation of the promoter E2BSs might be present in the 
absence of integration. This was because of reports of increased E2BS/LCR methylation with 
disease progression, and the apparent inability of E2 to bind methylated E2BSs and repress 
P97 which could be an alternative mechanism of transformation to integration (Snellenberg et 
al., 2012, Kim et al., 2003, Thain et al., 1996, Bhattacharjee and Sengupta, 2006a, Fernandez et 
al., 2009). For the P8 and A9 clones however, this did not appear to be the case, methylation 
was low in all regions and at a level roughly corresponding to low grade cervical disease 
(Chapter 5: 5.1.2, Chapter 6: 6.1.3).  
For clone Y8, it was intriguing that LCR1 (the enhancer) was specifically hypomethylated at all 
passages whilst LCR2 (the promoter) was methylated at 20-30% throughout. Four of the five 
LCR2 CpGs are located within the two E2BSs of the promoter, the LCR1 CpGs are located near 
to but not within the enhancer E2BS. Hypermethylation of the promoter E2BSs blocks E2 
binding (Thain et al., 1996, Kim et al., 2003). LCR2 hypermethylation might confer a growth 
advantage by blocking the repressive effects of E2 protein. For clone H9, there was also a 
decrease in promoter (LCR2) methylation which appeared to correspond to increased E6 and 
E7 RQ prior to passage 9. Whilst there is some evidence of an effect of E2BS methylation in 
these cell lines, it is far from conclusive. 
7.2.3.4.5.2. DNA Methylation, Gene Expression and Integration 
The D9 and H9 clones had integration events resulting in E2 disruption. Y8 and M8, but also H9 
had HPV-human mRNA fusion transcripts that mapped to E7/E1, and the DNAs were 
frequently heavily methylated. All E7/E1 integration events mapped to 880/882 bp, regardless 
of clone/initial biopsy. HPV16 E7 transcripts are spliced at 880 bp (Zheng and Baker, 2006) and 
APOT detects the junction between viral transcript sequence and human transcript sequence 
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suggesting that the fusion transcript has had the true site of integration spliced out at 880 bp. 
An unknown quantity of both HPV and human sequence has been spliced out such that the 
disrupted human/HPV site is downstream. Clone Y8 for instance had two integration events for 
E7/E1, both were within 1 kb (of the human genome) and at 882 bp (HPV genome) and appear 
to represent two splice variants. Downstream of HPV16 E7/E1 is E2 (Figure 1.1), a common site 
for HPV integration (Collins et al., 2009). Detected E2 integration junctions did not occur at 
recognised splice sites which makes it more likely that the sites represented the actual sites of 
integration. 
There are several potential results due to this unknown site of integration for several clones. 
First, integration is somewhere in E1, in which case E2 is intact but during integration when the 
genome is linearised, becomes positioned upstream of the P97 promoter. Expression of E2 
would likely require an adjacent, in frame and active human promoter, an actively transcribed 
concatemeric integrant or an episomal HPV genome. Alternatively, disruption could occur in 
E2, in which case production of functional E2 protein is unlikely but detection of mRNA by 
qPCR is possible, depending on where the disrupted site is. Finally, the integration event could 
occur downstream of E2 in which case functional E2 protein might be produced. It is worth 
noting that two of the three clones with E7/E1 integration junctions did express some E2, 
albeit at low level which could reconcile with several of the above scenarios. For the other 
clone, the E2 qPCR assay failed which might correspond to an E2 integration event, or an 
integration event upstream of E2 which leads to its silencing. All integrants appear capable of 
translating full length, functional E6/E7 oncoprotein (Zheng and Baker, 2006).  
For clone H9, large changes in E2 expression at around p8 coincided with changes in 
methylation at both the E2 and L1/L2 regions. A significant difference in E2 expression and 
L1/L2 methylation was observed between the early and late H9 passages, suggesting an event 
occurred around p8/p9 that triggered the changes. Whilst both early and late passages had a 
detected E7/E1 integration junction, an additional E2/E4 integration was detected for the later 
passage and might be associated with changes in DNA methylation and E2 transcription that 
are difficult to explain. Genomic instability caused by aberrant oncogene expression for 
instance might have promoted HPV integration or recombination of existing integrants within 
the genome. This is supported by E6/E7 levels being the highest at p8/p9, the same passage at 
which a large decrease in E2 expression and large changes in DNA methylation occurred. 
Alternatively, both integration events could have existed in early passage, but the second 
integrant might have been repressed and not detected. In this instance, episomal clearance is 
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a suitably rapid event (W12Ser7) and could be responsible for both the increase in L1/L2 
methylation and the decrease in E2 expression after p8/9. 
7.2.3.4.6. Unusual Observations 
For clone P8, some methylation of the L1/L2 region was observed. L1 and L2 methylation was 
more typically associated with integrated HPV genomes (VR series, other clones, W12) 
(Kalantari et al., 2010) so in this instance APOT may have failed to detect an integration event. 
APOT does not detect transcriptionally silent integrants. 
Passage 11 of the D9 clone was an unusual observation, all mRNA levels dropped considerably 
whilst DNA methylation continued to rise. The drastic changes (i.e. 10 fold) over a short period 
of time make experimental error (i.e. mislabelling) a possibility or the changes might represent 
a repressive or selective event.  
The reduction in transcription for passage 12 of the Y8 clone and the subsequent increase in 
transcription for passage 13 are difficult to explain. They could coincide with the slight 
decrease in methylation, including LCR2 (promoter) methylation observed at passage 13. 
E2 expression data was not present for clone M8 because the qPCR reactions consistently 
produced a melting peak that was atypical of the E2 qPCR amplimer. It seemed likely that this 
was due to sequence diversity or deletion such that the melting temperature of amplimers was 
reduced. Integration in the E7/E1 region was seen at passage 5 but not at passage 9, this could 
be a selective loss of cells containing the integration event, silencing of the HPV sequence 
expressing the integration event or a failing of the APOT assay. 
 
7.3. Conclusions 
The CaSki results were useful in that our data could be compared against published data. Our 
observation of the distinctive pattern of CpG methylation in each region was also seen both in 
our data and published data. W12Ser7 work also allowed the CpG specific pattern of 
methylation in LCR1 to be compared to published data. For W12Ser7, we observed dramatic 
methylation changes at the onset of integration that appeared to be both due to clonal 
selection for integrant containing cells but also progressive hypermethylation of integrated 
HPV genomes after clonal selection. 
There were differences among the PC08/09 clones, and changes over time (passage). This was 
a contrast to our longitudinal CRISP study (Chapter 6: 6.1.2) where few changes with time were 
observed. There is some evidence to suggest that deregulation of the oncogenes might be an 
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early event which is then subsequently tightly regulated. This is in line with observations for 
W12 and our observation of positive correlation of E2/E6/E7 mRNA transcripts in short term 
culture cell lines. These observations might also be explained by disparity between mRNA 
transcript and protein level. 
There was reason to suspect that rather than causing oncogene deregulation, integration 
might be a consequence of chromosomal instability caused by another deregulating event. For 
these clones, methylation could be the cause of initial deregulation however we did not 
observe an immediately evident mechanism. Our initial hypothesis of E2BS hypermethylation 
occurring in instances where E2 disruption had not occurred was not present for any of the 
non-integrated clones, but may have been observed for clone Y8.  
Another hypothesis was that intragenic methylation might have an effect on gene expression. 
Whilst intragenic methylation of the E2 region was observed in conjunction with reduced E2 
expression, it was also observed in conjunction with reduced E6/E7 expression. Whether 
intragenic HPV methylation is associated with reduced gene expression is still unclear. In 
summary, the relationship between methylation, gene expression and HPV integration is 
complex.  
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Chapter 8. The VR Study - DNA Methylation, Integration and Gene 
Expression in vivo 
 
A large series of anogenital biopsies of varying histological grade and sample site were 
collected for this investigation (n=171). The primary aim was to acquire a series of HPV16 
positive VIN biopsies for which DNA methylation could be determined and compared to other 
aspects of HPV biology. HPV typing was performed initially for the purpose of selecting HPV16 
positive samples for further analysis however the large cohort of HPV typing data represented 
a large and novel VIN HPV typing study. 
As such, two main components of this study are presented. The first considers the HPV type 
distribution in VIN whilst the second considers the basic biology of HPV methylation and how it 
may relate to HPV gene expression and integration in vivo. 
 
8.1. Results - HPV Type Distribution in VIN 
This HPV distribution in VIN study was published (Bryant et al., 2011) (Appendix VII) however 
since publication, more samples were collected. HPV infection was identified using the Greiner 
Bio-One PapilloCheck assay which detects and types 24 different HPV types in a single reaction 
(HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 82, 6, 11, 40, 42, 43, and 
44). The assay includes a series of internal controls to identify false negative results. Only 
histologically confirmed VIN samples were used in this study. A  total of 62 VIN biopsies were 
eligible for inclusion in the type distribution study, 57 of which passed the internal controls 
and produced valid typing results. Of these, 46 were VIN3, 6 were VIN2 and 5 were VIN1. Four 
of the five samples that failed the assay were VIN3 whilst one was VIN1. 
8.1.1. HPV Type Distribution 
HPV infection was present in 43/57 cases (75.4%: 95% CI 62.9-84.7%), HPV16 and/or HPV18 
were present in 35/57 cases (61.4%: 95% CI 48.4-72.9%) and HPV16 and/or HPV18 were the 
only types present in 27/57 cases (47.4%: 95% CI 35.0-60.1%). HrHPV types were present in 38 
cases and LrHPV types in eight cases, three of these cases contained both HrHPV and LrHPV 
types. The typing distribution is presented in Table 8.1. 
Nine cases had multiple HPV types present, one was a VIN1 sample with HPV18, 42 and 44/55 
present whilst the others were all VIN3 samples. The VIN3 samples had the following 
combinations of types; two cases had HPV16 and HPV82, and there was one case each of the 
following combinations: (16, 18), (16, 33), (16, 6), (16, 31, 33), (16, 51), (16, 82, 6). 
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Of the five cases with LrHPV only, three cases contained HPV6 (one VIN2, one VIN3 and one 
VIN3 with well differentiated carcinoma and viral warts) and the other two cases were VIN1 
lesions with HPV40 or HPV42. 
 
 
HPV type 
Histology HPV-ve HPV+ve 16 18 31 33 51 82 6 40 42 44/45
*1
 
VIN1 1 4 0 1 0 1 0 0 0 1 2 1 
VIN2 3 3 2 0 0 0 0 0 1 0 0 0 
VIN3 10 36 32 1 1 4 1 3 4 0 0 0 
Total 14 43 34 2 1 5 1 3 5 1 2 1 
% 24.6 75.4 59.6 3.5 1.8 8.8 1.8 5.3 8.8 1.8 3.5 1.8 
Table 8.1: HPV type distribution of VIN.  
There were 9 cases showing multiple infection, hence the number of types identified is greater than 
the number of cases. HPV+ve = HPV positive, HPV-ve = HPV negative. Percentages indicate the 
proportion of cases that tested positive for a given type. *1: The HPV44 probe cross-hybridises to 
HPV45, hence these types are reported together. 
 
8.1.1.1. Hypothesis 1: There is a Relationship between HPV Status and Age 
HPV positive cases were aged 22-81 (mean=45.0) and HPV negative cases were aged 33-82 
(mean=55.2). A two-sample T-test showed a significant difference between the mean ages of 
the HPV positive and negative groups (P=0.022). 
8.1.1.2. Hypothesis 2: There is a Relationship between HPV Status and 
Histology 
39/43 (90.7%) HPV positive cases had VIN2/3 whilst 13/14 (92.8%) HPV negative cases had 
VIN2 or higher. The proportion of cases with VIN2 or higher was not significantly associated 
with HPV positivity (Fisher’s exact test, P=1.000). Interestingly, all HPV16 positive cases were 
associated with VIN2 or worse. 
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8.2. Results - HPV DNA Methylation, Integration and Gene Expression 
Of the samples used for the assessment of HPV type distribution in VIN, 53 were biopsy 
samples from which both DNA and RNA were extracted, these samples were termed the VIN 
RNA (VR) series. From this series of biopsies, HPV16 containing samples (n=31) were selected 
for further study. Methylation and/or gene expression data were produced for 28 samples 
which comprised of mostly VIN3 (n=21), a small proportion of VIN2 (n=3), one VAIN3, one AIN2 
and two samples without histologically confirmed disease. Patient age ranged from 22-81 
years (mean = 46 years) The analysis of the HPV16 positive VR series samples was conducted 
by considering in a sequential manner, HPV integration status, HPV gene expression status and 
finally HPV methylation status in order to generate and test a series of hierarchical hypotheses. 
The study aimed to both determine the status of these three characteristics in the VIN series, 
but also to determine the relationships between the characteristics and with other variables 
within the data set. 
8.2.1. HPV DNA Integration 
DIPS was performed on all HPV16 positive VR series DNAs (n=31). In order to improve the 
negative predictive value of DIPS, the protocol was later changed such that a series of control 
PCRs were performed to check for DNA quality and samples that failed these controls were not 
analysed further. However, data for this study was collected prior to the protocol changes and 
several samples failed the DIPS controls but had detectable integration events. Four sample 
groups were generated based on the result of the control PCRs and the presence/absence of 
detected integration events (Table 8.2). For the purpose of investigating a relationship 
between HPV DNA integration and other characteristics of HPV biology, the X1 and 1 groups 
were frequently combined and groups were referred to as groups X, 0 and 1 only. 
 
 Detected integration events No detected integration events 
Control PCR(s) passed Group 1 (n=6) Group 0 (n=9) 
Control PCRs failed Group X1 (n=2) Group X (n=14) 
Table 8.2: The assignment of integration group based on the passing/failing of control PCRs and the 
detection/non-detection of integration events.  
Samples were entered into the control PCR(s) passed groups if a control PCR reaction was successful 
for the TaqI or Sau3AI digested DNAs. Samples that failed both PCRs were entered into the control 
PCRs failed groups. The number of samples that fell into each group (n) has been included.  
 
Out of 31 samples analysed by DIPS, the failure rate of the control PCRs was high (n=16, 
51.6%). Excluding those in the X1 group (Table 8.2), 6 of the remaining 15 samples that passed 
the control PCRs had detected integration events (40%). Details of the integration events, 
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including a list of the disrupted HPV genes and the region of the human genome where 
integration occurs have been summarised in Table 8.3. It was impossible to ascertain exactly 
where in the human genome the HPV16 in sample VR42 was integrated without using 
alternative assays. The VR42 human integration sequence identified corresponded to a 
satellite DNA repeat HSATII that is found in multiple locations throughout the human genome. 
Sample Gene disrupted Disruption (bp) Human genome region 
VR24 E1 1,540 Chr8 (q24.21)  
VR32 E2 3,348 Chr2 (q35) 
VR37 E2 & L2 3,161 & 4,917 Chr1 (q32.1) 
VR39 E1 1,786 Chr1 (p36.22)  
VR42 L2 4,910 Satellite DNA* 
VR44 E2 3,166 Chr17 (q24.3)  
VR46 E1 2,508 Chr9 (q21.31)  
VR53 L2 4,989 Chr3 (q26.31)  
Table 8.3: Summary of the detected integration events for the VR series.  
Gene disrupted refers to the HPV16 gene where the integration event occurs. Disruption (bp) gives 
the integration site into the HPV genome. Human genome region refers to the chromosome number 
and band number of the area of the human genome that has been detected in the integration events. 
*Homology was found to HSATII satellite DNA in Chr7, Chr22, Chr2, Chr16, Chr10 and ChrY. 
 
VR37 had two detected integration sites. Whilst two HPV regions were disrupted (E2 and L2), 
both events were within the same region of the human genome and close together. The 
events were facing in opposite directions so rather than representing two separate integration 
events, it likely represented the detection of one integration event (with a deletion between 
E2 and L2) by two DIPS primer sets. 
 
8.2.1.1. Hypothesis 3: There is a Relationship between HPV Integration and 
Patient Age 
A previous study observed a relationship between patient age and integration status 
(Vinokurova et al., 2008). Whilst the sample number in this study was relatively low, the 
hypothesis can still be tested for the data set. The patient age data was divided into the three 
integration groups (0, 1 and X) and compared to determine whether the mean age of each 
group differed significantly. The untransformed age data satisfied the assumptions of the one-
way ANOVA and the means of the three integration groups were compared. There was not a 
statistically significant difference between the mean patient age of each integration group 
(one-way ANOVA P=0.917). In summary, a relationship between integration status and patient 
age was not identified. 
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Figure 8.1: Patient age distribution of the VR series, separated by DNA integration status.  
Red circles represent individual patient ages, the bars represent the mean age of each group and the 
blue error bars are 95% confidence intervals for mean. 
 
8.2.2. HPV Gene Expression 
RNAs from the VR series were analysed by E2, E6, E7, HPRT and TBP qPCR assays, relative 
quantification was performed using the equation described by Vandesompele et al 
(Vandesompele et al., 2002). 
8.2.2.1. Hypothesis 4: There is Variation in RQ among Samples 
For the VR series as a whole, the three assays had a similar mean Log10 RQ (E2 = -0.657, E6 = -
0.498 and E7 = -0.608), however variation in RQ among the samples was considerable (Figure 
8.2). The VR series had a large 8.5 Log10 range (i.e. 10
8.5 = 316 million fold difference in RQ) 
between the highest and lowest E2 expressing samples (Log10 E2 RQ ranges from -6.70 to 
+1.78). Similarly, there was a 4.7 Log10 range (i.e. 10
4.7 = 50 thousand fold difference in RQ) for 
E6 RQ (Log10 E6 RQ ranges from -3.16 to +1.54) and a 5.1 Log10 range (i.e. 10
5.1 = 126 thousand 
fold difference in RQ) for E7 RQ (Log10 E7 RQ ranges from -3.92 to +1.18). The skewed 
distribution of the RQ data was highly unsuitable for multifactorial ANOVA GLM analysis and 
such analyses were not performed. 
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Figure 8.2: Log10 Relative quantification expression ratios (Log10 RQ) for the E2, E6 and E7 genes of the 
VR series.  
The ratios are expressed relative to CaSki as a calibrator sample (CaSki has a log10 RQ of zero for each 
assay). 
 
8.2.2.2. Hypothesis 4: There is Variation in RQ among Assays 
The qPCR data was unsuitable for multifactorial ANOVA so a non-parametric alternative was 
used. Friedman’s test compares median values of data with respect to two factors (i.e. qPCR 
assay and sample). The Freidman’s test requires a single result for each combination of factors 
and no missing sample data. Freidman’s test was performed on the Log10 RQ values presented 
in Figure 8.2 with the exception of samples where one or more RQ value was missing (i.e. 
VR04, VR38, VR44, VR45, VR50 and VR53). 
There were significant differences in median RQ among the VR series samples (P=0.000) and 
among the three assays (P=0.001) meaning that RQ among the samples varied significantly, 
but also that the median RQ values of the three gene expression assays were different. 
 
8.2.2.3. Hypothesis 5: There is a Relationship between gene Expression and 
HPV Integration 
To determine whether or not a relationship existed between gene expression (RQ) and HPV 
DNA integration status the data was divided into testable groups. The RQ ratios of samples 
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falling into the three integration groups, X (sample inadequate), 0 (sample adequate, no 
detected integration) and 1 (detected integration) were then compared statistically. 
The RQ data when separated with respect to qPCR assay and integration group were highly 
unsuitable for any of the multifactorial ANOVAs or non-parametric alternatives. Instead, 
multiple single factor Kruskall-Wallis tests were used with a Bonferroni corrected P-value 
(P=0.017). There were no significant differences among the median RQ values for integration 
group. 
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Figure 8.3: The Log10 RQ values of the VR series for each qPCR assay, separated by integration status 
group.  
Group 0 had no detected integration, group 1 had detected integration and group X were samples 
inadequate for integration analysis. Bars represent group means, red circles represent individual data 
points and blue bars are 95% confidence intervals. 
 
Another approach was taken to compare just the adequate group 0 (no integration detected) 
and group 1 (integration detected) samples using multiple Mann-Whitney U tests. These tests 
compared the median RQ values for each qPCR assay. Again, no significant difference was 
observed between the median Log10 RQ data for samples with and without detected 
integration events for any of the three qPCR assays (Mann-Whitney U test; E2 (P=0.444), E6 
(P=0.637) and E7 (P=0.666)). 
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As various HPV integration sites existed, a potential relationship between HPV genome 
integration site and gene expression in individual samples was investigated. There appeared to 
be wide variation in the RQ ratio of samples with integration events in similar areas of the 
HPV16 genome. Compared to the VR series mean, RQ of the integrated samples varied 
considerably (Figure 8.4) and there did not appear to be a clear relationship between HPV 
integration site and HPV gene expression (Table 8.4). 
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Figure 8.4: Gene expression Log10 RQ values for the VR series integration group 1 samples.  
A different graph pane is present for each gene expression assay, each bar represents Log10 RQ for 
that sample. The horizontal black line represents the mean RQ for all samples (not just integrated) 
and is shown to aid the interpretation of Table 8.4. 
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Integration Difference in Log10 from VR series mean 
Sample 
Gene 
disrupted ΔLog10 E2RQ ΔLog10 E6RQ ΔLog10 E7RQ 
VR24 E1 -1.38 (V low) -0.01 (Average) 0.24 (Above average) 
VR32 E2 2.43 (VV high) 2.04 (VV high) 1.78 (V high) 
VR37 E2 & L2 -3.18 (VV low) 0.33 (Above average) 0.48 (High) 
VR39 E1 0.34 (Above average) 0.04 (Average) 0.19 (Above average) 
VR42 L2 0.6 (High) -0.25 (Below average) 0.1 (Average) 
VR44 E2 * 0.12 (Average) 0.33 (Above average) 
VR46 E1 -2.11 (VV low) -0.25 (Below average) -0.16 (Below average) 
VR53 L2 * -0.09 (Average) -0.11 (Average) 
Table 8.4: The difference in E2, E6 and E7 RQ of the integrated VR series samples compared to the 
mean gene expression of the VR series.  
ΔLog10 RQ represents sample mRNA level minus VR series mean mRNA level and is used to quantify 
expression level statements. Colour coding is used to aid interpretation and is based on the difference 
from the mean (ΔLog10 RQ ): VV high (>2), V high (>1<2), High (>0.4<1), Above average (>0.15<0.4), 
Average (0 +/- 0.15), Below average (<-0.15>-0.4), Low (<-0.4>-1), V low (<-1>-2), VV low (<-2). * 
missing data. 
 
8.2.2.4. Hypothesis 6: The Relationship between E2, E6 and E7 Expression 
Might Coincide with an Accepted Model of Gene Regulation 
Relative quantification of Ct values accounts for variation in input cDNA and ratios are 
calibrated against CaSki gene expression Ct values. Equal RQ ratios between assays therefore 
represents an mRNA level ratio between the assays (i.e. E2:E6, E6:E7 etc) similar to that in 
CaSki rather than equal E2, E6 and E7 mRNA level. Nonetheless, comparison of RQ ratios for 
one VR sample with mRNA counts from deep sequencing suggested that RQ ratios were fairly 
indicative of true mRNA level (Chapter 4: 4.1.4.1). The relationship between E2, E6 and E7 RQ 
and the results of Spearman’s rank correlation analysis are presented in Figure 8.5 and Table 
8.5 respectively. E2, E6 and E7 RQ were strongly positively correlated, as per the PC08 and 
PC09 clones. 
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Figure 8.5: The relationship between E2, E6 and E7 gene expression is explored using scatter plots of 
ranked data.  
The data presented are ranked RQ, the relationship being presented is indicated by the plot header, 
i.e. E2*E6 represents E2 RQ ranks on the Y-axis and E6 RQ ranks on the X-axis. Both individual values 
(red circles) and linear regression lines (blue lines) are included. 
 
 E2 RQ vs. E6 RQ E2 RQ vs. E7 RQ E6 RQ vs. E7 RQ 
Spearman's rank correlation coefficient +0.641, P= 0.013 +0.824, P= 0.000 +0.909, P=0.000 
Table 8.5: The results of Spearman’s rank correlation analyses on the ranked gene expression data for 
E2, E6 and E7. 
Included are both the Spearman’s rank correlation coefficients and the P-value. Correlation is 
considered significant at P=<0.05. 
 
 
8.2.3. DNA Methylation 
8.2.3.1. Hypothesis 7: There is Variation in the Amount of DNA Methylation 
among Samples and among Regions 
DNA methylation at the E2, LCR1, LCR2 and L1/L2 regions was assessed. The mean amount of 
DNA methylation of each region, for each VR sample is shown in Figure 8.6. There was 
considerable variation in the amount of methylation among the VR samples and the level of 
methylation varied with region of the HPV16 genome (Figure 8.7). Methylation of the E2 
region was especially variable, whilst the mean E2 methylation was 16.5%, E2 methylation 
ranged from 1.2-89.7% between the least and most methylated samples. The L1/L2 region was 
similarly variable, mean L1/L2 methylation was 24.5% however a large range of 1.6-88.0% was 
observed. The LCR1 and LCR2 LCR regions were considerably less variable. The mean amount 
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of methylation at the LCR1 region was 2.6% with a narrow range of 1.0-4.7%. Similarly the 
mean for the LCR2 region was 1.3% with a small range of 0.0-4.3%. In summary, the E2 and 
L1/L2 regions were the most variable whilst the LCR1 and LCR2 regions of the HPV16 LCR were 
universally hypomethylated (Figure 8.7). 
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Figure 8.6: DNA methylation of HPV16 in the VR series.  
Coloured bars represent mean DNA methylation for each region of the HPV16 genome for the VR 
series. 
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Figure 8.7: VR series mean methylation at each HPV16 region. 
Bars represent the mean amount of methylation at each site for the entire VR series. The graph 
includes 95% confidence intervals for the mean (blue bars) and the level of methylation of each 
individual VR sample (red circles).  
 
A two-way ANOVA GLM was used to test for a significant difference in mean DNA methylation 
among samples and each HPV region. One violation of the assumptions of the two-way ANOVA 
was present, the variances were unequal (Bartlett’s P=0.000) however no suitable non-
parametric alternative exists. There was a significant difference in mean DNA methylation 
among the regions (P=0.000) but not among the samples (P=0.189).  
 
8.2.3.2. Hypothesis 8: There is CpG Specific Variation within Each Site 
Previous chapters reported a variation in the methylation of each CpG within each HPV region. 
CpG specific differences were also conserved between sample cohorts such that patterns of 
methylation were discernible, especially for the L1/L2 region where an “N” shaped profile was 
observed. It was of interest to consider whether or not a similar scenario existed for the VR 
series. 
There appeared to be a somewhat conserved pattern of CpG methylation for the VR series E2 
region (Figure 8.8). CpG E2-3 tended to be the lowest methylated in most samples and had the 
lowest mean methylation of all of the E2 CpGs (12.7%). E2-4 was the highest methylated in 
most samples and also had the highest mean methylation (20.3%), in two instances E2-4 was 
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almost 100% methylated. E2-1 and E2-2 were quite closely matched and in general, there was 
a decrease in methylation between CpGs E2-4 and E2-8. This was not paralleled perfectly by 
the E2 CpG methylation pattern of the PC08 and PC09 cell line clones but there were some 
similarities (e.g. a decrease between E2-4 and E2-8). 
For the LCR1 region, whilst the overall values were fairly low, there appeared to be a general 
decline in DNA methylation between LCR1-1 and LCR1-3 (Figure 8.9). This was the same as was 
observed for some previous studies.  
For the LCR2 region, there was an “M” shaped profile to many of the methylation curves, i.e. 
DNA methylation of LCR2-1, LCR2-3 and LCR2-5 was low whilst DNA methylation of LCR2-2 and 
LCR2-4 was higher (Figure 8.10). A similar pattern was observed for some of the PC08 and 
PC09 passage 9 cell line samples.  
The distinctive “N” shaped CpG methylation profile of L1/L2 was highly reminiscent of the 
L1/L2 methylation profile of other cohorts. Particularly fascinating about this methylation data 
was that the L1/L2 CpGs are all within 17 bp of each other yet varied considerably. VR51 for 
instance (Figure 8.11) had large differences among CpGs; not only was there a difference of 
45% between CpGs L1L2-1 and L1L2-4, but there was a 27.5% difference in DNA methylation 
between L1L2-2 and L1L2-3, two CpGs that are separated by only 1 bp. 
In order to attempt to confirm statistically the observation of considerable variation in the 
methylation of different CpGs and of different HPV regions, a two-way ANOVA GLM was 
applied. Several violations of the two-way ANOVA GLM occurred, the standardised residuals 
were not normally distributed (Anderson Darling P<0.005) and the variances were not equal 
(Bartlett’s P=0.000). As no suitable non-parametric alternative exists, the two-way ANOVA 
GLM was performed anyway. A significant difference among the means was observed for both 
HPV DNA region (P=0.000) and CpG (P=0.000), confirming the observations of variation in the 
methylation data. 
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Figure 8.8: E2 DNA methylation profile for the VR series.  
Each symbol represents a different VR sample. No relationship is inferred by the connecting lines 
between points; they are included only to improve interpretation of the figure data. 
 
 
Figure 8.9: LCR1 DNA methylation profiles for the VR series.  
Each symbol represents a different VR sample. No relationship is inferred by the connecting lines 
between points; they are included only to improve interpretation of the figure data. 
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Figure 8.10: LCR2 DNA methylation profiles for the VR series.  
Each symbol represents a different VR sample. No relationship is inferred by the connecting lines 
between points; they are included only to improve interpretation of the figure data. 
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Figure 8.11: L1/L2 DNA methylation profiles for the VR series.  
Each symbol represents a different VR sample. No relationship is inferred by the connecting lines 
between points; they are included only to improve interpretation of the figure data. 
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8.2.3.3. Hypothesis 9: There is a Relationship between DNA Methylation and 
HPV DNA Integration 
One of the most important questions that needed to be asked of the methylation data was 
whether or not the amount of DNA methylation could be associated with HPV16 integration 
into the host genome. Previous studies have found an association between DNA methylation 
and DNA integration whereby integrated genomes were typically hypermethylated, especially 
within the L1 region (Kalantari et al., 2008b).  
The VR samples were separated into the three integration groups previously described; group 
1 (detected integration events), group 0 (no detected integration events) and group X (sample 
inadequate for analysis). A notable characteristic of the VR samples with high DNA methylation 
(i.e. over 30%) at E2, L1/L2 or both E2 and L1/L2 was that they all had detected integration 
events. The relationship between DNA methylation and HPV integration of the VR series can 
be seen in Figure 8.12.  
The association between DNA methylation and HPV DNA integration appeared to be complex 
and there were considerable differences in the methylation profiles of integrated samples. 
Some samples had hypomethylation of both E2 and L1/L2, some had hypermethylation of E2, 
some samples had hypermethylation of L1/L2 whilst others had hypermethylation of both E2 
and L1/L2. It is worth noting that sample VR24 was the only sample not run through the L1/L2 
assay and that sample VR37 failed the E2 assay repeatedly. 
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Figure 8.12: DNA methylation of the VR series with integration state.  
Samples with detected integration events are highlighted in yellow. 
 
In order to explain the different DNA methylation profiles within the integrated samples, the 
site of disruption of the HPV genome was compared to the site of HPV hypermethylation. 
Table 8.6 lists both the hypermethylated genes (hypermethylation defined in this instance by 
>30% methylation) and the genes disrupted by HPV integration for the group 1 samples. A 
possible relationship existed between disruption site and hypermethylation site. Samples with 
E1 disruption (VR39 and VR46) had hypermethylation at both the E2 and L1/L2 regions; VR24 
also had E1 disruption and E2 hypermethylation however the L1/L2 result was missing. E2 
disruption for the VR44 sample was accompanied by L1/L2 hypermethylation and E2 
hypomethylation whilst conversely, L2 disruption for VR53 was accompanied by the exact 
opposite, E2 hypermethylation and L1/L2 hypomethylation. VR37 was a particularly interesting 
case because multiple integration events were detected (possibly due to deletion) and whilst it 
had failed the E2 assay repeatedly, the L1/L2 region was hypermethylated. Samples VR42 and 
VR32 may have had HPV present in both integrated and episomal forms; episomal HPV16s are 
typically maintained in very high copy number (Doorbar, 2006) and here, were lowly 
methylated. If VR42 and VR32 contain both integrated and episomal HPV this would allow for 
both the detection of integration for the DIPS assay and the observation of very low levels of 
DNA methylation with the quantitative pyrosequencing assay. 
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  Hypermethylation 
Sample Gene disrupted E2 L1/L2 
VR24 E1 Yes * 
VR32 E2 No No 
VR37 E2 & L2 * Yes 
VR39 E1 Yes Yes 
VR42 L2 No No 
VR44 E2 No Yes 
VR46 E1 Yes Yes 
VR53 L2 Yes No 
Table 8.6: Details of the disrupted HPV16 gene for the integrated VR samples along with the regions of 
hypermethylation. 
Hypermethylated regions are highlighted yellow. Samples showing both E2 and L1/L2 
hypomethylation are highlighted grey. * Data missing. 
 
8.2.3.3.1. Statistical Comparison of the Integration Groups 
To determine whether or not a relationship existed between DNA methylation and HPV DNA 
integration status, DNA methylation of the three integration groups was compared. Mean 
methylation of the E2 and L1/L2 regions appeared higher for the integrated group than other 
groups however there was variation in all groups (Figure 8.13). 
The mean methylation data was not quite suitable for analysis using a two-way ANOVA GLM 
for integration group and pyrosequencing assay as factors (Anderson Darling P=0.028, 
Bartlett’s test for equal variances P=0.000). However, because no non-parametric equivalent 
of the two-way ANOVA GLM exists that is capable of analysing data of an unbalanced design, 
with missing values and with repeated data, the two-way ANOVA GLM was used under the 
premise that the results were interpreted with caution. The two-way ANOVA GLM found that a 
significant difference in mean methylation existed as a consequence of both the region being 
tested (i.e. E2, LCR1, LCR2 and L1/L2; P=0.000) and the integration status (i.e. 0, 1 and X; 
P=0.006). As the GLM does not permit pairwise comparison, multiple one-way ANOVAs were 
used. Multiple analyses should be accompanied by a Bonferroni correction, however in this 
instance the investigation was hypothesis generating and so the usual level of significance 
(P=0.05) was also considered for interpretation. 
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Figure 8.13: Mean DNA methylation of each region for the VR series separated by integration group.  
Bars represent mean methylation, symbols represent individual samples and error bars represent 95% 
confidence intervals. 
 
First, the difference in mean methylation of the various integration states was compared for 
each of the pyrosequencing assays. For mean E2 methylation, there was a significant 
difference in mean methylation between each integration group as whole (one-way ANOVA 
P=0.024). Pairwise comparisons however revealed that there was not quite a significant 
(Tukey-Kramer at P=0.05) difference in mean methylation between the integration detected 
(1) and no integration detected (0) groups, but there was a significant difference between 
groups 1 and X. 
For the L1/L2 region, a significant difference existed among the mean L1/L2 methylation of the 
three integration groups (one-way ANOVA P=0.040) however pairwise comparison yielded 
similar results to the E2 comparison; there was not quite a significant (Tukey-Kramer at 
P=0.05) difference between groups 1 and 0, there was a significant difference between groups 
1 and X. This is difficult to explain, but seems likely the result of small sample number and the 
presence of region specific hyper/hypomethylation of the integrated samples. This further 
promotes the concept of a complex relationship between HPV DNA methylation and 
integration. Finally, there was no significant difference between the mean methylation of the 
three integration groups for the LCR1 region (P=0.260) or the LCR2 region (P=0.201). Pairwise 
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comparison by Tukey-Kramer revealed that none of the groups were significantly different 
from each other. The Bonferroni corrected P-value for these comparisons was P=0.0125. 
Integration appeared to be highly associated with DNA methylation for the VR series; 
therefore, for future analyses it was worth considering the relationship of DNA methylation 
with other biological factors both with and without the integrated samples included in the 
analysis. 
 
8.2.3.4. Hypothesis 10: There is a Relationship between DNA Methylation and 
Gene Expression 
A simple but limited way to determine whether a relationship exists between two quantitative 
factors is to perform correlation analysis. In this study, the correlation between the amount of 
HPV DNA methylation at each genomic site and the expression of the E2, E6 and E7 genes was 
tested. Previously, integration status was seen to be associated with hypermethylation of E2 
and L1/L2 but not with gene expression. As such, the analysis was performed several times, 
once with integrated samples included, once with the integrated samples excluded and once 
with the integrated samples alone. This was performed to isolate the effects of integration 
from the relationship between DNA methylation and gene expression. 
Spearman’s rank correlation analysis was performed on the ranked E2, LCR1, LCR2 and L1/L2 
mean methylation data and on the E2 RQ, E6 RQ and E7 RQ gene expression data (Table 8.7). 
Several significant correlations were observed.  
A significant negative correlation between L1/L2 methylation and E2 expression existed when 
all samples were considered and was conserved when the integrated samples were excluded 
from the analysis. There was a significant negative correlation between E2 methylation and E7 
expression for all samples however this was lost when the integrated samples were excluded. 
When considering the integrated samples alone, a significant negative correlation was 
observed between E2 methylation and E2 RQ. However, for the integrated samples alone 
results must be interpreted with caution as the sample number was very small and an 
association between gene expression and integration might confound any observed 
correlation. 
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Including integrated (group 1) samples 
 
E2 
methylation 
LCR1 
methylation 
LCR2 
methylation 
L1/L2 
methylation 
E2 RQ P= 0.201 P= 0.720 P= 0.667 P= 0.003 
  -0.327 -0.081 -0.095 -0.649 
E6 RQ P= 0.485 P= 0.814 P= 0.671 P= 0.619 
  -0.171 -0.051 0.089 -0.115 
E7 RQ P= 0.018 P= 0.900 P= 0.905 P= 0.121 
  -0.55 0.028 0.026 -0.359 
Table 8.7.a 
 
Excluding integrated (group 1) samples 
 
E2 
methylation 
LCR1 
methylation 
LCR2 
methylation 
L1/L2 
methylation 
E2 RQ P= 0.220 P= 0.659 P= 0.444 P= 0.044 
  0.382 -0.12 -0.199 -0.545 
E6 RQ P= 0.484 P= 0.996 P= 0.929 P= 0.336 
  0.224 0.001 0.024 -0.278 
E7 RQ P= 0.671 P= 0.765 P= 0.791 P= 0.151 
  -0.145 0.084 -0.072 -0.422 
Table 8.7.b 
 
Integrated samples (group 1) alone 
 
E2 
methylation 
LCR1 
methylation 
LCR2 
methylation 
L1/L2 
methylation 
E2 RQ P= 0.029 P= 0.892 P= 0.852 P= 0.275 
  -0.916 -0.072 0.099 -0.61 
E6 RQ P= 0.439 P= 0.408 P= 0.468 P= 0.613 
  -0.352 -0.342 0.301 0.234 
E7 RQ P= 0.276 P= 0.601 P= 0.468 P= 0.803 
  -0.145 0.084 -0.072 -0.422 
Table 8.7.c 
Table 8.7.a-c: The results of Spearman’s rank correlation analysis of the DNA methylation data for all 
VR samples with and without the group 1 integrated samples included.  
P-values are significant at P<0.05. Included are the Spearman’s rank correlation coefficients for each 
comparison. Significant results are highlighted in yellow. 
 
When these significant relationships were presented graphically, there were some interesting 
observations (Figure 8.14). The three comparisons where a significant relationship was 
observed are included (E2 methylation vs. E7 RQ, E2 methylation vs. E2 RQ and L1/L2 
methylation vs. E2 RQ) and the figure includes the data points of all of the integration group 
samples for reference purposes.  
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8.2.3.4.1. E2 Methylation vs. E7 Gene Expression 
This relationship was only deemed significant when all of the VR series were included for 
analysis. The integrated samples were the most variable in both gene expression and DNA 
methylation (Figure 8.14). E2 DNA methylation and E7 gene expression of the remaining 
samples was considerably less variable and the correlation was lost if the group 1 samples 
were excluded or analysed alone. 
8.2.3.4.2. E2 DNA Methylation and E2 Gene Expression 
A significant correlation between E2 DNA methylation and E2 gene expression was only 
observed for the integrated samples. There appeared to be a linear relationship present for 
these samples whereas for the group 0 and group X samples there was no discernible 
relationship present (Figure 8.14). E2 DNA methylation might be associated with E2 gene 
expression when HPV has integrated into the host genome. 
8.2.3.4.3. L1/L2 DNA Methylation vs. E2 Gene Expression 
For the comparisons with and without integrated samples, a significant correlation was 
observed between L1/L2 methylation and E2 RQ. A particularly interesting observation for this 
comparison was that the integrated samples occupied the extremes of both high DNA 
methylation and low/very high gene expression (Figure 8.14). The integrated samples 
appeared to be varied whilst the relationship for the group 0 and group X samples was more 
linear (as determined by Spearman’s rank) and over a narrower range. 
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Figure 8.14: Scatter plots of the significant correlations (as determined by Spearman’s rank) between 
HPV DNA methylation and HPV gene expression. 
Three comparisons are presented, E2 mean DNA methylation vs. Log10 E7 RQ, E2 mean DNA 
methylation vs. Log10 E2 RQ and L1/L2 mean DNA methylation vs. Log10 E2 RQ. The data presented 
includes all three integration groups (0, 1 and X) in order to see the differences among the groups 
where a significant relationship was observed for some groups and not others. The X-axis scale of the 
three scatter plots differs as a result of some samples having various missing DNA methylation or 
gene expression RQ values. 
 
8.2.3.5.   Further Analysis of the HPV DNA Methylation and Gene 
Expression 
The correlation analyses hinted at a relationship between DNA methylation and gene 
expression, however a more informative and robust approach to the analysis might be gained 
using ANOVA tests. The RQ data had a very large range and the distribution was highly skewed, 
non-parametric and very unsuitable for ANOVA. As such, a more suitable way of analysing a 
potential relationship between gene expression and DNA methylation was to divide the gene 
expression data (i.e. RQ) into groups and determine whether a relationship between RQ group 
and DNA methylation existed.  
Various ways of dividing the data were considered, initial attempts used the mean of the VR 
series and a range of values above and below the mean to generate the groups. This however 
meant that very large negative values affected the grouping, the grouping was subjective and 
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the groups were not representative of the sample distribution. Instead, the RQ data for each 
assay was divided by quartile group (i.e. RQ data were divided into four equal groups to make 
the 1st, 2nd, 3rd and 4th quartiles (Q1, Q2, Q3 and Q4 respectively)). As per previous analyses, 
statistical analysis was performed multiple times, once with integrated samples included and 
again with integrated samples excluded. This was in order to factor into the interpretation a 
potential association between HPV methylation and integration. 
 
8.2.3.5.1. Integrated Samples Included Analysis 
With the VR samples separated into gene expression RQ quartiles, statistical analysis was 
undertaken to determine a relationship between gene expression and DNA methylation. The 
DNA methylation data could not be transformed to an acceptable degree for use in a 
multifactorial ANOVA GLM. Instead, the data was separated by region (i.e. E2, LCR1, LCR2 and 
L1/L2) and assessed by one-way ANOVAs with Tukey-Kramer pair wise comparisons (i.e. one 
ANOVA for E2 RQ and E2 methylation, another for E2 RQ and LCR1 methylation etc). The 
nature of this investigation was exploratory and hypothesis generating so the Bonferroni 
correction was used during interpretation of the statistics however significance at P=0.05 was 
also considered. The samples were separated by RQ quartile for each gene expression assay 
and DNA methylation of each quartile was compared graphically and statistically. This data is 
presented in Figure 8.15, Figure 8.16, Figure 8.17 and Figure 8.18. 
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Figure 8.15: DNA methylation of the VR series E2 region, separated by gene expression assay and by 
RQ quartile. 
* Represents those samples where the gene expression assays have failed to produce an RQ result. 
Bars represent the mean methylation and 95% confidence intervals are included. 
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Figure 8.16: DNA methylation of the VR series LCR1 region, separated by gene expression assay and by 
RQ quartile. 
* Represents those samples where the gene expression assays have failed to produce an RQ result. 
Bars represent the mean methylation and 95% confidence intervals are included. 
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Figure 8.17: DNA methylation of the VR series LCR2 region, separated by gene expression assay and by 
RQ quartile. 
* Represents those samples where the gene expression assays have failed to produce an RQ result. 
Bars represent the mean methylation and 95% confidence intervals are included. 
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Figure 8.18: DNA methylation of the VR series L1/L2 region, separated by gene expression assay and 
by RQ quartile.  
* Represents those samples where the gene expression assays have failed to produce an RQ result. 
Bars represent the mean methylation and 95% confidence intervals are included. 
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8.2.3.5.1.1. E2 Methylation 
For the E2 region, there appeared to be a relationship between E2 methylation and RQ 
quartile for both E2 RQ and E7 RQ (Figure 8.15). There was a pronounced decrease in mean 
methylation between Q1 and Q2/Q3/Q4 for E2 RQ and a progressive decrease from Q1 to Q4 
for E7 RQ. There were however large confidence intervals for many of the quartile groups so 
these relationships needed to be confirmed statistically. 
For several comparisons by one-way ANOVA, some assumptions of the test were violated. It 
was felt that using the one-way ANOVA instead of Kruskall-Wallis tests followed by multiple 
Mann-Whitney U tests would be more informative. Nonetheless, the results were interpreted 
with caution. Table 8.8 contains the results of one-way ANOVA tests to determine differences 
in E2 DNA methylation between the E2, E6 and E7 RQ quartiles. Violations of the ANOVA are 
listed in the figure legend. There was a significant difference (significant at Bonferroni 
corrected P=0.006) in E2 DNA methylation among the samples in the various E2 RQ and E7 RQ 
quartiles, but not the E6 RQ quartiles. Pairwise comparisons reinforce the observation, for E2 
RQ, a significant difference was observed between Q1 and Q2/Q3/Q4. Similarly, for E7 RQ, 
significant differences in E2 DNA methylation were observed between Q1 and Q3, Q1 and Q4 
and Q2 and Q4; again reinforcing the general decline in E2 DNA methylation observed with 
increasing E7 transcription. 
In summary, samples expressing the least E2 mRNA had a significantly higher level of E2 DNA 
methylation which might signify an effect of intragenic methylation. Nonetheless, as E2 DNA 
methylation increased, E7 expression also decreased. The Spearman’s rank correlation analysis 
performed previously found a significant relationship between E2 DNA methylation and E7 
expression, but not between E2 DNA methylation and E2 expression. The relationship between 
DNA methylation and gene expression appears more complex than a simple linear correlation. 
 
 With integrated samples included 
Significant Tukey-
Kramer 
 E2 DNA methylation comparisons (P<0.05) 
vs. E2 RQ P=0.002*1 1 vs. 2, 1 vs. 3, 1 vs. 4 
vs. E6 RQ P=0.062 None 
vs. E7 RQ P=0.005*2 1 vs. 3, 1 vs. 4, 2 vs. 4 
Table 8.8: The results of multiple one-way ANOVA tests with Tukey-Kramer pairwise comparisons.  
Violations of the one-way ANOVA assumptions: *1, non-normally distributed residuals (Anderson 
Darling P=0.008) and unequal variances (Bartlett’s P=0.000); *2, unequal variances (Bartlett’s 
P=0.015). Significant results are highlighted yellow. 
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8.2.3.5.1.2. LCR1 Methylation 
There did not appear to be a relationship between RQ quartile and LCR1 DNA methylation. The 
methylation of samples in different RQ quartiles was consistent and evenly distributed (Figure 
8.16). Multiple one-way ANOVAs did not identify any significant results. 
8.2.3.5.1.3. LCR2 Methylation 
There did not appear to be a relationship between RQ quartile and LCR2 DNA methylation. As 
per the LCR1 region, DNA methylation of the LCR2 region was consistently low and evenly 
throughout the various RQ quartile groups (Figure 8.17). Multiple one-way ANOVAs did not 
identify any significant results. 
8.2.3.5.1.4. L1/L2 Methylation 
There appeared to be a relationship between L1/L2 DNA methylation and RQ quartile group 
for both the E2 and E7 RQ (Figure 8.18). With increasing E2 RQ quartile group, there appeared 
to be a progressive decline in L1/L2 methylation. For the E7 RQ groups, there was a less 
progressive decrease, with Q2 and Q3 being very similar and with large confidence intervals. 
Mean L1/L2 methylation of the samples in E7 Q4 was the lowest such that samples with the 
highest E7 RQ had low level L1/L2 methylation. 
Statistical comparison was performed using multiple one-way ANOVA tests (Table 8.9), one 
violation of the ANOVA assumptions existed and is detailed in the table legend. There was a 
significant difference in L1/L2 methylation (at Bonferroni corrected P=0.017) only among the 
E2 RQ quartiles. Pairwise comparisons found a significant difference between Q1 and Q3, and 
Q1 and Q4. The observed relationship between E7 RQ and L1/L2 methylation was not 
confirmed statistically. 
In summary, high L1/L2 methylation was associated with low E2 and E7 RQ. Similarly, low 
L1/L2 methylation was associated with high E2 and E7 RQ 
 
 With integrated samples included 
Significant Tukey-
Kramer 
 L1/L2 DNA methylation comparisons (P<0.05) 
vs. E2 RQ P=0.002 1 vs. 3, 1 vs. 4 
vs. E6 RQ P=0.853 None 
vs. E7 RQ P=0.198*1 None 
Table 8.9: The results of multiple One-way ANOVA tests with Tukey-Kramer pairwise comparisons.  
Violations of the one-way ANOVA assumptions: *1, unequal variances (Bartlett’s P=0.013). Significant 
results are highlighted yellow. 
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8.2.3.5.2. Integrated Samples Excluded Analysis 
Next, a similar set was performed for the data with the integrated samples excluded. As most 
comparisons were non-significant, the data are presented graphically in Appendix V and 
significant observations are summarised here.  
8.2.3.5.2.1. E2 Methylation 
For the E2 region, DNA methylation did not appear to be associated with RQ quartile. Multiple 
one-way ANOVAs did not identify any significant results. 
8.2.3.5.2.2. LCR1 Methylation 
There did not appear to be a relationship between RQ quartile and LCR1 DNA methylation. 
Multiple one-way ANOVAs did not identify any significant results. 
8.2.3.5.2.3. LCR2 Methylation 
There was a consistently low and even distribution of DNA methylation level between the RQ 
quartiles. One significant result was obtained (although not when considering the Bonferroni 
correction), LCR2 methylation varied with E2 RQ (P=0.039) and Tukey-Kramer identified Q1 vs. 
Q3 as significantly different. However there was a very low sample number in E2 RQ Q1 and 
the level of DNA methylation in each group was very low increasing the likelihood of error as a 
result of background experimental noise. This observation must be treated with scepticism 
unless further evidence is produced. No other significant differences were observed. 
8.2.3.5.2.4. L1/L2 Methylation 
There was a varied level of L1/L2 DNA methylation for each E6 RQ quartile. There was 
considerably less variation in the L1/L2 DNA methylation for the highest E2 and E7 expressing 
samples (i.e. Q4 for both assays). As per the data set with integrated samples included, there 
was a significant difference (although not when considering the Bonferroni correction) in L1/L2 
DNA methylation among E2 RQ quartiles (P=0.025), more specifically a pairwise difference 
between Q3 and Q4 (Tukey-Kramer). The relationship was less convincing than when analysing 
all samples due to the sample number and lower significance. Nonetheless, the highest E2 
expressing samples had a lower mean L1/L2 methylation than those with lower E2 RQ. The 
L1/L2 DNA methylation of the other E2 RQ quartiles was quite variable. No other significant 
differences were observed. 
 
8.2.3.5.3. Integrated Samples, Individual Consideration 
For the integrated samples, a complex relationship appeared to exist between methylation and 
gene expression that necessitated interpretation independent of the non-integrated samples. 
The low number of integrated samples and the diverse methylation/mRNA levels made 
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statistical analysis difficult and comparisons of means/medians problematic. Instead, each 
sample was considered and compared to the other samples separately in an attempt to 
investigate the affects of different integration events. The following sample descriptions are 
compiled from the data presented in Figure 8.4, Table 8.4 and Figure 8.19. 
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Figure 8.19: Mean DNA methylation of the VR series integration group 1 samples.  
A different graph pane is present for each HPV genome region and each bar represents mean DNA 
methylation for that sample.  
 
8.2.3.5.4. VR24 
The VIN3 VR24 sample contained HPV16 integrated in the E1 gene; there was 
hypermethylation of the E2 region however the L1/L2 data was not available to compare. 
There was hypomethylation of both the LCR1 and LCR2 regions. VR24 exhibited an average E6 
RQ, an above average E7 RQ and a very low E2 RQ.  
8.2.3.5.5. VR32 
The VIN3 VR32 sample, much like the VR42 sample was unusual in that there was no 
hypermethylation of E2 or L1/L2 observed despite a detected integration event. The VR32 
sample had a detected HVP16 integration event that resulted in disruption of the E2 gene. 
VR32 had very very high E2 and E6 RQ and a very high E7 RQ, several Log10 higher than average 
in every instance. Both LCR1 and LCR2 were hypomethylated. A possible explanation for the 
integration without hypermethylation at E2 and/or L1/L2 was that the HPV16 genomes in this 
214 
 
sample could exist as both an integrated form, and a highly numerous episomal form. If this 
were the case, the small numbers of integrated sequences were detectable by DIPS but 
episomal forms were still present. Episomal HPV are often maintained in very high numbers 
and are relatively hypomethylated (Kalantari et al., 2008a, Doorbar, 2006), the quantitative 
pyrosequencing assay would detect methylation as an average of each HPV16 genome in the 
sample, and an overabundance of unmethylated episomal HPV16 genomes would essentially 
mask any hypermethylated integrated HVP16 sequences. 
8.2.3.5.6. VR37 
The VIN3 VR37 sample contained HPV16 genomes with integration sites in two regions, the E2 
and L1/L2 regions which likely represented a deletion. There was no data for the E2 
methylation assay as it failed repeatedly however methylation of the L1/L2 region was high. 
The E2 RQ was very low, several Log10 lower than the average whereas the E6 and E7 RQ were 
considered above average and high respectively. The LCR1 and LCR2 regions were largely 
unmethylated. In other samples an association was observed between site of integration and 
site of hypomethylation. 
8.2.3.5.7. VR39 
The VIN3 VR39 sample had a detected integration event in the E1 region of the HPV16 
genome. It had a relatively high level of methylation in the E2 region and a high level of 
methylation in the L1/L2 region. Both LCR1 and LCR2 were hypomethylated. The E6 RQ was 
close to the average amount of expression, whereas the E2 and E7 RQ were above average.  
8.2.3.5.8. VR42 
The VIN3 VR42 sample had a detected integration event in the L2 region. The HPV16 genome 
was hypomethylated in every tested region, including the E2 and L1/L2 regions. There was 
below average E6 RQ, slightly above average E7 RQ and high E2 RQ. Again, a possible 
explanation for the integration status and the observed hypomethylation of E2 and L1/L2 was 
that both episomal and integrated HPV were present and the numerous, unmethylated 
episomal forms masked the methylation status of the integrated genomes.  
8.2.3.5.9. VR44 
The VIN3 VR44 sample was an interesting case. The E2 qPCR assay failed repeatedly however 
the E2 pyrosequencing assay worked well. The E6 and E7 RQ for VR46 were average and above 
average respectively. The HPV16 integration event into the human genome resulted in E2 
disruption. E2 was also hypomethylated whereas interestingly, the HPV16 L1/L2 region was 
highly methylated. 
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8.2.3.5.10. VR46 
The VAIN3 sample VR46 had both E2 and L1/L2 hypermethylation. HPV16 was integrated at 
the E1 region. mRNA level of the E6 and E7 genes were below average, however mRNA level of 
the E2 gene was very very low. The down regulation of E2 expression did not appear to be a 
result of E2BS (i.e. LCR2) methylation (very lowly methylated) but may be associated with E2 
and L1/L2 hypermethylation. The HPV16 integration event occurs within the MLT1D LTR 
sequence (Chr 9, q21.31) which may have an effect on the methylation profile of the 
integrated HPV16 DNA. 
8.2.3.5.11. VR53 
For VIN3 sample VR53, there was a low level of E6/E7 transcription (E2 RQ data missing). The 
L1/L2 region was hypomethylated whilst the E2 region was more methylated than all non-
integrated samples which might be related to the integration event in the L2 region of the 
HPV16 genome. As per all other samples, the LCR was hypomethylated. 
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8.3. Discussion - HPV Distribution in VIN 
This study used the Greiner Bio-One PapilloCheck DNA chip assay to identify HPV types present 
in histologically confirmed VIN. There were two aims; firstly to identify HPV16 positive samples 
that could be used for further molecular analysis, and secondly to determine the proportion of 
VIN potentially preventable by HPV prophylactic vaccination. 
8.3.1.1. Strengths and Weaknesses 
The main limitation of the study was the use of a self selected sample, i.e. women attending a 
specialist VIN clinic, which could bias the sample towards women with persistent or recurrent 
disease; this might result in some over-representation of more persistent types (e.g. HPV16). A 
further limitation was the use of separate biopsies for pathology and HPV analysis, in practice 
the biopsies were immediately adjacent and cases were only included if both biopsies were 
part of the same macroscopically visible lesion. It is however theoretically possible that the 
research biopsy may not be representative of the diagnostic biopsy. 
The strengths of the study were the large sample size, the use of histologically confirmed VIN, 
the availability of patient age data and the use of the accurate and increasingly common 
PapilloCheck DNA microarray assay. 
8.3.2. Meaning and Comparison to Other Studies  
This is the largest UK series of VIN in which HPV type has been determined. Several studies 
have investigated HPV prevalence in VIN in the UK and estimated HPV positivity at 37.5–100%, 
with the proportion of HPV positive cases containing HPV16 varying from 37.5% to 93.3% 
(Abdel-Hady et al., 2001, Gasco et al., 2002, Todd et al., 2002, Baldwin et al., 2003, Tristram 
and Fiander, 2005, Fiander et al., 2006, Woo et al., 2007, Daayana et al., 2010). The sample 
size in previous studies ranged from 8-29 cases. At n=57, the sample size for this study was 
much larger. HPV typing data from 57 samples were used and the findings are more consistent 
with the overall results of a recent international meta-analysis, in which 84.0% of VIN cases 
tested HPV positive (67.5% were HPV16, 7.7% were HPV33, and 4.6% were HPV18) (de Vuyst 
et al., 2009). For this study, the corresponding proportions were overall HPV positivity of 
75.4% (59.6% were positive for HPV16, 8.8% for HPV33, and 3.5% for HPV18). These 
proportions are also similar to another meta-analysis which indicated an overall HPV positivity 
of 80.4% for VIN2/3 (HPV16 present in 71.2%, HPV33 in 7.7%, and HPV18 in 5.5% (Smith et al., 
2009)). 
HPV positive patients were significantly younger than those testing negative (mean difference 
of over 10 years). This is consistent with HPV-associated VIN being more common in younger 
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women and VIN associated with LS being more common in older women (Bonvicini et al., 
2005).  
Three cases with VIN grade 2 or higher were associated with an LrHPV type alone (HPV6) 
which appears inconsistent with the suggestion that LrHPV types cause only warts and low 
grade lesions. However an association between LrHPV types and high-grade disease was 
observed in the De Vuyst meta analysis (de Vuyst et al., 2009) which reported approximately 
5% of VIN2/3 as linked to HPV6. 
HPV-associated VIN is most common in women in their 30’s and 40’s (Hart, 2001). The 
incidence of VIN is approximately 5 per 100,000 women per year and is increasing (Joura, 
2002). HPV infection is endemic in the UK, in Wales almost 30% of women in the 20–25 year 
age range are now infected with a HR anogenital HPV type (Hibbitts et al., 2008). Hence, in the 
short term, the number of women affected by VIN is likely to continue increasing. HPV 
vaccination has been shown to be 100% effective in prevention of VIN2/3 associated with 
HPV16/18 in a per protocol population (Joura et al., 2007). In the UK, vaccination of 12–13 
year old girls against HPV16/18 infection began in 2008. Hence it is likely to be 20–30 years 
before the effects of this intervention become apparent in reduced incidence of VIN. 
Ultimately however, as HPV16/18 were present in 61.4% of VIN, our data suggest that greater 
than half of VIN cases could be potentially prevented by vaccination and that vaccination with 
a quadrivalent vaccine (protection conferred against types 16, 18, 6 and 11) might also prevent 
HPV6 associated VIN. 
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8.4. Discussion – HPV DNA Methylation, Integration and Gene 
Expression 
8.4.1.1. Aims 
This study was devised to characterise a series of VIN2/3 biopsies and to test a series of 
hypotheses. The primary aim was to establish the relationship between HPV methylation, 
integration and gene expression. We hypothesised that where integration was not present, 
DNA methylation might constitute an alternative transforming event, either by 
hypermethylation of one or more regions of the HPV genome or by specific hypermethylation 
directed at the E2BSs. An alternative hypothesis was that DNA methylation might be a 
consequence of integration. 
8.4.1.2. Weaknesses 
A limitation of DIPS is that when integration is not detected, it does not necessarily mean that 
an integration event is not present (i.e. a true negative result). A negative result could arise if 
there genuinely was not an integration event present, because the method was not sensitive 
enough or because it had failed to work properly. In addition, DIPS cannot differentiate 
between HPV infections where a mix of integrated and episomal HPV forms are present and 
infections where concatemeric HPV integrants are present. 
For the qPCR assays, the biopsy dosage effect (Chapter 4: 4.1.3) could influence the RQ ratios 
produced. The biopsy dosage effect can essentially cause apparent differences in RQ ratio that 
are not the result of differences in mRNA level.  
The assumptions of several statistical analyses were violated in several instances. Where 
violations occurred, these are detailed in the text. Sometimes these data were used on the 
basis that the test produced data confirmed by other tests. It is common practice to use the 
tests with violations provided the results are interpreted with appropriate caution. 
Furthermore the results of these tests were used primarily in an exploratory nature to 
generate hypotheses. Where the data was wholly unsuitable for an analysis (i.e. the 
distribution of the RQ data was unsuitable for parametric multifactorial ANOVA) less powerful 
and less informative non-parametric alternatives were used. 
 
8.4.1.3. Strengths 
This study is unique in being the only study to compare DNA methylation, gene expression and 
integration status in VIN. Histology was reviewed by a consultant pathologist specialising in 
gynaecological oncology. The VR series comprise a clinically relevant cohort for which both 
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DNA and RNA were available. The study was designed to investigate the basic biology of HPV 
gene expression and to assess the potential of DNA methylation as a biomarker. From this 
perspective, the VR series was a well designed study which allowed the assessment of several 
biological characteristics.  
Use of pyrosequencing was a significant strength as it provides an accurate assessment of 
methylation status for numerous CpGs in a heterogeneous mix of DNAs, in a fully quantitative 
manner. The pyrosequencing assays used in this study are to be used as an adjunct to an 
ongoing clinical trial of topical therapy for VIN (RT3 VIN; CRUK trial number CRUK/06/024). 
 
8.4.2. Meaning and Comparison to Other Studies 
8.4.2.1. DNA Methylation of the VR Series 
DNA methylation varied considerably among samples, among HPV regions and among CpGs 
within each region. L1/L2 was the most heavily methylated region although E2 
hypermethylation was observed in several samples. The LCR1 (enhancer) and LCR2 (promoter) 
were hypomethylated in all samples. The patterns of CpG specific methylation were very 
similar to those observed in other sample cohorts and cell line studies (Chapter 5: 5.1.3, 
Chapter 6: 6.1.1, and Chapter 7: 7.1.3.3.2) and very large differences were observed between 
CpGs separated by only a few bp. The region and CpG specific methylation patterns observed 
are discussed in further detail in the general discussion (Chapter 9: 9.1.4 & 9.1.5). 
DNA methylation of the VR series (predominantly VIN2/3) was similar to the level of 
methylation observed for the severe dyskaryosis group (Chapter 5: 5.1.1) and for CIN2/3 
(Fernandez et al., 2009). HPV DNA methylation of other non-cervical, anogenital sites has been 
assessed (Kalantari et al., 2008b, Wiley et al., 2005) however this is the first instance of HPV 
DNA methylation being determined for VIN. The results for HPV methylation studies of other 
anogenital sites are generally consistent with cervical lesion studies, thus expanding the 
potential clinical utility that a knowledge of HPV methylation might have. 
8.4.2.2. Integration Status of the VR Series 
Integration was detected in 8 samples with a variety of human and HPV loci disrupted. 
Considering only samples where the sample controls were passed, 6/15 (40%) of VIN2/3 
samples had integration events; this is consistent with a previously estimated rate of 38.1% 
integration of HP16/HPV18 in VIN3 (Hillemanns and Wang, 2006). HPV integration in CIN has 
been reported in 11-60% of cases (Hafner et al., 2008, Klaes et al., 1999, Hopman et al., 2004, 
Li et al., 2012). Variation in the estimates may be a result of methodological differences and 
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differences in sample size and CIN grade. VR37 DIPS data appeared to show a deletion 
between the E2 and L2 regions. Interestingly, E2 pyrosequencing PCRs failed whilst E2 mRNA 
was detected by qPCR. Both pyrosequencing and qPCR targeted regions inside the potentially 
deleted zone which could hint at a low level presence of intact genomes and transcripts, and a 
difference in sensitivity of the pyrosequencing and qPCR assays such that qPCR but not 
pyrosequencing were capable of amplifying the E2 region of these genomes. 
8.4.2.3. Gene Expressions Status of the VR Series 
E2, E6 and E7 mRNA level varied considerably among samples and among the qPCR assays, the 
most variable mRNA was E2. E2 is a repressor of oncogene expression, and several factors (e.g. 
E2 disruption, E2BS methylation, non-functional E2 proteins, splice variation etc) may affect its 
expression and account for the greater variability (Zheng and Baker, 2006). E2/E6/E7 mRNA 
levels were positively correlated which was consistent with the PC08/PC09 data. The strong 
correlation between VR series E2, E6 and E7 RQ suggests that high/low transcription of one 
mRNA is accompanied by similar changes in the other mRNAs. However there were several 
exceptions to this observation where E2 RQ was much lower than E6/E7 RQ. The disparity 
might be explained by observations made on the W12 model, where E2 downregulation and 
E6/E7 upregulation were considered to be early events in cellular transformation and E2/E6/E7 
mRNA were present at similar levels after these early events (Gray et al., 2010). 
Biopsy samples are subject to the biopsy dosage effect (Chapter 4: 4.1.3). The biopsy dosage 
effect is caused by variation in the ratio of HPV containing versus non-HPV containing cells in 
each biopsy. Both cell types contain reference gene transcripts however only HPV positive cells 
contain HPV transcripts which leads to disparity during relative quantification. This variation 
could conceal differences in E2/E6/E7 mRNA level among biopsies and promote an apparent 
E2/E6/E7 correlation. However correlation between E2/E6/E7 was also observed in PC08/PC09 
which were not subject to this effect. 
8.4.2.3.1. Patient Age 
An association between age and integration status was observed previously (Vinokurova et al., 
2008) but was not apparent in our study, possibly due to the relatively small number of 
samples. 
8.4.2.4. Gene Expression and Integration 
It is interesting to note that as well as a low E6/E7:E2 RQ ratio, samples VR37, VR24 and VR46 
had integration events detected. Nonetheless, no significant difference in RQ was observed 
between the integrated and non-integrated samples when tested directly. This was consistent 
with one study (Hafner et al., 2008), but not with another (Ho et al., 2011). The lack of 
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correlation might correspond to the inability of DIPS to differentiate between different types 
of integration event which may exert distinct effects on gene expression. For instance 
differences in gene expression may exist between tissues containing only integrated genomes 
as opposed to both integrated and episomal HPV forms, and differences between 
concatemeric repeats and single insertions might also affect transcription.  
An association between site of integration and E2/E6/E7 level was considered but no 
relationship was apparent. VR32 was particularly interesting as it showed E2 disruption but 
also the highest levels of E2/E6/E7 mRNA. E2 was disrupted just downstream of the site 
amplified by qPCR, hence full length E2 protein could not be produced by the integrated 
genome (Kim et al., 2003), and E2 transcripts would not correspond to functional E2 protein. 
E6 and E7 could be highly expressed without being repressed by E2.  
8.4.2.5. DNA Methylation and Integration 
Integration of HPV into the host genome with associated disruption of the E2 ORF is commonly 
considered to be a mechanism of cellular transformation and carcinogenesis (Thierry, 2009). 
However, a substantial proportion of HPV-associated neoplasias do not contain integrated HPV 
or also contain episomal HPV such that functional E2 repressor may be produced (Arias-Pulido 
et al., 2006, Klaes et al., 1999, Pett and Coleman, 2007, Vinokurova et al., 2008, Bhattacharjee 
and Sengupta, 2006b). As such, it has been suggested that integration of HPV into the host 
genome could be a consequence of chromosomal instability caused by aberrant HPV oncogene 
expression, rather than the cause of aberrant oncogene expression (Pett and Coleman, 2007, 
Melsheimer et al., 2004). There is reason to suspect that HPV DNA methylation might be 
involved in initial oncogene deregulation in some instances (Vinokurova and von Knebel 
Doeberitz, 2011). 
Our initial hypothesis was that DNA hypermethylation could be an alternative transforming 
event to integration. If this were true, one might expect a characteristic level or pattern of 
hypermethylation in non-integrated samples that was not present in integrated samples, i.e. 
the transforming methylation pattern and the presence of integration would be mutually 
exclusive. 
For the VR series, this relationship was not present and hypermethylation of E2 and L1/L2 was 
strongly and significantly associated with HPV integration. We also suspected that E2BS 
methylation in the LCR might constitute an alternative transforming event by blocking binding 
of the E2 repressor proteins and enhancing P97 activity, however LCR hypermethylation was 
not observed in any instance (Thain et al., 1996, Kim et al., 2003). In fact, the highest level of 
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LCR methylation (still <10%) was observed for an integrated sample (VR42). LCR methylation of 
this sample might instead reflect the type of integration event (single insertion vs. 
concatemeric) as multiple insertions appear more likely to be silenced by dense LCR 
methylation (Kalantari et al., 2009). 
Rather than being mutually exclusive with integration, hypermethylation of the HPV genome 
could be specifically associated with integration. Integrated samples were significantly more 
methylated in the E2 and/or L1/L2 regions than the non-integrated samples. There were two 
exceptions to this, VR32 and VR42 (E2 and L1/L2 hypomethylation) may have had HPV in both 
integrated and episomal forms. Episomal HPV16s are typically maintained at high copy number 
and are hypomethylated (Kalantari et al., 2008a, Doorbar, 2006). The pyrosequencing assays 
would detect methylation as an average of each HPV16 genome in the sample, and an 
overabundance of unmethylated episomal HPV16 genomes could potentially mask any 
hypermethylated integrated HVP16 sequences. VR42 also had the highest level of LCR1 
methylation. LCR1 methylation of the VR42 integrated genomes could be considerably higher 
than indicated by the pyrosequencing assay but masked by the presence of episomal HPV, 
such that these integrated genomes were repressed (Rosl et al., 1993). Alternatively, episomal 
HPV genomes could be effectively targeted for LCR methylation which may or may not affect 
P97 activity (Bechtold et al., 2003, Kim et al., 2003). 
The association between DNA methylation and integration appeared to be complex. Some 
samples showed both E2 and L1/L2 hypermethylation, some had E2 or L1/L2 hypermethylation 
and others had E2 and L1/L2 hypomethylation. It appeared that an integration event in a 
particular HPV region could be associated with hypomethylation in adjacent regions and 
hypermethylation in distal regions. E1 disruption for instance was typically associated with 
hypermethylation of both E2 and L1/L2, E2 disruption was associated with L1/L2 
hypermethylation and L2 disruption with E2 hypermethylation. As this was also observed in 
the cell lines study, it is discussed in further detail in the general discussion (Chapter 9: 
9.1.1.1). 
8.4.2.6. DNA Methylation and Gene Expression 
Because DNA methylation in the integrated samples was different from the non-integrated 
samples, the relationship of DNA methylation with mRNA level was considered both with and 
without integrated samples included.  
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8.4.2.6.1. E2 Intragenic Methylation and E2 Expression 
Initially, the E2 pyrosequencing assay was adopted on the basis that intragenic methylation 
can affect gene transcription (Lorincz et al., 2004, Murrell et al., 2001), and so intragenic 
methylation might reduce E2 transcription. The samples with the least E2 mRNA showed 
significantly higher E2 DNA methylation. A negative correlation was also observed between E2 
methylation and E2 RQ for the integrated samples. Because E2/E6/E7 RQ were positively 
correlated, the relationship between E2 methylation and E6/E7 RQ was very similar to E2 RQ 
(albeit E6 was not quite significant). This data is consistent with E2 methylation contributing to 
regulation of E2 expression. This is also discussed in further detail in the general discussion 
(Chapter 9: 9.1.3 & 9.1.4). 
For the non-integrated samples, variation in E2 methylation was limited and no relationship 
between E2 methylation and transcription was observed. Intragenic methylation affects 
transcription by hindering elongation efficiency of RNA polymerase II in regions of dense 
methylation and condensed chromatin structure (Lorincz et al., 2004). Intragenic methylation 
might also affect transcription from alternative start sites (Maunakea et al., 2010), which has 
particular relevance for HPV where alternative transcription start sites are recognised 
(Lambert et al., 1990) and various E2 start sites are responsible for additional E2 ORF proteins 
(Introduction). Whether this form of repression would be apparent for an mRNA transcript 
based assay (i.e. qPCR) where an early part of the E2 ORF is amplified, and for HPV where post-
transcriptional regulation is important is difficult to determine.  
8.4.2.6.2. LCR Methylation and Gene Expression 
We did not see a clear relationship between LCR methylation and gene expression. We had 
initially hypothesised a relationship between LCR hypermethylation and transcription in the 
absence of integration, however this was not observed and the LCR of all samples was 
hypomethylated. LCR hypomethylation in VIN is consistent with the PC08/09 data (Chapter 7: 
7.1.3.3) and also cervical disease grade studies (Badal et al., 2003, Hublarova et al., 2009, Patel 
et al., 2012, Piyathilake et al., 2011). 
8.4.2.6.3. L1/L2 Methylation and Gene Expression 
A significant association between L1/L2 methylation and E2 RQ was observed. No relationship 
was observed for E6 RQ, and the E7 RQ relationship was deemed non-significant. Similar to E2 
methylation, the samples with the lowest levels of E2 mRNA had the highest levels of L1/L2 
methylation.  
That L1/L2 methylation is also associated with E2 transcription makes specific E2 repression by 
intragenic methylation less likely. These data would be more consistent with a model in which 
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low levels of E2 transcription are related to integration events and these integration events are 
characterised by high E2 and/or L1/L2 methylation. With this in mind, it is perhaps surprising 
that we did not observe a significant difference in E2/E6/E7 mRNA level between the 
integrated and non-integrated HPV containing samples in the previous analysis. This might 
stem from the lack of methylation data for several of the lowest mRNA expressing samples 
such that they were not included in this analysis of methylation and gene expression, but were 
included in the previous analysis just concerning gene expression and integration. Adequate 
DNA was retrieved from these biopsies, however if HPV genomes were only present at very 
low copy number within the biopsies, the less sensitive DNA based pyrosequencing assays 
might fail whilst the highly sensitive qPCR assays might not. Relative quantification normalises 
against input RNA amount, but the biopsy dosage effect (Chapter 4: 4.1.3) could artificially 
lower the RQ returned if a low number of HPV genomes were present in the biopsy.  
8.4.2.6.4. Summary 
In summary, L1/L2 and E2 hypermethylation and/or HPV integration appeared to be associated 
with low levels of E2/E6/E7 transcription. 
Whilst there was no clear difference in mRNA level between integrated and non-integrated 
samples, this observation was complicated by the apparent hypermethylation of integrated 
HPV genomes and the observation of these hypermethylated genomes typically having lower 
mRNA levels. Lower level of mRNA for E2, E6 and E7 in the integrated samples was unexpected 
but might be explained by the requirement of E6/E7 expression for the replication of episomal 
HPV genomes, but not the maintenance of integrated HPV that are replicated alongside the 
host genome (Pett et al., 2006). Alternatively, low level gene expression for hypermethylated 
integrated genomes might simply be a by-product of gene dosage; episomal HPV are typically 
maintained in high numbers, whilst integrated genomes are frequently integrated as single 
insertions. Indeed, the methylation profiles of our samples are more consistent with single 
insertions (Kalantari et al., 2009). Finally, only a small number of integrated samples were 
considered, there was variation in integration site (both HPV and human), potential biopsy 
dosage effects, and small violations of the analysis; together these factors could produce 
erroneous correlations.  
8.5. Conclusions 
In conclusion, there was considerable variation in integration state, gene transcription and 
DNA methylation among the VR series. There was also a pattern of CpG specific methylation 
reminiscent of other sample cohorts. 
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The hypothesis that DNA methylation is an alternative transforming event to integration was 
not supported by the data. Neither was E2BS methylation specifically observed in non-
integrated samples, instead the LCR was hypomethylated in all instances. The biggest 
determinant of HPV methylation appeared to be HPV integration whereby most integrated 
HPV were hypermethylated in E2 and/or L1/L2. There was also a potential relationship 
between HPV site of disruption by integration and site of hypomethylation. Whether HPV 
methylation is a cause or a consequence of HPV integration remains unclear. 
There was not a clear difference in HPV gene transcription between samples containing 
integrated and non-integrated HPV genomes, however there was a suggestion of lower 
transcription in integrated samples which was difficult to explain. There was an association 
between hypermethylation and low gene transcription however the role of intragenic 
methylation in HPV transcription also remains unclear. 
8.5.1. Further Work 
In samples where integration was identified, determination of the methylation status of 
adjacent human DNA might provide further insight into the mechanism of methylation of the 
integrated HPV genome. Analysis of the type of integration event (single or concatemeric 
insertion) and the detection of episomal HPV in combination with integrated HPV might also 
help to clarify the apparent association between integration and DNA methylation. 
A tissue biopsy is frequently a heterogeneous sample of cells, comprising of cells with 
differences in viral copy number, HPV integration, gene expression, DNA methylation, 
differentiation status and a plethora of other characteristics (Vinokurova and von Knebel 
Doeberitz, 2011, Kalantari et al., 2009, Kalantari et al., 2008a). When considering the limited 
amount of data published with regards to a potential link between HPV integration status and 
DNA methylation, it would be inherently interesting to study individual or small groups of cells 
within a tissue type. LCM allows individual and small numbers of cells to be isolated from a 
heterogeneous tissue by transferring cells to a transparent polymer film using a laser (Emmert-
Buck et al., 1996). DNA, RNA and proteins from LCM cells can then be extracted and analysed 
(Edwards, 2007). Whilst LCM has been used for HPV methylation studies with varying degrees 
of success, the limited amount of material available for analysis following LCM would likely 
prove problematic for DNA methylation assays, but especially for integration assays that 
require a large amount of nucleic acid (Vinokurova and von Knebel Doeberitz, 2011, Kalantari 
et al., 2009). 
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Chapter 9. General Discussion 
Several components of this investigation were common to and/or had broader relevance to 
multiple chapters. In order to avoid repetition and provide a more succinct discussion, these 
common components are discussed in this general discussion chapter.  
Briefly, this discussion will consider the association between HPV methylation and integration, 
the potential self methylation of HPV and the observation that HPV methylation might not be 
associated with gene expression in some instances. There is also discussion of the potential 
mechanisms of methylation that result in regional and CpG specific differences and further 
discussion of the potential effects of HPV methylation. 
Finally, several chapters determined methylation differences to be associated with clinical 
characteristics. This discussion therefore covers the broader relevance of these observations 
from the perspective of disease biomarkers. 
 
9.1. DNA Methylation 
Pyrosequencing was successfully applied to a range of sample DNAs including cell lines, LBC 
samples, biopsy samples and FFPE cervical cancers. It proved to be a versatile technique and 
benefitted significantly from an objective series of internal controls. 
9.1.1. HPV Methylation was Associated with HPV Integration 
For this study, integrated HPV genomes were typically hypermethylated at E2 and/or L1/L2 
both in vitro and in vivo. HPV does not encode DNA methyltransferases (DNMTs) so 
methylation must be performed by human DNMTs. It is difficult to determine whether the 
observed levels of HPV DNA methylation are specifically a consequence of the action of HPV 
proteins or the result of more general DNA methylation changes in human DNA methylation 
that are associated with neoplasia (Henken et al., 2007, Sun et al., 2012, Eijsink et al., 2012, 
Wentzensen et al., 2009, Leonard et al., 2012, Apostolidou et al., 2009). 
Human cells actively target foreign DNA elements for silencing by DNA methylation (Doerfler, 
2006, Doerfler, 2008, Doerfler et al., 2001). Upon integration, foreign DNAs including 
adenoviral, plasmid and bacteriophage DNAs are often de novo methylated by what might be a 
cellular defence mechanism to repress foreign DNA elements (Sutter et al., 1978, Orend et al., 
1995, Heller et al., 1995, Doerfler, 2008). Methylation of foreign DNAs seems to depend on the 
location of integration in the human genome in terms of local methylation density, 
methylation pattern and the strength of any foreign promoters (Doerfler, 2008). In some 
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instances DNA methylation of foreign elements could be a reflection of the DNA methylation 
status of regions adjacent to the integrant, where methylation could begin as an initial seed 
before spreading to adjacent regions (Heller et al., 1995, Turker, 2002, Doerfler et al., 2001). 
Unfortunately, we were unable to pursue assessment of the DNA methylation status of 
flanking human DNAs. 
Methylation of HPV integrants may also depend on the type of integration event, i.e. single or 
concatemeric integrants. A densely methylated, single insertion integrant would be effectively 
repressed to the extent that no selective growth advantage of the cell would be gained, and 
cells containing unmethylated HPV integrants would clonally expand (Van Tine et al., 2004b). 
For concatemeric insertions, dense methylation of most genomes could occur both as a result 
of targeting of foreign DNAs by host DNA methylation machinery and/or viral mechanisms that 
limit a copy number related gene dosage effect that is deleterious to the growth rate of the 
host cell (De-Castro Arce et al., 2011, Doerfler, 2008). Tandem repeats may also be better 
recognised as genomic parasites and more efficiently targeted by DNA methylation. There are 
however instances of unmethylated concatemeric W12 HPV16 genomes (Kalantari et al., 
2008a, Yoder et al., 1997).  
9.1.1.1. Site specific Hypomethylation and Site of Integration 
Whilst hypermethylation of integrated DNAs was a commonly observed event, there may also 
have been an association between site of disruption of the HPV genome, and the site of 
hypomethylation of the HPV genome. For many of the integrated VR series, but also for several 
of the PC08/PC09 clones, regions of the HPV genome adjacent to sites of the HPV genome 
disrupted by integration were frequently hypomethylated. Areas distal to the disruption site 
were typically hypermethylated. Furthermore in W12Ser7 we observed L1/L2 but not E2 
hypermethylation. 
This regional hypomethylation adjacent to the disruption site is the first report of such an 
observation for HPV. Nonetheless, hypomethylation of the ends of adenoviral integrants has 
been described previously (Hochstein et al., 2007) and can be seen in Figure 9.1. Doerfler 
speculated that a highly specific and localised, perhaps sequence dependent genome structure 
might be involved in topologically denying the methylation machinery access to the ends of 
the integrant (Doerfler, 2011). HPV L1 methylation has been described as a potential 
biomarker for integrated HPV (Kalantari et al., 2010). Our data, if confirmed in a larger sample 
set would suggest that L1 methylation alone would be a poor assessment of integration status 
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for HPV disrupted at or near to L1, and that assessment methylation of multiple regions would 
be more informative. 
 
 
Figure 9.1: The methylation profile of integrated Ad12 adenovirus genome.  
Adapted from (Hochstein et al., 2007). Black squares represent methylated CpGs whilst white squares 
represent unmethylated CpGs. Each column of squares represents a CpG whilst each row represents 
an individual bisulfite sequenced cloned DNA. The large core region represents most of the Ad12 
genome and apart from some exceptions is densely methylated throughout. The two flanker regions 
represent DNAs adjacent to host cell DNA after the integration event and are typically 
hypomethylated. 
 
Hypomethylation of host DNA in the area flanking the insertion site of foreign DNAs is also 
commonly observed (Hejnar et al., 2003, Lichtenberg et al., 1988, Doerfler, 2011). In this 
instance, hypomethylation of the ends of integrated DNAs might represent a mechanism of a 
spread of methylation (Turker, 2002). Alternatively, as host DNA methylation pattern might 
influence integrant de novo methylation, hypomethylation of the flanking host sequence might 
represent the adoption of the adjacent (i.e. human) DNA methylation profile (Doerfler, 2011). 
9.1.1.2. E2BS Methylation and Integration 
We hypothesised that hypermethylation of the promoter E2BSs would be present in the 
absence of integration and would act to block E2 trans-acting repression as a mechanism of 
oncogene deregulation. There was no evidence for such a mechanism in VIN2/3 or the 
PC08/09 short term cultures. LCR2 hypermethylation was very rarely observed in precancerous 
neoplasia, and was not even commonly observed in cancer. Other studies have reported E2BS 
methylation in association with cervical cancers, although more rarely in high grade 
precancerous lesions (Bhattacharjee and Sengupta, 2006a, Fernandez et al., 2009, Snellenberg 
et al., 2012). Another study that used LCM to dissect a biopsy specifically did not see promoter 
E2BS methylation in regions where CIN3 histology was present, but the integration state of 
HPV in the biopsy was not determined (Vinokurova and von Knebel Doeberitz, 2011). There is 
however reason to suggest that the LCR E2BSs need not be heavily methylated in order to 
enhance P97 activity such that one or two methylated E2BS CpGs per genome might suffice. As 
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pyrosequencing considers the mean methylation of a mix of DNAs, if each DNA were variably 
methylated in one or two E2BS CpGs the overall level of methylation might be low, but most 
genomes might still be repressed by E2BS methylation (Stunkel and Bernard, 1999, Kalantari et 
al., 2008a). 
9.1.2. HPV Methylation may be Self Determined 
HPV does not encode a DNMT, so DNA methylation is achieved using the cellular DNMTs 
(DNMT1, DNMT3A and DNMT3B) (Portela and Esteller, 2010). It is well established that 
oncogenic viruses can modulate DNA methylation either directly or indirectly; HBV, Hepatitis C, 
Kaposi’s sarcoma associated herpes virus and EBV are all known to interact with and modulate 
the expression of DNMTs with associated changes in DNA methylation (Leonard et al., 2012). 
HPV appears to affect the DNA methylation machinery indirectly via degradation of the p53 
tumour suppressor and directly by upregulation of DNMT1 expression (Au Yeung et al., 2010). 
Transfection of keratinocytes with episomal HPV16 led to DNMT1 and DNMT3B upregulation 
(Leonard et al., 2012). E6 can also bind to proteins involved in chromatin remodelling and E7 
binds DNMT1, enhancing its methyltransferase activity (Burgers et al., 2007, Thomas and 
Chiang, 2005). E7 also disrupts the pRb/E2F pathway, responsible for regulating the DNMT1 
promoter (McCabe et al., 2005). Hence HPV transfection is associated with numerous changes 
in human DNA methylation (Leonard et al., 2012).  
E2 and E6 ORF products have long been known to modulate P97 activity (Shirasawa et al., 
1994, Dostatni et al., 1991) and it appears that in some instances high E2, E6 and E7 activity 
promotes enhancer and promoter hypermethylation (De-Castro Arce et al., 2011). 
Overexpression of HPV genes could effectively target DNA methylation towards the LCR. HPV 
self-methylation has been proposed as a means by which to regulate HPV gene expression in 
multi copy integrants where promoter and gene copy number would otherwise contribute to 
excessive and deleterious levels of gene expression (De-Castro Arce et al., 2011). 
 
9.1.3. HPV DNA Methylation Might not be Associated with Gene Expression 
In HPV, leaky ribosome scanning and translation reinitiation are implicated in the regulation of 
gene expression (Zheng et al., 2004, Remm et al., 1999, Longworth and Laimins, 2004). 
Further, it is hypothesised that intragenic DNA methylation might prevent spurious initiation of 
transcription by preventing the binding of transcription factors to gene body binding sites 
(Zilberman et al., 2007). We had therefore hypothesised that intragenic HPV methylation 
might affect the level of transcription of more 3’ ORFs (i.e. E2 hypermethylation and E2 
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transcription). Whilst we did observe a negative correlation between E2 methylation and E2 
transcription in several instances, a similar relationship was also present for other regions of 
the HPV genome and for other mRNAs also. Typically, E2 and/or L1/L2 methylation were 
negatively associated with E2, E6 and/or E7 mRNA transcription. Whilst significant 
observations did exist, they appeared to be influenced heavily by the apparent relationship 
between DNA methylation and integration, with integration potentially having a negative 
effect on gene expression.  
9.1.4. Variation in Methylation 
9.1.4.1. Regional Variation 
There was variation in methylation among the four HPV genome regions for every clinical and 
cell line cohort tested in this investigation. Typically, the E2 and L1/L2 regions were more 
methylated than the LCR, which was almost universally hypomethylated.  
9.1.4.2. Permissive Infections 
Whilst E2 and L1/L2 were methylated in several instances of precancerous neoplasia, the LCR 
rarely was. The most plausible explanation for universal LCR hypomethylation is that 
methylation of the LCR constituted a selective disadvantage. In a productive infection for 
instance, the primary role of E2 is in the replication of the viral genome, where E2 in 
association with E1 directs cell factors to the origin of replication (Kadaja et al., 2009, Kim et 
al., 2009). Methylation of the origin adjacent E2BS (E2BS2) might interfere with episomal 
genome replication, whilst methylation of other parts of the LCR might induce conformation 
changes, impeding viral gene expression/replication (Rosl et al., 1993).  
Methylation of the promoter E2BSs might also cause deregulated expression of the viral 
oncogenes, a state undesirable to a productive infection and not part of the normal HPV 
lifecycle. Methylation of the promoter and origin adjacent E2BSs was not observed in LCM 
sections considered as permissive to viral replication which is consistent with this hypothesis; 
however enhancer (LCR1) methylation was frequently observed in these sections (Vinokurova 
and von Knebel Doeberitz, 2011). 
9.1.4.3. Transformed Infections 
Oncogene expression induces transformation, is required for the continued propagation of 
episomal genomes and also for the maintenance of the transformed cell state (Gray et al., 
2010, Van Tine et al., 2004b, Hawley-Nelson et al., 1989). Hypermethylation of E2BS1 and the 
promoter E2BSs would likely block E2 binding and enhance P97 activity, whilst general LCR 
hypermethylation is associated with P97 repression (Thain et al., 1996, De-Castro Arce et al., 
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2011, Vinokurova and von Knebel Doeberitz, 2011, Kim et al., 2003). LCR1 and LCR2 cover 
three CpGs of the viral enhancer and two repressive E2BSs within the promoter region 
respectively. It is interesting that the enhancer region was less methylated than the promoter 
E2BSs in our cancer samples. There were also more cancer samples with promoter 
hypermethylation than there were with enhancer hypermethylation. It seems that for the 
transformed phenotype, finding an equilibrium of methylation level at various sites of the LCR 
is required in order to permit oncogene expression without the potentially deleterious effects 
of oncogene overexpression (De-Castro Arce et al., 2011, Gray et al., 2010). 
9.1.4.4. E2 and L1/L2 
E2 and L1/L2 hypermethylation appear to confer less of a disadvantage and in some instances 
were very common (i.e. integrated genomes and cancer cell HPV genomes). We could not 
confirm a role for intragenic methylation in modulating E2 transcription, however possible 
consequences include both the enhancement and repression of P97 activity. If intragenic 
methylation did alter the ability of HPV to express functional E2 proteins, E2 methylation could 
potentially increase oncogene expression. Alternatively, intragenic methylation might interfere 
with the expression of truncated E2 proteins that could act as an inhibitor of E2 function, 
thereby repressing P97 activity (Zilberman et al., 2007, Kim et al., 2003). As L1/L2 expression is 
not required in non-productive infections, L1/L2 hypermethylation might also be irrelevant to 
the maintenance of a transformed phenotype.  
9.1.4.5. LCR 
LCR hypomethylation due to selection appears likely in several instances but there was a 
general tendency for increased LCR methylation in more severe disease. It is possible that LCR 
hypermethylation/hypomethylation might be a consequence of gene expression level, rather 
than a cause of gene expression level; DNA methylation is hypothesised to spread from 
densely methylated to sparsely methylated regions and methylate regions where open 
chromatin formations are not present (i.e. non-transcriptionally active regions) (Turker, 2002). 
As such, low gene transcription in itself might facilitate promoter methylation and further 
downregulation (Szyf et al., 2004). The relevance to HPV is that deregulated gene expression 
might be an undesirable state after cellular transformation where high levels of oncoprotein 
are sometimes detrimental to cell growth (Gray et al., 2010, De-Castro Arce et al., 2011). In 
summary, LCR methylation might both influence, and be influenced by gene expression level. 
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9.1.5. CpG Specific Pattern of Methylation 
The pattern of CpG specific methylation, especially for the L1/L2 and E2 regions was 
remarkably well conserved across a wide range of material. The “N” shaped L1/L2 methylation 
pattern for instance was seen in the VR series, most PC08 and PC09 clones, W12, CaSki, all 
three disease groups of the disease grade study and all outcome groups of the CRISP study. 
Upon closer inspection of published methylation data, the CaSki L1/L2 “N” shaped methylation 
pattern is also visible (Fernandez et al., 2009). There were also instances of massive 
methylation differences between CpGs separated by only a few bp. 
Initially, this pattern was thought to be a result of either a specific mechanism of DNA 
methylation targeting each CpG differently, or a selective advantage conferred by each pattern 
of DNA methylation. The latter, seems somewhat unlikely as methylation patterns in a 
non/lowly transcribed region of the HPV genome (i.e. L1/L2 in all but differentiated cells of a 
productive infection (Doorbar, 2006)) would need to confer a considerable selective advantage 
in order to be maintained and universally present. The selective benefit would need to be 
present for episomal and integrated HPV, HPV in precancerous lesions, cancers, normal 
cytology samples, samples with various levels of gene expression and methylation and even in 
transcriptionally inactive occluded chromatin (i.e. CaSki). Whilst hypomethylation of the LCR 
has a plausible basis for selection, a selective benefit of a CpG methylation pattern in L1/L2 
seems unlikely. Instead, the pattern is more likely produced as a result of enzymatic or 
structural differences within each region that might affect the ability of DNMTs and meCpG 
binding proteins to bind the DNA; these might include nucleosome position, nuclear matrix 
attachment regions and DNA secondary structure.  
HPV DNA is organised as nucleosomes (Stunkel and Bernard, 1999). DNA methylation varies in 
a periodic manner with an interval of 10 bp in many forms of human DNA; genes, promoters, 
pericentromeric regions and euchromatic arm regions which might be due to nucleosomal 
DNA structure (Chodavarapu et al., 2010). DNMTs access the major groove of nucleosomal 
DNA which would allow better access to DNA on the outside of nucleosomes (Chodavarapu et 
al., 2010). DNA has a helical pitch of 10-10.5 bp (Wang, 1979) which is consistent with the 10 
bp methylation periodicity. Figure 9.2 shows that the 10 bp methylation periodicity coincides 
perfectly with the period of the “N” shaped profile of the L1/L2 region that was particularly 
evident in the PC08/PC09 cell lines (Chapter 7: 7.1.3.3.2). 
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Figure 9.2: The position of CpGs within the L1/L2 region.  
Nucleotide positions are listed according to GenBank ID NC001526.1. Listed are the four CpGs of the 
L1/L2 region (red boxes) and the distance (bp) between CpGs with high and low methylation. 
 
DNA methylation is also associated with nucleosome position. Nucleosomal DNA was more 
methylated than flanking internucleosomal DNA and DNA methylation varied according to the 
distance from nucleosomes in a progressive manner (Chodavarapu et al., 2010). This 
progressive change in methylation might explain the upwards trend of the L1/L2 methylation 
profile (Chapter 7: 7.1.3.3.2). Nucleosome position analysis has not been performed for HPV16 
outside of the LCR so confirmation is difficult. Further, nucleosome analysis of the LCR is 
typically performed on integrated HPV containing cell lines so the relevance to episomal HPV is 
similarly difficult to establish (Stunkel and Bernard, 1999). 
For the E2 region, a similar 10 bp periodicity is observed for the first 4/5 CpGs, after which the 
relationship breaks down, possibly due to additional affects on methylation such as 
nucleosome positioning. The HPV16 LCR has several nucleosomes, one nucleosome 
encompasses the whole origin and promoter region whilst the large enhancer region contains 
two nucleosomes, with substantial linker regions (Stunkel and Bernard, 1999). Both the LCR1 
and LCR2 regions are fully encompassed within these nucleosome regions. Although some 
instances of the 10 bp periodicity were observed for the LCR, and present in published data 
(Ding et al., 2009), the relationship was less well defined which might stem from the potential 
selectable effect of LCR methylation on oncogene expression. 
 
9.2. Methylation and Carcinogenesis 
When considering the potential contribution of HPV methylation to carcinogenesis, two main 
topics should be considered. The first is the effect of methylation in transformed cells, the 
second is the initial deregulation of the oncogenes and the induction of cellular 
transformation. 
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9.2.1. The Potential Effects of HPV DNA Methylation 
The P97 promoter contains binding sites for various cellular transcription factors. Our LCR1 
region represents 3 CpGs of the viral enhancer and LCR2 represents five viral promoter CpGs, 
four of which are contained within the two promoter E2BSs (LCR2-1 is within a Sp1 binding 
site, LCR2-2+3 are in E2BS3 and LCR2-4+5 are in E2BS4) (Tan et al., 1994). E2 cannot bind 
methylated E2BSs (Fernandez et al., 2009). One of the LCR2 CpGs (LCR2-1) is not part of an 
E2BS but instead is present in a binding site for the Sp1 transcription factor (Tan et al., 1994). 
In this instance, one might expect LCR2-1 to be less methylated than the E2BS CpGs however 
this was not the case and LCR2-1 was methylated at a level comparable to LCR2-2 and LCR2-3. 
P97 activation is functionally dependent on Sp1 binding which can be displaced by E2 binding 
to E2BS3. However, Sp1 is capable of binding methylated DNA so methylation of LCR2-1 in 
addition to the adjacent E2BS3 CpGs might not confer a selectable disadvantage, hence its 
methylation at a level comparable to E2BS CpGs (Tan et al., 1994, Emili et al., 1994, Harrington 
et al., 1988). 
Methylation of E2BS1, the so called activator E2BS is also associated with increased P97 activity 
which may be due to an uncharacterised complex of transcription factors binding specifically 
to methylated E2BS1 (Vinokurova and von Knebel Doeberitz, 2011). E2BS1 methylation was also 
associated with cervical cancer (Bhattacharjee and Sengupta, 2006a). Our efforts to produce a 
pyrosequencing assay targeting E2BS1 were initially unsuccessful however in light of these 
more recent studies it seems appropriate to pursue the assessment of E2BS1 methylation. 
Whilst several cancers had high level LCR2 methylation, we did not frequently observe high 
levels of methylation of the LCR in precancerous neoplasia however it is possible that high 
level methylation is not required for P97 repression. Nucleosomes form over the LCR and thus 
mediation of HDAC activity by DNA methylation affects transcription at the promoter region as 
a result of topological changes (de Ruijter et al. 2003; Harrington et al. 1988; Stunkel et al. 
2000). Multiple CpGs are present in the promoter and enhancer regions, a single methylated 
CpG in these regions could bind methylated DNA binding proteins and could potentially induce 
sufficient topological changes to repress P97 activity (Stunkel and Bernard, 1999, Kalantari et 
al., 2008a). 
 
9.2.2. Initial Deregulation of Oncogenes 
Increased methylation of the E2 and L1/L2 regions was observed during and after the 
emergence of integrated HPV  in W12Ser7 (Chapter 7: 7.1.2). Integration and the frequent 
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disruption of the E2 ORF are commonly considered to be a mechanism of cellular 
transformation and carcinogenesis (Thierry, 2009). However, many HPV-associated cancers do 
not contain integrated HPV, many more do not contain E2 disrupted integrants and many high 
grade lesions contain both integrated and episomal forms which should be competent at 
producing functional E2 repressor protein (Arias-Pulido et al., 2006, Klaes et al., 1999, Pett and 
Coleman, 2007, Vinokurova et al., 2008, Bhattacharjee and Sengupta, 2006b). Instead, 
integration of HPV into the host genome could be a consequence of chromosomal instability 
caused by aberrant HPV oncogene expression, rather than the cause of initial aberrant 
oncogene expression (Pett and Coleman, 2007, Melsheimer et al., 2004). The initial causes of 
aberrant oncogene expression could be varied and are considerably understudied however 
there is reason to suspect that HPV DNA methylation might be involved (Vinokurova and von 
Knebel Doeberitz, 2011). We had initially hypothesised that heavy E2BS methylation would be 
present in the absence of integration however this was not observed either in vivo or in vitro. 
 
9.3. Methylation as a Biomarker 
During this study, we were mindful of the processes for biomarker development 
recommended by CRUK (Cancer Research UK, 2012d, Cancer Research UK, 2012e). Whilst this 
study was not exclusively designed for biomarker development, many aspects fit well within 
the advised framework for the predictive/prognostic and screening biomarker roadmaps 
(Appendix I). The early stages of biomarker development are common to multiple CRUK 
roadmaps. The rationale section for instance, is identical for each type of biomarker; there 
must be a clinical utility for a biomarker, a reliable assay, and a sample set with which to test 
the biomarker. All of these requirements were at least partially met by this investigation. 
9.3.1. Potential Clinical Utility for a HPV Methylation Biomarker 
Liquid based cytology (LBC) replaced traditional Pap smear testing in England between 2003-
2008 (Albrow et al., 2012). The UK HPV vaccination programme is expected to reduce the 
number of HPV positive LBC samples and therefore the efficiency of cytological screening 
(Wentzensen et al., 2009). Whilst HPV vaccination will substantially reduce the prevalence of 
HPV-associated disease, the current vaccines only target two of the HrHPV types. Due to the 
long time required for carcinogenesis, it is also likely to be many years before there is a 
reduction in cervical cancer rates due to vaccination (McIndoe et al., 1984). 
 HPV testing as a primary screening test would identify a large number of positive samples, 
many of which would be harmless transient infections with a low risk of progression. HPV 
236 
 
testing alone is unlikely to achieve a sufficient level of specificity (Unger et al., 2004). In order 
to prevent the treatment of the numerous clinically irrelevant HPV infections, many studies 
have attempted to develop specific CIN biomarkers to be used in conjunction with HPV testing 
(Wentzensen and von Knebel Doeberitz, 2007, Cuschieri and Wentzensen, 2008, Mirabello et 
al., 2012). Using cytology as a triage test for HPV primary testing has also been proposed 
(Naucler et al., 2009, Rijkaart et al., 2012). In this instance, many patients would be identified 
as HPV positive with low grade cytology, hence a prognostic biomarker to predict long/short 
term outcome and to determine a suitable management strategy would be of substantial 
benefit. 
9.3.2. CRUK Biomarker Roadmaps – Biomarker Discovery and Development 
Several components of this investigation were relevant to CRUK “biomarker discovery and 
development” roadmap components (Roadmaps presented in Appendix I). We tested and 
developed assays for potential biomarkers (Chapter 4) and performed studies to address the 
early stages of biomarker development.  
The components of this investigation with relevance to the biomarker roadmaps are shown in 
Table 9.1. We addressed several stage 1 and stage 2 biomarker development requirements. A 
reproducible assay was developed and applied to determine the DNA methylation status of 
various clinical cohorts. In these cohorts methylation was seen to vary among disease stages, 
between cancer and non-cancer, and even among samples of a more homogeneous VIN2/3 
cohort (Chapter 5: 5.1.2 & Chapter 8: 8.2.3.1). Differences in DNA methylation were also 
observed among samples with low grade cytological abnormalities but different longitudinal 
outcomes (Chapter 6: 6.1.3). 
9.3.3. Progress 
Several aspects of the results were consistent with similar published studies. In the CRISP study 
(Chapter 6: 6.1.3), the most informative regions appeared to be LCR2 and L1/L2, and the most 
informative CpGs appeared to be located in the LCR (LCR1-1 and LCR2-3). We also observed 
differences in DNA methylation between samples with normal cytology/severe dyskaryosis and 
cancer (Chapter 5: 5.1.2); in this study, the most informative region appeared to be L1/L2 and 
the most informative CpG was likely to be L1L2-2. The difference in CpGs identified as 
informative in the NSC and CRISP studies is likely the result of study design and sample 
selection. In the CRISP series, grouping was determined by eventual outcome and all samples 
were initially low grade cytology. For the NSC series, grouping was performed with respect to 
cytology grade/cancer.  
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Other biomarker type studies have considered multiple CpGs within the genome and identified 
several informative CpGs or methylation patterns indicative of disease state (Brandsma et al., 
2009, Mirabello et al., 2012). In light of our observation of large differences among clinical 
groups at single CpGs, and published reports using multiple CpGs; any clinically relevant HPV 
methylation biomarker is likely to be comprised of several HPV CpGs considered using an 
algorithm (Brandsma et al., 2009, Mirabello et al., 2012). That different regions/CpGs of the 
HPV genome appear to be more discerning for different purposes (Chapter 5: 5.1.2 & Chapter 
6: 6.1.3) further support the idea that considering multiple CpGs at different regions is a useful 
strategy. 
  
 Biomarker discovery and development (Cancer Research UK 2012) 
 
Prognostic/predictive BM Screening BM 
 
Do you have an assay? Do you have an assay?  
 
Yes Yes 
Requirement Development of an accurate and reproducible assay to measure BM 
Result 
Pyrosequencing assays were shown to be reproducible and accurate (Method 
development) 
Requirement Define BM distribution on specimens representative of the target patient population 
Result The NSC study and VR series achieved this 
Requirement 
Does the distribution of BM values 
indicate a BM with potential clinical 
utility? 
Can the biomarker distinguish between 
subjects with and without cancer? 
Result 
There is variation among disease 
grades (NSC study) and within a group 
of similar samples (VR series) 
There was a significant difference between 
cancer and non-cancer samples (NSC 
study) 
Requirement 
Study the relationship between the BM 
and clinical outcome retrospectively 
Can the BM detect cancer earlier than the 
time of clinical diagnosis?  
Result The CRISP study achieved this  -  
Requirement 
Is there a correlation between the BM 
and clinical outcome? -  
Result 
There was a significant difference 
between outcome groups -  
Table 9.1: How relevant aspects of this investigation relate to the CRUK biomarker roadmaps.  
Components of the CRUK biomarker roadmaps are detailed under the row title “requirement”. Where 
an aspect of this investigation has relevance to this requirement, the details of the study which 
achieved it or the result of the study are detailed under “result”. Pink and blue highlights represent 
the prognostic/predictive and screening biomarker requirements respectively whilst yellow highlights 
indicate commonalities between the biomarker roadmaps. 
 
9.3.4. Potential Application 
Only the very early stages of biomarker development have been performed but methylation of 
HPV DNA shows potential as a biomarker in several contexts. While cytology remains the 
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primary screen to prevent cervical cancer, a prognostic biomarker capable of differentiating 
clinical outcomes would be of particular use for mild/second borderline cytology cases where 
it is difficult to determine a suitable management strategy (Castanon et al., 2012). HPV testing 
has been suggested as a triage for low grade cytological abnormalities (and is being adopted in 
England (Albrow et al., 2012)) but is likely to substantially increase the number of patients 
referred to colposcopy (Moss et al., 2006). HPV triage testing is also being used as a test of 
cure for women treated for CIN. Nonetheless, there is probably a limited scope for a CIN 
biomarker in these instances. 
The greatest potential use of an HPV disease associated biomarker will probably arise once 
HPV testing is implemented as the primary screen for cervical neoplasia. Primary HPV testing 
has been suggested as a more cost effective alternative to primary cytology screening for 
European countries (Kok et al., 2012) and offers greater sensitivity and negative predictive 
value, but at the cost of reduced specificity relative to cytology (Unger et al., 2004, Katki et al., 
2011). As such, primary HPV testing will identify numerous patients with little risk of CIN or 
cancer, especially young patients where HPV infection is highly prevalent (Hibbitts et al., 2006). 
A screening biomarker in this setting would have potential to identify those patients with 
clinically significant infections. HPV testing triaged with cytology has also been suggested as a 
suitable primary screening system, this would identify a large number of HPV positive patients 
with low grade cytology (Naucler et al., 2009, Rijkaart et al., 2012). It has previously proven 
difficult to determine a suitable management strategy for patients with low grade cytology and 
further triage of these patients using a prognostic biomarker may prove clinically useful 
(Castanon et al., 2012). 
Further, a DNA based screening system (i.e. HPV testing triaged with a DNA based biomarker) 
might allow self collected samples to be used (Brink et al., 2006). Self collection has been 
shown to increase the coverage of the screening programme (Gok et al., 2010). An objective 
DNA based primary screening technology might also find application in countries where a well 
established cytological screening programme is not present. 
As the relationship between HPV DNA methylation and HPV-associated disease of the cervix 
appears to be similar for other anogenital sites (i.e. vulva, penis, anus) and other HPV types, 
HPV DNA methylation biomarkers could have a broad clinical utility (Kalantari et al., 2008b, 
Turan et al., 2007, Wiley et al., 2005, Mirabello et al., 2012). Human genes are also 
differentially methylated in association with HPV disease and represent potential biomarkers 
(Eijsink et al., 2012, Wentzensen et al., 2009). Our finding of E2 and/or L1/L2 hypermethylation 
also partially supports the hypothesis that L1 methylation might be a surrogate marker for HPV 
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integration and a potential cervical disease biomarker (Kalantari et al., 2010). Our observations 
would however suggest that methylation analysis of more than one HPV region would be more 
suitable as integrated HPV genomes appear to be hypomethylated at the HPV-human DNA 
boundaries.  
9.4. Further Work 
Further investigation into the biology of HPV is required to fully understand the apparently 
complex relationship between integration, methylation and gene expression. There is a 
potential role for DNA methylation as an initiator of deregulation that should be more 
thoroughly explored and also a potential relationship between HPV methylation and clearance 
of an infection. In a productive infection, methylation of E2BS2 (the origin adjacent E2BS) could 
interfere with genome replication. As such, it is worth considering whether E2BS2 methylation 
is implicated in the transition from a productive to a transformed phenotype, as a precursor to 
integration or is involved with viral clearance; three events where the inhibition of episomal 
replication might be involved. 
The results of this investigation are promising in terms of a biomarker of HPV-associated 
disease, further development is required on a larger sample set to further explore the clinical 
relevance of HPV methylation. 
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Chapter 10. General Conclusion 
This investigation began by assessing several methods for determining HPV DNA methylation. 
MS-PCR and bisulfite sequencing were trialled but the limitations of these assays were quickly 
realised. Eventually, the relatively new technology of pyrosequencing was trialled and adopted 
because it is quantitative, assesses multiple CpGs and in comparison to bisulfite sequencing 
with cloning, is high throughput. Pyrosequencing was shown to be both sensitive and 
reproducible and could be applied to a diverse range of sample DNAs including clinically 
relevant LBC samples. 
Pyrosequencing was applied to various DNAs with two main objectives, to better understand 
the basic biology of HPV DNA methylation and to evaluate the clinical utility of HPV DNA 
methylation. The cell lines and VR series studies allowed several conclusions to be drawn. First, 
we did not see evidence that methylation was an alternative transforming event to HPV 
integration. LCR and E2BS methylation was very rarely observed and the largest determinant 
of HPV methylation state was the presence of integrated HPV. Integrants were typically 
hypermethylated in E2 or L1/L2, but not in regions of the genome adjacent to human DNA, 
similar to the methylation profile of other foreign DNAs inserted into the human genome. In 
general, E2 and/or L1/L2 methylation were negatively associated with E2, E6 and/or E7 mRNA 
transcription and a relationship between integration and gene expression was not successfully 
established. 
To better understand the potential clinical utility of HPV DNA methylation, the relationship 
between HPV DNA methylation and disease state/clinical outcome was evaluated in LBC 
material from the CRISP clinical series and from routine screening, and in biopsy material from 
invasive cervical cancers. These studies demonstrated that there were significant differences in 
DNA methylation among samples with normal cytology, severe dyskaryosis and invasive 
cervical cancer. There were also considerable differences in methylation of the cohort of low 
grade cytology samples with a variety of 6 month outcomes. Methylation differences were 
apparent for samples that were cleared, and those that were persistent and associated with 
either low or high grade disease. Several regions and CpGs of the HPV genome were further 
identified that were the most significantly different among the various disease and outcome 
groups. 
Throughout the investigation, consistent patterns of CpG specific methylation were observed 
which might be explained by subtle positioning differences in reference to the nucleosomal 
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structure, and the subsequent level of access that this structure provides for the cellular 
methylation machinery. 
In summary, the relationship between methylation, integration and gene expression is 
complex and assessment of HPV DNA methylation status does appear to hold potential as a 
triage test for HPV positive women. 
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Appendices 
Appendix I – Cancer Research UK Biomarker Roadmaps 
 
Figure I.a: The CRUK prognostic/predictive biomarker roadmap. 
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Figure I.b: The CRUK screening biomarker roadmap. 
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Figure I.c: The CRUK diagnostic biomarker roadmap. 
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Appendix II – Chapter 4 qPCR Method Validation 
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Figure II.a: The relationship between Ct value and DNA concentration for the E6 qPCR primer pair. 
Included are regression lines for each of the three repeats. Each colour and point shape represents an 
experimental repeat. 
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Figure II.b: The relationship between Ct value and DNA concentration for the E7 qPCR primer pair. 
Included are regression lines for each of the three repeats. Each colour and point shape represents an 
experimental repeat. 
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Figure II.c: The relationship between Ct value and DNA concentration for the E2 qPCR primer pair. 
Included are regression lines for each of the three repeats. Each colour and point shape represents an 
experimental repeat. 
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Figure II.d: The relationship between Ct value and DNA concentration for the HPRT qPCR primer pair. 
Included are regression lines for each of the three repeats. Each colour and point shape represents an 
experimental repeat. One data point was missing from one of experimental repeats. 
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Figure II.e: The relationship between Ct value and DNA concentration for the TBP2 qPCR primer pair.  
Included are regression lines for each of the three repeats. Each colour and point shape represents an 
experimental repeat. One data point was missing from one of experimental repeats. 
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Appendix III – Chapter 4 Pyrosequencing Method Validation 
Appendix III contains the results of 6x CaSki Pyrosequencing analyses used to determine 
variability among runs. 
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Figure III.a: Variation in CaSki E2 methylation for each CpG. 
Bars represent mean values, red circles represent individual values and error bars represent 95% 
confidence intervals. 
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Figure III.b: Variation in CaSki LCR1 methylation for each CpG. 
Bars represent mean values, red circles represent individual values and error bars represent 95% 
confidence intervals 
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Figure III.c: Variation in CaSki LCR2 methylation for each CpG. 
Bars represent mean values, red circles represent individual values and error bars represent 95% 
confidence intervals 
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Figure III.d: Variation in CaSki L1/L2 methylation for each CpG. 
Bars represent mean values, red circles represent individual values and error bars represent 95% 
confidence intervals 
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Appendix IV – Chapter 6 Supplementary Statistics 
Appendix IV contains the statistical analyses that were performed for Chapter 6, section 
6.1.3.1. The so that the chapter was more concise, the mostly non-significant results were 
briefly summarised in the main body of the text. These tables represent supplementary 
information. 
Each region was considered separately with the aim of identifying which CpG was the most 
significantly differently methylated among the three outcome groups. The Bonferroni 
corrected P-value of significance was used (E2 CpG, P=0.006; LCR1 CpG, P=0.017; LCR2 CpG, 
P=0.010; L1/L2 CpG, P=0.013) however comparisons significant at P=0.05 were considered. 
 
 
E2-1 E2-2 E2-3 E2-4 E2-5 E2-6 E2-7 E2-8 
Kruskall-Wallis P-
value 0.463 0.122 0.321 0.012 0.700 0.179 0.123 0.518 
H-value (DF) 
1.54 
(2) 
4.21 
(2) 
2.28 
(2) 
8.85 
(2) 
0.71 
(2) 
3.44 
(2) 
4.19 
(2) 
1.34 
(2) 
  
       
  
ANOVA P-value 0.696 0.112 0.341 0.034 0.674 0.099 0.049 0.336 
F-value (DF) 
0.37 
(2) 
2.40 
(2) 
1.13 
(2) 
3.90 
(2) 
0.40 
(2) 
2.55 
(2) 
3.45 
(2) 
1.14 
(2) 
Equal variances Yes Yes Yes Close Yes Yes Yes Yes 
Normal residuals No No No No No Yes Yes Yes 
  
       
  
  Significant Tukey-Kramer Pairwise Comparison? 
  E2-1 E2-2 E2-3 E2-4 E2-5 E2-6 E2-7 E2-8 
C vs. PL No No No No No No No No 
C vs. PH No No No Yes No No No No 
PL vs. PH No No No No No No Yes No 
Table IV.a: The results of multiple statistical analyses on E2 CpG methylation data.  
The non-parametric Kruskall-Wallis P-values and H-values represent the significant differences among 
the medians of each disease group, higher significance is represented by a lower P-value and a larger 
H-value. ANOVA P-values and F-values are accompanied by degrees of freedom (DF) and two 
statements for violations of the ANOVA assumptions (equal variances and normally distributed 
residuals), here three degrees of success are present, No; a violation (P=<0.01), Close; P=0.01-0.05 and 
Yes; P>0.05. Finally, the results of C vs. Pl, C vs. PH and PL vs. PH Tukey-Kramer pairwise comparisons 
are listed where No = no significant difference in means at P=0.05 and Yes = a significant difference in 
means at P=0.05. 
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LCR1-1 LCR1-2 LCR1-3 
Kruskall-Wallis P-value 0.017 0.639 0.579 
H-value (DF) 8.13 (2) 0.89 (2) 1.09 (2) 
    
 
  
ANOVA P-value 0.014 0.581 0.650 
F-value (DF) 5.02 (2) 0.55 (2) 0.44 (2) 
Equal variances Close Yes Yes 
Normal residuals No Yes No 
    
 
  
  Significant Tukey-Kramer Pairwise Comparison? 
  LCR1-1 LCR1-2 LCR1-3 
C vs. PL Yes No No 
C vs. PH No No No 
PL vs. PH Yes No No 
Table IV.b: The results of multiple statistical analyses on LCR1 CpG methylation data.  
The non-parametric Kruskall-Wallis P-values and H-values represent the significant differences among 
the medians of each disease group, higher significance is represented by a lower P-value and a larger 
H-value. ANOVA P-values and F-values are accompanied by degrees of freedom (DF) and two 
statements for violations of the ANOVA assumptions (equal variances and normally distributed 
residuals), here three degrees of success are present, No; a violation (P=<0.01), Close; P=0.01-0.05 and 
Yes; P>0.05. Finally, the results of C vs. Pl, C vs. PH and PL vs. PH Tukey-Kramer pairwise comparisons 
are listed where No = no significant difference in means at P=0.05 and Yes = a significant difference in 
means at P=0.05. 
 
 
LCR2-1 LCR2-2 LCR2-3 LCR2-4 LCR2-5 
Kruskall-Wallis P-value 0.364 0.069 0.000 0.486 0.269 
H-value (DF) 2.02 (2) 5.36 (2) 18.53 (2) 1.44 (2) 2.63 (2) 
      ANOVA P-value 0.338 0.058 0.000 0.381 0.278 
F-value (DF) 1.13 (2) 3.18 (2) 23.14 (2) 1.00 (2) 1.34 (2) 
Equal variances Yes Yes Yes Close N/A
*1
 
Normal residuals No Close No No No 
      
 
Significant Tukey-Kramer Pairwise Comparison? 
 
LCR2-1 LCR2-2 LCR2-3 LCR2-4 LCR2-5 
C vs. PL No No No No No 
C vs. PH No Yes Yes No No 
PL vs. PH No No Yes No No 
Table IV.c: The results of multiple statistical analyses on LCR2 CpG methylation data.  
The non-parametric Kruskall-Wallis P-values and H-values represent the significant differences among 
the medians of each disease group, higher significance is represented by a lower P-value and a larger 
H-value. ANOVA P-values and F-values are accompanied by degrees of freedom (DF) and two 
statements for violations of the ANOVA assumptions (equal variances and normally distributed 
residuals), here three degrees of success are present, No; a violation (P=<0.01), Close; P=0.01-0.05 and 
Yes; P>0.05. Finally, the results of C vs. Pl, C vs. PH and PL vs. PH Tukey-Kramer pairwise comparisons 
are listed where No = no significant difference in means at P=0.05 and Yes = a significant difference in 
means at P=0.05. 
 
278 
 
 
 
L1L2-1 L1L2-2 L1L2-3 L1L2-4 
Kruskall-Wallis P-value 0.122 0.202 0.318 0.493 
H-value (DF) 4.21 (2) 3.20 (2) 2.29 (2) 1.42 (2) 
    
  
  
ANOVA P-value 0.107 0.291 0.277 0.300 
F-value (DF) 2.42 (2) 1.29 (2) 1.34 (2) 1.27 (2) 
Equal variances Yes No No Yes 
Normal residuals Yes No No No 
    
  
  
  Significant Tukey-Kramer Pairwise Comparison? 
  L1L2-1 L1L2-2 L1L2-3 L1L2-4 
C vs. PL No No No No 
C vs. PH No No No No 
PL vs. PH No No No No 
Table IV.d: The results of multiple statistical analyses on L1/L2 CpG methylation data.  
The non-parametric Kruskall-Wallis P-values and H-values represent the significant differences among 
the medians of each disease group, higher significance is represented by a lower P-value and a larger 
H-value. ANOVA P-values and F-values are accompanied by degrees of freedom (DF) and two 
statements for violations of the ANOVA assumptions (equal variances and normally distributed 
residuals), here three degrees of success are present, No; a violation (P=<0.01), Close; P=0.01-0.05 and 
Yes; P>0.05. Finally, the results of C vs. Pl, C vs. PH and PL vs. PH Tukey-Kramer pairwise comparisons 
are listed where No = no significant difference in means at P=0.05 and Yes = a significant difference in 
means at P=0.05. 
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Appendix V – Chapter 8 Supplementary Tables  
Appendix V contains tables with data summarised in the main body of text. The tables are 
supplementary to the analysis performed in Chapter 8. 
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Figure V.a: DNA methylation of the VR series integration groups 0 and X E2 region, separated by gene 
expression assay (RQ assay) and by RQ quartile within each assay.  
* Represents those samples whereby the gene expression assays have failed to produce an RQ result. 
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Figure V.b: DNA methylation of the VR series integration groups 0 and X LCR1 region, separated by 
gene expression assay (RQ assay) and by RQ quartile within each assay.  
* Represents those samples whereby the gene expression assays have failed to produce an RQ result. 
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Figure V.c1: DNA methylation of the VR series integration groups 0 and X LCR2 region, separated by 
gene expression assay (RQ assay) and by RQ quartile within each assay. 
* Represents those samples whereby the gene expression assays have failed to produce an RQ result. 
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Figure V.d: DNA methylation of the VR series integration groups 0 and X L1/L2 region, separated by 
gene expression assay (RQ assay) and by RQ quartile within each assay.  
* Represents those samples whereby the gene expression assays have failed to produce an RQ result. 
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Appendix VI – HPV Methylation Studies, Methodology Summary 
Appendix VI contains a summary of the methodologies used by a number of HPV16 DNA 
methylation studies. 
 
Summary of HPV16 methylation studies 
Authors Methylation assay used Size (n) Quantitative regions Material 
Badal et al 2003 
Restriction enzyme/Bisulfite 
sequencing 81 No LCR, E6 
Biopsy and 
exfoliated 
Kalantari et al 2004 Bisulfite sequencing 115 Yes LCR, L1 Biopsy 
Bhattacharjee et al 
2006 
Restriction enzyme/Bisulfite 
sequencing 72 No LCR 
Biopsy and 
exfoliated 
Hong et al 2008 Pyrosequencing 70 Yes LCR Exfoliated 
Kalantari et al 2008 Bisulfite sequencing 19 Yes LCR, L1 Biopsy*1 
Brandsma et al 
2009 Bisulfite sequencing 13 Yes Genome Exfoliated 
Ding et al 2009 Bisulfite sequencing 53 Yes LCR 
Biopsy and 
exfoliated 
Fernandez et al 
2009 Bisulfite sequencing, MS-PCR 18 Yes, No Genome  *2 
Hublarova et al 
2009 Restriction enzyme 121 No LCR Exfoliated 
Kalantari et al 2010 Bisulfite sequencing 21 Yes L1 Exfoliated 
Piyathilake et al 
2011 Pyrosequencing 75 Yes LCR Exfoliated 
Vinokurova et al 
2011 Bisulfite sequencing 3 Yes LCR LCM biopsy*3 
Mirabello et al 
2012 Pyrosequencing 108 yes Genome Exfoliated 
Patel et al 2012 Pyrosequencing 89 Yes LCR Exfoliated 
Snellenberg et al 
2012 Luminex xMAP 84 Yes LCR 
FFPE and 
exfoliated*4 
Sun et al 2012 EpiTyper/Pyrosequencing 85 Yes LCR, L1 Exfoliated 
TableVI.a: A summary of the methods of a number of HPV16 DNA methylation studies.  
Here, each study is listed along with the main methylation assays used, the sample size of the study 
(n), whether the techniques produced quantitative data, the regions of the HPV genome studied and 
finally the type of clinical material used. Under material, biopsy and exfoliated represent cervical 
biopsies and exfoliated cervical cells as obtained for cytological testing respectively. Notes: *1, 
material was penile biopsy; *2 insufficient detail included in the paper to determine origin of samples; 
*3 cervical biopsies were microdissected into several components; *4 FFPE represents formalin fixed 
paraffin embedded tissue samples. 
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Appendix VII – Published HPV Typing Study 
Appendix VII contains the published VIN HPV typing study (Bryant et al., 2011). 
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